0000950170-24-09385610-Q SCYNEXIS INC 20240808202408081601311601311601310 0 0000950170-24-093856 10-Q 67 20240630 20240808 20240808 SCYNEXIS INC 0001178253 2834 562181648 1231 10-Q 34 001-36365 241188037 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548 201-884-5485 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548 10-Q 1 scyx-20240630.htm 10-Q 10-Q 0001178253false--12-31Q20001178253us-gaap:CorporateBondSecuritiesMemberscyx:LongTermInvestmentMember2024-06-300001178253us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253us-gaap:AdditionalPaidInCapitalMember2023-03-310001178253us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001178253us-gaap:AdditionalPaidInCapitalMember2024-03-310001178253us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-06-300001178253us-gaap:ProductMember2024-01-012024-06-300001178253scyx:ProductReturnsMember2022-12-310001178253us-gaap:AccountingStandardsUpdate202006Member2024-06-3000011782532023-02-012023-02-280001178253us-gaap:ShortTermInvestmentsMember2023-12-310001178253scyx:SeniorConvertibleNotePurchaseAgreementMember2024-06-300001178253us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2023-12-310001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMembersrt:MaximumMemberscyx:AchivementOfTwoInterimMilestoneOfOngoingMarioStudyMember2023-12-262023-12-260001178253scyx:ProductReturnsMember2023-01-012023-06-300001178253us-gaap:RetainedEarningsMember2023-12-310001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMemberscyx:LicenseTransferMember2024-01-012024-06-300001178253scyx:April2022PublicOfferingMemberus-gaap:WarrantMember2024-01-012024-06-300001178253scyx:ExclusiveLicenseAndCollaborationAgreementMember2024-04-012024-06-300001178253us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001178253scyx:PrefundedWarrantsMemberscyx:December2020PublicOfferingMember2024-06-300001178253us-gaap:WarrantMemberscyx:WarrantsAssociatedWithLoanAgreementMember2024-04-012024-06-300001178253us-gaap:WarrantMember2024-06-300001178253us-gaap:RestrictedStockUnitsRSUMember2023-12-3100011782532024-03-310001178253us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012024-06-300001178253scyx:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253scyx:PrefundedWarrantsMemberscyx:December2020PublicOfferingMember2023-06-300001178253us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253us-gaap:WarrantMemberscyx:December2020PublicOfferingSeries2Member2024-01-012024-06-300001178253scyx:DiscountsAndChargebacksMember2024-06-300001178253us-gaap:LicenseAndServiceMember2023-04-012023-06-300001178253us-gaap:WarrantMemberscyx:April2022PublicOfferingMember2024-06-300001178253scyx:DiscountsAndChargebacksMember2023-01-012023-06-300001178253us-gaap:OtherNoncurrentLiabilitiesMember2021-12-310001178253scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2023-12-310001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMember2023-01-012023-06-300001178253us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001178253us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001178253us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001178253us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2023-12-310001178253us-gaap:RetainedEarningsMember2024-03-310001178253us-gaap:CommonStockMember2023-04-012023-06-300001178253us-gaap:ProductMember2024-04-012024-06-300001178253scyx:ProductRecallMember2023-06-300001178253us-gaap:WarrantMemberscyx:December2020PublicOfferingSeries2Member2023-04-012023-06-300001178253us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-06-300001178253scyx:RebatesAndIncentivesMember2023-12-310001178253scyx:PrefundedWarrantsMemberscyx:April2022PublicOfferingMember2023-04-012023-06-300001178253us-gaap:RetainedEarningsMember2023-03-310001178253scyx:TwoThousandAndFifteenInducementAwardPlanMember2023-01-012023-06-300001178253us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253us-gaap:WarrantMemberscyx:WarrantsAssociatedWithLoanAgreementMember2023-12-310001178253scyx:TwoThousandAndFifteenInducementAwardPlanMember2024-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:RelaunchDateTwoMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto200MillionMember2023-12-262023-12-2600011782532023-12-310001178253us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-06-300001178253us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-300001178253scyx:SeniorConvertibleNotePurchaseAgreementMember2019-03-072019-03-070001178253scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember2024-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:RelaunchDateThreeMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto750MillionTo1BillionMember2012-262023-12-2600011782532024-06-300001178253us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001178253us-gaap:CommonStockMember2023-12-310001178253scyx:HerculesCapitalIncorporatedAndSiliconValleyBankAndOtherLendersMemberscyx:LoanAgreementAmendmentMember2023-03-300001178253us-gaap:WarrantMemberscyx:WarrantsAssociatedWithLoanAgreementMember2024-01-012024-06-300001178253scyx:ProductRecallMember2024-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMembersrt:MaximumMember2023-12-262023-12-260001178253us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100011782532024-08-010001178253us-gaap:WarrantMember2024-01-012024-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMemberscyx:LicenseTransferMember2023-01-012023-06-300001178253scyx:CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember2023-01-012023-06-300001178253scyx:TwoThousandAndFourteenEquityIncentivePlanMember2023-01-012023-01-010001178253scyx:DiscountsAndChargebacksMember2024-01-012024-06-300001178253us-gaap:FairValueInputsLevel2Memberscyx:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DerivativeMember2023-12-310001178253us-gaap:CommonStockMember2024-03-310001178253us-gaap:EmployeeStockOptionMember2023-12-310001178253us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001178253srt:MaximumMember2024-01-012024-06-300001178253us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-06-300001178253us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001178253scyx:DiscountsAndChargebacksMember2023-12-310001178253scyx:TwoThousandAndFifteenInducementAwardPlanMember2023-12-310001178253scyx:RebatesAndIncentivesMember2023-01-012023-06-300001178253scyx:April2022PublicOfferingMemberus-gaap:WarrantMember2023-04-012023-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:RelaunchDateTwoMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto300MillionTo500MillionMember212-262023-12-260001178253scyx:WarrantAssociatedWithDanforthMemberus-gaap:WarrantMember2024-04-012024-06-300001178253us-gaap:ProductMember2023-04-012023-06-300001178253scyx:WarrantAssociatedWithDanforthMemberus-gaap:WarrantMember2024-01-012024-06-300001178253us-gaap:DerivativeMember2024-01-012024-06-3000011782532023-04-012023-06-300001178253scyx:SeniorConvertibleNotePurchaseAgreementMember2023-01-012023-06-300001178253us-gaap:CorporateBondSecuritiesMemberscyx:LongTermInvestmentMember2023-12-310001178253us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LoanAgreementAmendmentMember2021-05-132021-05-130001178253scyx:ProductRecallMember2022-12-310001178253scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember2023-12-310001178253scyx:April2022PublicOfferingMemberus-gaap:WarrantMember2023-01-012023-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMember2024-06-300001178253scyx:ProductReturnsMember2023-12-310001178253us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2024-06-300001178253us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253us-gaap:AdditionalPaidInCapitalMember2023-12-310001178253us-gaap:CommonStockMember2022-12-310001178253us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberscyx:WholesalerTwoMember2023-01-012023-06-300001178253us-gaap:FairValueInputsLevel3Memberscyx:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001178253scyx:SeniorConvertibleNotePurchaseAgreementMember2019-03-070001178253scyx:TwoThousandAndFourteenEquityIncentivePlanMember2024-01-012024-01-010001178253scyx:CompletionFuriCaresAndNatureClinicalStudiesMemberscyx:LicenseAgreementMember2023-12-262023-12-260001178253us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253scyx:April2022PublicOfferingMember2023-04-012023-06-300001178253us-gaap:WarrantMemberscyx:April2022PublicOfferingMember2023-12-310001178253us-gaap:WarrantMemberscyx:WarrantsAssociatedWithLoanAgreementMember2023-04-012023-06-3000011782532023-06-300001178253us-gaap:WarrantMemberscyx:December2020PublicOfferingSeries2Member2024-06-300001178253scyx:LoanAgreementAmendmentMember2023-03-30001178253us-gaap:LicenseAndServiceMember2024-01-012024-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMemberscyx:RelaunchDateOneMembersrt:MaximumMember2023-12-262023-12-2600011782532023-12-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:RelaunchDateTwoMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto750MillionTo1BillionMember20212-262023-12-260001178253us-gaap:FairValueMeasurementsRecurringMember2024-06-3000011782532022-12-310001178253us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2023-12-310001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMemberscyx:LicenseTransferMember2024-04-012024-06-300001178253scyx:LongTermInvestmentMember2024-06-300001178253us-gaap:CommonStockMember2023-03-310001178253us-gaap:ProductMember2023-01-012023-06-300001178253us-gaap:RetainedEarningsMember2023-04-012023-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:RelaunchDateThreeMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto300MillionTo500MillionMember12-262023-12-260001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMembersrt:MaximumMember2023-03-302023-03-300001178253us-gaap:DerivativeMember2023-12-310001178253us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253scyx:RebatesAndIncentivesMember2023-06-300001178253us-gaap:WarrantMemberscyx:WarrantsAssociatedWithLoanAgreementMember2023-01-012023-06-300001178253us-gaap:ShortTermInvestmentsMemberscyx:AgencyBondsMember2023-12-310001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:RelaunchDateTwoMemberscyx:LicenseAgreementMembersrt:MaximumMember2023-12-262023-12-260001178253us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DerivativeMember2023-12-310001178253us-gaap:EmployeeStockOptionMember2024-06-300001178253scyx:CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember2024-04-012024-06-300001178253us-gaap:SalesRevenueNetMemberscyx:WholesalerOneMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001178253us-gaap:AdditionalPaidInCapitalMember2023-06-300001178253us-gaap:FairValueInputsLevel2Memberscyx:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253scyx:TwoThousandAndTwentyFourEquityIncentivePlanMember2023-12-310001178253us-gaap:WarrantMember2023-12-310001178253us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-06-300001178253us-gaap:WarrantMemberscyx:December2020PublicOfferingSeries2Member2024-04-012024-06-3000011782532018-03-010001178253us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-06-300001178253us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001178253scyx:ProductReturnsMember2023-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto300MillionTo500MillionMemberscyx:RelaunchDateOneMember212-262023-12-260001178253us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001178253us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-06-300001178253us-gaap:CommonStockMember2023-01-012023-06-300001178253scyx:TwoThousandAndFifteenInducementAwardPlanMember2024-01-012024-06-300001178253scyx:TermLoanMemberscyx:HerculesCapitalIncorporatedAndSiliconValleyBankMemberscyx:LoanAndSecurityAgreementMember2021-05-130001178253us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DerivativeMember2023-12-310001178253scyx:PrefundedWarrantsMemberscyx:April2022PublicOfferingMember2023-01-012023-06-300001178253scyx:ProductReturnsMember2024-06-300001178253us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel3Member2024-06-300001178253us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253scyx:ProductRecallMember2024-01-012024-06-300001178253scyx:DiscountsAndChargebacksMember2023-06-300001178253scyx:PrefundedWarrantsMemberscyx:April2022PublicOfferingMember2024-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMembersrt:ScenarioForecastMember2024-07-012024-09-300001178253us-gaap:AdditionalPaidInCapitalMember2022-12-310001178253us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001178253us-gaap:AdditionalPaidInCapitalMember2024-06-300001178253us-gaap:RetainedEarningsMember2024-01-012024-06-300001178253scyx:WarrantAssociatedWithDanforthMemberus-gaap:WarrantMember2023-04-012023-06-300001178253us-gaap:WarrantMemberscyx:WarrantsAssociatedWithLoanAgreementMember2024-06-300001178253us-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253us-gaap:WarrantMemberscyx:WarrantsAssociatedWithApril2022PublicOfferingMember2023-12-3100011782532024-01-012024-06-300001178253srt:MaximumMemberscyx:TwoThousandAndTwentyFourEquityIncentivePlanMember2024-01-012024-06-300001178253us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2023-12-310001178253scyx:CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember2023-04-012023-06-300001178253us-gaap:WarrantMemberscyx:DanforthMember2024-06-3000011782532023-01-012023-12-310001178253scyx:WarrantAssociatedWithDanforthMemberus-gaap:WarrantMember2023-01-012023-06-300001178253us-gaap:RestrictedStockUnitsRSUMember2024-06-300001178253us-gaap:WarrantMemberscyx:DanforthMember2023-12-310001178253scyx:CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember2024-01-012024-06-300001178253scyx:RestrictedCashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMemberscyx:LicenseTransferMember2023-04-012023-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMember2023-06-012023-06-300001178253us-gaap:WarrantMemberscyx:December2020PublicOfferingSeries2Member2023-12-310001178253us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-300001178253scyx:RestrictedCashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253us-gaap:LicenseAndServiceMember2023-01-012023-06-300001178253us-gaap:ShortTermInvestmentsMember2024-06-300001178253us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember2024-06-300001178253scyx:April2022PublicOfferingMember2023-01-012023-06-3000011782532018-03-012018-03-010001178253scyx:TermLoanMemberscyx:HerculesCapitalIncorporatedAndSiliconValleyBankMemberscyx:LoanAndSecurityAgreementMember2021-05-

132021-05-1300011782532024-04-012024-06-300001178253us-gaap:LicenseAndServiceMember2024-04-012024-06-300001178253us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001178253us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001178253scyx:ProductReturnsMember2024-01-012024-06-300001178253scyx:SeniorConvertibleNotePurchaseAgreementMember2024-01-012024-06-300001178253us-gaap:RetainedEarningsMember2023-01-012023-06-300001178253scyx:WholesalerThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001178253scyx:PrefundedWarrantsMemberscyx:April2022PublicOfferingMember2023-06-300001178253scyx:ProductRecallMember2023-01-012023-06-300001178253us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001178253scyx:TwoThousandAndTwentyFourEquityIncentivePlanMember2024-06-300001178253us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001178253scyx:RebatesAndIncentivesMember2024-06-300001178253scyx:SeniorConvertibleNotePurchaseAgreementMember2023-12-310001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:SuccessfulCompletionOfMarioStudyMemberscyx:LicenseAgreementMember2023-12-262023-12-260001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto750MillionTo1BillionMemberscyx:RelaunchDateOneMember2023-12-262023-12-260001178253us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001178253us-gaap:WarrantMemberscyx:December2020PublicOfferingSeries2Member2023-01-012023-06-300001178253scyx:SeniorConvertibleNotePurchaseAgreementMember2024-04-012024-06-300001178253us-gaap:RetainedEarningsMember2024-06-300001178253us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMember2023-04-012023-06-300001178253us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-06-300001178253scyx:RebatesAndIncentivesMember2022-12-310001178253us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001178253us-gaap:FairValueInputsLevel2Memberscyx:CorporateAndAgencyBondSecuritiesMember2023-12-310001178253scyx:ExclusiveLicenseAndCollaborationAgreementMember2023-04-012023-06-300001178253us-gaap:WarrantMemberscyx:December2020PublicOfferingMember2024-06-300001178253scyx:ProductRecallMember2023-12-310001178253us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2024-06-300001178253us-gaap:FairValueInputsLevel2Memberscyx:CorporateAndAgencyBondSecuritiesMember2024-06-300001178253us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253us-gaap:CommonStockMember2024-01-012024-06-300001178253us-gaap:RetainedEarningsMember2023-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:RelaunchDateThreeMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto200MillionMember2023-12-262023-12-260001178253us-gaap:FairValueInputsLevel3Memberscyx:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253scyx:ExclusiveLicenseAndCollaborationAgreementMember2023-01-012023-06-300001178253scyx:RebatesAndIncentivesMember2024-01-012024-06-300001178253us-gaap:WarrantMemberscyx:December2020PublicOfferingMember2023-12-310001178253us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300001178253us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DerivativeMember2023-12-310001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto200MillionMemberscyx:RelaunchDateOneMember2023-12-262023-12-260001178253us-gaap:CommonStockMember2024-06-300001178253scyx:RestrictedCashMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001178253us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001178253scyx:ExclusiveLicenseAndCollaborationAgreementMember2024-01-012024-06-300001178253us-gaap:OtherNoncurrentLiabilitiesMember2022-12-310001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:LicenseAgreementMemberscyx:AchivementOfThresholdUpto200MillionMemberscyx:RelaunchDateOneMember2023-12-262023-12-260001178253scyx:April2022PublicOfferingMemberus-gaap:WarrantMember2024-04-012024-06-300001178253scyx:DiscountsAndChargebacksMember2022-12-310001178253us-gaap:WarrantMemberscyx:WarrantsAssociatedWithApril2022PublicOfferingMember2024-06-300001178253scyx:LongTermInvestmentMember2023-12-310001178253scyx:SeniorConvertibleNotePurchaseAgreementMember2023-04-012023-06-300001178253scyx:GlaxosmithklineIntellectualPropertyMemberscyx:RelaunchDateThreeMemberscyx:LicenseAgreementMembersrt:MaximumMember2023-12-262023-12-260001178253us-gaap:CommonStockMember2024-04-012024-06-300001178253us-gaap:CommonStockMember2023-06-300001178253us-gaap:RetainedEarningsMember2024-04-012024-06-300001178253us-gaap:DerivativeMember2024-06-300001178253us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001178253us-gaap:ShortTermInvestmentsMemberus-gaap:CorporateBondSecuritiesMember2024-06-300001178253us-gaap:ShortTermInvestmentsMemberscyx:AgencyBondsMember2024-06-300001178253us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputCreditSpreadMember2024-06-30xbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesiso4217:USDscyx:Tranche Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 Â SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Â Â Delaware Â 56-2181648 (State or other jurisdiction ofincorporation or organization) Â (I.R.S. EmployerIdentification No.) Â Â Â Â 1 Evertrust Plaza, 13th FloorJersey City, New Jersey Â 07302-6548 (Address of principal executive offices) Â (Zip Code) Â (201)-884-5485 (Registrantâ€™s telephone number, including area code) Â Â Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share SCYX Nasdaq Global Market Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and "emerging growth company" in Rule 12b-2 of the Exchange Act. Â Large accelerated filer Â â˜ Â Accelerated filer Â â˜ Â Â Â Â Non-accelerated filer Â â˜’ Â Smaller reporting company Â â˜’ Â Â Â Â Emerging growth company Â â˜ Â Â Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of August 1, 2024, there were 37,856,463 shares of the registrantâ€™s Common Stock outstanding. Â Â Table of ContentsÂ SCYNEXIS, INC. QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 TABLE OF CONTENTS Â Â Â Â Â Page Â Â Â PART I FINANCIAL INFORMATION Â 1 Â Â Â Â Â Item 1. Â Financial Statements Â 1 Â Â Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 Â 1 Â Â Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 Â 2 Â Â Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 Â 3 Â Â Notes to the Condensed Consolidated Financial Statements (unaudited) Â 4 Item 2. Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 18 Item 3. Â Quantitative and Qualitative Disclosures About Market Risk Â 26 Item 4. Â Controls and Procedures Â 26 Â Â Â Â PART II OTHER INFORMATION Â 27 Â Â Â Â Â Â Item 1. Â Legal Proceedings Â 27 Item 1A. Â Risk Factors Â 27 Item 6. Â Exhibits Â 28 Â Â Â Signatures Â 29 Â Â Table of ContentsÂ PART I. FINANCIAL INFORMATION Item 1. Financial Statements. SCYNEXIS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) Â Â June 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Cash and cash equivalents Â $ 25,994 Â Â $ 34,050 Â Short-term investments Â Â 47,044 Â Â Â 40,312 Â Prepaid expenses and other current assets Â Â 1,418 Â Â Â 5,548 Â License agreement receivable Â Â 233 Â Â Â 2,463 Â License agreement contract asset Â Â 19,509 Â Â Â 19,363 Â Restricted cash Â Â 380 Â Â Â 380 Â Total current assets Â Â 94,578 Â Â Â 102,116 Â Investments Â Â 10,657 Â Â Â 23,594 Â Deferred offering costs Â Â 175 Â Â Â 175 Â Restricted cash Â Â 163 Â Â Â 163 Â Operating lease right-of-use asset (See Note 7) Â Â 2,233 Â Â Â 2,364 Â Total assets Â $ 107,806 Â Â $ 128,412 Â Liabilities and stockholdersâ€™ equity Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Accounts payable Â $ 5,350 Â Â $ 7,149 Â Accrued expenses Â Â 5,498 Â Â Â 7,495 Â Deferred revenue, current portion Â Â 1,229 Â Â Â 1,189 Â Operating lease liability, current portion (See Note 7) Â Â 372 Â Â Â 340 Â Warrant liabilities Â Â Â â€” Â Â Â 130 Â Convertible debt and derivative liability (See Note 6) Â Â 12,784 Â Â Â â€” Â Total current liabilities Â Â 25,233 Â Â Â 16,303 Â Deferred revenue Â Â 1,817 Â Â Â 2,727 Â Warrant liabilities Â Â 17,962 Â Â Â 21,680 Â Convertible debt and derivative liability (See Note 6) Â Â Â â€” Â Â Â 12,159 Â Operating lease liability (See Note 7) Â Â 2,388 Â Â Â 2,581 Â Total liabilities Â Â 47,400 Â Â Â 55,450 Â Commitments and contingencies Â Â Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Preferred stock, $0.001Â par value, authorized 5,000,000Â shares as of June 30, 2024 and December 31, 2023; 0Â shares issued and outstanding as of June 30, 2024 and December 31, 2023 Â Â Â â€” Â Â Â â€” Â Common stock, $0.001Â par value, 150,000,000Â shares authorized as of June 30, 2024 and December 31, 2023; 37,856,463Â and 37,207,799Â shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Â Â 41 Â Â Â 40 Â Additional paid-in capital Â Â 429,659 Â Â Â 428,169 Â Accumulated deficit Â Â (369,294) Â Â (355,247) Total stockholdersâ€™ equity Â Â 60,406 Â Â Â 72,962 Â Total liabilities and stockholdersâ€™ equity Â $ 107,806 Â Â $ 128,412 Â The accompanying notes are an integral part of the financial statements. 1 Table of ContentsÂ SCYNEXIS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Â Product revenue, net Â $ â€” Â Â $ 468 Â Â $ â€” Â Â $ 1,598 Â License agreement revenue Â Â 736 Â Â Â 130,986 Â Â Â 2,109 Â Â Â 130,986 Â Total revenue Â Â 736 Â Â Â 131,454 Â Â Â 2,109 Â Â Â 132,584 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Cost of product revenue Â Â Â â€” Â Â Â 426 Â Â Â â€” Â Â Â 562 Â Research and development Â Â 6,807 Â Â Â 7,040 Â Â Â 14,019 Â Â Â 13,875 Â Selling, general and administrative Â Â 3,166 Â Â Â 7,474 Â Â Â 6,835 Â Â Â 12,314 Â Total operating expenses Â Â 9,973 Â Â Â 14,940 Â Â Â 20,854 Â Â Â 26,751 Â (Loss) income from operations Â Â (9,237) Â Â 116,514 Â Â Â (18,745) Â Â 105,833 Â Other (income) expense: Â Â Â Â Â Â Â Â Â Â Â Â Amortization of debt issuance costs and discount Â Â 421 Â Â Â 1,998 Â Â Â 822 Â Â Â 2,256 Â Interest income Â Â (1,130) Â Â (737) Â Â (2,402) Â Â (1,325) Interest expense Â Â 197 Â Â Â 1,249 Â Â Â 403 Â Â Â 2,695 Â Warrant liabilities fair value adjustment Â Â 5,761 Â Â Â (8,214) Â Â (3,848) Â Â 13,459 Â Derivative liabilities fair value adjustment Â Â (28) Â Â (42) Â Â (196) Â Â 364 Â Total other expense (income) Â Â 5,221 Â Â Â (5,746) Â Â (5,221) Â Â 17,449 Â (Loss) income before taxes Â Â (14,458) Â Â 122,260 Â Â Â (13,524) Â Â 88,384 Â Income tax expense Â Â Â â€” Â Â Â â€” Â Â Â 523 Â Â Â â€” Â Net (loss) income Â $ (14,458) Â $ 122,260 Â Â $ (14,047) Â $ 88,384 Â Net (loss) income per share attributable to common stockholders â€“ basic Â Â Â Â Â Â Â Â Â Â Â Â Net (loss) income per share â€“ basic Â $ (0.30) Â $ 2.56 Â Â $ (0.29) Â $ 1.85 Â Net (loss) income per share attributable to common stockholders â€“ diluted Â Â Â Â Â Â Â Â Â Â Â Â Net (loss) income per share â€“ diluted Â $ (0.30) Â $ 2.46 Â Â $ (0.29) Â $ 1.82 Â Weighted average common shares outstanding â€“ basic and diluted Â Â Â Â Â Â Â Â Â Â Â Â Basic Â Â 48,511,656 Â Â Â 47,837,393 Â Â Â 48,379,256 Â Â Â 47,797,731 Â Diluted Â Â 48,511,656 Â Â Â 49,923,361 Â Â Â 48,379,256 Â Â Â 49,166,251 Â The accompanying notes are an integral part of the financial statements. 2 Table of ContentsÂ SCYNEXIS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Net (loss) income Â $ (14,047) Â $ 88,384 Â Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: Â Â Â Â Â Â Depreciation and amortization Â Â Â â€” Â Â Â 304 Â Stock-based compensation expense Â Â 1,464 Â Â Â 1,435 Â Accretion of investments discount Â Â (621) Â Â 100 Â Amortization of debt issuance costs and discount Â Â 822 Â Â Â 2,256 Â Change in fair value of warrant liabilities Â Â (3,848) Â Â 13,459 Â Change in fair value of derivative liabilities Â Â (196) Â Â 364 Â Noncash operating lease expense for right-of-use asset Â Â 131 Â Â Â 110 Â Write off of deferred asset for commitment fees Â Â Â â€” Â Â Â 514 Â Prepayment fee for loan payable payment Â Â Â â€” Â Â Â 263 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Prepaid expenses, other assets, deferred costs, and other Â Â 4,131 Â Â Â (165) License agreement receivable Â Â 2,230 Â Â Â (25,000) License agreement contract asset Â Â (146) Â Â (19,249) Accounts receivable Â Â Â â€” Â Â Â (243) Inventory Â Â Â â€” Â Â Â (4,563) Accounts payable Â Â (1,759) Â Â (2,521) Accrued expenses Â Â (1,997) Â Â 1,562 Â Deferred revenue Â Â (870) Â Â 4,369 Â Other liabilities and other Â Â (161) Â Â (5,904) Net cash (used in) provided by operating activities Â Â (14,867) Â Â 55,475 Â Cash flows from investing activities: Â Â Â Â Â Â Purchase of investments Â Â (10,719) Â Â (26,941) Maturity of investments Â Â 17,545 Â Â Â 20,557 Â Net cash provided by (used in) investing activities Â Â 6,826 Â Â Â (6,384) Cash flows from financing activities: Â Â Â Â Â Â Proceeds from common stock issued Â Â Â â€” Â Â Â 4 Â Payments of deferred offering costs Â Â (40) Â Â Â â€” Â Payments of loan payable Â Â Â â€” Â Â Â (36,383) Payment of loan payable prepayment fee Â Â Â â€” Â Â Â (263) Proceeds from employee stock purchase plan issuances Â Â 25 Â Â Â 4 Â Repurchase of shares to satisfy tax withholdings Â Â Â â€” Â Â Â 18 Â Net cash used in by financing activities Â Â (15) Â Â (36,620) Net (decrease) increase in cash, cash equivalents, and restricted cash Â Â (8,056) Â Â 12,471 Â Cash, cash equivalents, and restricted cash at beginning of period Â Â 34,593 Â Â Â 46,032 Â Cash, cash equivalents, and restricted cash at end of period Â $ 26,537 Â Â $ 58,503 Â Supplemental cash flow information: Â Â Â Â Â Â Cash paid for interest Â $ 420 Â Â $ 2,828 Â Cash received for interest Â $ 1,721 Â Â $ 1,434 Â Â The accompanying notes are an integral part of the financial statements. 3 Table of ContentsÂ SCYNEXIS, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) 1. Description of Business and Basis of PreparationOrganizationSCYNEXIS, Inc. (â€œSCYNEXISâ€ or the â€œCompanyâ€) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, and is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. The Company is developing its proprietary class of enfumafungin-derived antifungal compounds (â€œfungerps") as broad-spectrum, systemic antifungal agents for multiple fungal indications. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the â€œfungerpâ€ family, including SCY-247, in preclinical stages of development. In June 2021, the U.S. Food and Drug Administration (â€œFDAâ€) approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (â€œVVCâ€), also known as vaginal yeast infection, and in December 2022, the Company announced that the FDA approved a second indication for BREXAFEMME for the reduction in the incidence of recurrent vulvovaginal candidiasis ("RVVC").In March 2023, the Company entered into a license agreement (the "GSK License Agreement") with GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK") in which the Company granted GSK an exclusive (even as to the Company and its affiliates), royalty-bearing, sublicensable license for the development and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications, in all countries other than Greater China and certain other countries already licensed to third parties.Following a review by GSK of the manufacturing process and equipment at the vendor that manufactures the ibrexafungerp drug substance, the Company became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp. Current FDA draft guidance recommends segregating the manufacture of non-antibacterial beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people. In the absence of the recommended segregation, there is a risk of cross contamination. It is not known whether any ibrexafungerp has been contaminated with a beta-lactam compound and the Company has not received reports of any adverse events due to the possible beta-lactam cross contamination. Nonetheless, out of an abundance of caution and in line with GSKâ€™s recommendation, the Company has recalled BREXAFEMMEÂ® (ibrexafungerp tablets) from the market and placed a temporary hold on clinical studies of ibrexafungerp, including the Phase 3 MARIO study.The patient-level and clinical product recall is ongoing and the Company is working with an experienced vendor to manage the process. In September 2023, after the Company announced its voluntary clinical hold, the FDA concurred with the Company's voluntary hold and placed a clinical hold. The Company is working with the FDA to discuss paths for resolution of this issue. The clinical hold and recall affect the Company's two ongoing

clinical studies: the Phase 3 MARIO study and a Phase 1 lactation study. The hold does not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. The FDA determined that the compassionate use program for ibrexafungerp, which provides ibrexafungerp to patients with limited or no other treatment options, can continue provided the patientâ€™s treating physician concludes a favorable benefit-risk assessment and the patient is made aware of and consents to the risk. This applies to patients currently in the program, as well as for new patients, pending confirmation of available supply. The Company's preclinical stage compound, SCY-247, is not affected by these developments. The Company had an accumulated deficit of $369.3 million at June 30, 2024. The Company's capital resources primarily comprised cash and cash equivalents and investments of $83.7 million at June 30, 2024. While the Company believes its capital resources are sufficient to fund the Companyâ€™s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements, the Company's liquidity could be materially affected over this period by: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of SCY-247 and ibrexafungerp; (4) its ability to successfully achieve the development, regulatory, and commercial milestones under its License Agreement with GSK; and (5) any other unanticipated material negative events or costs. One or more of these events or costs could materially affect the Companyâ€™s liquidity. If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.4 Table of ContentsÂ The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany balances and transactions are eliminated in consolidation. Use of EstimatesThe preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and judgments include: revenue recognition including gross to net estimates and the identification of performance obligations in licensing arrangements; estimates for the relative standalone selling price and measure of progress under the input method for the GSK License Agreement; estimates for product recall reserves; determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period.Unaudited Condensed Consolidated Financial InformationThe accompanying unaudited condensed consolidated financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States (â€œUS GAAPâ€), as contained in the Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (the â€œCodificationâ€ or â€œASCâ€) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes set forth in the Companyâ€™s Annual Report on Form 10-K filed with the Securities and Exchange Commission (â€œSECâ€) on March 28, 2024. 2. Summary of Significant Accounting PoliciesThe accompanying unaudited condensed consolidated financial statements and notes follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2023, except as described below.Basic and Diluted Net (Loss) Income per Share of Common StockThe Company calculates net (loss) income per common share in accordance with ASC 260, Earnings Per Share. Basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined by dividing net (loss) income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 includes the outstanding prefunded warrants to purchase 7,516,267 and 3,200,000 shares of common stock issued in the April 2022 public offering and December 2020 public offering. Diluted net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined as follows (in thousands, except share and per share amounts): Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net (loss) income allocated to common shares $ (14,458) Â $ 122,260 Â Â $ (14,047) Â $ 88,384 Â Dilutive effect of convertible debt Â â€” Â Â Â 433 Â Â Â â€” Â Â $ 1,047 Â Net (loss) income allocated to common shares $ (14,458) Â $ 122,693 Â Â $ (14,047) Â $ 89,431 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding â€“ basic Â 48,511,656 Â Â Â 47,837,393 Â Â Â 48,379,256 Â Â Â 47,797,731 Â Dilutive effect of convertible debt Â â€” Â Â Â 1,138,200 Â Â Â â€” Â Â Â 1,138,200 Â Dilutive effect of restricted stock units Â â€” Â Â Â 947,768 Â Â Â â€” Â Â Â 230,320 Â Weighted average common shares outstanding â€“ diluted Â 48,511,656 Â Â Â 49,923,361 Â Â Â 48,379,256 Â Â Â 49,166,251 Â Â Â Â Â Â Â Â Â Â Â Â Net (loss) income per share â€“ diluted $ (0.30) Â $ 2.46 Â Â $ (0.29) Â $ 1.82 Â Â 5 Table of ContentsÂ The following potentially dilutive shares of common stock and outstanding restricted stock units that contain certain performance contingencies have not been included in the computation of diluted net (loss) income per share for the three and six months ended June 30, 2024 and 2023, as the result would be anti-dilutive or the performance contingencies have not been met: Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Outstanding stock options Â 2,842,808 Â Â Â 1,970,536 Â Â Â 2,842,808 Â Â Â 1,970,536 Â Outstanding restricted stock units Â 3,263,345 Â Â Â 400,000 Â Â Â 3,263,345 Â Â Â 400,000 Â Warrants to purchase common stock associated with December 2020 public offering - Series 2 Â â€” Â Â Â 6,800,000 Â Â Â â€” Â Â Â 6,800,000 Â Warrants to purchase common stock associated with April 2022 public offering Â 15,000,000 Â Â Â 15,000,000 Â Â Â 15,000,000 Â Â Â 15,000,000 Â Warrants to purchase common stock associated with Loan Agreement Â 198,811 Â Â Â 198,811 Â Â Â 198,811 Â Â Â 198,811 Â Common stock associated with March 2019 Notes Â 1,138,200 Â Â Â â€” Â Â Â 1,138,200 Â Â Â â€” Â Warrants to purchase common stock associated with Danforth Â 50,000 Â Â Â 50,000 Â Â Â 50,000 Â Â Â 50,000 Â Total Â 22,493,164 Â Â Â 24,419,347 Â Â Â 22,493,164 Â Â Â 24,419,347 Â Reclassification of Prior Year AmountsCertain prior year amounts within the changes in operating assets and liabilities on the unaudited condensed consolidated statement of cash flows and certain prior year accrued expenses have been reclassified for consistency with the current year presentation.Recently Adopted Accounting PronouncementsIn August 2020, the FASB issued ASU No. 2020-06, Debtâ€”Debt with Conversion and Other Options and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity: Accounting for Convertible Instruments and Contracts in Entityâ€™s Own Equity (â€œASU 2020-06â€). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. The Company adopted ASU 2020-06 on January 1, 2024 and the adoption did not materially impact the unaudited condensed consolidated financial statements.Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which introduced new guidance on disclosures for reportable segments and significant segment expenses, including for entities with a single reportable segment. This guidance is effective for the Company for annual reporting periods beginning January 1, 2024 and interim periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which introduced new guidance on disclosures for income taxes, including enhancements to the rate reconciliation and income taxes paid disclosures. This guidance is effective for the Company for annual reporting periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements.Â 3. InvestmentsThe following table summarizes the investments at June 30, 2024 (in thousands):6 Table of ContentsÂ Â Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â Fair Value Â As of June 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities < 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 44,527 Â Â $ 6 Â Â $ (47) Â $ 44,486 Â Agency bonds Â Â 2,517 Â Â Â â€” Â Â Â (2) Â Â 2,515 Â Total short-term investments Â $ 47,044 Â Â $ 6 Â Â $ (49) Â $ 47,001 Â Â Â Â Â Â Â Â Â Â Â Â Maturities > 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 10,657 Â Â $ 10 Â Â $ (23) Â $ 10,644 Â Total investments Â $ 10,657 Â Â $ 10 Â Â $ (23) Â $ 10,644 Â Â Â Â Â Â Â Â Â Â Â Â Â As of December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities < 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 35,286 Â Â $ 25 Â Â $ (13) Â $ 35,298 Â Agency bonds Â Â 5,026 Â Â Â 6 Â Â Â â€” Â Â Â 5,032 Â Total short-term investments Â $ 40,312 Â Â $ 31 Â Â $ (13) Â $ 40,330 Â Â Â Â Â Â Â Â Â Â Â Â Maturities > 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 23,594 Â Â $ 143 Â Â $ (9) Â $ 23,728 Â Total investments Â $ 23,594 Â Â $ 143 Â Â $ (9) Â $ 23,728 Â The Company carries investments at amortized cost. As of June 30, 2024 and December 31, 2023, the fair value of the corporate and agency bonds totals $57.6 million and $64.1 million, respectively, which is determined based on â€œLevel 2â€ inputs, which consist of quoted prices for similar assets in active markets. The Company has evaluated the unrealized loss position in the corporate and agency bonds as of the balance sheet dates and did not consider it to be indicative of an other-than-temporary impairment as the securities are highly-rated and the Company expects to realize the full principal amount at maturity. 4. Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following (in thousands): Â Â June 30, 2024 Â Â December 31, 2023 Â Prepaid research and development services Â $ â€” Â Â $ 196 Â Prepaid insurance Â Â 651 Â Â Â 264 Â Other prepaid expenses Â Â 213 Â Â Â 182 Â Other current assets Â Â 554 Â Â Â 4,906 Â Total prepaid expenses and other current assets Â $ 1,418 Â Â $ 5,548 Â Â 5. Accrued ExpensesAccrued expenses consisted of the following (in thousands):Â Â Â June 30, 2024 Â Â December 31, 2023 Â Accrued research and development expenses Â $ 2,348 Â Â $ 2,830 Â Accrued employee bonus compensation Â Â 906 Â Â Â 1,692 Â Other accrued expenses Â Â 862 Â Â Â 1,040 Â Accrued product recall Â Â 1,382 Â Â Â 1,933 Â Total accrued expenses Â $ 5,498 Â Â $ 7,495 Â Â 7 Table of ContentsÂ Â Â Â Â Â 6. BorrowingsLoan AgreementOn May 13, 2021 (the â€œClosing Dateâ€), the Company entered into the Loan and Security Agreement (the "Loan Agreement") with Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank) (the "Lenders") for an aggregate principal amount of $60.0 million (the â€œTerm Loanâ€). Pursuant to the Loan Agreement, the Term Loan was available to the Company in four tranches, subject to certain terms and conditions. In connection with the entering into of the GSK License Agreement, the Company entered into a First Amendment and Consent to Loan and Security Agreement with the Lenders pursuant to which the Lenders consented to the Company entering into the GSK License Agreement and the Company agreed to pay to the Lenders an amount equal to the sum of (i) all outstanding principal plus all accrued and unpaid interest with respect to the amounts loaned under the Loan Agreement (approximately $35.4 million), (ii) the prepayment fee payable under the Loan Agreement ($262,500), (iii) the final payment payable under the Loan Agreement ($1,382,500), and (iv) all other sums, if any, that shall have become due and payable with respect to loan advances under the Loan Agreement. Upon receipt by the Company of the $90.0 million upfront payment from GSK in May 2023, all amounts payable under the Loan Agreement were fully paid. In connection with the repayment of those amounts due, in May 2023, the Company and the Lenders executed a payoff letter confirming the amounts due under the Loan Agreement, and the Companyâ€™s confirmation that the Loan Agreement was terminated. For the three and six months ended June 30, 2023, the Company recognized $1.7 million and $2.0 million, respectively, in amortization for the remaining debt issuance costs and discount associated with the Loan Agreement which was fully paid in May 2023.March 2019 Note Purchase AgreementOn March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the â€œMarch 2019 Note Purchase Agreementâ€) with Puissance. Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $16.0 million aggregate principal amount of its 6.0% Senior Convertible Notes due 2025 (â€œMarch 2019 Notesâ€), resulting in $14.7 million in net proceeds after deducting $1.3 million for an advisory fee and other issuance costs. As of June 30, 2024 and December 31, 2023, the Companyâ€™s March 2019 Notes consist of the convertible debt balance of $12.8 million and $12.0 million and the bifurcated embedded conversion option derivative liability of zero and $0.2 million, respectively. In connection with the Companyâ€™s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Companyâ€™s balance sheet in accordance with ASC 815, Derivatives and Hedging, at its initial fair value of $7.0 million as the interest make-whole provision is settled in shares of common stock. The convertible debt and derivative liability associated with the March 2019 Notes are presented in total on the accompanying unaudited condensed consolidated balance sheets as the convertible debt and derivative liability. The derivative liability will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the statements of operations in other (income) expense. For the three months ended June 30, 2024 and 2023, the Company recognized gains of $28,000 and $42,000, respectively, on the fair value adjustment for the derivative liability. For the six months ended June 30, 2024 and 2023, the Company recognized a gain of $0.2 million and a loss of $0.4 million, respectively, on the fair value adjustment for the derivative liability. For the three months ended June 30, 2024 and 2023, the Company recognized $0.4 million and $0.3 million, respectively, in amortization of debt issuance costs and discount related to the March 2019 Notes. For the six months ended June 30, 2024 and 2023, the Company recognized $0.8 million and $0.3 million, respectively, in amortization of debt issuance costs and discount related to the March 2019 Notes. The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At June 30, 2024 and December 31, 2023, the fair value of the convertible debt and derivative liability for the March 2019 Notes is $12.8 million and $12.7 million, respectively.The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company.8 Table of ContentsÂ Other Liabilities In February 2021, the Company partnered with Amplity for the commercial launch of BREXAFEMME for the treatment of VVC. Under the terms of the agreement with Amplity, the Company was to utilize Amplityâ€™s commercial execution and resources for sales force, remote engagement, training, market access and select operations services. In October 2022, the Company announced that it was actively pursuing a U.S. commercialization partner to out-license BREXAFEMME in order to refocus the Company's resources on the further clinical development of ibrexafungerp for severe, hospital-based indications. As a result, the Company wound down its promotional activities associated with BREXAFEMME. On November 30, 2022, the Company terminated the agreement with Amplity. Under the terms of the original agreement, Amplity deferred a portion of its direct service fees in the first two years (2021 and 2022) that accrued interest at an annual rate of 12.75% (â€œDeferred Feesâ€). The Deferred Fees of $5.8 million as of December 31, 2022, classified as other liabilities on the consolidated balance sheet, were fully paid as of February 2023. 7. Commitments and ContingenciesLeasesOn March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the â€œLeaseâ€). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of $7.3 million over the lease term. The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years. The security deposit is classified as restricted cash in the accompanying unaudited condensed consolidated balance sheets. The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands):Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost Â $ 166 Â Â $ 166 Â Â $ 332 Â Â $ 332 Â Variable lease cost Â Â 27 Â Â Â 46 Â Â Â 4 Â Â Â 104 Â Total operating lease expense Â $ 193 Â Â $ 212 Â Â $ 336 Â Â $ 436 Â Â Â Â Â Â Â Â Â Â Â Â Cash paid for amounts included in the measurement of operating lease liability Â $ 181 Â Â $ 177 Â Â $ 362 Â Â $ 355 Â June 30, 2024 Â Â December 31, 2023 Â Remaining Lease term (years) Â Â Â Â Â Â Â Â 5.09 Â Â Â 5.59 Â Discount rate Â Â Â Â Â Â Â Â 15 % Â Â 15 % Â Future minimum lease payments for the Lease as of June 30, 2024 are as follows (in thousands): Â Â June 30, 2024 Â 2024 Â $ 368 Â 2025 Â 744 Â 2026 Â 759 Â 2027 Â 774 Â 2028 Â 790 Â Thereafter Â Â 466 Â Total Â $ 3,901 Â Â 9 Table of ContentsÂ The presentations of the operating lease liability as of June 30, 2024 are as follows (in thousands):Â Â Â June 30, 2024 Â Present value of future minimum lease

payments Â $ 2,760 Â Â Â Â Operating lease liability, current portion Â $ 372 Â Operating lease liability, long-term portion Â Â 2,388 Â Total operating lease liability Â $ 2,760 Â Â Â Â Difference between future minimum lease payments and discounted cash flows Â $ 1,141 Â License Arrangement with Potential Future ExpendituresAs of June 30, 2024, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health. In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company. Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total $19.0 million upon occurrence of specific events, including initiation of a Phase 2 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits.In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the â€œDeferred Milestoneâ€). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound. In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment. In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck. The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of an NDA, triggered by the FDA acceptance for filing of the Companyâ€™s NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S. Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck. All other key terms of the license agreement are unchanged.Legal ProceedingsOn November 7, 2023, a securities class action was filed by Brian Feldman against the Company and certain of the Company's executives in the United States District Court, District of New Jersey, alleging that, during the period from March 31, 2023 to September 22, 2023, the Company made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects, alleging specifically that the Company failed to disclose to investors: (1) that the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination; (2) that the Company did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP); (3) that, due to the substantial risk of cross-contamination, the Company were reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies; and (4) as a result of the foregoing, the Company's statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis. The complaint seeks unspecified damages, interest, fees and costs on behalf of all persons and entities who purchased and/or acquired shares of the Company's common stock between March 31, 2023 to September 22, 2023. On May 1, 2024, and again on June 4, 2024, purported shareholder derivative complaints were filed in the United States District Court, District of New Jersey. The complaints name the Companyâ€™s directors and certain of its officers and assert state and federal claims based on the same alleged misstatements as the securities class action complaint. We disagree with the allegations and intend to defend these litigations vigorously and the Company has not recognized any expense for these contingencies. 8. Stockholdersâ€™ EquityAuthorized, Issued, and Outstanding Common Stock10 Table of ContentsÂ The Companyâ€™s authorized common stock has a par value of $0.001 per share and consists of 150,000,000 shares as of June 30, 2024, and December 31, 2023; 37,856,463 and 37,207,799 shares were issued and outstanding at June 30, 2024 and December 31, 2023, respectively. For the three and six months ended June 30, 2023, 3,787,400 and 4,150,400 of the prefunded warrants from the April 2022 public offering were exercised for total proceeds of $3,787 and $4,150, respectively. The following table summarizes common stock share activity for the three and six months ended June 30, 2024 and 2023 (dollars in thousands): Â Â Three Months Ended June 30, 2024 Â Â Â Shares ofCommon Stock Â Â CommonStock Â Â Additional Paid-in Capital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™ Equity Â Balance, March 31, 2024 Â Â 37,779,796 Â Â $ 41 Â Â $ 428,900 Â Â $ (354,836) Â $ 74,105 Â Net loss Â Â â€” Â Â Â â€” Â Â Â (14,458) Â Â (14,458) Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 759 Â Â Â â€” Â Â Â 759 Â Common stock issued for vested restricted stock units Â Â 76,667 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Balance, June 30, 2024 Â Â 37,856,463 Â Â $ 41 Â Â $ 429,659 Â Â $ (369,294) Â $ 60,406 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended June 30, 2023 Â Â Â Shares ofCommon Stock Â Â CommonStock Â Â Additional Paid-in Capital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™(Deficit) Equity Â Balance, March 31, 2023 Â Â 33,327,627 Â Â $ 36 Â Â $ 426,214 Â Â $ (456,164) Â $ (29,914) Net income Â Â â€” Â Â Â â€” Â Â Â 122,260 Â Â Â 122,260 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 728 Â Â Â â€” Â Â Â 728 Â Common stock issued, net of expenses Â Â 3,787,400 Â Â Â 4 Â Â Â â€” Â Â Â 4 Â Common stock issued for vested restricted stock units Â Â 60,638 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Balance, June 30, 2023 Â Â 37,175,665 Â Â $ 40 Â Â $ 426,942 Â Â $ (333,904) Â $ 93,078 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Six Months Ended June 30, 2024 Â Â Â Shares ofCommon Stock Â Â CommonStock Â Â Additional Paid-in Capital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™Equity Â Balance, December 31, 2023 Â Â 37,207,799 Â Â $ 40 Â Â $ 428,169 Â Â $ (355,247) Â $ 72,962 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (14,047) Â Â (14,047) Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 1,464 Â Â Â â€” Â Â Â 1,464 Â Common stock issued through employee stock purchase plan Â Â 18,815 Â Â Â â€” Â Â Â 26 Â Â Â â€” Â Â Â 26 Â Common stock issued for vested restricted stock units Â Â 629,849 Â Â Â 1 Â Â Â â€” Â Â Â â€” Â Â Â 1 Â Balance, June 30, 2024 Â Â 37,856,463 Â Â $ 41 Â Â $ 429,659 Â Â $ (369,294) Â $ 60,406 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Six Months Ended June 30, 2023 Â Â Â Shares ofCommon Stock Â Â CommonStock Â Â Additional Paid-in Capital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™Equity Â Balance, December 31, 2022 Â Â 32,682,342 Â Â $ 36 Â Â $ 425,485 Â Â $ (422,288) Â $ 3,233 Â Net income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 88,384 Â Â Â 88,384 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 1,435 Â Â Â â€” Â Â Â 1,435 Â Common stock issued through employee stock purchase plan Â Â 2,662 Â Â Â â€” Â Â Â 4 Â Â Â â€” Â Â Â 4 Â Common stock issued, net of expenses Â Â 4,150,400 Â Â Â 4 Â Â Â â€” Â Â Â â€” Â Â Â 4 Â Common stock issued for vested restricted stock units Â Â 340,261 Â Â Â â€” Â Â Â 18 Â Â Â â€” Â Â Â 18 Â Balance, June 30, 2023 Â Â 37,175,665 Â Â $ 40 Â Â $ 426,942 Â Â $ (333,904) Â $ 93,078 Â Â 11 Table of ContentsÂ Shares Reserved for Future IssuanceThe Company had reserved shares of common stock for future issuance as follows:Â Â Â June 30, 2024 Â Â December 31, 2023 Â Outstanding stock options Â Â 2,842,808 Â Â Â 1,867,795 Â Outstanding restricted stock units Â Â 3,263,345 Â Â Â 1,886,374 Â Warrants to purchase common stock associated with December 2020 public offering - Series 2 Â Â â€” Â Â Â 6,800,000 Â Prefunded warrants to purchase common stock associated with December 2020 public offering Â Â 3,200,000 Â Â Â 3,200,000 Â Warrants to purchase common stock associated with April 2022 public offering Â Â 15,000,000 Â Â Â 15,000,000 Â Prefunded warrants to purchase common stock associated with April 2022 public offering Â Â 7,516,267 Â Â Â 7,516,267 Â Warrants to purchase common stock associated with Loan Agreement Â Â 198,811 Â Â Â 198,811 Â Warrant to purchase common stock associated with Danforth Â Â 50,000 Â Â Â 50,000 Â For possible future issuance for the conversion of the March 2019 Notes Â Â 1,138,200 Â Â Â 1,138,200 Â For possible future issuance under 2024 Plan (Note 9) Â Â 5,874,196 Â Â Â 848,202 Â For possible future issuance under employee stock purchase plan Â Â 1,458,171 Â Â Â 1,474,045 Â For possible future issuance under 2015 Plan (Note 9) Â Â 637,050 Â Â Â 633,590 Â Total common shares reserved for future issuance Â Â 41,178,848 Â Â Â 40,613,284 Â Warrants Associated with the December 2020 and April 2022 Public OfferingsThe outstanding warrants associated with the December 2020 public offering contains a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying unaudited condensed consolidated statements of operations. The outstanding warrants associated with the April 2022 public offering meet the definition of a derivative pursuant to ASC 815, Derivatives and Hedging, and do not meet the derivative scope exception given the warrants do not qualify under the indexation guidance. As a result, the April 2022 public offering warrants were initially recognized as liabilities and measured at fair value using the Black-Scholes valuation model. For the three months ended June 30, 2024 and 2023, the Company recognized a loss of $5.8 million and a gain of $8.2 million, respectively, and for the six months ended June 30, 2024 and 2023, recognized a gain of $3.8 million and a loss of $13.5 million, respectively, on the warrant liabilities fair value adjustment. As of June 30, 2024 and December 31, 2023, the fair value of the warrant liabilities was $18.0 million and $21.8 million, respectively. 9. Stock-based CompensationPursuant to the terms of the Companyâ€™s 2014 Equity Incentive Plan (â€œ2014 Planâ€), on January 1, 2024 and 2023, the Company automatically added 1,916,962 and 1,901,960 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. 2024 Equity Incentive PlanIn April 2024, the Companyâ€™s board of directors adopted the 2024 Equity Incentive Plan (â€œ2024 Planâ€), which was subsequently approved by the Companyâ€™s stockholders and became effective on June 19, 2024. The 2024 Plan is the successor to the 2014 Plan. The 2014 Plan terminated on February 11, 2024 and no new grants may be made under the 2014 Plan after that date, although all outstanding awards granted under the 2014 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such awards and the terms of the 2014 Plan. The purpose of the 2024 Plan is to allow the Company to utilize equity incentives in order to secure and retain the services of the Company's employees, directors, and consultants, and to provide long-term incentives that align the interests of the Company's employees, directors, and consultants with the interests of the Company's stockholders.The aggregate number of shares of the Company's common stock that may be issued under the 2024 Plan will not exceed the sum of (i) 6,150,000 new shares, plus (ii) certain shares subject to outstanding awards granted under the 2014 Plan that may become available for grant under the 2024 Plan as such shares become available from time to time. As of June 30, 2024, there were 5,874,196 shares of common stock available for future issuance under the 2024 Plan.12 Table of ContentsÂ 2015 Inducement Award PlanAs of June 30, 2024, there were 637,050 shares of common stock available for future issuance under the Companyâ€™s 2015 Inducement Award Plan (â€œ2015 Planâ€). During both the six months ended June 30, 2024 and 2023, there were options to purchase zero shares of the Companyâ€™s common stock granted under the 2015 Plan.The activity for the Companyâ€™s 2024 Plan, 2014 Plan, and 2015 Plan, for the six months ended June 30, 2024, is summarized as follows:Â Â Â Number ofShares Â Â Weighted-AverageExercisePrice Â Â WeightedAverageRemainingContractualLife (in years) Â Â AggregateIntrinsicValue ($000) Â Outstanding â€” December 31, 2023 Â Â 1,867,795 Â Â $ 10.72 Â Â Â 6.10 Â Â $ 184 Â Granted Â Â 1,000,060 Â Â $ 1.86 Â Â Â Â Â Â Â Â Forfeited/Cancelled Â Â (25,047) Â $ 36.36 Â Â Â Â Â Â Â Â Outstanding â€” June 30, 2024 Â Â 2,842,808 Â Â $ 7.38 Â Â Â 7.04 Â Â $ 254 Â Exercisable â€” June 30, 2024 Â Â 1,545,764 Â Â $ 11.78 Â Â Â 5.22 Â Â $ 59 Â Vested or expected to vest â€” June 30, 2024 Â Â 2,842,808 Â Â $ 7.38 Â Â Â 7.04 Â Â $ 254 Â Restricted stock unit (â€œRSUâ€) activity under the 2024 Plan, 2014 Plan, and 2015 Plan for the six months ended June 30, 2024, is summarized as follows: Â Â Number of Shares Â Â WeightedAverageGrant DateFair ValuePer Share Â Non-vested at December 31, 2023 Â Â 1,886,374 Â Â $ 2.28 Â Granted Â Â 2,015,940 Â Â $ 1.88 Â Vested Â Â (629,849) Â $ 3.00 Â Forfeited Â Â (9,120) Â $ 2.15 Â Non-vested at June 30, 2024 Â Â 3,263,345 Â Â $ 1.89 Â The fair value of RSUs is based on the market price of the Companyâ€™s common stock on the date of grant. RSUs generally vest 33% annually over a three-year period from the date of grant. Upon vesting, the RSUs generally are net share settled to cover the required withholding tax with the remaining shares issued to the holder. The Company recognizes compensation expense for such awards ratably over the corresponding vesting period.Compensation CostThe compensation cost that has been charged against income for stock awards was $0.8 million and $0.7 million for the three months ended June 30, 2024 and 2023, and was $1.5 million and $1.4 million for the six months ended June 30, 2024 and 2023, respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was zero for each of the three and six months ended June 30, 2024 and 2023.Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): Â Â Â Three Months Ended June 30, Â Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 216 Â Â $ 301 Â Â $ 411 Â Â $ 675 Â Selling, general and administrative Â Â 543 Â Â Â 427 Â Â Â 1,053 Â Â Â 760 Â Total Â $ 759 Â Â $ 728 Â Â $ 1,464 Â Â $ 1,435 Â Â 13 Table of ContentsÂ 10. Fair Value MeasurementsThe carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, investments, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments.Assets and Liabilities Measured at Fair Value on a Recurring BasisThe Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of June 30, 2024 and December 31, 2023 for financial instruments measured at fair value on a recurring basis (in thousands): Â Â Â Â Â Fair Value Hierarchy Classification Â Â Â Balance Â Â QuotedPrices inActiveMarkets forIdenticalAssets(Level 1) Â Â SignificantOtherObservableInputs(Level 2) Â Â SignificantUnobservableInputs (Level 3) Â June 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Cash Â $ 1,364 Â Â $ 1,364 Â Â Â Â â€” Â Â Â â€” Â Restricted cash Â Â 543 Â Â Â 543 Â Â Â â€” Â Â Â â€” Â Money market funds Â Â 24,630 Â Â Â 24,630 Â Â Â â€” Â Â Â â€” Â Total assets Â $ 26,537 Â Â $ 26,537 Â Â Â â€” Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Warrant liabilities Â $ 17,962 Â Â Â â€” Â Â Â $ 17,962 Â Total liabilities Â $ 17,962 Â Â Â Â â€” Â Â Â â€” Â Â Â $ 17,962 Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Cash Â $ 767 Â Â $ 767 Â Â Â â€” Â Â Â â€” Â Restricted cash Â Â 543 Â Â Â 543 Â Â Â â€” Â Â Â â€” Â Money market funds Â Â 33,283 Â Â Â 33,283 Â Â Â â€” Â Â Â â€” Â Total assets Â $ 34,593 Â Â Â $ 34,593 Â Â Â â€” Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Warrant liabilities Â $ 21,810 Â Â Â â€” Â Â Â â€” Â Â Â $ 21,810 Â Derivative liability Â Â 196 Â Â Â â€” Â Â Â â€” Â Â Â 196 Â Total liabilities Â $ 22,006 Â Â Â â€” Â Â Â â€” Â Â Â $ 22,006 Â The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on â€œLevel 1â€ inputs, which consist of quoted prices in active markets for identical assets. As of June 30, 2024, the cash and cash equivalents of $26.0 million and the restricted cash balances of $0.4 million and $0.2 million within short and long term on the unaudited condensed consolidated balance sheet, respectively, sum to the total of $26.5 million as shown in the unaudited condensed consolidated statement of cash flows.Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Companyâ€™s stock price, contractual terms, maturity, risk free rates, as well as volatility. The unobservable input for all of the Level 3 warrant liabilities includes volatility. The historical and implied volatility of the Company, using its closing common stock prices and market data, is utilized to reflect future volatility over the expected term of the warrants. At June 30, 2024, the Level 3 volatility utilized in the Black-Scholes model to fair value the warrant liability was 86.6%.The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Companyâ€™s stock price, contractual terms, dividend yield, risk-free rate, adjusted equity volatility, credit rating, market credit spread, and estimated effective yield. The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield. As of June 30, 2024, these inputs were 71.8%, 1,477 basis points, and 20.0%, respectively. The senior 14 Table of ContentsÂ convertible notes are initially fair valued using the binomial lattice model and with the straight debt fair value calculated using the discounted cash flow method. The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Â Â Â Warrant Liabilities Â Balance â€” December 31, 2023 Â Â $ 21,810 Â Gain adjustment to fair value Â Â Â (3,848) Balance â€” June 30, 2024 Â Â $ 17,962 Â Â Â Â Â Â Â Â Â Derivative Liability Â Balance â€” December 31, 2023 Â Â $ 196 Â Gain adjustment to fair value Â Â Â (196) Balance â€” June 30, 2024 Â Â $ â€” Â Â 11. RevenueProduct Revenue, NetNet product revenue was zero and $0.5 million for the three months ended June 30, 2024 and 2023,

respectively, and zero and $1.6 million for the six months ended June 30, 2024 and 2023, respectively. Products are sold primarily to wholesalers and specialty pharmacies. Revenue is reduced from wholesaler list price at the time of recognition for expected chargebacks, rebates, discounts, incentives, and returns, which are referred to as gross to net (â€œGTNâ€) adjustments. These reductions are currently attributed to various commercial arrangements. Chargebacks and discounts are recognized as a reduction in accounts receivable or as accrued expenses based on their nature and settled through the issuance of credits to the customer or through cash payments to the customer, respectively. All other returns, rebates, and incentives are reflected as accrued expenses and settled through cash payments to the customer. Revenue attributed to sales to three wholesalers comprised 46%, 26%, and 25% of the Companyâ€™s gross revenue for the six months ended June 30, 2023.Â The following table summarizes activity in each of the Companyâ€™s product revenue provision and allowance categories as of June 30, 2024 and 2023 (in thousands):Â Â Â Discounts and Chargebacks (1) Â Â Product Returns (2) Â Â Rebates and Incentives (3) Â Â Product Recall (4) Â Â Total Â Balance as of December 31, 2023 Â $ â€” Â Â $ 36 Â Â $ 89 Â Â $ 1,932 Â Â $ 2,057 Â Provision related to current period revenue Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Changes in estimate related to prior period revenue Â Â â€” Â Â Â 51 Â Â Â (26) Â Â Â â€” Â Â Â 25 Â Credit/payments Â Â â€” Â Â Â â€” Â Â Â (39) Â Â (550) Â Â (589) Balance as of June 30, 2024 Â $ â€” Â Â $ 87 Â Â $ 24 Â Â $ 1,382 Â Â $ 1,493 Â Discounts and Chargebacks (1) Â Â Product Returns (2) Â Â Rebates and Incentives (3) Â Â Product Recall (4) Â Â Total Â Balance as of December 31, 2022 Â $ 255 Â Â $ 73 Â Â $ 1,213 Â Â $ â€” Â Â $ 1,541 Â Provision related to current period revenue Â Â 773 Â Â Â 316 Â Â Â 2,054 Â Â Â â€” Â Â Â 3,143 Â Changes in estimate related to prior period revenue Â Â â€” Â Â Â 693 Â Â Â â€” Â Â Â â€” Â Â Â 693 Â Credit/payments Â Â (708) Â Â (74) Â Â (1,347) Â Â â€” Â Â Â (2,129) Balance as of June 30, 2023 Â $ 320 Â Â $ 1,008 Â Â $ 1,920 Â Â $ â€” Â Â $ 3,248 Â Â (1)Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Companyâ€™s unaudited condensed consolidated balance sheet.15 Table of ContentsÂ (2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Companyâ€™s unaudited condensed consolidated balance sheet.(3)Rebates and incentives include rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Companyâ€™s unaudited condensed consolidated balance sheets.(4)Provisions for product recall are deducted from gross revenues to the extent of revenue recorded related to the recalled product and are included in accrued expenses on the Companyâ€™s unaudited condensed consolidated balance sheet.License Agreement with GSKOn March 30, 2023, the Company entered into the GSK License Agreement. Pursuant to the terms of the GSK License Agreement, the Company granted GSK an exclusive (even as to the Company and its affiliates), royalty-bearing, sublicensable license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the â€œGSK Territoryâ€). If the existing licenses granted to or agreements with third parties are terminated with respect to any country, GSK will have an exclusive first right to negotiate with the Company to add those additional countries to the GSK Territory. The parties closed the transactions contemplated by the GSK License Agreement in May 2023.As previously disclosed, the Company became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp. Current FDA draft guidance recommends segregating the manufacture of non-antibacterial beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people. In the absence of the recommended segregation, there is a risk of cross contamination. It is not known whether any ibrexafungerp has been contaminated with a beta-lactam compound. Nonetheless, in light of this risk and out of an abundance of caution, BREXAFEMME (ibrexafungerp tablets) was recalled from the market and clinical studies of ibrexafungerp were placed on temporary hold. On December 26, 2023, the Company and GSK entered into a binding memorandum of understanding ("Binding MOU") for amendment to the GSK License Agreement. The GSK License Agreement was amended in connection with the delay in the commercialization of BREXAFEMME and further clinical development of ibrexafungerp associated with this event. Under the terms of the updated GSK License Agreement, as amended by Binding MOU, the Company is now eligible to receive potential: â€¢regulatory approval milestone payments of up to $49 million (revised from up to $70 million as provided in the GSK License Agreement);â€¢commercial milestone payments of up to $57.5 million based on first commercial sale in invasive candidiasis (U.S./EU) (revised from up to $115 million as provided in the GSK License Agreement); andâ€¢and sales milestone payments of up to $179.5 / $169.75 / $145.5 million (depending on the date of GSKâ€™s relaunch of BREXAFEMME in the U.S.) (revised from up to $242.5 million as provided in the GSK License Agreement). These milestones are based on annual net sales in the GSK Territory, with a total of $64 / $54.25 / $46.5 million to be paid upon achievement of multiple sales thresholds up through $200 million; a total of $45.5 / $45.5 / $39 million to be paid upon achievement of multiple sales thresholds between $300 million and $500 million; and $35 / $35 / $30 million to be paid at each sales threshold of $750 million and $1 billion.The Company will continue to be responsible for the execution and costs of the ongoing clinical studies of ibrexafungerp but will have the potential to receive up to $72.35 million in development milestones (revised from up to $75.5 million as provided in the GSK License Agreement), which comprise: $25 million already paid; $10 million for the delivery to GSK of final clinical study reports for the completed FURI, CARES, and NATURE clinical studies; up to $30 million for the achievement of two interim milestones associated with the Company's resumption and continued performance of the MARIO Study after the clinical hold is lifted; and $7.35 million for the successful completion of the MARIO Study. In the case of each of the above milestones, such milestone events are defined in the GSK License Agreement, as amended by the Binding MOU. In July 2024, the Company delivered to GSK the final clinical study reports for the completed FURI, CARES, and NATURE clinical studies and the Company expects to collect the $10.0 million development milestone in the third quarter of 2024. GSK will also pay royalties based on cumulative annual sales to us in the mid-single digit to mid-teen range. The royalty terms are not amended by the Binding MOU.The Company evaluated the GSK License Agreement in accordance with ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The Company assessed the terms of the GSK License Agreement and identified the following performance obligations which include: (1) the license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME, in the 16 Table of ContentsÂ GSK Territory, (2) the research and development activities for the MARIO study, and (3) performance obligations for the remaining research and development activities for the ongoing clinical and preclinical studies of ibrexafungerp. The Company provided all necessary information to GSK for it to benefit from the license under the license term in 2023 when the Company transferred the license.As of June 30, 2024, the Company maintains a $19.5 million contract asset associated with the success-based milestones associated with the ongoing clinical studies of ibrexafungerp. The Company believes that the $19.5 million contract asset is collectible given the Company's probability assessment of achieving the milestones as defined in the GSK License Agreement, ongoing development activities, and other information available to the Company. The Company reassessed the transaction price as of June 30, 2024, including estimated variable consideration included in the transaction price and the remaining milestones continued to be constrained.The Company recognizes the revenue associated with the MARIO study and the remaining ongoing clinical and preclinical studies of ibrexafungerp over time using an input method. The input method is based on the actual costs incurred as a percentage of total budgeted costs towards satisfying the performance obligation as this method provides the most faithful depiction of the Companyâ€™s performance in transferring control of the services promised to GSK and represents the Companyâ€™s best estimate of the period of the obligation. As of June 30, 2023, the Company provided all necessary information to GSK for it to benefit from the license under the license term. Accordingly, for the three months and six months ended June 30, 2023, the Company recognized $130.1 million in license revenue at a point in time upon the transfer of the license to GSK and completion of the initial technology transfer. For the three months ended June 30, 2024 and 2023, the Company recognized $0.7 million and $131.0 million of license agreement revenue, respectively, and for the six months ended June 30, 2024 and 2023, the Company recognized $2.1 million and $131.0 million, respectively. As of June 30, 2024, there is $1.2 million and $1.8 million of current and long-term deferred revenue, respectively, which is expected to be recognized by the end of 2025. License Agreement with HansohIn February 2021, the Company entered into an Exclusive License and Collaboration Agreement (the â€œHansoh Agreementâ€) with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, â€œHansohâ€), pursuant to which the Company granted to Hansoh an exclusive license to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan (the â€œTerritoryâ€). The Company also granted to Hansoh a non-exclusive license to manufacture ibrexafungerp solely for development and commercialization in the Territory. For the three and six months ended June 30, 2024 and 2023, there was no license agreement revenue recognized associated with the Hansoh Agreement given the variable consideration was fully constrained as of June 30, 2024 and 2023, respectively. Â 17 Table of ContentsÂ Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. Operating results for the three and six months ended June 30, 2024, are not necessarily indicative of results that may occur in future interim periods or future fiscal years. Some of the statements in this â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ are forward-looking statements. These forward-looking statements are based on managementâ€™s beliefs and assumptions and on information currently available to our management and involve significant elements of subjective judgment and analysis. Words such as â€œexpects,â€ â€œwill,â€ â€œanticipate,â€ â€œtarget,â€ â€œgoal,â€ â€œintend,â€ â€œplan,â€ â€œseek,â€ â€œestimate,â€ â€œpotential,â€ â€œshould,â€ â€œcould,â€ variations of such words, and similar expressions are intended to identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed under the heading â€œRisk Factorsâ€ in Item 1A of Part I of our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 28, 2024, and in Part II, Item 1A of this Quarterly Report on Form 10-Q. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this Quarterly Report on Form 10-Q. In addition, statements that â€œwe believeâ€ and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely on these statements. Overview SCYNEXIS, Inc. is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. We are developing our proprietary antifungal platform â€œfungerpsâ€, a novel class of antifungal agents called triterpenoids, that are a structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and in vivo activity against most common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals. In June 2021 and December 2022, we announced that the United States (U.S.) Food and Drug Administration (FDA) approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively. Oral ibrexafungerp is also under development for other systemic fungal diseases. SCY-247, a second-generation antifungal compound from this novel class, is in preclinical development stage. We anticipate initiating a Phase 1 study for SCY-247 in the fourth quarter of 2024. The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to ibrexafungerp for the indications of VVC (including the prevention of recurrent VVC), invasive candidiasis (IC) (including candidemia), and invasive aspergillosis (IA), and has granted Orphan Drug designations for the IC and IA indications. The European Medicines Agency has granted Orphan Medicinal Product designation to ibrexafungerp for IC. We anticipate that the FDA may grant QIDP and Fast Track designations for the IV and oral formulations of SCY-247. These designations may provide us with additional market exclusivity and expedited regulatory paths. In March 2023, we entered into a license agreement (the GSK License Agreement) with GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) in which we granted GSK an exclusive (even as to us and our affiliates), royalty-bearing, sublicensable license for the development and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications, in all countries other than Greater China and certain other countries already licensed to third parties. In July 2024, we delivered to GSK the final clinical study reports for the completed FURI, CARES, and NATURE clinical studies and we expect to collect a $10.0 million development milestone in the third quarter of 2024. As of June 30, 2024, we have received $115.0 million in upfront and development milestones under the GSK License Agreement. See further details of the GSK License Agreement, including financial terms, as described in Note 11 of Item 1 on this Quarterly Report on Form 10-Q. Product Recall and Clinical Hold Following a review by GSK of the manufacturing process and equipment at the vendor that manufactures the ibrexafungerp drug substance, we became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp. Current FDA draft guidance recommends segregating the manufacture of non-antibacterial beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people. In the absence of the recommended segregation, there is a risk of cross contamination. It is not known whether any ibrexafungerp has been 18 Table of ContentsÂ contaminated with a beta-lactam compound and we have not received any reports of adverse events due to the possible beta-lactam cross contamination. Nonetheless, out of an abundance of caution and in line with GSKâ€™s recommendation, we have recalled BREXAFEMME (ibrexafungerp tablets) from the market and placed a temporary hold on clinical studies of ibrexafungerp, including the Phase 3 MARIO study. The patient-level and clinical product recall is ongoing and we are working with an experienced vendor to manage the process. In September 2023, after we announced our voluntary clinical hold, the FDA concurred with our voluntary hold and placed a clinical hold. We are working with the FDA to discuss paths for resolution of this issue. The clinical hold and recall affected two ongoing clinical studies: the Phase 3 MARIO study and a Phase 1 lactation study. The clinical hold does not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. The NATURE study, which is an observational study in patients with IC treated with standard of care antifungals (not ibrexafungerp), is also not affected by this hold. The FDA determined that the compassionate use program for ibrexafungerp, which provides ibrexafungerp to patients with limited or no other treatment options, can continue provided the patientâ€™s treating physician concludes a favorable benefit-risk assessment and the patient is made aware of and consents to the risk. This applies to patients currently in the program as well as for new patients, pending confirmation of available supply. Our preclinical stage compound, SCY-247, is not affected by these developments. In response to the hold on clinical studies of ibrexafungerp by the FDA due to possible beta-lactam cross contamination, we have entered into certain new manufacturing agreements with third-party contract manufacturers to begin producing new batches of ibrexafungerp which we believe will allow us to lift the clinical hold and restart our impacted clinical studies, the Phase 3 MARIO study and a Phase 1 lactation study. Legal Proceedings On November 7, 2023, a securities class action was filed by Brian Feldman against us and certain of our executives in the United States District Court, District of New Jersey, alleging that, during the period from March 31, 2023 to September 22, 2023, we made materially false and/or misleading statements, as well as failed to disclose material adverse facts about our business, operations, and prospects, alleging specifically that we failed to disclose to investors: (1) that the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination; (2) that we did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP); (3) that, due to the substantial risk of cross-contamination, we were reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies; and (4) as a result of the foregoing, our statements about our business, operations, and prospects were materially misleading and/or lacked a reasonable basis. The complaint seeks unspecified damages, interest, fees and costs on behalf of all persons and entities who purchased and/or acquired shares of our common stock between March 31, 2023 to September 22, 2023. On May 1, 2024, and again on June 4, 2024, purported shareholder derivative complaints were filed in the United States District Court, District of New Jersey. The complaints name our directors and certain of our officers and assert state and federal claims based on the same alleged misstatements as the securities class action complaint. We disagree with the allegations and intend to defend these litigations vigorously. Repaid Loan Agreement We, Hercules Capital, Inc. (Hercules Capital) and Silicon Valley Bridge Bank, N.A. (now a division of First Citizens Bank, SVB) were parties to a Loan and Security Agreement dated as of May 13, 2021 (the Loan Agreement), pursuant to which Hercules Capital, SVB and each of the other lenders from time-to-time party to the Loan Agreement (collectively, the Lenders) loaned to us $35 million. In connection with the entering into of the License Agreement, we entered into a First Amendment and Consent to Loan and Security Agreement with the Lenders pursuant to which the Lenders consented to us entering into the License Agreement and we agreed to pay to the Lenders an amount equal to the sum of (i) all outstanding principal plus all accrued and unpaid interest with respect to the amounts loaned under the Loan Agreement (approximately $35.4

million), (ii) the prepayment fee payable under Loan Agreement ($262,500), (iii) the final payment payable under Loan Agreement ($1,382,500), and (iv) all other sums, if any, that shall have become due and payable with respect to loan advances under the Loan Agreement. These payments became due upon the earliest of (A) one business day following receipt by us of the $90 million upfront payment payable to us under the License Agreement, (B) June 1, 2023, or (C) the termination of the License Agreement. Following the closing of the transactions under the License Agreement, in May 2023, we received the upfront payment pursuant to the terms of the License Agreement, which triggered the obligation of us to repay the amounts due under the terms of the First Amendment. In connection with the repayment of those amounts due, in May 2023, we and the Lenders executed a payoff letter confirming the amounts due under the First Amendment, and our confirmation that the Loan Agreement, as amended by the First Amendment, was terminated. 19 Table of ContentsÂ Liquidity We have operated as a public entity since we completed our initial public offering in May 2014, which we refer to as our IPO. We also completed a follow-on public offering of our common stock in April 2015 and public offerings of our common stock and warrants in June 2016, March 2018, December 2019, December 2020, and April 2022. Our principal source of liquidity is cash, cash equivalents, and investments which totaled $83.7 million as of June 30, 2024. As of June 30, 2024, our accumulated deficit was $369.3 million. We expect we will continue to incur significant research and development expense as we continue to execute our research and drug development strategy. Consistent with our operating plan, we also expect that we will continue to incur significant selling, general and administrative expenses to support our public reporting company operations and ongoing operations. As a result, we will need additional capital to fund our operations, which we may obtain through one or more of equity offerings, debt financings, other non-dilutive third-party funding (e.g., grants), strategic alliances and licensing or collaboration arrangements. We may offer shares of our common stock pursuant to our effective shelf registration statements. Collaborations and Licensing Agreements We are party to a number of licensing and collaboration agreements with partners in human health, including: (1) GSK, a pharmaceutical company, which we exclusively (even as to us and our affiliates) provide a, royalty-bearing, sublicensable license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications, in the GSK Territory; (2) Merck, a pharmaceutical company, under which we exclusively licensed the rights to ibrexafungerp in the field of human health, and agreed to pay Merck milestones upon the occurrence of specified events as well as tiered royalties based on worldwide sales of ibrexafungerp when and if it is approved (in 2014, Merck assigned to us the patents related to ibrexafungerp that it had exclusively licensed to us and, as contemplated by the agreement, we will continue to pay milestones and royalties); (3) Hansoh, a pharmaceutical company, which we exclusively provide a license from us to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan, under which we are entitled to receive development and commercial milestones and royalties (4) R-Pharm, CJSC, or "R-Pharm," a leading supplier of hospital drugs in Russia, granting it exclusive rights in the field of human health to develop and commercialize ibrexafungerp in Russia and several non-core markets, under which we are entitled to receive potential milestones and royalties and reimbursement for certain development costs incurred by us (this agreement is not material to our unaudited condensed consolidated balance sheets, statements of operations, or statements of cash flows); (5) Waterstone, an international pharmaceutical business, granting Waterstone exclusive worldwide rights to development and commercialization of SCY-635 for the treatment of viral diseases in humans, under which we are entitled to receive potential milestones and royalties; and (6) Cypralis Limited, or "Cypralis," a life sciences company, transferring to it certain cyclophilin inhibitor assets of ours, under which we are eligible to receive milestone payments upon the successful progression of certain Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. Components of Operating Results Revenue Revenue consists of license agreement revenue associated with GSK and product sales of BREXAFEMME. For the three and six months ended June 30, 2023, our product revenue, net comprised of sales of BREXAFEMME that we sold as principal given we control BREXAFEMME product until delivery to our wholesalers at which point control is transferred. Cost of Product Revenue Cost of product revenue consists primarily of distribution, freight expenses, royalties due to Merck, and other manufacturing costs associated with BREXAFEMME. Research and Development Expense Research and development expense consists of expenses incurred while performing research and development activities to discover, develop, or improve potential product candidates we seek to develop. This includes conducting preclinical studies and clinical trials, manufacturing and other development efforts, and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily consists of: â€¢costs related to executing preclinical and clinical trials, including development milestones, drug formulation, manufacturing and other development; â€¢salaries and personnel-related costs, including benefits and any stock-based compensation, for personnel in research and development functions; 20 Table of ContentsÂ â€¢fees paid to consultants and other third parties who support our product candidate development and intellectual property protection; â€¢medical affairs related expense and salary that is incurred to discover, develop, or improve potential product candidates; â€¢other costs in seeking regulatory approval of our products; and â€¢allocated overhead. Ibrexafungerp and SCY-247 were the only key research and development project during the periods presented. We expect to continue to incur significant research and development expense for the foreseeable future as we continue our effort to develop ibrexafungerp and SCY-247, and to potentially develop our other product candidates, subject to the availability of additional funding. The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates. Selling, General and Administrative Expense Selling, general and administrative expense consists primarily of salaries and personnel-related costs, including employee benefits and any stock-based compensation. This includes personnel in executive, finance, human resources, business development, medical affairs, marketing and commercial, and administrative support functions. Other expenses include facility-related costs not otherwise allocated to research and development expense, professional fees for accounting, auditing, tax and legal services, consulting costs for general and administrative purposes, information systems and marketing efforts. Other Expense (Income) All of our other expense (income) recognized in the three and six months ended June 30, 2024 and 2023, consists of amortization of debt issuance costs and discount, interest income, interest expense, the warrant liabilities fair value adjustment, and the derivative liabilities fair value adjustment. Income Tax Expense For the six months ended June 30, 2024, our income tax expense recognized consists primarily of an expense for U.S. federal income tax. Results of Operations for the Three Months Ended June 30, 2024 and 2023 The following table summarizes our results of operations for the three months ended June 30, 2024 and 2023, together with the changes in those items in dollars and percentage (dollars in thousands): Â Â Â Three Months Ended June 30, Â Â Â Â 2024 Â Â 2023 Â Â Period-to-Period Change Â Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenue, net Â $ â€” Â Â $ 468 Â Â $ (468) Â Â (100.0) % License agreement revenue Â Â 736 Â Â Â 130,986 Â Â Â (130,250) Â Â (99.4) % Total revenue Â Â 736 Â Â Â 131,454 Â Â Â (130,718) Â Â (99.4) % Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of product revenue Â Â â€” Â Â Â 426 Â Â Â (426) Â Â (100.0) % Research and development Â Â 6,807 Â Â Â 7,040 Â Â Â (233) Â Â (3.3) % Selling, general and administrative Â Â 3,166 Â Â Â 7,474 Â Â Â (4,308) Â Â (57.6) % Total operating expenses Â Â 9,973 Â Â Â 14,940 Â Â Â (4,967) Â Â (33.2) % (Loss) income from operations Â Â (9,237) Â Â 116,514 Â Â Â (125,751) Â Â (107.9) % Other (income) expense: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Amortization of debt issuance costs and discount Â Â 421 Â Â Â 1,998 Â Â Â (1,577) Â Â (78.9) % Interest income Â Â (1,130) Â Â (737) Â Â (393) Â Â 53.3 Â % Interest expense Â Â 197 Â Â Â 1,249 Â Â Â (1,052) Â Â (84.2) % Warrant liabilities fair value adjustment Â Â 5,761 Â Â Â (8,214) Â Â 13,975 Â Â Â (170.1) % Derivative liabilities fair value adjustment Â Â (28) Â Â (42) Â Â 14 Â Â Â (33.3) % Total other expense (income) Â Â 5,221 Â Â Â (5,746) Â Â 10,967 Â Â Â (190.9) % Net (loss) income Â $ (14,458) Â $ 122,260 Â Â $ (136,718) Â Â (111.8) % Â 21 Table of ContentsÂ Revenue. For the three months ended June 30, 2024, revenue consists of the $0.7 million in license agreement revenue associated with the License Agreement with GSK. For the three months ended June 30, 2023, revenue primarily consists of the $130.1 million recognized upon the transfer of the license associated with the License Agreement with GSK in May 2023. Cost of Product Revenue. Cost of product revenue for the three months ended June 30, 2023 consists primarily of distribution, freight, and royalty costs associated with BREXAFEMME. Research and Development. For the three months ended June 30, 2024, research and development expenses decreased to $6.8 million compared to $7.0 million for the three months ended June 30, 2023. The decrease of $0.2 million, or 3%, for the three months ended June 30, 2024, was primarily driven by a decrease of $1.1 million in clinical expense and a decrease of $0.3 million in salaries primarily associated with medical affairs, offset in part by an increase of $0.7 million in chemistry, manufacturing, and controls (CMC) expense and an increase of $0.5 million in preclinical expense. The $1.1 million decrease in clinical expense was primarily due to a $0.5 million decrease in clinical expense for the MARIO study and a $0.6 million decrease in clinical expense associated with the FURI, CARES, VANQUISH, and SCYNERGIA studies, which were substantially completed in the third quarter of 2023. The $0.7 million increase in CMC expense is primarily associated with a $0.9 million increase in expense associated with the manufacturing of drug product for SCY-247 and ibrexafungerp. The $0.5 million increase in preclinical expense for the three months ended June 30, 2024 was primarily associated with certain preclinical costs associated with SCY-247. Selling, General & Administrative. For the three months ended June 30, 2024, selling, general and administrative expenses decreased to $3.2 million from $7.5 million for the three months ended June 30, 2023. The decrease of $4.3 million, or 58%, for the three months ended June 30, 2024, was primarily driven by a decrease of $3.5 million in professional fees and a decrease of $0.3 million in commercial expense due to the costs incurred in the prior comparable period associated with BREXAFEMME. The $3.5 million decrease in professional fees was primarily due to a $3.1 million expense incurred during the prior period for business development associated with the GSK License Agreement. Amortization of Debt Issuance Costs and Discount. For the three months ended June 30, 2024 and 2023, we recognized $0.4 million and $2.0 million in amortization of debt issuance costs and discount, respectively. The decrease of $1.6 million, or 79%, was primarily driven by the recognition, in the prior period, of $1.7 million in amortization for the remaining debt issuance costs and discount associated with the Loan Agreement which was fully paid in May 2023. The debt issuance costs and discount for our March 2019 convertible notes primarily consisted of an allocated portion of advisory fees and other issuance costs and the initial fair value of the derivative liability. Interest Income. For the three months ended June 30, 2024 and 2023, we recognized $1.1 million and $0.7 million, respectively, in interest income; the increase was primarily due to the increase in the interest rates on our money market funds and investments. Interest Expense. For the three months ended June 30, 2024 and 2023, we recognized $0.2 million and $1.2 million, respectively. The decrease in interest expense was primarily due to the repayment of the Loan Agreement in May 2023. Warrant Liabilities Fair Value Adjustment. For the three months ended June 30, 2024 and 2023, we recognized a loss of $5.8 million and a gain of $8.2 million, respectively, in the fair value adjustment related to the warrant liabilities primarily due to the increase and decrease in our stock price during the periods, respectively. Derivative Liabilities Fair Value Adjustment. For the three months ended June 30, 2024 and 2023, we recognized gains of $28,000 and $42,000, respectively, in the fair value adjustment related to the derivative liabilities primarily due to the decreases in our stock price during both the periods. Â 22 Table of ContentsÂ Results of Operations for the Six Months Ended June 30, 2024 and 2023 The following table summarizes our results of operations for the six months ended June 30, 2024 and 2023, together with the changes in those items in dollars and percentage (dollars in thousands): Â Â Six Months Ended June 30, Â Â Â Â 2024 Â Â 2023 Â Â Period-to-Period Change Â Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenue, net Â $ â€” Â Â $ 1,598 Â Â $ (1,598) Â Â (100.0) % License agreement revenue Â Â 2,109 Â Â Â 130,986 Â Â Â (128,877) Â Â (98.4) % Total revenue Â Â 2,109 Â Â Â 132,584 Â Â Â (130,475) Â Â (98.4) % Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cost of product revenue Â Â â€” Â Â Â 562 Â Â Â (562) Â Â (100.0) % Research and development Â Â 14,019 Â Â Â 13,875 Â Â Â 144 Â Â Â 1.0 Â % Selling, general and administrative Â Â 6,835 Â Â Â 12,314 Â Â Â (5,479) Â Â (44.5) % Total operating expenses Â Â 20,854 Â Â Â 26,751 Â Â Â (5,897) Â Â (22.0) % (Loss) income from operations Â Â (18,745) Â Â 105,833 Â Â Â (124,578) Â Â (117.7) % Other expense (income): Â Â Â Â Â Â Â Â Â Â Â Â Â Â Amortization of debt issuance costs and discount Â Â 822 Â Â Â 2,256 Â Â Â (1,434) Â Â (63.6) % Interest income Â Â (2,402) Â Â (1,325) Â Â (1,077) Â Â 81.3 Â % Interest expense Â Â 403 Â Â Â 2,695 Â Â Â (2,292) Â Â (85.0) % Warrant liabilities fair value adjustment Â Â (3,848) Â Â 13,459 Â Â Â (17,307) Â Â (128.6) % Derivative liabilities fair value adjustment Â Â (196) Â Â 364 Â Â Â (560) Â Â (153.8) % Total other (income) expense Â Â (5,221) Â Â 17,449 Â Â Â (22,670) Â Â (129.9) % (Loss) income before taxes Â Â (13,524) Â Â 88,384 Â Â Â (101,908) Â Â (115.3) % Income tax expense Â Â 523 Â Â Â â€” Â Â 523 Â Â Â â€” Â % Net (loss) income Â $ (14,047) Â $ 88,384 Â Â $ (102,431) Â Â (115.9) % Revenue. For the six months ended June 30, 2024, revenue consists of the $2.1 million in license agreement revenue associated with the License Agreement with GSK. For the six months ended June 30, 2023, revenue primarily consists of the $130.1 million recognized upon the transfer of the license associated with the License Agreement with GSK in May 2023 and $1.6 million in product sales of BREXAFEMME. Cost of Product Revenue. Cost of product revenue for the six months ended June 30, 2023 consists primarily of distribution, freight, and royalty costs associated with BREXAFEMME. Research and Development. For the six months ended June 30, 2024, research and development expenses increased to $14.0 million compared to $13.9 million for the six months ended June 30, 2023. The increase of $0.1 million, or 1%, for the six months ended June 30, 2024, was primarily driven by an increase of $2.2 million in chemistry, manufacturing, and controls (CMC) expense and an increase of $0.8 million in preclinical expense, offset in part by a decrease of $1.9 million in clinical expense, a decrease of $0.7 million in salaries primarily associated with medical affairs and a $0.3 million decrease in other research and development expense. The $2.2 million increase in CMC expense is primarily associated with a $1.1 million expense for drug product purchased in the current period and a $1.4 million increase in expense associated with manufacturing costs for SCY-247 and ibrexafungerp. The $0.8 million increase in preclinical expense for the three months ended June 30, 2024 was primarily associated with certain preclinical costs associated with SCY-247. The $1.9 million decrease in clinical expense was primarily due to a $0.8 million decrease in expense associated with a Phase 1 study of oral ibrexafungerp that was substantially completed in the prior period and is intended to support the potential NDA filing for the treatment of IC, a $0.8 million decrease in clinical expense for the MARIO study, and a $0.3 million decrease in other clinical expense. Selling, General & Administrative. For the six months ended June 30, 2024, selling, general and administrative expenses decreased to $6.8 million from $12.3 million for the six months ended June 30, 2023. The decrease of $5.5 million, or 44%, for the six months ended June 30, 2024, was primarily driven by a decrease of $4.2 million in professional fees and a decrease of $0.7 million in commercial expense due to the costs incurred in the prior comparable period associated with BREXAFEMME. The $4.2 million decrease in professional fees was primarily due to a $3.1 million expense incurred during the prior period for business development associated with the GSK License Agreement, a $0.7 million decrease in legal costs associated with the GSK License Agreement, and a $0.5 million expense recognized in the prior period to write off a deferred asset for certain commitment fees associated with the Loan Agreement. Amortization of Debt Issuance Costs and Discount. For the six months ended June 30, 2024 and 2023, we recognized $0.8 million and $2.3 million in amortization of debt issuance costs and discount. The decrease of $1.4 million, or 64%, was 23 Table of ContentsÂ primarily driven by the recognition, in the prior period, of $2.0 million in amortization for the remaining debt issuance costs and discount associated with the Loan Agreement which was fully paid in May 2023. The debt issuance costs and discount for our March 2019 convertible notes primarily consisted of an allocated portion of advisory fees and other issuance costs and the initial fair value of the derivative liability. Interest Income. For the six months ended June 30, 2024 and 2023, we recognized $2.4 million and $1.3 million, respectively, in interest income; the increase was primarily due to the increase in the interest rates on our money market funds and investments. Interest Expense. For the six months ended June 30, 2024 and 2023, we recognized $0.4 million and $2.7 million, respectively. The decrease in interest expense was primarily due to the repayment of the Loan Agreement in May 2023. Warrant Liabilities Fair Value Adjustment. For the six months ended June 30, 2024 and 2023, we recognized a gain of $3.8 million and a loss of $13.5 million, respectively, in the fair value adjustment related to the warrant liabilities primarily due to the decrease and increase in our stock price during the periods, respectively. Derivative Liabilities Fair Value Adjustment. For the six months ended June 30, 2024 and 2023, we recognized a gain of $0.2 million and a loss of $0.4 million, respectively, in the fair value adjustment related to the derivative liabilities primarily due to the decrease and increase in our stock price during the periods, respectively. Liquidity and Capital Resources Sources of Liquidity As of June 30, 2024, we had cash and cash equivalents and investments of $83.7 million, compared to cash and cash equivalents and short-term investments of $98.0 million as of December 31, 2023. We believe our capital resources are sufficient to fund our on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements. As of June 30, 2024, our accumulated deficit was $369.3 million. Consistent with our operating plan, we expect to incur significant research and development expenses and selling, general and administrative expenses. As a result of our continued significant expenses, we may need additional capital to fund our operations, which we may obtain through one or more of equity offerings, debt financings, or other non-dilutive third-party funding, strategic alliances and licensing or collaboration arrangements. Cash Flows The following table sets forth the significant sources and uses of cash for the six months ended June 30, 2024 and 2023 (in thousands): Â Â Six Months Ended June 30, Â Â Â Â 2024 Â Â 2023 Â Cash, cash equivalents, and restricted cash, January 1 Â $ 34,593 Â Â $ 46,032 Â Net cash (used in) provided by operating activities Â Â (14,867) Â Â 55,475 Â Net cash provided

by (used in) investing activities Â Â 6,826 Â Â Â (6,384) Net cash used in financing activities Â Â (15) Â Â (36,620) Net (decrease) increase in cash, cash equivalents, and restricted cash Â Â (8,056) Â Â 12,471 Â Cash, cash equivalents, and restricted cash, June 30 Â $ 26,537 Â Â $ 58,503 Â Operating Activities The $70.3 million decrease in net cash (used in) provided by operating activities for the six months ended June 30, 2024, as compared to the six months ended June 30, 2023 was primarily due to the $90.0 million upfront receipt from the closing of the GSK License Agreement in the prior period, the continued development costs associated with SCY-247 and ibrexafungerp, and the payment of the deferred fees associated with Amplity in the current period. Net cash used in operating activities of $14.9 million for the six months ended June 30, 2024, primarily consisted of the $14.0 million net loss adjusted for non-cash charges that included the gain on change in fair value of the warrant liabilities of $3.8 million, stock-based compensation expense of $1.5 million, and amortization of debt issuance costs and discount of $0.8 million, partially offset by a net favorable change in operating assets and liabilities of $1.4 million. The net favorable change in operating assets and liabilities was due to a net decrease in operating liabilities of $4.8 million and by a net decrease of $6.2 million in operating assets. The net $6.2 million decrease in operating assets is primarily due to a $2.2 million decrease in the license agreement receivable associated with the License Agreement with GSK which was collected in the current period and a $4.1 million decrease in prepaid expenses, other assets, deferred costs, and other. The $4.1 million decrease in prepaid expenses, other assets, deferred costs, and other was primarily due to the collection of a $4.4 million unbilled receivable in the current period from GSK. 24 Table of ContentsÂ Net cash provided by operating activities of $55.5 million for the six months ended June 30, 2023, primarily consisted of the $88.4 million net income adjusted for non-cash charges that included the loss on change in fair value of the warrant liabilities of $13.5 million, stock-based compensation expense of $1.4 million, and amortization of debt issuance costs and discount of $2.3 million, partially offset by a net unfavorable change in operating assets and liabilities of $51.7 million. The net unfavorable change in operating assets and liabilities was due to a net decrease in operating liabilities of $2.5 million and by a net increase of $49.2 million in operating assets. The net $49.2 million increase in operating assets is primarily due to a $19.2 million increase in license agreement contract asset associated with the License Agreement with GSK, an increase of $25.0 million in license agreement receivable associated with the License Agreement with GSK, a $4.6 million increase in inventory for raw material purchased in the current period, and a net increase in prepaid expenses, other assets, and other and accounts receivable of $0.4 million. The $2.5 million decrease in accounts payable, accrued expenses, deferred revenue, other liabilities, and other was primarily due to the decrease of $5.8 million in other liabilities associated with the deferred fees due to Amplity that were fully paid as of February 2023, offset by a $4.4 million increase in deferred revenue associated with the License Agreement with GSK. Investing Activities Net cash provided by investing activities of $6.8 million for the six months ended June 30, 2024 consisted of purchases and maturities of investments of $10.7 million and $17.5 million, respectively. Net cash used in investing activities of $6.4 million for the six months ended June 30, 2023 consisted of purchases and maturities of short-term investments of $26.9 million and $20.6 million, respectively. Financing Activities Net cash used in financing activities of $15,000 for the six months ended June 30, 2024, consisted primarily of deferred financing costs of $40,000. Net cash used in financing activities of $36.4 million for the six months ended June 30, 2023, consisted primarily of the full repayment of the Loan Agreement with Hercules and SVB in May 2023. Future Funding Requirements We expect to incur expenses in connection with our efforts to further development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, product candidates. We anticipate that we will need substantial additional funding in connection with our continuing future operations. We are continually evaluating our operating plan and assessing the optimal cash utilization for our SCY-247 and ibrexafungerp development strategy. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenses necessary to complete the development of product candidates. Our future capital requirements will depend on many factors, including: â€¢our ability to successfully achieve the development, regulatory, and commercial milestones under our License Agreement with GSK; â€¢the progress, and costs, of the clinical development of SCY-247 and ibrexafungerp; â€¢the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals; â€¢the ability of product candidates to progress through clinical development successfully; â€¢our need to expand our research and development activities; â€¢the costs associated with securing, establishing and maintaining commercialization and manufacturing capabilities; â€¢our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; â€¢our need and ability to hire additional management and scientific and medical personnel; â€¢our need to implement additional, as well as to enhance existing, internal systems and infrastructure, including financial and reporting processes and systems and the associated compliance costs; and 25 Table of ContentsÂ â€¢the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of net proceeds from equity offerings, debt financings, or other non-dilutive third-party funding (e.g., grants), strategic alliances and licensing arrangements, in particular the License Agreement with GSK. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, similar to our Loan Agreement or the convertible senior notes we sold in March 2019 and April 2020, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through sales of assets, other third-party funding, strategic alliances and licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Significant Estimates and Judgments Our managementâ€™s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, as well as the reported revenues and expenses during the reported periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Our critical estimates and judgments are described within Item 7 to our Annual Report on Form 10-K for the year ended December 31, 2023. Item 3. Quantitative and Qualitative Disclosure about Market Risk. This item is not applicable to smaller reporting companies. Item 4. Controls and Procedures. Managementâ€™s Evaluation of our Disclosure Controls and Procedures We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act") is (1) recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. As of June 30, 2024, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of June 30, 2024, our disclosure controls and procedures were effective at the reasonable assurance level. Changes in Internal Control Over Financial Reporting During the quarter ended June 30, 2024, there have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 26 Table of ContentsÂ Â PART II. OTHER INFORMATION Item 1. Legal Proceedings. On November 7, 2023, a securities class action was filed by Brian Feldman against us and certain of our executives in the United States District Court, District of New Jersey, alleging that, during the period from March 31, 2023 to September 22, 2023, we made materially false and/or misleading statements, as well as failed to disclose material adverse facts about our business, operations, and prospects, alleging specifically that we failed to disclose to investors: (1) that the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination; (2) that we did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP); (3) that, due to the substantial risk of cross-contamination, we were reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies; and (4) as a result of the foregoing, our statements about our business, operations, and prospects were materially misleading and/or lacked a reasonable basis. The complaint seeks unspecified damages, interest, fees and costs on behalf of all persons and entities who purchased and/or acquired shares of our common stock between March 31, 2023 to September 22, 2023. On May 1, 2024, and again on June 4, 2024, purported shareholder derivative complaints were filed in the United States District Court, District of New Jersey. The complaints name our directors and certain of our officers and assert state and federal claims based on the same alleged misstatements as the securities class action complaint. We disagree with the allegations and intend to defend these litigations vigorously. Item 1A. Risk Factors. Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023. Â Â 27 Table of ContentsÂ Item 6. Exhibits. Â ExhibitNumber Â Description of Document Â Â Â 3.1 Â Amended and Restated Certificate of Incorporation (Filed with the SEC as Exhibit 3.1 to our current report on Form 8-K, filed with the SEC on May 12, 2014, SEC File No. 001-36365, and incorporated by reference here). Â Â Â 3.2 Â Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed with the SEC as Exhibit 3.2 to our Form 10-Q, filed with the SEC on August 7, 2019, SEC File No. 001-36365, and incorporated by reference here). Â Â Â 3.3 Â Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed with the SEC as Exhibit 3.1 to our Form 8-K, filed with the SEC on July 16, 2020, SEC File No. 001-36365, and incorporated by reference here). Â Â Â 3.4 Â Certificate of Amendment of Amended and Restated Certificate of Incorporation of SCYNEXIS, Inc. (Filed with the SEC as Exhibit 3.4 to our Form 10-Q, filed with SEC on November 9, 2022, SEC File No. 001-36365, and incorporated by reference here). Â Â Â 3.5 Â Amended and Restated By-Laws (Filed with the SEC as Exhibit 3.4 to our Registration Statement on Form S-1, filed with the SEC on February 27, 2014, SEC File No. 333-194192, and incorporated by reference here). Â Â Â 4.1 Â Reference is made to Exhibits 3.1Â through 3.5. Â Â Â 10.1 Â SCYNEXIS, Inc. 2024 Equity Incentive Plan (Filed with the SEC as Exhibit 99.1 to our Registration Statement on Form S-8, filed with the SEC on June 20, 2024, SEC File No. 333-280328, and incorporated by reference here). Â Â Â 10.2 Â Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the SCYNEXIS, Inc. 2024 Equity Incentive Plan (Filed with the SEC as Exhibit 99.2 to our Registration Statement on Form S-8, filed with the SEC on June 20, 2024, SEC File No. 333-280328, and incorporated by reference here). Â Â Â 10.3 Â Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the SCYNEXIS, Inc. 2024 Equity Incentive Plan (Filed with the SEC as Exhibit 99.3 to our Registration Statement on Form S-8, filed with the SEC on June 20, 2024, SEC File No. 333-280328, and incorporated by reference here). Â Â Â 31.1* Â Certification of Chief Executive Officer pursuant to Rule 13-a-14(a) or Rule 15(d)-14(a) of the Exchange Act. Â Â Â 31.2* Â Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act. Â Â Â 32.1** Â Certification of Chief Executive Officer and Chief Financial Officer pursuant to 13a-14(b) or 15d-14(b) of the Exchange Act. Â Â Â 101.INS Â Inline XBRL Instance Document Â Â Â 101.SCH Â Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents. Â Â Â 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Â * Filed herewith. ** Furnished herewith. Exhibit 32.1 is being furnished and shall not be deemed to be â€œfiledâ€ for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing. 28 Table of ContentsÂ SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SCYNEXIS, INC. Â Â Â By: Â /s/ David Angulo, M.D. Â Â David Angulo, M.D. Â Â Chief Executive Officer(Principal Executive Officer) Â Â Â Date: Â August 7, 2024 Â Â Â By: Â /s/ Ivor Macleod Â Â Ivor Macleod Â Â Chief Financial Officer(Principal Financial and Accounting Officer) Â Â Â Date: Â August 7, 2024 29 EX-31.1 2 scyx-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATIONS I, David Angulo, certify that: Â 1.I have reviewed this Form 10-Q of SCYNEXIS, Inc.; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Â Date: August 7, 2024 /s/ David Angulo, M.D. David Angulo, M.D.Chief Executive OfficerPrincipal Executive Officer Â Â EX-31.2 3 scyx-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATIONS I, Ivor Macleod, certify that: Â 1.I have reviewed this Form 10-Q of SCYNEXIS, Inc.; Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based

on such evaluation; and Â d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Â Â Â Â Â Date: August 7, 2024 /s/ Ivor Macleod Ivor MacleodChief Financial OfficerPrincipal Financial Officer Â Â EX-32.1 4 scyx-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Â§1350), David Angulo, Chief Executive Officer of SCYNEXIS, Inc. (the â€œCompanyâ€), and Ivor Macleod, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge: Â 1.The Companyâ€™s Quarterly Report on Form 10-Q for the period ended June 30, 2024, to which this Certification is attached as Exhibit 32.1 (the â€œPeriodic Reportâ€), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and Â 2.The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. In Witness Whereof, the undersigned have set their hands hereto as of August 7, 2024. Â Â Â Â Â Â Â /s/ David Angulo, M.D. Â Â Â /s/ Ivor Macleod David Angulo, M.D.Chief Executive Officer Â Â Â Ivor MacleodChief Financial Officer This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of SCYNEXIS, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. Â EX-101.SCH 5 scyx-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Unaudited Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100050 - Disclosure - Description of Business and Basis of Preparation link:presentationLink link:calculationLink link:definitionLink 100060 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100070 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Description of Business and Basis of Preparation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Summary of Significant Accounting Policies - Schedule of Diluted Net (Loss) Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Detail) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Investments - Summary of Investments (Details) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Borrowings - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease (Detail) link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Detail) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Commitments and Contingencies - Presentation of Operating Lease Liability (Detail) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Stockholders' Equity - Summary of Common Stock Shares Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Stock-based Compensation - 2014 Equity Incentive Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Stock-based Compensation - 2015 Inducement Award Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Stock-based Compensation - 2024 Equity Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Stock-based Compensation - Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 100470 - Disclosure - Stock-based Compensation - Compensation Cost (Detail) link:presentationLink link:calculationLink link:definitionLink 100480 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense Related to Stock Options (Detail) link:presentationLink link:calculationLink link:definitionLink 100490 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 100500 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100510 - Disclosure - Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 100520 - Disclosure - Revenue - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100530 - Disclosure - Revenue - Summary of Activity in Each of Product Revenue Provision and Allowance Categories (Detail) link:presentationLink link:calculationLink link:definitionLink Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Document Transition Report Document Transition Report Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Balance - Outstanding Money Market Funds [Member] Money market funds Option Indexed to Issuer's Equity [Axis] Option Indexed to Issuer's Equity Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage Vesting percentage Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period of options Restricted Stock Units (RSUs) [Member] Outstanding restricted stock units Restricted Stock Units Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Lessee, Operating Lease, Liability, to be Paid, Year Four 2028 Weighted Average [Member] Weighted Average Fair Value Disclosures [Text Block] Fair Value Measurements Total revenue Product revenue, net Total revenue Net product revenue Loan Agreement Amendment Loan Agreement Amendment [Member] Loan Agreement Amendment. Common stock reserved for future issuances. Common Stock Reserved For Future Issuances Table Table [Text Block] Common Stock Reserved For Future Issuances Concentration Risk Type [Axis] Concentration Risk Type Embedded Derivative, Fair Value of Embedded Derivative Liability Bifurcated embedded conversion option derivative liability Operating Lease, Liability, Noncurrent Operating lease liability, long-term portion Operating lease liability (See Note 7) Schedule of Stock by Class [Table] Schedule Of Stock By Class [Table] Liabilities, Fair Value Disclosure Fair value of financial liabilities Liabilities, Fair Value Disclosure, Total Deferred fees, fully paid Deferred Fees Paid Deferred fees paid. Class of Stock [Line Items] Class of Stock [Line Items] Balance Sheet Location [Axis] Balance Sheet Location Assets, Current Total current assets Liabilities and Equity Total liabilities and stockholdersâ€™ equity Entity Address, State or Province Entity Address, State or Province Amortization of remaining financing costs and discounts Amortization of remaining financing costs and discounts Amortization of remaining financing costs and discounts. Stock Issued During Period, Value, New Issues Common stock issued, net of expenses Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Ending balance - Outstanding (shares) Beginning balance - Outstanding (shares) Trading Symbol Trading Symbol Common Stock, Shares, Issued Common stock, shares issued (in shares) Common stock, shares issued (in shares) Development milestones recevied. Development Milestones Recevied Development milestones recevied Measurement input secured yield. Measurement Input Secured Yield [Member] Secured Yield Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Write off of deferred asset for commitment fees Write Off of Deferred Asset for Commitment Fees Write off of deferred asset for commitment fees. Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Common Stock, Capital Shares Reserved for Future Issuance Common shares reserved for future issuance Development milestones receivable. Development Milestones Receivable Development milestones receivable Completion furi, cares, and nature clinical studies member. Completion FURI, CARES, and NATURE Clinical Studies [Member] Completion FURI, CARES, and NATURE Clinical Studies License transfer. License Transfer [Member] License Transfer Discounts and Chargebacks Discounts And Chargebacks [Member] Discounts and chargebacks. Entity Address, City or Town Entity Address, City or Town Warrants associated with loan agreement. Warrants Associated With Loan Agreement [Member] Warrants to purchase common stock associated with Loan Agreement Operating Lease, Weighted Average Discount Rate, Percent Discount rate Dilutive effect of convertible debt Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Lessee, Operating Lease, Renewal Term Renewal term Debt Disclosure [Text Block] Borrowings Increase (Decrease) in Security Deposits Decrease in security deposit Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Exercisable (shares) Payment of loan payable prepayment fee Payment of loan payable prepayment fee Payment of loan payable prepayment fee. Commitment and contingencies. Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Measurement Input, Expected Dividend Rate [Member] Estimated Yield Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Forfeited/Cancelled (in dollars per share) Additional Paid-in Capital [Member] Additional Paid-in Capital Liabilities, Current [Abstract] Current liabilities: Assets, Current [Abstract] Current assets: Counterparty Name [Axis] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Wholesaler Two Wholesaler Two [Member] Wholesaler two. Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested or expected to vest (in dollars per share) Operating Lease, Liability, Current Operating lease liability, current portion Operating lease liability, current portion (See Note 7) Lender Name [Axis] Lender Name Debt Instrument, Maturity Date Notes maturity date Success-based development milestones receivable Success-based Development Milestones Receivable Success-based development milestones receivable. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Vested and expected to vest Scenario [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Increase (Decrease) in Prepaid Expenses, Other Prepaid expenses, other assets, deferred costs, and other Entity Central Index Key Entity Central Index Key Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of warrants issued to purchase common stock (in shares) Number of outstanding warrants issued to purchase common stock (in shares) Plan Name [Domain] Plan Name Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Accrued product recall Accrued Product Recall Accrued product recall. Restricted Cash, Noncurrent Restricted cash Assets, Fair Value Disclosure Fair value of financial assets Assets, Fair Value Disclosure, Total Lessee, Operating Lease, Option to Extend Renewal term, description Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Wholesaler One Wholesaler One [Member] Wholesaler one. Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Amortized Cost Debt instrument maximum additional borrowing capacity amount. Debt Instrument Maximum Additional Borrowing Capacity Amount Additional borrowing amount available Liabilities, Current Total current liabilities Entity Tax Identification Number Entity Tax Identification Number (Loss) income before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Payments of Debt Issuance Costs Payment of debt issuance costs Financial Instruments [Domain] Financial Instruments Achivement of Threshold Upto 300 million to 500 Million Achivement of Threshold Upto 300 million to 500 Million [Member] Achivement of threshold upto 300 million to 500 million. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted- Average Remaining Contractual Life (in years) 2024 Plan 2024 Equity Incentive Plan Two Thousand And Twenty Four Equity Incentive Plan [Member] Two thousand and twenty four equity incentive plan. Wholesaler Three Wholesaler Three [Member] Wholesaler three. Stock Issued During Period, Value, Employee Stock Purchase Plan Common stock issued through employee stock purchase plan Award Type [Axis] Award Type Convertible debt and derivative liability fair value disclosures. Convertible Debt And Derivative Liability Fair Value Disclosures Fair value of convertible debt and derivative liability Plan Name [Axis] Plan Name Lessee, Operating Lease, Term of Contract Lease term Payment of transaction price Payment Of Transaction Price Payment of transaction price Assets Total assets Operating Lease, Right-of-Use Asset Operating lease right-of-use asset (See Note 7) Entity Registrant Name Entity Registrant Name Registrant Name Lessee, Operating Lease, Existence of Option to Extend [true false] Lessee, operating lease, existence of option to extend Warrant liability, current. Warrant Liabilities, Current Warrant liabilities Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract] Aggregate Intrinsic Value ($000) Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total December 2020 public offering. December2020 Public Offering [Member] December 2020 Public Offering Prefunded Warrants to Purchase Common Stock Associated with December 2020 Public Offering Prepayment fee for loan payable payment Prepayment fee for loan payable payment. Common stock, $0.001 par value, 150,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 37,856,463 and 37,207,799 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Common Stock, Value, Outstanding Supplemental Cash Flow Information [Abstract] Supplemental cash flow information: Share-Based Payment Arrangement, Expense, Tax Benefit Tax benefit from compensation expense Retained Earnings [Member] Accumulated Deficit Share-Based Compensation Arrangement by Share-Based Payment Award,

Equity Instruments Other than Options, Nonvested, Number Ending balance - Outstanding (shares) Beginning balance - Outstanding (shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Common stock issued through employee stock purchase (in shares) Minimum [Member] Minimum Derivative, Fair Value, Net Derivative, fair value Derivative, Fair Value, Net, Total Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Schedule of Prepaid Expenses and Other Current Assets Operating Lease, Liability Total operating lease liability Present value of future minimum lease payments Forecast Forecast [Member] Fair value of liabilities. Fair Value Of Liabilities Warrant liabilities Equity Component [Domain] Equity Component Employee Stock Option [Member] Outstanding stock options Stock options Relaunch date two member. Relaunch Date Two [Member] Relaunch Date Two Change in Accounting Principle, Accounting Standards Update, Adoption Date Change in Accounting Principle, Accounting Standards Update, Adoption Date Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Amortization of Debt Issuance Costs and Discounts Amortization of debt issuance costs and discount Amortization of debt issuance costs and discount Amortization of Debt Issuance Costs and Discounts, Total Proceeds from Interest Received Cash received for interest Lease agreement area of office space. Lease Agreement Area Of Office Space Long-term lease agreement, area of office space Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Measurement Frequency [Axis] Measurement Frequency Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted- Average Exercise Price Debt Disclosure [Abstract] License transfer performance obligation revenue. License Transfer Performance Obligation Revenue License transfer performance obligation revenue Net Income (Loss) Available to Common Stockholders, Diluted Net income (loss) allocated to common shares Prefunded warrants. Prefunded Warrants [Member] Pre-funded Warrants Debt Instrument, Basis Spread on Variable Rate Basis spread on variable rate (as a percent) Entity Current Reporting Status Entity Current Reporting Status Remaining transaction price. Remaining Transaction Price Remaining transaction price Common Stock, Shares Authorized Common stock, shares authorized (in shares) Research and Development Expense Research and development Research and Development Expense, Total Fair Value, by Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Assets [Abstract] Assets Schedule of Diluted Net (Loss) Income Per Common Share Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Proceeds from common stock issued Proceeds from Issuance of Common Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Possible future issuance under equity compensation plan (in shares) License Agreement Receivable License agreement receivable License agreement receivable. Increase (decrease) in license agreement contract asset. Increase (Decrease) In License Agreement Contract Asset License agreement contract asset Restricted cash. Restricted Cash [Member] Restricted cash Subsidiary, Sale of Stock [Line Items] Subsidiary Sale Of Stock [Line Items] Prepayment fee payable Prepayment Fee Payable Prepayment fee payable. Debt Instrument, Offering Date Date of issuance and sale of notes Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Exercisable Revenue recognized Contract with Customer, Liability, Revenue Recognized Accrued Liabilities, Current Accrued expenses Total accrued expenses Current Fiscal Year End Date Current Fiscal Year End Date Share-Based Payment Arrangement, Noncash Expense, Total Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Proceeds from employee stock purchase plan issuances (Loss) income from operations Operating Income (Loss) Income tax expense Income Tax Expense (Benefit) Income tax expense Research and Development Expense [Member] Research and development Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Concentration Risk, Percentage Percentage of gross revenue Share-Based Payment Arrangement, Expense Stock-based compensation expense Stock-based compensation expense Relaunch date one member. Relaunch Date One [Member] Relaunch Date One Disaggregation of Revenue [Table] Disaggregation Of Revenue [Table] Measurement Input Type [Domain] Measurement Input Type Convertible debt and derivative liability. Convertible Debt And Derivative Liability Net carrying amount of convertible debt and derivative liability Convertible debt and derivative liability (See Note 6) Number of available tranches Number Of Available Tranches Number of available tranches Revenue from Contract with Customer [Text Block] Revenue Loan and security agreement. Loan And Security Agreement [Member] Loan and Security Agreement Stock Issued During Period, Shares, Restricted Stock Award, Gross Common stock issued for vested restricted stock units (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Balance - Outstanding Repurchase of shares to satisfy tax withholdings Payments For Proceeds From Repurchase Of Shares To Satisfy Tax Withholdings Payments for proceeds from repurchase of shares to satisfy tax withholdings. Debt Instrument, Face Amount Face amount Total principal and final fee payment Basic and Diluted Net (Loss) Income per Share of Common Stock Earnings Per Share, Policy [Policy Text Block] Payments of loan payable Payments of loan payable Repayments of Short-Term Debt Repayments of Short-Term Debt, Total Sales milestone payments receivable Sales Milestone Payments Receivable Sales milestone payments receivable Embedded Derivative, Gain (Loss) on Embedded Derivative, Net Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total Gain (loss) on fair value adjustment of derivative liability Operating Expenses [Abstract] Operating expenses: Long-Term Debt, Type [Domain] Long-term Debt, Type Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction, Total Commitments and Contingencies Disclosure [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Option to purchase (shares) Granted (shares) Other Accrued Liabilities, Current Other accrued expenses Derivative fair value gain (loss) from mark to market adjustment. Derivative Fair Value Gain Loss From Mark To Market Adjustment Gain adjustment to fair value Equity [Text Block] Stockholders' Equity Warrants to purchase common stock associated with Danforth Danforth [Member] Danforth. Warrant to purchase common stock associated with Danforth Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Unrealized Losses Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Additional Paid in Capital Additional paid-in capital Additional Paid in Capital, Total Two thousand and fourteen employee stock purchase plan. Two Thousand And Fourteen Employee Stock Purchase Plan [Member] 2014 Employee Stock Purchase Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Exercisable (in dollars per share) Equity, Attributable to Parent [Abstract] Stockholdersâ€™ equity: Lease, Cost [Table Text Block] Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease Achivement of two interim milestone of ongoing mario study member. Achivement of Two Interim Milestone of Ongoing Mario Study [Member] Achivement of Two Interim Milestone of Ongoing Mario Study Derivative Liability, Measurement Input Derivative liabilities, unobservable inputs rate Senior convertible note purchase agreement. Senior Convertible Note Purchase Agreement [Member] Senior Convertible Note Purchase Agreement Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Future Minimum Lease Payments Accounting Policies [Abstract] Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Changes in estimate related to prior period revenue Accrued research and development expense, current. Accrued Researchand Development Expense Current Accrued research and development expenses Scenario [Axis] License and Service [Member] License Agreement Revenue Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Warrants associated with april 2022 public offering. Warrants Associated With April2022 Public Offering [Member] Warrants to Purchase Common Stock Associated With April 2022 Public Offering Debt Instrument, Interest Rate, Effective Percentage Interest rate, deferred fees Net (loss) income per share - basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Customer Concentration Risk [Member] Customer Concentration Risk Commitments and Contingencies Commitments and contingencies Income Statement [Abstract] Investments, Total Investments Investments Total transaction price, Total transaction price Corporate and agency bond securities. Corporate and Agency Bond Securities [Member] Corporate and Agency Bonds Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Summary of Activity in Each of Product Revenue Provision and Allowance Categories Operating Lease, Cost Operating lease cost Measurement Input Type [Axis] Measurement Input Type Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested or expected to vest (shares) Statistical Measurement [Domain] Statistical Measurement Net cash (used in) provided by operating activities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Schedule of Capitalization, Equity [Table] Schedule Of Capitalization Equity [Table] Weighted average shares outstanding. Weighted Average Shares Outstanding [Abstract] Weighted average common shares outstanding â€“ basic and diluted Warrants to purchase common stock associated with Danforth Advisors Warrants to purchase common stock associated with Danforth Warrant Associated With Danforth [Member] Warrants associated with Danforth. All Award Types Award Type Document Period End Date Document Period End Date Statistical Measurement [Axis] Statistical Measurement Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Operating Lease, Payments Total lease payments Cash paid for amounts included in the measurement of operating lease liability Net (loss) income per share - diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Net (loss) income per share - diluted Product and Service [Domain] Product and Service Concentration Risk Benchmark [Domain] Concentration Risk Benchmark Revenue from Contract with Customer [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Non refundable upfront payment received Upfront Payment Received Upfront payment received. Fair Value, Recurring [Member] Fair Value, Measurements, Recurring Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net decrease in cash, cash equivalents, and restricted cash Two thousand and fourteen equity incentive plan. Two Thousand And Fourteen Equity Incentive Plan [Member] 2014 Plan 2014 Equity Incentive Plan Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Shares Derivative [Member] Derivative liabilities Cash, Cash Equivalents, and Short-Term Investments, Total Cash, Cash Equivalents, and Short-Term Investments Cash and cash equivalents and short-term investments Research and development activity expense. Research and Development Activity Expense Research and development activity Liabilities and Equity [Abstract] Liabilities and stockholdersâ€™ equity Relaunch Date [Axis]. Relaunch Date [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product Recall Product Recall [Member] Product recall. Entity Interactive Data Current Entity Interactive Data Current Increase (Decrease) in Accounts Payable, Total Increase (Decrease) in Accounts Payable Accounts payable Equity [Abstract] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Difference between future minimum lease payments and discounted cash flows Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Options granted in period (shares) Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Changes in operating assets and liabilities: Debt Instrument, Payment Terms Payment terms Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Net (loss) income per share attributable to common stockholders - basic Earnings Per Share, Basic [Abstract] Equity Components [Axis] Equity Components Increase (Decrease) in Accounts Receivable Accounts receivable Accounts receivable Term loan. Term Loan [Member] Term Loan Increase (Decrease) in Other Operating Liabilities Other liabilities and other Investments, Debt and Equity Securities [Abstract] Pre-funded warrants were exercised for proceeds Proceeds from Issuance of Warrants Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Local Phone Number Local Phone Number Sale of Stock [Axis] Sale of Stock Preferred stock, $0.001 par value, authorized 5,000,000 shares as of June 30, 2024 and December 31, 2023; 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023 Preferred Stock, Value, Outstanding Increase (Decrease) in Deferred Revenue Deferred revenue Restricted Cash, Current Restricted cash Transaction price Transaction Price Transaction price. Statement of Cash Flows [Abstract] Debt Securities, Held-to-Maturity [Table] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Held-to-Maturity Securities [Line Items] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Deferred Revenue, Noncurrent, Total Deferred revenue Deferred revenue, long term Debt Instrument, Interest Rate, Stated Percentage Interest rate Product Returns Product Returns [Member] Product returns. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested or expected to vest Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Maximum [Member] Maximum Convertible Debt, Noncurrent Senior convertible notes Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing Net (loss) income per share attributable to common stockholders - diluted Earnings Per Share, Diluted [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Description of Business and Basis of Preparation Fair Value, Inputs, Level 3 [Member] Level 3 Inputs Significant Unobservable Inputs (Level 3) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Fair Value Adjustment of Warrants Warrant liabilities fair value adjustment Change in fair value of warrant liabilities Payables and Accruals [Abstract] Prepaid research and development expenses, current. Prepaid Researchand Development Expenses Current Prepaid research and development services Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock and Outstanding Restricted Stock Units Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Gain (Loss) on Derivative Instruments, Net, Pretax Derivative liabilities fair value adjustment Change in fair value of derivative liabilities Gain (Loss) on Derivative Instruments, Net, Pretax, Total City Area Code City Area Code Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Investments Commitment and contingencies. Commitment And Contingencies [Table] Commitment And Contingencies [Table] Interest Income, Other Interest income Customer [Domain] Customer Selling, General and Administrative Expenses [Member] Selling, general and administrative Weighted Average Number of Shares Outstanding, Basic Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted average common shares outstanding, basic Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain Unrealized Gains Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Schedule of Restricted Stock Units ("RSU") Activity Statement [Table] Statement [Table] Share-Based Payment Arrangement, Option, Activity [Table Text Block] Stock Option Activity Convertible debt and derivative liability, current. Convertible Debt And Derivative Liability Current Convertible debt and derivative liability (See Note 6) Increase (Decrease) in Contract with Customer, Liability Credit/payments Document Fiscal Period Focus Document Fiscal Period Focus Lessee, Operating Lease, Liability, to be Paid Total Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total Proceeds from Sale and Maturity of Held-to-Maturity Securities Maturity of investments Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Statement [Line Items] Statement [Line Items] Cost of product revenues. Cost Of Product Revenues Cost of product revenues Measurement Input, Credit Spread [Member] Secured Spread Market Credit Spread Provision related to current period revenue Contract With Customer Liability Provision Related To Current Period Revenue Contract with customer liability provision related to current period revenue. Hercules Capital Incorporated And Silicon Valley Bank And Other Lenders Hercules Capital Incorporated And Silicon Valley Bank And Other Lenders [Member] Hercules Capital Incorporated And Silicon Valley Bank And Other Lenders. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive securities (in shares) Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Ending balance Beginning balance Lease, Cost Total operating lease expense Warrant [Member] Warrant Warrant liabilities Customer [Axis] Customer Common Stock [Member] Common Stock Debt Instrument [Line Items] Debt Instrument [Line Items] Regulatory milestone payments receivable Regulatory Milestone Payments Receivable Regulatory milestone payments receivable. Operating lease liability. Operating Lease Liability Table [Text Block] Presentation of Operating Lease Liability Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Stock-Based Compensation Expense Related to Stock Options Other Assets, Current Other current assets Measurement Input, Risk Free Interest Rate [Member] Risk Free Rate Corporate Bond Securities [Member] Corporate bonds Common stock associated with March 2019 notes. Common Stock Associated With March Two Thousand Nineteen Notes [Member] Common stock associated with March 2019 Notes Accretion (Amortization) of Discounts and Premiums, Investments Accretion of investment discount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Two thousand and fifteen inducement award plan. Two Thousand And Fifteen Inducement Award Plan [Member] 2015 Plan 2015 Inducement Award Plan Cash [Member] Cash Cover [Abstract] Cover Selling, General and Administrative Expense Selling, general and administrative Selling, General and Administrative Expense, Total Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Summary of Common Stock Shares Activity Successful Completion of Mario Study Successful

Completion of Mario Study [Member] Successful completion of Mario study. Document Fiscal Year Focus Document Fiscal Year Focus GlaxoSmithKline Intellectual Property GlaxoSmithKline Intellectual Property [Member] GlaxoSmithKline Intellectual Property. Performance based development milestones receivable. Performance Based Development Milestones Receivable Performance-based development milestones receivable Commercial milestones payments receivable Commercial Milestones Payments Receivable Commercial milestones payments receivable. Sale of Stock [Domain] Sale of Stock Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type Upfront payment Upfront Payment Receivable Upfront payment receivable. Achivement of Threshold Upto 200 Million Achivement of Threshold Upto 200 Million [Member] Achivement of threshold upto 200 million. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Restricted cash current fair value disclosure. Restricted Cash Current Fair Value Disclosure Short term restricted cash balance Security Exchange Name Name of Each Exchange on Which Registered December 2020 public offering series 2. December2020 Public Offering Series2 [Member] December 2020 Public Offering Series 2 Recently issued accounting pronouncements. Recently Issued Accounting Pronouncements Policy [Text Block] Recently Issued Accounting Pronouncements Variable lease cost Variable Lease Cost Credit Variable lease (cost) credit. Initial tranche of term loan. Initial Tranche Of Term Loan [Member] Initial Tranche of Term Loan Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Hercules Capital Incorporated and Silicon Valley Bank. Hercules Capital Incorporated And Silicon Valley Bank [Member] Hercules Capital Inc. and Silicon Valley Bank March 2018 public offering series 2. March2018 Public Offering Series2 [Member] March 2018 Public Offering Series 2 Financial Instrument [Axis] Financial Instrument Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Debt Securities, Held-to-Maturity, Fair Value, Total Debt Securities, Held-to-Maturity, Fair Value Fair Value Stock Issued During Period, Value, Restricted Stock Award, Gross Common stock issued for vested restricted stock units Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing Restricted cash noncurrent fair value disclosure. Restricted Cash Noncurrent Fair Value Disclosure Long term restricted cash balance Incremental common shares attributable to restricted stock units. Incremental Common Shares Attributable To Restricted Stock Units Dilutive effect of restricted stock units License agreement receivable Increase (Decrease) In License Agreement Receivable Increase (decrease) in license agreement receivable Accounting Standards Update [Domain] Other Current Assets [Text Block] Prepaid Expenses and Other Current Assets Second tranche of term loan. Second Tranche Of Term Loan [Member] Second Tranche of Term Loan Loans Payable, Fair Value Disclosure Fair value of loan payable Variable Rate [Domain] Variable Rate March 2018 public offering. March2018 Public Offering [Member] March 2018 Public Offering Six percent convertible senior notes due two thousand and twenty five. Six Percent Convertible Senior Notes Due Two Thousand And Twenty Five [Member] March 2019 Notes Securities Act File Number Entity File Number Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Exercisable Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents, and restricted cash at end of period Cash, cash equivalents, and restricted cash at beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total Debt Instrument, Measurement Input Debt instrument, measurement input Share-Based Payment Arrangement [Abstract] Warrants and Rights Outstanding, Measurement Input Warrant liabilities, stock price volatility rate Schedule of Capitalization, Equity [Line Items] Schedule Of Capitalization Equity [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Number of Shares Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Debt Instrument [Axis] Debt Instrument Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Ending balance - Outstanding (in dollars per share) Beginning balance - Outstanding (in dollars per share) Operating Expenses Total operating expenses Entity Address, Address Line Two Entity Address, Address Line Two Entity Small Business Entity Small Business License agreement. License Agreement [Member] License Agreement Entity Shell Company Entity Shell Company Investment Type [Axis] Proceeds from Debt, Net of Issuance Costs Proceeds from debt, net of issuance costs Accrued Bonuses, Current Accrued employee bonus compensation Class of Warrant or Right [Domain] Class of Warrant or Right Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Per Share Revenues [Abstract] Revenue: Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Forfeited/Cancelled (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total Accrued other rebates Accrued Other Rebates Accrued other rebates. Entity Address, Address Line One Entity Address, Address Line One Revenue Benchmark [Member] Sales Revenue Net Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Exclusive License And Collaboration Agreement Exclusive License And Collaboration Agreement [Member] Exclusive license and collaboration agreement. Antidilutive Securities [Axis] Antidilutive Securities The base number of new shares of common stock that may be issued after the effective date of the 2024 equity incentive plan, adjusted by certain amounts as described in the plan agreement, to arrive at an aggregate number of new shares of common stock that may be issued under the plan. Base number of new shares available for future issuance under equity incentive plan (in shares) Base Number of Additional Awards Authorized Under Two Thousand Twenty Four Equity Incentive Plan Measurement Input, Price Volatility [Member] Stock Price Volatility License agreement contract asset. License Agreement Contract Asset License agreement contract asset Sales milestone payable upon achievement of threshold limit Sales Milestone Payable upon Achievement of Threshold Limit Sales milestone payable upon achievement of threshold limit. April 2022 public offering. April2022 Public Offering [Member] April 2022 Public Offering April 2022 Public Offering Income Statement Location [Axis] Income Statement Location Dilutive effect of convertible debt Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Accrued severance Accrued Severance Accrued severance. Debt Securities, Held-to-Maturity [Table Text Block] Summary of Investments Final payment payable under loan agreement Final Loan Payment Payable Final loan payment payable. Long-Term Debt, Type [Axis] Long-term Debt, Type Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Net income (loss) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Relaunch date three member. Relaunch Date Three [Member] Relaunch Date Three Prepaid Insurance Prepaid insurance Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) Level 2 Product [Member] Product Revenue, Net Product and Service [Axis] Product and Service Third tranche of term loan. Third Tranche Of Term Loan [Member] Third Tranche of Term Loan Title of 12(b) Security Title of Each Class Prime Rate [Member] Prime Rate Achivement of Three Interim Milestone of Ongoing Mario Study Achivement of Three Interim Milestone of Ongoing Mario Study [Member] Achivement of three interim milestone of ongoing Mario study. Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary of Financial Instruments Measured on a Recurring Basis Investments [Domain] Accounting Standards Update [Axis] Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Lessee operating lease liability payments due after year four. Lessee Operating Lease Liability Payments Due After Year Four Thereafter Increase (Decrease) in Inventories, Total Increase (Decrease) in Inventories Inventory Inventory Contract with Customer, Liability Balance Balance Contract with Customer, Liability, Total Cash and Cash Equivalents [Axis] Cash and Cash Equivalents Achivement of Threshold Upto 750 million to 1 Billion Achivement of Threshold Upto 750 million to 1 Billion [Member] Achivement of threshold upto 750 million to 1 billion. Common Stock, Shares, Outstanding Ending balance (in shares) Beginning balance (in shares) Common stock, shares outstanding (in shares) Common stock, shares outstanding (in shares) Share-Based Payment Arrangement [Text Block] Stock-based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Ongoing clinical and preclinical studies expense. Ongoing Clinical and Preclinical Studies Expense Ongoing clinical and preclinical studies Concentration Risk Type [Domain] Concentration Risk Type Income Statement Location [Domain] Income Statement Location Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Document Type Document Type Outstanding principal plus all accrued and unpaid interest amount payable to lenders Loans Payable, Noncurrent Loan payable Loans Payable, Noncurrent, Total Accounting Standards Update 2020-06 [Member] ASU 2020-06 Other Prepaid Expense, Current Other prepaid expenses Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Document Quarterly Report Document Quarterly Report Counterparty Name [Domain] Warrants and Rights Outstanding Warrant liabilities Security Deposit Security deposit in the form of a standby letter of credit Relaunch Date [Domain]. Relaunch Date [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited (shares) Net cash used in by financing activities Net cash used in by financing activities Net Cash Provided by (Used in) Financing Activities Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Share-based compensation arrangement by share-based payment award, number of additional shares authorized Short-Term Investments [Member] Maturities Less than 1 Year Entity Filer Category Entity Filer Category Balance Sheet Location [Domain] Balance Sheet Location Increase (Decrease) in Accrued Liabilities, Total Increase (Decrease) in Accrued Liabilities Accrued expenses Variable Rate [Axis] Variable Rate Short-Term Investments, Total Short-Term Investments Short-term investments Total other expense (income) Nonoperating Income (Expense) Nonoperating Income (Expense), Total Liabilities Total liabilities Deferred Costs, Noncurrent Deferred offering costs Deferred Costs, Noncurrent, Total Common stock outstanding roll forward. Common Stock Outstanding Roll Forward Roll Forward Common Stock Outstanding Roll Forward [Roll Forward] Equity, Attributable to Parent Ending balance Beginning balance Total stockholders' equity Rebates and Incentives Rebates And Incentives [Member] Rebates and incentives. Net (loss) income Net (loss) income allocated to common shares Net Income (Loss) Net Income (Loss) Nonoperating Income (Expense) [Abstract] Other (income) expense: Interest Expense Interest expense Interest Expense, Total Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total Contract with Customer, Asset, after Allowance for Credit Loss, Current License agreement contract asset Cash and Cash Equivalents [Domain] Cash and Cash Equivalents Payments to Acquire Held-to-Maturity Securities Purchase of investments Statement of Financial Position [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted average common shares outstanding, diluted Operating Lease, Right-of-Use Asset, Periodic Reduction Noncash operating lease expense for right-of-use asset Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Accrued Expenses Operating Lease, Weighted Average Remaining Lease Term Remaining Lease term (years) Payments of deferred offering costs. Payments Of Deferred Offering Costs Payments of deferred offering costs Payments of deferred offering costs Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Ending balance - Outstanding (in dollars per share) Beginning balance - Outstanding (in dollars per share) Disaggregation of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Fair Value Disclosures [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Measurement Frequency [Domain] Measurement Frequency Other Noncurrent Liabilities [Member] Other Liabilities Agency bonds Agency Bonds [Member] Agency bonds. Reclassification, Comparability Adjustment [Policy Text Block] Reclassification of Prior Year Amounts Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (shares) Long term investment. Long Term Investment [Member] Maturities Greater than 1 Year Stock Issued During Period, Shares, New Issues Common stock issued, net of expenses (in shares) Common stock issued, net of expenses (in shares) Deferred Revenue, Current, Total Deferred Revenue, Current Deferred revenue, current portion Class of Warrant or Right [Axis] Class of Warrant or Right Milestone payments. Milestone Payments Milestone payments from the Company XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document and Entity Information - shares 6 Months Ended Jun. 30, 2024 Aug. 01, 2024 Cover [Abstract] Â Â Entity Registrant Name SCYNEXIS, Inc. Â Trading Symbol SCYX Â Entity Central Index Key 0001178253 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Document Type 10-Q Â Document Period End Date Jun. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â Amendment Flag false Â Entity Common Stock, Shares Outstanding Â 37,856,463 Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Shell Company false Â Entity File Number 001-36365 Â Entity Tax Identification Number 56-2181648 Â Entity Incorporation, State or Country Code DE Â Entity Address, Address Line One 1 Evertrust Plaza Â Entity Address, Address Line Two 13th Floor Â Entity Address, City or Town Jersey City Â Entity Address, State or Province NJ Â Entity Address, Postal Zip Code 07302-6548 Â City Area Code 201 Â Local Phone Number 884-5485 Â Document Quarterly Report true Â Document Transition Report false Â Title of Each Class Common Stock, par value $0.001 per share Â Name of Each Exchange on Which Registered NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital

or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 25,994 $ 34,050 Short-term investments 47,044 40,312 Prepaid expenses and other current assets 1,418 5,548 License agreement receivable 233 2,463 License agreement contract asset 19,509 19,363 Restricted cash 380 380 Total current assets 94,578 102,116 Investments 10,657 23,594 Deferred offering costs 175 175 Restricted cash 163 163 Operating lease right-of-use asset (See Note 7) 2,233 2,364 Total assets 107,806 128,412 Current liabilities: Â Â Accounts payable 5,350 7,149 Accrued expenses 5,498 7,495 Deferred revenue, current portion 1,229 1,189 Operating lease liability, current portion (See Note 7) 372 340 Warrant liabilities 0 130 Convertible debt and derivative liability (See Note 6) 12,784 0 Total current liabilities 25,233 16,303 Deferred revenue 1,817 2,727 Warrant liabilities 17,962 21,680 Convertible debt and derivative liability (See Note 6) 0 12,159 Operating lease liability (See Note 7) 2,388 2,581 Total liabilities 47,400 55,450 Commitments and contingencies Stockholdersâ€™ equity: Â Â Preferred stock, $0.001 par value, authorized 5,000,000 shares as of June 30, 2024 and December 31, 2023; 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023 0 0 Common stock, $0.001 par value, 150,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 37,856,463 and 37,207,799 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 41 40 Additional paid-in capital 429,659 428,169 Accumulated deficit (369,294) (355,247) Total stockholders' equity 60,406 72,962 Total liabilities and stockholdersâ€™ equity $ 107,806 $ 128,412 X - DefinitionConvertible debt and derivative liability. + ReferencesNo definition available. + Details Name: scyx_ConvertibleDebtAndDerivativeLiability Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionConvertible debt and derivative liability, current. + ReferencesNo definition available. + Details Name: scyx_ConvertibleDebtAndDerivativeLiabilityCurrent Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLicense agreement receivable. + ReferencesNo definition available. + Details Name: scyx_LicenseAgreementReceivable Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWarrant liability, current. + ReferencesNo definition available. + Details Name: scyx_WarrantLiabilitiesCurrent Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_DeferredCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher

FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionValue of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesNo definition available. + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 9 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized (in shares) 5,000,000 5,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 150,000,000 150,000,000 Common stock, shares issued (in shares) 37,856,463 37,207,799 Common stock, shares outstanding (in shares) 37,856,463 37,207,799 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number

of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenue: Â Â Â Â Total revenue $ 736 $ 131,454 $ 2,109 $ 132,584 Operating expenses: Â Â Â Â Cost of product revenues 0 426 0 562 Research and development 6,807 7,040 14,019 13,875 Selling, general and administrative 3,166 7,474 6,835 12,314 Total operating expenses 9,973 14,940 20,854 26,751 (Loss) income from operations (9,237) 116,514 (18,745) 105,833 Other (income) expense: Â Â Â Â Amortization of debt issuance costs and discount 421 1,998 822 2,256 Interest income (1,130) (737) (2,402) (1,325) Interest expense 197 1,249 403 2,695 Warrant liabilities fair value adjustment 5,761 (8,214) (3,848) 13,459 Derivative liabilities fair value adjustment (28) (42) (196) 364 Total other expense (income) 5,221 (5,746) (5,221) 17,449 (Loss) income before taxes (14,458) 122,260 (13,524) 88,384 Income tax expense 0 0 523 Â Net (loss) income $ (14,458) $ 122,260 $ (14,047) $ 88,384 Net (loss) income per share attributable to common stockholders - basic Â Â Â Â Net (loss) income per share - basic $ (0.3) $ 2.56 $ (0.29) $ 1.85 Net (loss) income per share attributable to common stockholders - diluted Â Â Â Â Net (loss) income per share - diluted $ (0.3) $ 2.46 $ (0.29) $ 1.82 Weighted average common shares outstanding â€“ basic and diluted Â Â Â Â Basic 48,511,656 47,837,393 48,379,256 47,797,731 Diluted 48,511,656 49,923,361 48,379,256 49,166,251 Product Revenue, Net Â Â Â Â Revenue: Â Â Â Â Total revenue $ 0 $ 468 $ 0 $ 1,598 License Agreement Revenue Â Â Â Â Revenue: Â Â Â Â Total revenue $ 736 $ 130,986 $ 2,109 $ 130,986 X - DefinitionCost of product revenues. + ReferencesNo definition available. + Details Name: scyx_CostOfProductRevenues Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted average shares outstanding. + ReferencesNo definition available. + Details Name: scyx_WeightedAverageSharesOutstandingAbstract Namespace Prefix: scyx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareDilutedAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A + Details Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 1 -SubTopic 20 -Topic 940 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income earned from interest bearing assets classified as other. + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo

definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities: Â Â Net (loss) income $ (14,047) $ 88,384 Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities Â Â Depreciation and amortization 0 304 Stock-based compensation expense 1,464 1,435 Accretion of investment discount (621) 100 Amortization of debt issuance costs and discount 822 2,256 Change in fair value of warrant liabilities (3,848) 13,459 Change in fair value of derivative liabilities (196) 364 Noncash operating lease expense for right-of-use asset 131 110 Write off of deferred asset for commitment fees 0 514 Prepayment fee for loan payable payment Â 263 Changes in operating assets and liabilities: Â Â Prepaid expenses, other assets, deferred costs, and other 4,131 (165) License agreement receivable 2,230 (25,000) License agreement contract asset (146) (19,249) Accounts receivable 0 (243) Inventory 0 (4,563) Accounts payable (1,759) (2,521) Accrued expenses (1,997) 1,562 Deferred revenue (870) 4,369 Other liabilities and other (161) (5,904) Net cash (used in) provided by operating activities (14,867) 55,475 Cash flows from investing activities: Â Â Purchase of investments (10,719) (26,941) Maturity of investments 17,545 20,557 Net cash provided by (used in) investing activities 6,826 (6,384) Cash flows from financing activities: Â Â Proceeds from common stock issued Â 4 Payments of deferred offering costs (40) 0 Payments of loan payable Â (36,383) Payment of loan payable prepayment fee Â (263) Proceeds from employee stock purchase plan issuances 25 4 Repurchase of shares to satisfy tax withholdings 0 18 Net cash used in by financing activities (15) (36,620) Net (decrease) increase in cash, cash equivalents, and restricted cash (8,056) 12,471 Cash, cash equivalents, and restricted cash at beginning of period 34,593 46,032 Cash, cash equivalents, and restricted cash at end of period 26,537 58,503 Supplemental cash flow information: Â Â Cash paid for interest 420 2,828 Cash received for interest $ 1,721 $ 1,434 X - DefinitionIncrease (decrease) in license agreement contract asset. + ReferencesNo definition available. + Details Name: scyx_IncreaseDecreaseInLicenseAgreementContractAsset Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in license agreement receivable + ReferencesNo definition available. + Details Name: scyx_IncreaseDecreaseInLicenseAgreementReceivable Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayment of loan payable prepayment fee. + ReferencesNo definition available. + Details Name: scyx_PaymentOfLoanPayablePrepaymentFee Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments for proceeds from repurchase of shares to satisfy tax withholdings. + ReferencesNo definition available. + Details Name: scyx_PaymentsForProceedsFromRepurchaseOfSharesToSatisfyTaxWithholdings Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPayments of deferred offering costs. + ReferencesNo definition available. + Details Name: scyx_PaymentsOfDeferredOfferingCosts Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPrepayment fee for loan payable payment. + ReferencesNo definition available. + Details Name: scyx_PrepaymentFeeForLoanPayablePayment Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWrite off of deferred asset for commitment fees. + ReferencesNo definition available. + Details Name: scyx_WriteOffOfDeferredAssetForCommitmentFees Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A + Details Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpensesOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration

X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow through purchase of long-term held-to-maturity securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireHeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionInterest received on loans and other debt instruments during the current period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-16 + Details Name: us-gaap_ProceedsFromInterestReceived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from the sale or maturity of long-term held-to-maturity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4JReference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4KReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Description of Business and Basis of Preparation 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Description of Business and Basis of Preparation 1. Description of Business and Basis of PreparationOrganizationSCYNEXIS, Inc. (â€œSCYNEXISâ€ or the â€œCompanyâ€) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, and is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. The Company is developing its proprietary class of enfumafungin-derived antifungal compounds (â€œfungerps") as broad-spectrum, systemic antifungal agents for multiple fungal indications. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the â€œfungerpâ€ family, including SCY-247, in preclinical stages of development. In June 2021, the U.S. Food and Drug Administration (â€œFDAâ€) approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (â€œVVCâ€), also known as vaginal yeast infection, and in December 2022, the Company announced that the FDA approved a second indication for BREXAFEMME for the reduction in the incidence of recurrent vulvovaginal candidiasis ("RVVC").In March 2023, the Company entered into a license agreement (the "GSK License Agreement") with GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK") in which the Company granted GSK an exclusive (even as to the Company and its affiliates), royalty-bearing, sublicensable license for the development and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications, in all countries other than Greater China and certain other countries already licensed to third parties.Following a review by GSK of the manufacturing process and equipment at the vendor that manufactures the ibrexafungerp drug substance, the Company became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp. Current FDA draft guidance recommends segregating the manufacture of non-antibacterial beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people. In the absence of the recommended segregation, there is a risk of cross contamination. It is not known whether any ibrexafungerp has been contaminated with a beta-lactam compound and the Company has not received reports of any adverse events due to the possible beta-lactam cross contamination. Nonetheless, out of an abundance of caution and in line with GSKâ€™s recommendation, the Company has recalled BREXAFEMMEÂ® (ibrexafungerp tablets) from the market and placed a temporary hold on clinical studies of ibrexafungerp, including the Phase 3 MARIO study.The patient-level and clinical product recall is ongoing and the Company is working with an experienced vendor to manage the process. In September 2023, after the Company announced its voluntary clinical hold, the FDA concurred with the Company's voluntary hold and placed a clinical hold. The Company is working with the FDA to discuss paths for resolution of this issue. The clinical hold and recall affect the Company's two ongoing clinical studies: the Phase 3 MARIO study and a Phase 1 lactation study. The hold does not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. The FDA determined that the compassionate use program for ibrexafungerp, which provides ibrexafungerp to patients with limited or no other treatment options, can continue provided the patientâ€™s treating physician concludes a favorable benefit-risk assessment and the patient is made aware of and consents to the risk. This applies to patients currently in the program, as well as for new patients, pending confirmation of available supply. The Company's preclinical stage compound, SCY-247, is not affected by these developments. The Company had an accumulated deficit of $369.3 million at June 30, 2024. The Company's capital resources primarily comprised cash and cash equivalents and investments of $83.7 million at June 30, 2024. While the Company believes

its capital resources are sufficient to fund the Companyâ€™s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements, the Company's liquidity could be materially affected over this period by: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of SCY-247 and ibrexafungerp; (4) its ability to successfully achieve the development, regulatory, and commercial milestones under its License Agreement with GSK; and (5) any other unanticipated material negative events or costs. One or more of these events or costs could materially affect the Companyâ€™s liquidity. If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany balances and transactions are eliminated in consolidation. Use of EstimatesThe preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and judgments include: revenue recognition including gross to net estimates and the identification of performance obligations in licensing arrangements; estimates for the relative standalone selling price and measure of progress under the input method for the GSK License Agreement; estimates for product recall reserves; determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period.Unaudited Condensed Consolidated Financial InformationThe accompanying unaudited condensed consolidated financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States (â€œUS GAAPâ€), as contained in the Financial Accounting Standards Board (â€œFASBâ€) Accounting Standards Codification (the â€œCodificationâ€ or â€œASCâ€) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes set forth in the Companyâ€™s Annual Report on Form 10-K filed with the Securities and Exchange Commission (â€œSECâ€) on March 28, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 13 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting PoliciesThe accompanying unaudited condensed consolidated financial statements and notes follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2023, except as described below.Basic and Diluted Net (Loss) Income per Share of Common StockThe Company calculates net (loss) income per common share in accordance with ASC 260, Earnings Per Share. Basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined by dividing net (loss) income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 includes the outstanding prefunded warrants to purchase 7,516,267 and 3,200,000 shares of common stock issued in the April 2022 public offering and December 2020 public offering. Diluted net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined as follows (in thousands, except share and per share amounts): Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net (loss) income allocated to common shares $ (14,458) Â $ 122,260 Â Â $ (14,047) Â $ 88,384 Â Dilutive effect of convertible debt Â â€” Â Â Â 433 Â Â Â â€” Â Â $ 1,047 Â Net (loss) income allocated to common shares $ (14,458) Â $ 122,693 Â Â $ (14,047) Â $ 89,431 Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding â€“ basic Â 48,511,656 Â Â Â 47,837,393 Â Â Â 48,379,256 Â Â Â 47,797,731 Â Dilutive effect of convertible debt Â â€” Â Â Â 1,138,200 Â Â Â â€” Â Â Â 1,138,200 Â Dilutive effect of restricted stock units Â â€” Â Â Â 947,768 Â Â Â â€” Â Â Â 230,320 Â Weighted average common shares outstanding â€” diluted Â 48,511,656 Â Â Â 49,923,361 Â Â Â 48,379,256 Â Â Â 49,166,251 Â Â Â Â Â Â Â Â Â Â Â Net (loss) income per share â€“ diluted $ (0.30) Â $ 2.46 Â Â $ (0.29) Â $ 1.82 Â Â The following potentially dilutive shares of common stock and outstanding restricted stock units that contain certain performance contingencies have not been included in the computation of diluted net (loss) income per share for the three and six months ended June 30, 2024 and 2023, as the result would be anti-dilutive or the performance contingencies have not been met: Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Outstanding stock options Â 2,842,808 Â Â Â 1,970,536 Â Â Â 2,842,808 Â Â Â 1,970,536 Â Outstanding restricted stock units Â 3,263,345 Â Â Â 400,000 Â Â Â 3,263,345 Â Â Â 400,000 Â Warrants to purchase common stock associated with December 2020 public offering - Series 2 Â â€” Â Â Â 6,800,000 Â Â Â â€” Â Â Â 6,800,000 Â Warrants to purchase common stock associated with April 2022 public offering Â 15,000,000 Â Â Â 15,000,000 Â Â Â 15,000,000 Â Â Â 15,000,000 Â Warrants to purchase common stock associated with Loan Agreement Â 198,811 Â Â Â 198,811 Â Â Â 198,811 Â Â Â 198,811 Â Common stock associated with March 2019 Notes Â 1,138,200 Â Â Â â€” Â Â Â 1,138,200 Â Â Â â€” Â Warrants to purchase common stock associated with Danforth Â 50,000 Â Â Â 50,000 Â Â Â 50,000 Â Â Â 50,000 Â Total Â 22,493,164 Â Â Â 24,419,347 Â Â Â 22,493,164 Â Â Â 24,419,347 Â Reclassification of Prior Year AmountsCertain prior year amounts within the changes in operating assets and liabilities on the unaudited condensed consolidated statement of cash flows and certain prior year accrued expenses have been reclassified for consistency with the current year presentation.Recently Adopted Accounting PronouncementsIn August 2020, the FASB issued ASU No. 2020-06, Debtâ€”Debt with Conversion and Other Options and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity: Accounting for Convertible Instruments and Contracts in an Entityâ€™s Own Equity (â€œASU 2020-06â€). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. The Company adopted ASU 2020-06 on January 1, 2024 and the adoption did not materially impact the unaudited condensed consolidated financial statements.Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which introduced new guidance on disclosures for reportable segments and significant segment expenses, including for entities with a single reportable segment. This guidance is effective for the Company for annual reporting periods beginning January 1, 2024 and interim periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which introduced new guidance on disclosures for income taxes, including enhancements to the rate reconciliation and income taxes paid disclosures. This guidance is effective for the Company for annual reporting periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements.Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 14 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Investments 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Investments 3. InvestmentsThe following table summarizes the investments at June 30, 2024 (in thousands): Â Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â Fair Value Â As of June 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities < 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 44,527 Â Â $ 6 Â Â $ (47) Â $ 44,486 Â Agency bonds Â Â 2,517 Â Â Â â€” Â Â (2) Â Â 2,515 Â Total short-term investments Â $ 47,044 Â Â $ 6 Â Â $ (49) Â $ 47,001 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities > 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 10,657 Â Â $ 10 Â Â $ (23) Â $ 10,644 Â Total investments Â $ 10,657 Â Â $ 10 Â Â $ (23) Â $ 10,644 Â As of December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities < 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 35,286 Â Â $ 25 Â Â $ (13) Â $ 35,298 Â Agency bonds Â Â 5,026 Â Â Â 6 Â Â Â â€” Â Â 5,032 Â Total short-term investments Â $ 40,312 Â Â $ 31 Â Â $ (13) Â $ 40,330 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities > 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 23,594 Â Â $ 143 Â Â $ (9) Â $ 23,728 Â Total investments Â $ 23,594 Â Â $ 143 Â Â $ (9) Â $ 23,728 Â The Company carries investments at amortized cost. As of June 30, 2024 and December 31, 2023, the fair value of the corporate and agency bonds totals $57.6 million and $64.1 million, respectively, which is determined based on â€œLevel 2â€ inputs, which consist of quoted prices for similar assets in active markets. The Company has evaluated the unrealized loss position in the corporate and agency bonds as of the balance sheet dates and did not consider it to be indicative of an other-than-temporary impairment as the securities are highly-rated and the Company expects to realize the full principal amount at maturity. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6BReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph (b) -Publisher SECReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//946-320/tableOfContentReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//940-320/tableOfContentReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 15 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Current Assets 6 Months Ended Jun. 30, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â Prepaid Expenses and Other Current Assets 4. Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following (in thousands): Â Â June 30, 2024 Â Â December 31, 2023 Â Prepaid research and development services Â $ â€” Â Â $ 196 Â Prepaid insurance Â Â 651 Â Â Â 264 Â Other prepaid expenses Â Â 213 Â Â Â 182 Â Other current assets Â Â 554 Â Â Â 4,906 Â Total prepaid expenses and other current assets Â $ 1,418 Â Â $ 5,548 Â X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other current assets. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentAssetsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 16 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] Â Accrued Expenses 5. Accrued ExpensesAccrued expenses consisted of the following (in thousands):Â Â Â June 30, 2024 Â Â December 31, 2023 Â Accrued research and development expenses Â $ 2,348 Â Â $ 2,830 Â Accrued employee bonus compensation Â Â 906 Â Â Â 1,692 Â Other accrued expenses Â Â 862 Â Â Â 1,040 Â Accrued product recall Â Â 1,382 Â Â Â 1,933 Â Total accrued expenses Â $ 5,498 Â Â $ 7,495 Â Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Borrowings 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Borrowings 6. BorrowingsLoan AgreementOn May 13, 2021 (the â€œClosing Dateâ€), the Company entered into the Loan and Security Agreement (the "Loan Agreement") with Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank) (the "Lenders") for an aggregate principal amount of $60.0 million (the â€œTerm Loanâ€). Pursuant to the Loan Agreement, the Term Loan was available to the Company in four tranches, subject to certain terms and conditions. In connection with the entering into of the GSK License Agreement, the Company entered into a First Amendment and Consent to Loan and Security Agreement with the Lenders pursuant to which the Lenders consented to the Company entering into the GSK License Agreement and the Company agreed to pay to the Lenders an amount equal to the sum of (i) all outstanding principal plus all accrued and unpaid interest with respect to the amounts loaned under the Loan Agreement (approximately $35.4 million), (ii) the prepayment fee payable under the Loan Agreement ($262,500), (iii) the final payment payable under the Loan Agreement ($1,382,500), and (iv) all other sums, if any, that shall have become due and payable with respect to loan advances under the Loan Agreement. Upon receipt by the Company of the $90.0 million upfront payment from GSK in May 2023, all amounts payable under the Loan Agreement were fully paid. In connection with the repayment of those amounts due, in May 2023, the Company and the Lenders executed a payoff letter confirming the amounts due under the Loan Agreement, and the Companyâ€™s confirmation that the Loan Agreement was terminated. For the three and six months ended June 30, 2023, the Company recognized $1.7 million and $2.0 million, respectively, in amortization for the remaining debt issuance costs and discount associated with the Loan Agreement which was fully paid in May 2023.March 2019 Note Purchase AgreementOn March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the â€œMarch 2019 Note Purchase Agreementâ€) with Puissance. Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $16.0 million aggregate principal amount of its 6.0% Senior Convertible Notes due 2025 (â€œMarch 2019 Notesâ€), resulting in $14.7 million in net proceeds after deducting $1.3 million for an advisory fee and other issuance costs. As of June 30, 2024 and December 31, 2023, the Companyâ€™s March 2019 Notes consist of the convertible debt balance of $12.8 million and $12.0 million and the bifurcated embedded conversion option derivative liability of zero and $0.2 million, respectively. In connection with the Companyâ€™s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the

Companyâ€™s balance sheet in accordance with ASC 815, Derivatives and Hedging, at its initial fair value of $7.0 million as the interest make-whole provision is settled in shares of common stock. The convertible debt and derivative liability associated with the March 2019 Notes are presented in total on the accompanying unaudited condensed consolidated balance sheets as the convertible debt and derivative liability. The derivative liability will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the statements of operations in other (income) expense. For the three months ended June 30, 2024 and 2023, the Company recognized gains of $28,000 and $42,000, respectively, on the fair value adjustment for the derivative liability. For the six months ended June 30, 2024 and 2023, the Company recognized a gain of $0.2 million and a loss of $0.4 million, respectively, on the fair value adjustment for the derivative liability. For the three months ended June 30, 2024 and 2023, the Company recognized $0.4 million and $0.3 million, respectively, in amortization of debt issuance costs and discount related to the March 2019 Notes. For the six months ended June 30, 2024 and 2023, the Company recognized $0.8 million and $0.3 million, respectively, in amortization of debt issuance costs and discount related to the March 2019 Notes. The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At June 30, 2024 and December 31, 2023, the fair value of the convertible debt and derivative liability for the March 2019 Notes is $12.8 million and $12.7 million, respectively.The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. The March 2019 Notes constitute general, senior unsecured obligations of the Company.Other LiabilitiesIn February 2021, the Company partnered with Amplity for the commercial launch of BREXAFEMME for the treatment of VVC. Under the terms of the agreement with Amplity, the Company was to utilize Amplityâ€™s commercial execution and resources for sales force, remote engagement, training, market access and select operations services. In October 2022, the Company announced that it was actively pursuing a U.S. commercialization partner to out-license BREXAFEMME in order to refocus the Company's resources on the further clinical development of ibrexafungerp for severe, hospital-based indications. As a result, the Company wound down its promotional activities associated with BREXAFEMME. On November 30, 2022, the Company terminated the agreement with Amplity. Under the terms of the original agreement, Amplity deferred a portion of its direct service fees in the first two years (2021 and 2022) that accrued interest at an annual rate of 12.75% (â€œDeferred Feesâ€). The Deferred Fees of $5.8 million as of December 31, 2022, classified as other liabilities on the consolidated balance sheet, were fully paid as of February 2023. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1IReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1IReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies 7. Commitments and ContingenciesLeasesOn March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the â€œLeaseâ€). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of $7.3 million over the lease term. The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years. The security deposit is classified as restricted cash in the accompanying unaudited condensed consolidated balance sheets. The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands):Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost Â $ 166 Â Â $ 166 Â Â $ 332 Â Â $ 332 Â Variable lease cost Â Â 27 Â Â Â 46 Â Â Â 4 Â Â Â 104 Â Total operating lease expense Â $ 193 Â Â $ 212 Â Â $ 336 Â Â $ 436 Â Â Â

OfferingsThe outstanding warrants associated with the December 2020 public offering contains a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying unaudited condensed consolidated statements of operations. The outstanding warrants associated with the April 2022 public offering meet the definition of a derivative pursuant to ASC 815, Derivatives and Hedging, and do not meet the derivative scope exception given the warrants do not qualify under the indexation guidance. As a result, the April 2022 public offering warrants were initially recognized as liabilities and measured at fair value using the Black-Scholes valuation model. For the three months ended June 30, 2024 and 2023, the Company recognized a loss of $5.8 million and a gain of $8.2 million, respectively, and for the six months ended June 30, 2024 and 2023, recognized a gain of $3.8 million and a loss of $13.5 million, respectively, on the warrant liabilities fair value adjustment. As of June 30, 2024 and December 31, 2023, the fair value of the warrant liabilities was $18.0 million and $21.8 million, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock-based Compensation 9. Stock-based CompensationPursuant to the terms of the Companyâ€™s 2014 Equity Incentive Plan (â€œ2014 Planâ€), on January 1, 2024 and 2023, the Company automatically added 1,916,962 and 1,901,960 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. 2024 Equity Incentive PlanIn April 2024, the Companyâ€™s board of directors adopted the 2024 Equity Incentive Plan (â€œ2024 Planâ€), which was subsequently approved by the Companyâ€™s stockholders and became effective on June 19, 2024. The 2024 Plan is the successor to the 2014 Plan. The 2014 Plan terminated on February 11, 2024 and no new grants may be made under the 2014 Plan after that date, although all outstanding awards granted under the 2014 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such awards and the terms of the 2014 Plan. The purpose of the 2024 Plan is to allow the Company to utilize equity incentives in order to secure and retain the services of the Company's employees, directors, and consultants, and to provide long-term incentives that align the interests of the Company's employees, directors, and consultants with the interests of the Company's stockholders.The aggregate number of shares of the Company's common stock that may be issued under the 2024 Plan will not exceed the sum of (i) 6,150,000 new shares, plus (ii) certain shares subject to outstanding awards granted under the 2014 Plan that may become available for grant under the 2024 Plan as such shares become available from time to time. As of June 30, 2024, there were 5,874,196 shares of common stock available for future issuance under the 2024 Plan.2015 Inducement Award PlanAs of June 30, 2024, there were 637,050 shares of common stock available for future issuance under the Companyâ€™s 2015 Inducement Award Plan (â€œ2015 Planâ€). During both the six months ended June 30, 2024 and 2023, there were options to purchase zero shares of the Companyâ€™s common stock granted under the 2015 Plan.The activity for the Companyâ€™s 2024 Plan, 2014 Plan, and 2015 Plan, for the six months ended June 30, 2024, is summarized as follows:Â Â Â Number ofShares Â Â Weighted-AverageExercisePrice Â Â Weighted-AverageRemainingContractualLife (in years) Â Â AggregateIntrinsicValue ($000) Â Outstanding â€” December 31, 2023 Â Â 1,867,795 Â Â $ 10.72 Â Â Â 6.10 Â Â $ 184 Â Granted Â Â 1,000,060 Â Â $ 1.86 Â Â Â Â Â Â Â Â Forfeited/Cancelled Â Â (25,047) Â $ 36.36 Â Â Â Â Â Â Â Outstanding â€” June 30, 2024 Â Â 2,842,808 Â Â $ 7.38 Â Â Â 7.04 Â Â $ 254 Â Exercisable â€” June 30, 2024 Â Â 1,545,764 Â Â $ 11.78 Â Â Â 5.22 Â Â $ 59 Â Vested or expected to vest â€” June 30, 2024 Â Â 2,842,808 Â Â $ 7.38 Â Â Â 7.04 Â Â $ 254 Â Restricted stock unit (â€œRSUâ€) activity under the 2024 Plan, 2014 Plan, and 2015 Plan for the six months ended June 30, 2024, is summarized as follows: Â Â Number of Shares Â Â WeightedAverageGrant DateFair ValuePer Share Â Non-vested at December 31, 2023 Â Â 1,886,374 Â Â $ 2.28 Â Granted Â Â 2,015,940 Â Â $ 1.88 Â Vested Â Â (629,849) Â $ 3.00 Â Forfeited Â Â (9,120) Â $ 2.15 Â Non-vested at June 30, 2024 Â Â 3,263,345 Â Â $ 1.89 Â Â The fair value of RSUs is based on the market price of the Companyâ€™s common stock on the date of grant. RSUs generally vest 33% annually over a three-year period from the date of grant. Upon vesting, the RSUs generally are net share settled to cover the required withholding tax with the remaining shares issued to the holder. The Company recognizes compensation expense for such awards ratably over the corresponding vesting period.Compensation CostThe compensation cost that has been charged against income for stock awards was $0.8 million and $0.7 million for the three months ended June 30, 2024 and 2023, and was $1.5 million and $1.4 million for the six months ended June 30, 2024 and 2023, respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was zero for each of the three and six months ended June 30, 2024 and 2023.Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 216 Â Â $ 301 Â Â $ 411 Â Â $ 675 Â Selling, general and administrative Â Â 543 Â Â Â 427 Â Â Â 1,053 Â Â Â 760 Â Total Â $ 759 Â Â $ 728 Â Â $ 1,464 Â Â $ 1,435 Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements 10. Fair Value MeasurementsThe carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, investments, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments.Assets and Liabilities Measured at Fair Value on a Recurring BasisThe Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of June 30, 2024 and December 31, 2023 for financial instruments measured at fair value on a recurring basis (in thousands): Â Â Â Â Â Fair Value Hierarchy Classification Â Â Â Balance Â Â QuotedPrices inActiveMarkets forIdenticalAssets(Level 1) Â Â SignificantOtherObservableInputs(Level 2) Â Â SignificantUnobservableInputs (Level 3) Â June 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash Â $ 1,364 Â Â $ 1,364 Â Â Â Â â€” Â Â Â â€” Â Restricted cash Â Â 543 Â Â Â 543 Â Â Â â€” Â Â Â â€” Â Money market funds Â Â 24,630 Â Â Â 24,630 Â Â Â Â â€” Â Â Â â€” Â Total assets Â $ 26,537 Â Â $ 26,537 Â Â Â Â â€” Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant liabilities Â $ 17,962 Â Â Â â€” Â Â Â â€” Â Â $ 17,962 Â Total liabilities Â $ 17,962 Â Â Â Â â€” Â Â Â â€” Â Â $ 17,962 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash Â $ 767 Â Â $ 767 Â Â Â â€” Â Â Â â€” Â Restricted cash Â Â 543 Â Â Â 543 Â Â Â â€” Â Â Â â€” Â Money market funds Â Â 33,283 Â Â Â 33,283 Â Â Â â€” Â Â Â â€” Â Total assets Â $ 34,593 Â Â $ 34,593 Â Â Â â€” Â Â Â â€” Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant liabilities Â $ 21,810 Â Â Â â€” Â Â Â â€” Â Â $ 21,810 Â Derivative liability Â Â 196 Â Â Â â€” Â Â Â â€” Â Â Â 196 Â Total liabilities Â $ 22,006 Â Â Â â€” Â Â Â â€” Â Â $ 22,006 Â The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on â€œLevel 1â€ inputs, which consist of quoted prices in active markets for identical assets. As of June 30, 2024, the cash and cash equivalents of $26.0 million and the restricted cash balances of $0.4 million and $0.2 million within short and long term on the unaudited condensed consolidated balance sheet, respectively, sum to the total of $26.5 million as shown in the unaudited condensed consolidated statement of cash flows.Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Companyâ€™s stock price, contractual terms, maturity, risk free rates, as well as volatility. The unobservable input for all of the Level 3 warrant liabilities includes volatility. The historical and implied volatility of the Company, using its closing common stock prices and market data, is utilized to reflect future volatility over the expected term of the warrants. At June 30, 2024, the Level 3 volatility utilized in the Black-Scholes model to fair value the warrant liability was 86.6%.The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Companyâ€™s stock price, contractual terms, dividend yield, risk-free rate, adjusted equity volatility, credit rating, market credit spread, and estimated effective yield. The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield. As of June 30, 2024, these inputs were 71.8%, 1,477 basis points, and 20.0%, respectively. The senior convertible notes are initially fair valued using the binomial lattice model and with the straight debt fair value calculated using the discounted cash flow method. The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Â Â Â Warrant Liabilities Â Balance â€” December 31, 2023 Â Â $ 21,810 Â Gain adjustment to fair value Â Â Â (3,848) Balance â€” June 30, 2024 Â Â $ 17,962 Â Â Â Â Â Â Â Â Â Derivative Liability Â Balance â€” December 31, 2023 Â Â $ 196 Â Gain adjustment to fair value Â Â Â (196) Balance â€” June 30, 2024 Â Â $ â€” Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue 6 Months Ended Jun. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenue 11. RevenueProduct Revenue, NetNet product revenue was zero and $0.5 million for the three months ended June 30, 2024 and 2023, respectively, and zero and $1.6 million for the six months ended June 30, 2024 and 2023, respectively. Products are sold primarily to wholesalers and specialty pharmacies. Revenue is reduced from wholesaler list price at the time of recognition for expected chargebacks, rebates, discounts, incentives, and returns, which are referred to as gross to net (â€œGTNâ€) adjustments. These reductions are currently attributed to various commercial arrangements. Chargebacks and discounts are recognized as a reduction in accounts receivable or as accrued expenses based on their nature and

settled through the issuance of credits to the customer or through cash payments to the customer, respectively. All other returns, rebates, and incentives are reflected as accrued expenses and settled through cash payments to the customer. Revenue attributed to sales to three wholesalers comprised 46%, 26%, and 25% of the Companyâ€™s gross revenue for the six months ended June 30, 2023.Â The following table summarizes activity in each of the Companyâ€™s product revenue provision and allowance categories as of June 30, 2024 and 2023 (in thousands):Â Â Â Discounts and Chargebacks (1) Â Â Product Returns (2) Â Â Rebates and Incentives (3) Â Â Product Recall (4) Â Â Total Â Balance as of December 31, 2023 Â $ â€” Â Â $ 36 Â Â $ 89 Â Â $ 1,932 Â Â $ 2,057 Â Provision related to current period revenue Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Changes in estimate related to prior period revenue Â Â â€” Â Â Â 51 Â Â Â (26) Â Â â€” Â Â Â 25 Â Credit/payments Â Â â€” Â Â Â â€” Â Â Â (39) Â Â (550) Â Â (589) Balance as of June 30, 2024 Â $ â€” Â Â $ 87 Â Â $ 24 Â Â $ 1,382 Â Â $ 1,493 Â Discounts and Chargebacks (1) Â Â Product Returns (2) Â Â Rebates and Incentives (3) Â Â Product Recall (4) Â Â Total Â Balance as of December 31, 2022 Â $ 255 Â Â $ 73 Â Â $ 1,213 Â Â $ â€” Â Â $ 1,541 Â Provision related to current period revenue Â Â 773 Â Â Â 316 Â Â Â 2,054 Â Â Â â€” Â Â Â 3,143 Â Changes in estimate related to prior period revenue Â Â â€” Â Â Â 693 Â Â Â â€” Â Â Â â€” Â Â Â 693 Â Credit/payments Â Â (708) Â Â (74) Â Â (1,347) Â Â â€” Â Â Â (2,129) Balance as of June 30, 2023 Â $ 320 Â Â $ 1,008 Â Â $ 1,920 Â Â $ â€” Â Â $ 3,248 Â Â (1)Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Companyâ€™s unaudited condensed consolidated balance sheet.(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Companyâ€™s unaudited condensed consolidated balance sheet.(3)Rebates and incentives include rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Companyâ€™s unaudited condensed consolidated balance sheets.(4)Provisions for product recall are deducted from gross revenues to the extent of revenue recorded related to the recalled product and are included in accrued expenses on the Companyâ€™s unaudited condensed consolidated balance sheet.License Agreement with GSKOn March 30, 2023, the Company entered into the GSK License Agreement. Pursuant to the terms of the GSK License Agreement, the Company granted GSK an exclusive (even as to the Company and its affiliates), royalty-bearing, sublicensable license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the â€œGSK Territoryâ€). If the existing licenses granted to or agreements with third parties are terminated with respect to any country, GSK will have an exclusive first right to negotiate with the Company to add those additional countries to the GSK Territory. The parties closed the transactions contemplated by the GSK License Agreement in May 2023.As previously disclosed, the Company became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp. Current FDA draft guidance recommends segregating the manufacture of non-antibacterial beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people. In the absence of the recommended segregation, there is a risk of cross contamination. It is not known whether any ibrexafungerp has been contaminated with a beta-lactam compound. Nonetheless, in light of this risk and out of an abundance of caution, BREXAFEMME (ibrexafungerp tablets) was recalled from the market and clinical studies of ibrexafungerp were placed on temporary hold. On December 26, 2023, the Company and GSK entered into a binding memorandum of understanding ("Binding MOU") for amendment to the GSK License Agreement. The GSK License Agreement was amended in connection with the delay in the commercialization of BREXAFEMME and further clinical development of ibrexafungerp associated with this event. Under the terms of the updated GSK License Agreement, as amended by Binding MOU, the Company is now eligible to receive potential: â€¢regulatory approval milestone payments of up to $49 million (revised from up to $70 million as provided in the GSK License Agreement);â€¢commercial milestone payments of up to $57.5 million based on first commercial sale in invasive candidiasis (U.S./EU) (revised from up to $115 million as provided in the GSK License Agreement); andâ€¢and sales milestone payments of up to $179.5 / $169.75 / $145.5 million (depending on the date of GSKâ€™s relaunch of BREXAFEMME in the U.S.) (revised from up to $242.5 million as provided in the GSK License Agreement). These milestones are based on annual net sales in the GSK Territory, with a total of $64 / $54.25 / $46.5 million to be paid upon achievement of multiple sales thresholds up through $200 million; a total of $45.5 / $45.5 / $39 million to be paid upon achievement of multiple sales thresholds between $300 million and $500 million; and $35 / $35 / $30 million to be paid at each sales threshold of $750 million and $1 billion.The Company will continue to be responsible for the execution and costs of the ongoing clinical studies of ibrexafungerp but will have the potential to receive up to $72.35 million in development milestones (revised from up to $75.5 million as provided in the GSK License Agreement), which comprise: $25 million already paid; $10 million for the delivery to GSK of final clinical study reports for the completed FURI, CARES, and NATURE clinical studies; up to $30 million for the achievement of two interim milestones associated with the Company's resumption and continued performance of the MARIO Study after the clinical hold is lifted; and $7.35 million for the successful completion of the MARIO Study. In the case of each of the above milestones, such milestone events are defined in the GSK License Agreement, as amended by the Binding MOU. In July 2024, the Company delivered to GSK the final clinical study reports for the completed FURI, CARES, and NATURE clinical studies and the Company expects to collect the $10.0 million development milestone in the third quarter of 2024. GSK will also pay royalties based on cumulative annual sales to us in the mid-single digit to mid-teen range. The royalty terms are not amended by the Binding MOU.The Company evaluated the GSK License Agreement in accordance with ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The Company assessed the terms of the GSK License Agreement and identified the following performance obligations which include: (1) the license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME, in the GSK Territory, (2) the research and development activities for the MARIO study, and (3) performance obligations for the remaining research and development activities for the ongoing clinical and preclinical studies of ibrexafungerp. The Company provided all necessary information to GSK for it to benefit from the license under the license term in 2023 when the Company transferred the license.As of June 30, 2024, the Company maintains a $19.5 million contract asset associated with the success-based milestones associated with the ongoing clinical studies of ibrexafungerp. The Company believes that the $19.5 million contract asset is collectible given the Company's probability assessment of achieving the milestones as defined in the GSK License Agreement, ongoing development activities, and other information available to the Company. The Company reassessed the transaction price as of June 30, 2024, including estimated variable consideration included in the transaction price and the remaining milestones continued to be constrained.The Company recognizes the revenue associated with the MARIO study and the remaining ongoing clinical and preclinical studies of ibrexafungerp over time using an input method. The input method is based on the actual costs incurred as a percentage of total budgeted costs towards satisfying the performance obligation as this method provides the most faithful depiction of the Companyâ€™s performance in transferring control of the services promised to GSK and represents the Companyâ€™s best estimate of the period of the obligation. As of June 30, 2023, the Company provided all necessary information to GSK for it to benefit from the license under the license term. Accordingly, for the three months and six months ended June 30, 2023, the Company recognized $130.1 million in license revenue at a point in time upon the transfer of the license to GSK and completion of the initial technology transfer. For the three months ended June 30, 2024 and 2023, the Company recognized $0.7 million and $131.0 million of license agreement revenue, respectively, and for the six months ended June 30, 2024 and 2023, the Company recognized $2.1 million and $131.0 million, respectively. As of June 30, 2024, there is $1.2 million and $1.8 million of current and long-term deferred revenue, respectively, which is expected to be recognized by the end of 2025. License Agreement with HansohIn February 2021, the Company entered into an Exclusive License and Collaboration Agreement (the â€œHansoh Agreementâ€) with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, â€œHansohâ€), pursuant to which the Company granted to Hansoh an exclusive license to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan (the â€œTerritoryâ€). The Company also granted to Hansoh a non-exclusive license to manufacture ibrexafungerp solely for development and commercialization in the Territory. For the three and six months ended June 30, 2024 and 2023, there was no license agreement revenue recognized associated with the Hansoh Agreement given the variable consideration was fully constrained as of June 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Basic and Diluted Net (Loss) Income per Share of Common Stock Basic and Diluted Net (Loss) Income per Share of Common StockThe Company calculates net (loss) income per common share in accordance with ASC 260, Earnings Per Share. Basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined by dividing net (loss) income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 includes the outstanding prefunded warrants to purchase 7,516,267 and 3,200,000 shares of common stock issued in the April 2022 public offering and December 2020 public offering. Diluted net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined as follows (in thousands, except share and per share amounts): Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net (loss) income allocated to common shares $ (14,458) Â $ 122,260 Â Â $ (14,047) Â $ 88,384 Â Dilutive effect of convertible debt Â â€” Â Â Â 433 Â Â Â â€” Â Â $ 1,047 Â Net (loss) income allocated to common shares $ (14,458) Â $ 122,693 Â Â $ (14,047) Â $ 89,431 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding â€” basic Â 48,511,656 Â Â Â 47,837,393 Â Â Â 48,379,256 Â Â Â 47,797,731 Â Dilutive effect of convertible debt Â â€” Â Â Â 1,138,200 Â Â Â â€” Â Â Â 1,138,200 Â Dilutive effect of restricted stock units Â â€” Â Â Â 947,768 Â Â Â â€” Â Â Â 230,320 Â Weighted average common shares outstanding â€” diluted Â 48,511,656 Â Â Â 49,923,361 Â Â Â 48,379,256 Â Â Â 49,166,251 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net (loss) income per share â€” diluted $ (0.30) Â $ 2.46 Â Â $ (0.29) Â $ 1.82 Â Â The following potentially dilutive shares of common stock and outstanding restricted stock units that contain certain performance contingencies have not been included in the computation of diluted net (loss) income per share for the three and six months ended June 30, 2024 and 2023, as the result would be anti-dilutive or the performance contingencies have not been met: Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Outstanding stock options Â 2,842,808 Â Â Â 1,970,536 Â Â Â 2,842,808 Â Â Â 1,970,536 Â Outstanding restricted stock units Â 3,263,345 Â Â Â 400,000 Â Â Â 3,263,345 Â Â Â 400,000 Â Warrants to purchase common stock associated with December 2020 public offering - Series 2 Â â€” Â Â Â 6,800,000 Â Â Â â€” Â Â Â 6,800,000 Â Warrants to purchase common stock associated with April 2022 public offering Â 15,000,000 Â Â Â 15,000,000 Â Â Â 15,000,000 Â Â Â 15,000,000 Â Warrants to purchase common stock associated with Loan Agreement Â 198,811 Â Â Â 198,811 Â Â Â 198,811 Â Â Â 198,811 Â Common stock associated with March 2019 Notes Â 1,138,200 Â Â Â â€” Â Â Â 1,138,200 Â Â Â â€” Â Warrants to purchase common stock associated with Danforth Â 50,000 Â Â Â 50,000 Â Â Â 50,000 Â Â Â 50,000 Â Total Â 22,493,164 Â Â Â 24,419,347 Â Â Â 22,493,164 Â Â Â 24,419,347 Â Reclassification of Prior Year Amounts Reclassification of Prior Year AmountsCertain prior year amounts within the changes in operating assets and liabilities on the unaudited condensed consolidated statement of cash flows and certain prior year accrued expenses have been reclassified for consistency with the current year presentation. Recently Issued Accounting Pronouncements Recently Adopted Accounting PronouncementsIn August 2020, the FASB issued ASU No. 2020-06, Debtâ€”Debt with Conversion and Other Options and Derivatives and Hedgingâ€”Contracts in Entityâ€™s Own Equity: Accounting for Convertible Instruments and Contracts in and Entityâ€™s Own Equity (â€œASU 2020-06â€). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. The Company adopted ASU 2020-06 on January 1, 2024 and the adoption did not materially impact the unaudited condensed consolidated financial statements.Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which introduced new guidance on disclosures for reportable segments and significant segment expenses, including for entities with a single reportable segment. This guidance is effective for the Company for annual reporting periods beginning January 1, 2024 and interim periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements.In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which introduced new guidance on disclosures for income taxes, including enhancements to the rate reconciliation and income taxes paid disclosures. This guidance is effective for the Company for annual reporting periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements.Â X - DefinitionRecently issued accounting pronouncements. + ReferencesNo definition available. + Details Name: scyx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock Namespace Prefix: scyx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph

1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Schedule of Diluted Net (Loss) Income Per Common Share The Company calculates net (loss) income per common share in accordance with ASC 260, Earnings Per Share. Basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined by dividing net (loss) income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 includes the outstanding prefunded warrants to purchase 7,516,267 and 3,200,000 shares of common stock issued in the April 2022 public offering and December 2020 public offering. Diluted net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined as follows (in thousands, except share and per share amounts): Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net (loss) income allocated to common shares $ (14,458) Â $ 122,260 Â Â $ (14,047) Â $ 88,384 Â Dilutive effect of convertible debt Â â€” Â Â Â 433 Â Â Â â€” Â Â $ 1,047 Â Net (loss) income allocated to common shares $ (14,458) Â $ 122,693 Â Â $ (14,047) Â $ 89,431 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average common shares outstanding â€“ basic Â 48,511,656 Â Â Â 47,837,393 Â Â Â 48,379,256 Â Â Â 47,797,731 Â Dilutive effect of convertible debt Â â€” Â Â Â 1,138,200 Â Â Â â€” Â Â Â 1,138,200 Â Dilutive effect of restricted stock units Â â€” Â Â Â 947,768 Â Â Â â€” Â Â Â 230,320 Â Weighted average common shares outstanding â€“ diluted Â 48,511,656 Â Â Â 49,923,361 Â Â Â 48,379,256 Â Â Â 49,166,251 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net (loss) income per share â€“ diluted $ (0.30) Â $ 2.46 Â Â $ (0.29) Â $ 1.82 Â Â Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock and Outstanding Restricted Stock Units The following potentially dilutive shares of common stock and outstanding restricted stock units that contain certain performance contingencies have not been included in the computation of diluted net (loss) income per share for the three and six months ended June 30, 2024 and 2023, as the result would be anti-dilutive or the performance contingencies have not been met: Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Outstanding stock options Â 2,842,808 Â Â Â 1,970,536 Â Â Â 2,842,808 Â Â Â 1,970,536 Â Outstanding restricted stock units Â 3,263,345 Â Â Â 400,000 Â Â Â 3,263,345 Â Â Â 400,000 Â Warrants to purchase common stock associated with December 2020 public offering - Series 2 Â â€” Â Â Â 6,800,000 Â Â Â â€” Â Â Â 6,800,000 Â Warrants to purchase common stock associated with April 2022 public offering Â 15,000,000 Â Â Â 15,000,000 Â Â Â 15,000,000 Â Â Â 15,000,000 Â Warrants to purchase common stock associated with Loan Agreement Â 198,811 Â Â Â 198,811 Â Â Â 198,811 Â Â Â 198,811 Â Common stock associated with March 2019 Notes Â 1,138,200 Â Â Â â€” Â Â Â 1,138,200 Â Â Â â€” Â Warrants to purchase common stock associated with Danforth Â 50,000 Â Â Â 50,000 Â Â Â 50,000 Â Â Â 50,000 Â Total Â 22,493,164 Â Â Â 24,419,347 Â Â Â 22,493,164 Â Â Â 24,419,347 Â X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the effect of income (loss) on an entity's diluted earnings per share. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52 + Details Name: us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Investments (Tables) 6 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Summary of Investments The following table summarizes the investments at June 30, 2024 (in thousands): Â Â AmortizedCost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â Fair Value Â As of June 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities < 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 44,527 Â Â $ 6 Â Â $ (47) Â $ 44,486 Â Agency bonds Â 2,517 Â Â Â â€” Â Â Â (2) Â Â 2,515 Â Total short-term investments Â $ 47,044 Â Â $ 6 Â Â $ (49) Â $ 47,001 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities > 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 10,657 Â Â $ 10 Â Â $ (23) Â $ 10,644 Â Total investments Â $ 10,657 Â Â $ 10 Â Â $ (23) Â $ 10,644 Â Â Â Â Â Â Â Â Â Â Â Â Â Â As of December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities < 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 35,286 Â Â $ 25 Â Â $ (13) Â $ 35,298 Â Agency bonds Â 5,026 Â Â Â 6 Â Â Â â€” Â Â Â 5,032 Â Total short-term investments Â $ 40,312 Â Â $ 31 Â Â $ (13) Â $ 40,330 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maturities > 1 Year Â Â Â Â Â Â Â Â Â Â Â Â Â Â Corporate bonds Â $ 23,594 Â Â $ 143 Â Â $ (9) Â $ 23,728 Â Total investments Â $ 23,594 Â Â $ 143 Â Â $ (9) Â $ 23,728 Â X - DefinitionTabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 15: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5B + Details Name: us-gaap_HeldToMaturitySecuritiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Current Assets (Tables) 6 Months Ended Jun. 30, 2024 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â Schedule of Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): Â Â June 30, 2024 Â Â December 31, 2023 Â Prepaid research and development services Â $ â€” Â Â $ 196 Â Prepaid insurance Â Â 651 Â Â Â 264 Â Other prepaid expenses Â Â 213 Â Â Â 182 Â Other current assets Â Â 554 Â Â Â 4,906 Â Total prepaid expenses and other current assets Â $ 1,418 Â Â $ 5,548 Â X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs. + ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses (Tables) 6 Months Ended Jun. 30, 2024 Payables and Accruals [Abstract] Â Schedule of Accrued Expenses Accrued expenses consisted of the following (in thousands):Â Â Â June 30, 2024 Â Â December 31, 2023 Â Accrued research and development expenses Â $ 2,348 Â Â $ 2,830 Â Accrued employee bonus compensation Â Â 906 Â Â Â 1,692 Â Other accrued expenses Â Â 862 Â Â Â 1,040 Â Accrued product recall Â Â 1,382 Â Â Â 1,933 Â Total accrued expenses Â $ 5,498 Â Â $ 7,495 Â Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands):Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Operating lease cost Â $ 166 Â Â $ 166 Â Â $ 332 Â Â $ 332 Â Variable lease cost Â Â 27 Â Â Â 46 Â Â Â 4 Â Â Â 104 Â Total operating lease expense Â $ 193 Â Â $ 212 Â Â $ 336 Â Â $ 436 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Cash paid for amounts included in the measurement of operating lease liability Â $ 181 Â Â $ 177 Â Â $ 362 Â Â $ 355 Â Â Â Â Â Â Â Â Â Â Â Â Â Â June 30, 2024 Â December 31, 2023 Â Remaining Lease term (years) Â Â Â Â Â Â Â Â Â Â 5.09 Â Â Â 5.59 Â Discount rate Â Â Â Â Â Â Â Â Â Â 15 % Â Â 15 % Â Future Minimum Lease Payments Future minimum lease payments for the Lease as of June 30, 2024 are as follows (in thousands): Â Â June 30, 2024 Â 2024 Â $ 368 Â 2025 Â Â 744 Â 2026 Â Â 759 Â 2027 Â Â 774 Â 2028 Â Â 790 Â Thereafter Â Â 466 Â Total Â $ 3,901 Â Presentation of Operating Lease Liability The presentations of the operating lease liability as of June 30, 2024 are as follows (in thousands):Â Â Â June 30, 2024 Â Present value of future minimum lease payments Â $ 2,760 Â Â Â Â Operating lease liability, current portion Â $ 372 Â Operating lease liability, long-term portion Â Â 2,388 Â Total operating lease liability Â $ 2,760 Â Â Â Â Difference between future minimum lease payments and discounted cash flows Â $ 1,141 Â X - DefinitionOperating lease liability. + ReferencesNo definition available. + Details Name: scyx_OperatingLeaseLiabilityTableTextBlock Namespace Prefix: scyx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Tables) 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â Summary of Common Stock Shares Activity The following table summarizes common stock share activity for the three and six months ended June 30, 2024 and 2023 (dollars in thousands): Â Â Three Months Ended June 30, 2024 Â Â Â Â Shares ofCommon Stock Â Â CommonStock Â Â Additional Paid-in Capital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™ Equity Â Balance, March 31, 2024 Â Â 37,779,796 Â Â $ 41 Â Â $ 428,900 Â Â $ (354,836) Â $ 74,105 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â (14,458) Â Â (14,458) Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 759 Â Â Â â€” Â Â Â 759 Â Common stock issued for vested restricted stock units Â Â 76,667 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Balance, June 30, 2024 Â Â 37,856,463 Â Â $ 41 Â Â $ 429,659 Â Â $ (369,294) Â $ 60,406 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended June 30, 2023 Â Â Shares ofCommon Stock Â Â CommonStock Â Â Additional Paid-in Capital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™ (Deficit) Equity Â Balance, March 31, 2023 Â Â 33,327,627 Â Â $ 36 Â Â $ 426,214 Â Â $ (456,164) Â $ (29,914) Net income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 122,260 Â Â Â 122,260 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 728 Â Â Â â€” Â Â Â 728 Â Common stock issued, net of expenses Â Â 3,787,400 Â Â Â 4 Â Â Â â€” Â Â Â â€” Â Â Â 4 Â Common stock issued for vested restricted stock units Â Â 60,638 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Balance, June 30, 2023 Â Â 37,175,665 Â Â $ 40 Â Â $ 426,942 Â Â $ (333,904) Â $ 93,078 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Six Months Ended June 30, 2024 Â Â Â Â Shares ofCommon Stock Â Â CommonStock Â Â Additional Paid-in Capital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™ Equity Â Balance, December 31, 2023 Â Â 37,207,799 Â Â $ 40 Â Â $ 428,169 Â Â $ (355,247) Â $ 72,962 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (14,047) Â Â (14,047) Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 1,464 Â Â Â â€” Â Â Â 1,464 Â Common stock issued through employee stock purchase plan Â Â 18,815 Â Â Â â€” Â Â Â 26 Â Â Â â€” Â Â Â 26 Â Common stock issued for vested restricted stock units Â Â 629,849 Â Â Â 1 Â Â Â â€” Â Â Â â€” Â Â Â 1 Â Balance, June 30, 2024 Â Â 37,856,463 Â Â $ 41 Â Â $ 429,659 Â Â $ (369,294) Â $ 60,406 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Six Months Ended June 30, 2023 Â Â Â Â Shares ofCommon

Stock Â Â CommonStock Â Â Additional Paid-in Capital Â Â AccumulatedDeficit Â Â TotalStockholdersâ€™Equity Â Balance, December 31, 2022 Â Â 32,682,342 Â Â $ 36 Â Â $ 425,485 Â Â $ (422,288) Â $ 3,233 Â Net income Â Â â€” Â Â Â â€” Â Â Â 88,384 Â Â Â 88,384 Â Stock-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 1,435 Â Â Â â€” Â Â Â 1,435 Â Common stock issued through employee stock purchase plan Â Â 2,662 Â Â Â â€” Â Â Â 4 Â Â Â â€” Â Â Â 4 Â Common stock issued, net of expenses Â Â 4,150,400 Â Â Â 4 Â Â Â â€” Â Â Â 4 Â Common stock issued for vested restricted stock units Â Â 340,261 Â Â Â â€” Â Â Â 18 Â Â Â â€” Â Â Â 18 Â Balance, June 30, 2023 Â Â 37,175,665 Â Â $ 40 Â Â $ 426,942 Â Â $ (333,904) Â $ 93,078 Â Common Stock Reserved For Future Issuances The Company had reserved shares of common stock for future issuance as follows:Â Â Â June 30, 2024 Â Â December 31, 2023 Â Outstanding stock options Â Â 2,842,808 Â Â Â 1,867,795 Â Outstanding restricted stock units Â Â 3,263,345 Â Â Â 1,886,374 Â Warrants to purchase common stock associated with December 2020 public offering - Series 2 Â Â â€” Â Â Â 6,800,000 Â Prefunded warrants to purchase common stock associated with December 2020 public offering Â Â 3,200,000 Â Â Â 3,200,000 Â Warrants to purchase common stock associated with April 2022 public offering Â Â 15,000,000 Â Â Â 15,000,000 Â Prefunded warrants to purchase common stock associated with April 2022 public offering Â Â 7,516,267 Â Â Â 7,516,267 Â Warrants to purchase common stock associated with Loan Agreement Â Â 198,811 Â Â Â 198,811 Â Warrant to purchase common stock associated with Danforth Â Â 50,000 Â Â Â 50,000 Â For possible future issuance for the conversion of the March 2019 Notes Â Â 1,138,200 Â Â Â 1,138,200 Â For possible future issuance under 2024 Plan (Note 9) Â Â 5,874,196 Â Â Â 848,202 Â For possible future issuance under employee stock purchase plan Â Â 1,458,171 Â Â Â 1,474,045 Â For possible future issuance under 2015 Plan (Note 9) Â Â 637,050 Â Â Â 633,590 Â Total common shares reserved for future issuance Â Â 41,178,848 Â Â Â 40,613,284 Â X - DefinitionCommon stock reserved for future issuances. + ReferencesNo definition available. + Details Name: scyx_CommonStockReservedForFutureIssuancesTableTableTextBlock Namespace Prefix: scyx_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in common stock outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Stock Option Activity The activity for the Companyâ€™s 2024 Plan, 2014 Plan, and 2015 Plan, for the six months ended June 30, 2024, is summarized as follows:Â Â Â Number ofShares Â Â Weighted-AverageExercisePrice Â Â Weighted-AverageRemainingContractualLife (in years) Â Â AggregateIntrinsicValue ($000) Â Outstanding â€” December 31, 2023 Â Â 1,867,795 Â Â $ 10.72 Â Â Â 6.10 Â Â $ 184 Â Granted Â Â 1,000,060 Â Â $ 1.86 Â Â Â Â Â Â Â Forfeited/Cancelled Â Â (25,047) Â $ 36.36 Â Â Â Â Â Â Â Outstanding â€” June 30, 2024 Â Â 2,842,808 Â Â $ 7.38 Â Â Â 7.04 Â Â $ 254 Â Exercisable â€” June 30, 2024 Â Â 1,545,764 Â Â $ 11.78 Â Â Â 5.22 Â Â $ 59 Â Vested or expected to vest â€” June 30, 2024 Â Â 2,842,808 Â Â $ 7.38 Â Â Â 7.04 Â Â $ 254 Â Schedule of Restricted Stock Units ("RSU") Activity Restricted stock unit (â€œRSUâ€) activity under the 2024 Plan, 2014 Plan, and 2015 Plan for the six months ended June 30, 2024, is summarized as follows: Â Â Number of Shares Â Â WeightedAverageGrant DateFair ValuePer Share Â Non-vested at December 31, 2023 Â Â 1,886,374 Â Â $ 2.28 Â Granted Â Â 2,015,940 Â Â $ 1.88 Â Vested Â Â (629,849) Â $ 3.00 Â Forfeited Â Â (9,120) Â $ 2.15 Â Non-vested at June 30, 2024 Â Â 3,263,345 Â Â $ 1.89 Â Stock-Based Compensation Expense Related to Stock Options Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): Â Â Â Three Months Ended June 30, Â Â Six Months Ended June 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 216 Â Â $ 301 Â Â $ 411 Â Â $ 675 Â Selling, general and administrative Â Â 543 Â Â Â 427 Â Â Â 1,053 Â Â Â 760 Â Total Â $ 759 Â Â $ 728 Â Â $ 1,464 Â Â $ 1,435 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Summary of Financial Instruments Measured on a Recurring Basis The following table summarizes the conclusions reached as of June 30, 2024 and December 31, 2023 for financial instruments measured at fair value on a recurring basis (in thousands): Â Â Â Â Â Fair Value Hierarchy Classification Â Â Â Balance Â Â QuotedPrices inActiveMarkets forIdenticalAssets(Level 1) Â Â SignificantOtherObservableInputs(Level 2) Â Â SignificantUnobservableInputs (Level 3) Â June 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Cash Â $ 1,364 Â Â $ 1,364 Â Â Â Â â€” Â Â Â â€” Â Restricted cash Â Â 543 Â Â Â 543 Â Â Â â€” Â Â Â â€” Â Money market funds Â Â 24,630 Â Â Â 24,630 Â Â Â â€” Â Â Â â€” Â Total assets Â $ 26,537 Â Â $ 26,537 Â Â Â â€” Â Â Â â€” Â Warrant liabilities Â $ 17,962 Â Â Â â€” Â Â Â $ 17,962 Â Total liabilities Â $ 17,962 Â Â Â â€” Â Â Â $ 17,962 Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Cash Â $ 767 Â Â $ 767 Â Â Â â€” Â Â Â â€” Â Restricted cash Â Â 543 Â Â Â 543 Â Â Â â€” Â Â Â â€” Â Money market funds Â Â 33,283 Â Â Â 33,283 Â Â Â â€” Â Â Â â€” Â Total assets Â $ 34,593 Â Â $ 34,593 Â Â Â â€” Â Â Â â€” Â Warrant liabilities Â $ 21,810 Â Â Â â€” Â Â Â $ 21,810 Â Derivative liability Â Â 196 Â Â Â â€” Â Â Â â€” Â Â Â 196 Â Total liabilities Â $ 22,006 Â Â Â â€” Â Â Â $ 22,006 Â Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Â Â Â Warrant Liabilities Â Balance â€” December 31, 2023 Â Â $ 21,810 Â Gain adjustment to fair value Â Â Â (3,848) Balance â€” June 30, 2024 Â Â $ 17,962 Â Â Â Â Â Â Â Â Â Derivative Liability Â Balance â€” December 31, 2023 Â Â $ 196 Â Gain adjustment to fair value Â Â Â (196) Balance â€” June 30, 2024 Â Â $ â€” Â X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue (Tables) 6 Months Ended Jun. 30, 2024 Revenue from Contract with Customer [Abstract] Â Summary of Activity in Each of Product Revenue Provision and Allowance Categories The following table summarizes activity in each of the Companyâ€™s product revenue provision and allowance categories as of June 30, 2024 and 2023 (in thousands):Â Â Â Discounts and Chargebacks (1) Â Â Product Returns (2) Â Â Rebates and Incentives (3) Â Â Product Recall (4) Â Â Total Â Balance as of December 31, 2023 Â $ â€” Â Â $ 36 Â Â $ 89 Â Â $ 1,932 Â Â $ 2,057 Â Provision related to current period revenue Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Changes in estimate related to prior period revenue Â Â â€” Â Â Â 51 Â Â Â (26) Â Â â€” Â Â Â 25 Â Credit/payments Â Â â€” Â Â Â â€” Â Â Â (39) Â Â (550) Â Â (589) Balance as of June 30, 2024 Â $ â€” Â Â $ 87 Â Â $ 24 Â Â $ 1,382 Â Â $ 1,493 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Discounts and Chargebacks (1) Â Â Product Returns (2) Â Â Rebates and Incentives (3) Â Â Product Recall (4) Â Â Total Â Balance as of December 31, 2022 Â $ 255 Â Â $ 73 Â Â $ 1,213 Â Â $ â€” Â Â $ 1,541 Â Provision related to current period revenue Â Â 773 Â Â Â 316 Â Â Â 2,054 Â Â Â â€” Â Â Â 3,143 Â Changes in estimate related to prior period revenue Â Â â€” Â Â Â 693 Â Â Â â€” Â Â Â â€” Â Â Â 693 Â Credit/payments Â Â (708) Â Â (74) Â Â (1,347) Â Â â€” Â Â Â (2,129) Balance as of June 30, 2023 Â $ 320 Â Â $ 1,008 Â Â $ 1,920 Â Â $ â€” Â Â $ 3,248 Â Â (1)Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Companyâ€™s unaudited condensed consolidated balance sheet. (2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Companyâ€™s unaudited condensed consolidated balance sheet.(3)Rebates and incentives include rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Companyâ€™s unaudited condensed consolidated balance sheets.(4)Provisions for product recall are deducted from gross revenues to the extent of revenue recorded related to the recalled product and are included in accrued expenses on the Companyâ€™s unaudited condensed consolidated balance sheet. X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Description of Business and Basis of Preparation - Additional Information (Detail) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Accumulated deficit $ (369,294) $ (355,247) Cash and cash equivalents and short-term investments $ 83,700 Â X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 34 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Additional Information (Detail) - shares Jun. 30, 2024 Jun. 30, 2023 ASU 2020-06 Â Â Subsidiary Sale Of Stock [Line Items] Â Â Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true Â Change in Accounting

Principle, Accounting Standards Update, Adoption Date Jan. 01, 2024 Â Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true Â December 2020 Public Offering | Pre-funded Warrants Â Â Subsidiary Sale Of Stock [Line Items] Â Â Number of outstanding warrants issued to purchase common stock (in shares) 7,516,267 3,200,000 April 2022 Public Offering | Pre-funded Warrants Â Â Subsidiary Sale Of Stock [Line Items] Â Â Number of outstanding warrants issued to purchase common stock (in shares) 7,516,267 3,200,000 X - DefinitionIndicates (true false) whether accounting standards update was adopted. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -SubTopic 10 -Topic 326 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -SubTopic 10 -Topic 326 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -SubTopic 10 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4 + Details Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: instant X - DefinitionDate accounting standards update was adopted, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 50 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 832 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (a) -SubTopic 10 -Topic 326 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 3 -Subparagraph (b) -SubTopic 10 -Topic 326 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -SubTopic 10 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 250 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3 + Details Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: instant X - DefinitionIndicates (true false) whether effect from applying amendment to accounting standards is immaterial. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -SubTopic 20 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3 + Details Name: us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to,

500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=scyx_December2020PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=scyx_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=scyx_April2022PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Schedule of Diluted Net (Loss) Income Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Accounting Policies [Abstract] Â Â Â Â Net (loss) income allocated to common shares $ (14,458) $ 122,260 $ (14,047) $ 88,384 Dilutive effect of convertible debt 0 433 0 1,047 Net income (loss) allocated to common shares $ (14,458) $ 122,693 $ (14,047) $ 89,431 Weighted average common shares outstanding, basic 48,511,656 47,837,393 48,379,256 47,797,731 Dilutive effect of convertible debt 0 1,138,200 0 1,138,200 Dilutive effect of restricted stock units 0 947,768 0 230,320 Weighted average common shares outstanding, diluted 48,511,656 49,923,361 48,379,256 49,166,251 Net (loss) income per share - diluted $ (0.3) $ 2.46 $ (0.29) $ 1.82 X - DefinitionIncremental common shares attributable to restricted stock units. + ReferencesNo definition available. + Details Name: scyx_IncrementalCommonSharesAttributableToRestrictedStockUnits Namespace Prefix: scyx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units. + ReferencesNo definition available. + Details Name: us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40 + Details Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1

-Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 36 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Detail) - shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities (in shares) 22,493,164 24,419,347 22,493,164 24,419,347 Outstanding stock options Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities (in shares) 2,842,808 1,970,536 2,842,808 1,970,536 Outstanding restricted stock units Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities (in shares) 3,263,345 400,000 3,263,345 400,000 December 2020 Public Offering Series 2 | Warrant Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities (in shares) 0 6,800,000 0 6,800,000 April 2022 Public Offering | Warrant Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities (in shares) 15,000,000 15,000,000 15,000,000 15,000,000 Warrants to purchase common stock associated with Loan Agreement | Warrant Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities (in shares) 198,811 198,811 198,811 198,811 Common stock associated with March 2019 Notes Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities (in shares) 1,138,200 0 1,138,200 0 Warrants to purchase common stock associated with Danforth | Warrant Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Anti-dilutive securities (in shares) 50,000 50,000 50,000 50,000 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_December2020PublicOfferingSeries2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_April2022PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_WarrantsAssociatedWithLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_WarrantAssociatedWithDanforthMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Investments - Summary of Investments (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Maturities Less than 1 Year Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Amortized Cost $ 47,044 $ 40,312 Unrealized Gains 6 31 Unrealized Losses (49) (13) Fair Value 47,001 40,330 Maturities Greater than 1 Year Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Amortized Cost 10,657 23,594 Unrealized Gains 10 143 Unrealized Losses (23) (9) Fair Value 10,644 23,728 Corporate bonds | Maturities Less than 1 Year Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Amortized Cost 44,527 35,286 Unrealized Gains 6 25 Unrealized Losses (47) (13) Fair Value 44,486 35,298 Corporate bonds | Maturities Greater than 1 Year Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Amortized Cost 10,657 23,594 Unrealized Gains 10 143 Unrealized Losses (23) (9) Fair Value 10,644 23,728 Agency bonds | Maturities Less than 1 Year Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Amortized Cost 2,517 5,026 Unrealized Gains 0 6 Unrealized Losses (2) 0 Fair Value $ 2,515 $ 5,032 X - DefinitionAmount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7A -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-7A + Details Name: us-gaap_HeldToMaturitySecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_HeldToMaturitySecuritiesFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=scyx_LongTermInvestmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=scyx_AgencyBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Investments - Additional Information (Details) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Corporate and Agency Bonds | Level 2 Â Â Schedule of Held-to-Maturity Securities [Line Items] Â Â Fair Value $ 57.6 $ 64.1 X - DefinitionFair value of investment in debt security measured at amortized cost (held-to-maturity). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_HeldToMaturitySecuritiesFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org//1943274/2147481800/320-10-50-5AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5 + Details Name: us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=scyx_CorporateAndAgencyBondSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Â Â Prepaid research and development services $ 0 $ 196 Prepaid insurance 651 264 Other prepaid expenses 213 182 Other current assets 554 4,906 Total prepaid expenses and other current assets $ 1,418 $ 5,548 X - DefinitionPrepaid research and development expenses, current. + ReferencesNo definition available. + Details Name: scyx_PrepaidResearchandDevelopmentExpensesCurrent Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 40 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Accrued research and development expenses $ 2,348 $ 2,830 Accrued employee bonus compensation 906 1,692 Other accrued expenses 862 1,040 Accrued product recall 1,382 1,933 Total accrued expenses $ 5,498 $ 7,495 X - DefinitionAccrued product recall. + ReferencesNo definition available. + Details Name: scyx_AccruedProductRecall Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued research and development expense, current. + ReferencesNo definition available. + Details Name: scyx_AccruedResearchandDevelopmentExpenseCurrent Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedBonusesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Borrowings - Additional Information (Detail) 1 Months Ended 3 Months Ended 6 Months Ended May 13, 2021 USD ($) Tranche Mar. 07, 2019 USD ($) Feb. 28, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Mar. 30, 2023 USD ($) Dec. 31, 2022 Dec. 31, 2021 Debt Instrument [Line Items] Â Â Â

SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDate the debt instrument was offered for sale, in YYYY-MM-DD format. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_DebtInstrumentOfferingDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionDescription of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentPaymentTerms Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of the assets less the liabilities of a derivative or group of derivatives. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeFairValueOfDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNet Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 15 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//815-15/tableOfContent + Details Name: us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermLoansPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=scyx_LoanAgreementAmendmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=scyx_GlaxosmithklineIntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=scyx_HerculesCapitalIncorporatedAndSiliconValleyBankAndOtherLendersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=scyx_TermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=scyx_LoanAndSecurityAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=scyx_HerculesCapitalIncorporatedAndSiliconValleyBankMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=scyx_SeniorConvertibleNotePurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Additional Information (Detail) 3 Months Ended 6 Months Ended Mar. 01, 2018 USD ($) ftÂ² Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Commitment And Contingencies [Line Items] Â Â Â Â Â Long-term lease agreement, area of office space | ftÂ² 19,275 Â Â Â Â Lease term 11 years Â Â Â Â Total lease payments $ 7,300,000 $ 181,000 $ 177,000 $ 362,000 $ 355,000 Lessee, operating lease, existence of option to extend true Â Â Â Â Renewal term 5 years Â Â Â Â Renewal term, description Â Â Â The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years. Â Security deposit in the form of a standby letter of credit $ 300,000 Â Â Â Â Decrease in security deposit $ 55,000 Â Â Â Â Maximum Â Â Â Â Â Commitment And Contingencies [Line Items] Â Â Â Â Â Milestone payments from the Company Â Â Â $ 19,000,000 Â X - DefinitionCommitment and contingencies. + ReferencesNo definition available. + Details Name: scyx_CommitmentAndContingenciesLineItems Namespace Prefix: scyx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLease agreement area of office space. + ReferencesNo definition available. + Details Name: scyx_LeaseAgreementAreaOfOfficeSpace Namespace Prefix: scyx_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionMilestone payments. + ReferencesNo definition available. + Details Name: scyx_MilestonePayments Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in security deposits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInSecurityDeposits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionDescription of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_SecurityDeposit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease (Detail) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Mar. 01, 2018 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Â Â Â Â Operating lease cost Â $ 166 $ 166 $ 332 $ 332 Â Variable lease cost Â 27 46 4 104 Â Total operating lease expense Â 193 212 336 436 Â Cash paid for amounts included in the measurement of operating lease liability $ 7,300 $ 181 $ 177 $ 362 $ 355 Â Remaining Lease term (years) Â 5 years 1 month 2 days Â 5 years 1 month 2 days Â 5 years 7 months 2 days Discount rate Â 15.00% Â 15.00% Â 15.00% X - DefinitionVariable lease (cost) credit. + ReferencesNo definition available. + Details Name: scyx_VariableLeaseCostCredit Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -

Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification - Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification - Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 44 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Future Minimum Lease Payments (Detail) $ in Thousands Jun. 30, 2024 USD ($) Commitments and Contingencies Disclosure [Abstract] Â 2024 $ 368 2025 744 2026 759 2027 774 2028 790 Thereafter 466 Total $ 3,901 X - DefinitionLessee operating lease liability payments due after year four. + ReferencesNo definition available. + Details Name: scyx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies - Presentation of Operating Lease Liability (Detail) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Present value of future minimum lease payments $ 2,760 Â Operating lease liability, current portion 372 $ 340 Operating lease liability, long-term portion 2,388 $ 2,581 Total operating lease liability 2,760 Â Difference between future minimum lease payments and discounted cash flows $ 1,141 Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 46 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Schedule Of Capitalization Equity [Line Items] Â Â Â Â Â Common stock, par value (in dollars per share) $ 0.001 Â $ 0.001 Â $ 0.001 Common stock, shares authorized (in shares) 150,000,000 Â 150,000,000 Â 150,000,000 Common stock, shares issued (in shares) 37,856,463 Â 37,856,463 Â 37,207,799 Common stock, shares outstanding (in shares) 37,856,463 Â 37,856,463 Â 37,207,799 Warrant liabilities fair value adjustment $ 5,761 $ (8,214) $ (3,848) $ 13,459 Â Warrant liabilities $ 18,000 Â $ 18,000 Â $ 21,800 April 2022 Public Offering Â Â Â Â Â Schedule Of Capitalization Equity [Line Items] Â Â Â Â Â Pre-funded warrants were exercised for proceeds Â $ 3,787 Â $ 4,150 Â April 2022 Public Offering | Pre-funded Warrants Â Â Â Â Â Schedule Of Capitalization Equity [Line Items] Â Â Â Â Â Common stock issued, net of expenses (in shares) Â 3,787,400 Â 4,150,400 Â X - DefinitionFair value of liabilities. + ReferencesNo definition available. + Details Name: scyx_FairValueOfLiabilities Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCapitalizationEquityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=scyx_April2022PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=scyx_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - Summary of Common Stock Shares Activity (Detail) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Common Stock Outstanding Roll Forward [Roll Forward] Â Â Â Â Beginning balance $ 74,105 $ (29,914) $ 72,962 $ 3,233 Beginning balance (in shares) Â Â 37,207,799 Â Net (loss) income allocated to common shares (14,458) 122,260 $ (14,047) 88,384 Stock-based compensation expense 759 728 1,464 1,435 Common stock issued through employee stock purchase plan Â Â 26 4 Common stock issued, net of expenses Â 4 Â 4 Common stock issued for vested restricted stock units 0 0 1 18 Ending balance $ 60,406 93,078 $ 60,406 93,078 Ending balance (in shares) 37,856,463 Â 37,856,463 Â Common Stock Â Â Â Â Common Stock Outstanding Roll Forward [Roll Forward] Â Â Â Â Beginning balance $ 41 $ 36 $ 40 $ 36 Beginning balance (in shares) 37,779,796 33,327,627 37,207,799 32,682,342 Net (loss) income allocated to common shares $ 0 $ 0 $ 0 $ 0 Stock-based compensation expense 0 0 0 0 Common stock issued through employee stock purchase plan Â Â $ 0 $ 0 Common stock issued through employee stock purchase (in shares) Â Â 18,815 2,662 Common stock issued, net of expenses Â $ 4 Â $ 4 Common stock issued, net of expenses (in shares) Â 3,787,400 Â 4,150,400 Common stock issued for vested restricted stock units $ 0 $ 0 $ 1 $ 0 Common stock issued for vested restricted stock units (in shares) 76,667 60,638 629,849 340,261 Ending balance $ 41 $ 40 $ 41 $ 40 Ending balance (in shares) 37,856,463 37,175,665 37,856,463 37,175,665 Additional Paid-in Capital Â Â Â Â Common Stock Outstanding Roll Forward [Roll Forward] Â Â Â Â Beginning balance $ 428,900 $ 426,214 $ 428,169 $ 425,485 Net (loss) income allocated to common shares 0 0 0 0 Stock-

based compensation expense 759 728 1,464 1,435 Common stock issued through employee stock purchase plan Â Â 26 4 Common stock issued, net of expenses Â 0 Â 0 Common stock issued for vested restricted stock units 0 0 0 18 Ending balance 429,659 426,942 429,659 426,942 Accumulated Deficit Â Â Â Â Common Stock Outstanding Roll Forward [Roll Forward] Â Â Â Â Beginning balance (354,836) (456,164) (355,247) (422,288) Net (loss) income allocated to common shares (14,458) 122,260 (14,047) 88,384 Stock-based compensation expense 0 0 0 0 Common stock issued through employee stock purchase plan Â Â 0 0 Common stock issued, net of expenses Â 0 Â 0 Common stock issued for vested restricted stock units 0 0 0 0 Ending balance $ (369,294) $ (333,904) $ (369,294) $ (333,904) X - DefinitionCommon stock outstanding roll forward. + ReferencesNo definition available. + Details Name: scyx_CommonStockOutstandingRollForwardRollForward Namespace Prefix: scyx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X -

DefinitionAggregate value of stock related to Restricted Stock Awards issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares Jun. 30, 2024 Dec. 31, 2023 Class of Stock [Line Items] Â Â Common shares reserved for future issuance 41,178,848 40,613,284 Stock options Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 2,842,808 1,867,795 Restricted Stock Units Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 3,263,345 1,886,374 Warrant | December 2020 Public Offering Series 2 Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 0 6,800,000 Warrant | Prefunded Warrants to Purchase Common Stock Associated with December 2020 Public Offering Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 3,200,000 3,200,000 Warrant | Warrants to Purchase Common Stock Associated With April 2022 Public Offering Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 15,000,000 15,000,000 Warrant | April 2022 Public Offering Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 7,516,267 7,516,267 Warrant | Warrant to purchase common stock associated with Danforth Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 50,000 50,000 Warrant | Warrants to purchase common stock associated with Loan Agreement Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 198,811 198,811 March 2019 Notes Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 1,138,200 1,138,200 2014 Employee Stock Purchase Plan Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 1,458,171 1,474,045 2024 Plan Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 5,874,196 848,202 2015 Plan Â Â Class of Stock [Line Items] Â Â Common shares reserved for future issuance 637,050 633,590 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_December2020PublicOfferingSeries2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_December2020PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_WarrantsAssociatedWithApril2022PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_April2022PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_DanforthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=scyx_WarrantsAssociatedWithLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=scyx_SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=scyx_TwoThousandAndFourteenEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=scyx_TwoThousandAndTwentyFourEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=scyx_TwoThousandAndFifteenInducementAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - 2014 Equity Incentive Plan (Detail) - shares Jan. 01, 2024 Jan. 01, 2023 2014 Equity Incentive Plan Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Share-based compensation arrangement by share-based payment award, number of additional shares authorized 1,916,962 1,901,960 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI

https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=scyx_TwoThousandAndFourteenEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - 2015 Inducement Award Plan (Detail) - shares 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Option to purchase (shares) 1,000,060 Â 2015 Inducement Award Plan Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Possible future issuance under equity compensation plan (in shares) 637,050 Â Option to purchase (shares) 0 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=scyx_TwoThousandAndFifteenInducementAwardPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - 2024 Equity Incentive Plan (Details) - 2024 Equity Incentive Plan 6 Months Ended Jun. 30, 2024 shares Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Possible future issuance under equity compensation plan (in shares) 5,874,196 Maximum Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Base number of new shares available for future issuance under equity incentive plan (in shares) 6,150,000 X - DefinitionThe base number of new shares of common stock that may be issued after the effective date of the 2024 equity incentive plan, adjusted by certain amounts as described in the plan agreement, to arrive at an aggregate number of new shares of common stock that may be issued under the plan. + ReferencesNo definition available. + Details Name: scyx_BaseNumberOfAdditionalAwardsAuthorizedUnderTwoThousandTwentyFourEquityIncentivePlan Namespace Prefix: scyx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=scyx_TwoThousandAndTwentyFourEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Number of Shares Â Â Beginning balance - Outstanding (shares) 1,867,795 Â Granted (shares) 1,000,060 Â Forfeited/Cancelled (shares) (25,047) Â Ending balance - Outstanding (shares) 2,842,808 1,867,795 Exercisable (shares) 1,545,764 Â Vested or expected to vest (shares) 2,842,808 Â Weighted- Average Exercise Price Â Â Beginning balance - Outstanding (in dollars per share) $ 10.72 Â Granted (in dollars per share) 1.86 Â Forfeited/Cancelled (in dollars per share) 36.36 Â Ending balance - Outstanding (in dollars per share) 7.38 $ 10.72 Exercisable (in dollars per share) 11.78 Â Vested or expected to vest (in dollars per share) $ 7.38 Â Weighted- Average Remaining Contractual Life (in years) Â Â Balance - Outstanding 7 years 14 days 6 years 1 month 6 days Exercisable 5

years 2 months 19 days Â Vested or expected to vest 7 years 14 days Â Aggregate Intrinsic Value ($000) Â Â Balance - Outstanding $ 254 $ 184 Exercisable 59 Â Vested and expected to vest $ 254 Â X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price of options that were either forfeited or expired. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionAmount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration XML 53 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Detail) - Outstanding restricted stock units 6 Months Ended Jun. 30, 2024 $ / shares shares Number of Shares Â Beginning balance - Outstanding (shares) | shares 1,886,374 Options granted in period (shares) | shares 2,015,940 Vested (shares) | shares (629,849) Forfeited (shares) | shares (9,120) Ending balance - Outstanding (shares) | shares 3,263,345 Weighted Average Grant Date Fair Value Per Share Â Beginning balance - Outstanding (in dollars per share) | $ / shares $ 2.28 Granted (in dollars per share) | $ / shares 1.88 Vested (in dollars per share) | $ / shares 3 Forfeited (in dollars per share) | $ / shares 2.15 Ending balance - Outstanding (in dollars per share) | $ / shares $ 1.89 Vesting percentage 33.00% Vesting period of options 3 years X - DefinitionPercentage of employer's matching contributions to a defined contribution plan that vests in a given year. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -

Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type:
XML 54 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Compensation Cost (Detail) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-Based Payment Arrangement [Abstract] Â Â Â Â Stock-based compensation expense $ 759,000 $ 728,000 $ 1,464,000 $ 1,435,000 Tax benefit from compensation expense $ 0 $ 0 $ 0 $ 0 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of tax benefit for recognition of expense of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration
XML 55 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stock-based Compensation - Stock-Based Compensation Expense Related to Stock Options (Detail) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense $ 759 $ 728 $ 1,464 $ 1,435 Research and development Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense 216 301 411 675 Selling, general and administrative Â Â Â Â Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Â Â Â Â Stock-based compensation expense $ 543 $ 427 $ 1,053 $ 760 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type:
XML 56 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets $ 26,537 $ 34,593 Fair value of financial liabilities 17,962 22,006 Warrant liabilities Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial liabilities 17,962 21,810 Derivative liabilities Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial liabilities Â 196 Cash Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 1,364 767 Restricted cash Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 543 543 Money market funds Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 24,630 33,283 Quoted Prices in Active Markets for Identical Assets (Level 1) Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 26,537 34,593 Fair value of financial liabilities 0 0 Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liabilities Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial liabilities 0 0 Quoted Prices in Active Markets for Identical Assets (Level 1) | Derivative liabilities Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial liabilities Â 0 Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 1,364 767 Quoted Prices in Active Markets for Identical Assets (Level 1) | Restricted cash Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 543 543 Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 24,630 33,283 Significant Other Observable Inputs (Level 2) Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 0 0 Fair value of financial liabilities 0 0 Significant Other Observable Inputs (Level 2) | Warrant liabilities Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial liabilities 0 0 Significant Other Observable Inputs (Level 2) | Derivative liabilities Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial liabilities Â 0 Significant Other Observable Inputs (Level 2) | Cash Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 0 0 Significant Other Observable Inputs (Level 2) | Restricted cash Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 0 0 Significant Other Observable Inputs (Level 2) | Money market funds Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 0 0 Significant Unobservable Inputs (Level 3) Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 0 0 Fair value of financial liabilities 17,962 22,006 Significant Unobservable Inputs (Level 3) | Warrant liabilities Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial liabilities 17,962 21,810 Significant Unobservable Inputs (Level 3) | Derivative liabilities Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial liabilities Â 196 Significant Unobservable Inputs (Level 3) | Cash Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 0 0 Significant Unobservable Inputs (Level 3) | Restricted cash Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets 0 0 Significant Unobservable Inputs (Level 3) | Money market funds Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets $ 0 $ 0 X - DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=scyx_RestrictedCashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Additional Information (Detail) $ in Thousands Jun. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Fair Value, Measurements, Recurring Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets $ 26,537 $ 34,593 Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Cash and cash equivalents 26,000 Â Short term restricted cash balance 400 Â Long term restricted cash balance 200 Â Fair value of financial assets $ 26,537 34,593 Significant Unobservable Inputs (Level 3) | Stock Price Volatility Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Warrant liabilities, stock price volatility rate 86.6 Â Derivative liabilities, unobservable inputs rate 71.8 Â Significant Unobservable Inputs (Level 3) | Market Credit Spread Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Derivative liabilities, unobservable inputs rate 1,477 Â Significant Unobservable Inputs (Level 3) | Estimated Yield Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Derivative liabilities, unobservable inputs rate 20 Â Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring Â Â Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Â Â Fair value of financial assets $ 0 $ 0 X - DefinitionRestricted cash current fair value disclosure. + ReferencesNo definition available. + Details Name: scyx_RestrictedCashCurrentFairValueDisclosure Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRestricted cash noncurrent fair value disclosure. + ReferencesNo definition available. + Details Name: scyx_RestrictedCashNoncurrentFairValueDisclosure Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionValue of input used to measure derivative liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DerivativeLiabilityMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) $ in Thousands 6 Months Ended Jun. 30, 2024 USD ($) Warrant liabilities Â Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning balance $ 21,810 Gain adjustment to fair value (3,848) Ending balance 17,962 Derivative liabilities Â Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Â Beginning balance 196 Gain adjustment to fair value (196) Ending balance $ 0 X - DefinitionDerivative fair value gain (loss) from mark to market adjustment. + ReferencesNo definition available. + Details Name: scyx_DerivativeFairValueGainLossFromMarkToMarketAdjustment Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue - Additional Information (Detail) - USD ($) 1 Months Ended 3 Months Ended 6 Months Ended Dec. 26, 2023 Mar. 30, 2023 Jun. 30, 2023 Sep. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Net product revenue Â Â Â Â $ 736,000 $ 131,454,000 $ 2,109,000 $ 132,584,000 Â License agreement receivable Â Â Â Â 233,000 Â 233,000 Â $ 2,463,000 Deferred revenue, current portion Â Â Â Â 1,229,000 Â 1,229,000 Â 1,189,000 Deferred revenue, long term Â Â Â Â 1,817,000 Â 1,817,000 Â $ 2,727,000 Product Revenue, Net Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Net product revenue Â Â Â Â 0 468,000 0 1,598,000 Â GlaxoSmithKline Intellectual Property Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â License agreement contract asset Â Â Â Â 19,500,000 Â 19,500,000 Â Â License Agreement | GlaxoSmithKline Intellectual Property Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Development milestones recevied Â Â $ 25,000,000 Â Â Â Â Â Â License transfer performance obligation revenue Â Â Â Â Â 130,100,000 Â 130,100,000 Â License Agreement | GlaxoSmithKline Intellectual Property | License Transfer Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â 700,000 131,000,000 2,100,000 131,000,000 Â Exclusive License And Collaboration Agreement Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â $ 0 $ 0 $ 0 $ 0 Â Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payable upon achievement of threshold limit $ 64,000,000 Â Â Â Â Â Â Â Â Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payable upon achievement of threshold limit 54,250,000 Â Â Â Â Â Â Â Â Achivement of Threshold Upto 200 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payable upon achievement of threshold limit 46,500,000 Â Â Â Â Â Â Â Â Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payable upon achievement of threshold limit 45,500,000 Â Â Â Â Â Â Â Â Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payable upon achievement of threshold limit 45,500,000 Â Â Â Â Â Â Â Â Achivement of Threshold Upto 300 million to 500 Million | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payable upon achievement of threshold limit 39,000,000 Â Â Â Â Â Â Â Â Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payable upon achievement of threshold limit 35,000,000 Â Â Â Â Â Â Â Â Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payable upon achievement of threshold limit 35,000,000 Â Â Â Â Â Â Â Â Achivement of Threshold Upto 750 million to 1 Billion | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payable upon achievement of threshold limit 30,000,000 Â Â Â Â Â Â Â Â Successful Completion of Mario Study | License Agreement | GlaxoSmithKline Intellectual Property Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Development milestones recevied 7,350,000 Â Â Â Â Â Â Â Â Completion FURI, CARES, and NATURE Clinical Studies | License Agreement Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Development milestones recevied 10,000,000 Â Â Â Â Â Â Â Â Forecast | License Agreement | GlaxoSmithKline Intellectual Property Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Development milestones receivable Â Â Â $ 10,000,000 Â Â Â Â Â Maximum | License Agreement | GlaxoSmithKline Intellectual Property Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Regulatory milestone payments receivable 49,000,000 $ 70,000,000 Â Â Â Â Â Â Â Â Commercial milestones payments receivable 57,500,000 115,000,000 Â Â Â Â Â Â Â Â Sales milestone payments receivable Â 242,500,000 Â Â Â Â Â Â Â Â Development milestones receivable 72,350,000 $ 75,500,000 Â Â Â Â Â Â Â Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date One Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payments receivable 179,500,000 Â Â Â Â Â Â Â Â Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Two Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payments receivable 169,750,000 Â Â Â Â Â Â Â Â Maximum | License Agreement | GlaxoSmithKline Intellectual Property | Relaunch Date Three Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Sales milestone payments receivable 145,500,000 Â Â Â Â Â Â Â Â Maximum | Achivement of Two Interim Milestone of Ongoing Mario Study | License Agreement | GlaxoSmithKline Intellectual Property Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Development milestones receivable $ 30,000,000 Â Â Â Â Â Â Â Â Sales Revenue Net | Customer Concentration Risk | Wholesaler One Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Percentage of gross revenue Â Â Â Â Â Â Â Â 46.00% Â Sales Revenue Net | Customer Concentration Risk | Wholesaler Two Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Percentage of gross revenue Â Â Â Â Â Â Â Â 26.00% Â Sales Revenue Net | Customer Concentration Risk | Wholesaler Three Â Â Â Â Â Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Â Â Â Â Â Percentage of gross revenue Â Â Â Â Â Â Â Â 25.00% Â X - DefinitionCommercial milestones payments receivable. + ReferencesNo definition available. + Details Name: scyx_CommercialMilestonesPaymentsReceivable Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDevelopment milestones receivable. + ReferencesNo definition available. + Details Name: scyx_DevelopmentMilestonesReceivable Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDevelopment milestones recevied. + ReferencesNo definition available. + Details Name: scyx_DevelopmentMilestonesRecevied Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLicense agreement contract asset. + ReferencesNo definition available. + Details Name: scyx_LicenseAgreementContractAsset Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLicense agreement receivable. + ReferencesNo definition available. + Details Name: scyx_LicenseAgreementReceivable Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLicense transfer performance obligation revenue. + ReferencesNo definition available. + Details Name: scyx_LicenseTransferPerformanceObligationRevenue Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRegulatory milestone payments receivable. + ReferencesNo definition available. + Details Name: scyx_RegulatoryMilestonePaymentsReceivable Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSales milestone payable upon achievement of threshold limit. + ReferencesNo definition available. + Details Name: scyx_SalesMilestonePayableUponAchievementOfThresholdLimit Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSales milestone payments receivable + ReferencesNo definition available. + Details Name: scyx_SalesMilestonePaymentsReceivable Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenueNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic

10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=scyx_GlaxosmithklineIntellectualPropertyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=scyx_LicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=scyx_LicenseTransferMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=scyx_ExclusiveLicenseAndCollaborationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=scyx_AchivementOfThresholdUpto200MillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: scyx_RelaunchDateAxis=scyx_RelaunchDateOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: scyx_RelaunchDateAxis=scyx_RelaunchDateTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: scyx_RelaunchDateAxis=scyx_RelaunchDateThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=scyx_AchivementOfThresholdUpto300MillionTo500MillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=scyx_AchivementOfThresholdUpto750MillionTo1BillionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=scyx_SuccessfulCompletionOfMarioStudyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=scyx_CompletionFuriCaresAndNatureClinicalStudiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=scyx_AchivementOfTwoInterimMilestoneOfOngoingMarioStudyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=scyx_WholesalerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=scyx_WholesalerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=scyx_WholesalerThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue - Summary of Activity in Each of Product Revenue Provision and Allowance Categories (Detail) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Disaggregation Of Revenue [Line Items] Â Â Balance $ 2,057 $ 1,541 Provision related to current period revenue 0 3,143 Changes in estimate related to prior period revenue 25 693 Credit/payments (589) (2,129) Balance 1,493 3,248 Discounts and Chargebacks Â Â Disaggregation Of Revenue [Line Items] Â Â Balance 0 255 Provision related to current period revenue 0 773 Changes in estimate related to prior period revenue 0 0 Credit/payments 0 (708) Balance 0 320 Product Returns Â Â Disaggregation Of Revenue [Line Items] Â Â Balance 36 73 Provision related to current period revenue 0 316 Changes in estimate related to prior period revenue 51 693 Credit/payments 0 (74) Balance 87 1,008 Rebates and Incentives Â Â Disaggregation Of Revenue [Line Items] Â Â Balance 89 1,213 Provision related to current period revenue 0 2,054 Changes in estimate related to prior period revenue (26) 0 Credit/payments (39) (1,347) Balance 24 1,920 Product Recall Â Â Disaggregation Of Revenue [Line Items] Â Â Balance 1,932 0 Provision related to current period revenue 0 0 Changes in estimate related to prior period revenue 0 0 Credit/payments (550) 0 Balance $ 1,382 $ 0 X - DefinitionContract with customer liability provision related to current period revenue. + ReferencesNo definition available. + Details Name: scyx_ContractWithCustomerLiabilityProvisionRelatedToCurrentPeriodRevenue Namespace Prefix: scyx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=scyx_DiscountsAndChargebacksMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=scyx_ProductReturnsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=scyx_RebatesAndIncentivesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContractWithCustomerBasisOfPricingAxis=scyx_ProductRecallMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ("N "%D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\QO;=!P4)B0-!2L+ (/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " K@ A93.+OR.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)^V*:.CFHGA2$%Q0O(5D=C=LDX9DI-VW-XV[740?0,@E,W^^ M^0;2Z2#T$/$E#@$C64Q7D^M]$CJLV9XH"("D]^4&JG/"Y^9VB$Y1OL8=!*4/ M:H?0!W'[/K#[^+L!N,W=I_ M;'P6E!W\^A?R"U!+ P04 " K@ A9F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)- NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z"\>P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+', <$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\VZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90- !1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;]\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU= [=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!? 8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#*F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\- L,+$CN'MB[\!4$L#!!0 (M "N "%D%9:VO^ 4 -X? 8 >&PO=V]R:W-H965T&UL MM9GAG_6 $(_0^4;(;VG N2+/<92D%[U J=7;P2#U AZS]%2L M> +?+(2,F8)-N1RD*\F9GQ? %T8!:UG@0LS#I3<_S??=R>BXR%84)OY*8 MR>TEC\3FHF?W=CL>PF6@]([!]'S%EGS.U>^K>PE;@RK%#V.>I*%(B.2+B][, M?NLZCB[(C_@CY)MT[S/1*$]"?-,;M_Y%S] (MXA'WE(Y@\&_-71Y%.@G:\4\9 MVJM^4Q?N?]ZEW^3P //$4NZ*Z'/HJ^"B-^D1GR]8%JD'L?F5ET CG>>)*,W_ MDDUQ['#8(UZ6*A&7Q="".$R*_^RY/!'[!79# 2T+Z*L"N^D7G+(@/W.#HF4Y MUA53;'HNQ89(?32DZ0_YNCY0\&NZ9N"5R9=%,FU('I,/(E%!"]D^]U_6#Z"555/I MKJF7% U\ER6GQ+%."+7HT- >%R^?9*]9,[<_7IW_>5V?@*=S#LU4:+U+2E'%>4(;=VC M9'Z8+,E\&S^)R$2'UP/=%Q,36M62:5PQC8^Y/$;7Z! M!!405\0KEABOZ(!8M2(R=>UQ9T3RULM%V56SQN5\;[\$"];?4 &;'0LK98 MM,:BQV'=,Y:7M9D2C_M$C8Q=>(U=BXV-F\D, /T",F)+ (Q4>T#S&="$W=FTW M]G%Z(^(89BMS);QO)V2>3UG(QTRE"N8U,,@:B;^3LI3GH4@;Y6EZ\KR>.F>3 MT7@X!EU:FQAKN[%Q(=DQEI;SP%="]MQ3%5,-?11/_&J^SC,'/4D'WPX$3 7$1G,+?48 M[!L=Z$#ZU;41N0OOH;7W4%Q52N29[T-Z>K+[0-[#<>1C8N;$(VURO>82IB0I MF&/$_F5&["Y4B-8J1(]ZS6/&?MP((S8>:3LPM[F)A#!.,O'BMKRU%E'<:E[S MNGH+NO2CV"1&5CSN'9W\E#$)QAMM2[,W+B3@64TONO"RMHBU*#G'O@"2+$G#7)$01CRL47?Q MNK:0M1TYN+\\A@I$5RS(-?,"XD;,_*;R0,K+">R*2;)F4<;)C]8IJ#!9<5DL MQ!E/0!>NY.RM@^%BHU>"*O[K9R]@R1)V).1S$,*>8LV(R]=K@.5I.9]FU_- MC"\!\<+_"SW86T'5[V7SA>64>%IMB\74:F^U>#W+EVP']>"%RO<'IE_KIB3B M"RBU3L_@J2^+Q>1B0XE5OA[])02P[,5CHQ"*_$/HW?RZ!H85VXX_VYN/A87L\ @HB7-E3%!],>.KFA9 M&DL:QX^#T5FWIE$\OGZP_EOKO';FADBZXN4W5JC-Q2R=@8*N25.JS_SN=WIP MJ 68\U*V_\'=03:8@;R1BE<'98V@8O7^D_P\!.)(883"NB@@)ZJ@ *N'5T MCZQUZY(HLCP7_X((ZVMF8LV-JVV]H;5YC%>*Z%_95I/+;_6I"F8H@58\;K0 MCV=_)7G)"F*^_D!*4N<47)LE)#@!7Z\OP:^OWX+7@-7@RX8WDM2%/%\HC<;8 M7.2'E3_L5T83*W]JZE. @SE 0H=ZBN_^B7-M3ILU?%0?:%CT 4"=8% K3T\ M86_5"$%K!8B4VL\SES][Z';@,FW,[DE.;V8Z8225.SH;/GF%8R#=R[O7LC8 MP%?<^8I]UIG-<;+M2)HJ+2>VU'I;JF0.[M1$?+ATD0CD$ZI (,D1MD MU(&,O"'O!-T25@#Z@IMV<%,OW,]ZDPJ6F\)IS&"(.>C0(ORH_^-#]H#]>- MHV2$SB&&<'14LX;HCK@2>M%=TC75\=/IO=87K+[5FU%.((4VTB0:X_0+#5'V M1 :]W/&4/7BP,%@X']?S(T)#=#WU0#_W_+VE@B@3NY+J]@L(TV>=\/5)8[+< M;$OPZS6EX"^N*$C>.M%C^_ ':U<@EA>.I/=!3$O1STCZ/IO,'VB0#@R0-XC$\ MAQQ*PRDV@CT=P>A)C4S)R TKF6+4WY_GO-%% M VS)_12%09N?(AR-2Z]#*H%A-O%4>AJ#?A[3 $5#^R[!"="FI"C,QJ77(96$ MV535Z(D+^IFKJVV"[FC=T'G'%5O=A.D3EQ.Q3500H3'3NJ1@.A72GM"@G]'& ME>1AP]];T!^O*#:?X02-W7 (A1.LC'K&0W[&^T:$(,-T=9X];$H;[UR'",13 M^'K.0W[.TX?!'=51U$FEC\ 9&? 9^Z8QT$EV3Q.*L<8@C&4]TNZFD0^8]E+[AO[?.7E7J.Q'(?I8J0--ZWP*K]>>N\,!SLG/_SO@- B@;A@%V)'2-#RD41LNV+]:)IH'06#^@-P0888Z4A_ZP*>F MIMW,LMTVES2GU0T5W2CR'>ATF)2FY6OG08V22E^85'ZR*>#'NH"JTGW49.A@%%@1ZZ/YC.#A9)Y&\3R,<2NA;U&0S),L>ZF@SC6ORBUM MWQZ4]\X0VPU(",'GG-GE4? 7[Y5#WG(#MCB0.0NL [Q!+T'%_,P3;-R[8W[A8 MY-GN8SE9NITN1-8XWCF$<,FYAA"+HQ=,YNW>GT3ICV8Q!"KCIW9#G3[];MVT@QH MRD5$:+18\ZX&CN9UL6EZZHD(SE6'5$0#D\60N98 MPU0N755(@E,+RID;>%[?S3'E3CRR:U,9CT2I&>5D*I$J\QS+7]>$B?78\9VG MA3NZS+19<.-1@9=D1O1],94PHM0>%W@4*O*#; I_LA]^0!."^ MA8?;C MS6K%W6WG-M? Q4A4X(6,'[ILB(K_MZ&K)YG/SOR#\=M&>@U M!GJO,D"5*@^+[ST3M2M[7\26X'XCN/\JP?#>4!KSE/+E(=7]@ZKW16RICAK5 MT5[5$Y'G<*O_HW_>F=[KZ$^J]IC_"0VMDJPEW

MHP\P3=@7+)>4*\3(J!>)P(.6?4UU42+PK8&YN%L_0FFWR8RD_\:=_L-Z@H.%;\5*T?]%3C_5F:'44DN_[QJH'^Z+J?O-O MO2,N&B@>N 'I&Q"]@3_1@/8-Z&O?X/<-_->^(>@;M*;/.]M;QZ6YS!>W-7]" M=8-6;,U%Z_VVM?)7436)\BAK]=]"M9.+SU5^7!>2K=$#K]8J ;HKP/ M'Z7Z49DA!>(;]*\#J_,FP@)=H<^/*7KSXUOT(RH]},>.'T5>K<7M7*1^->$S M5=^'^ZX/9*(/%/W&*[D3*%,]6 /M4WO[T-)^KOQQ=@IY=LHJL1+^\UA=(^J] M0\0C/M"?A]_?>0,>LX0VO+1";Y/[,2J([N!XMJU].&638V[M$8=\Q>YFJH@)5I_8;/'3#SCT?H:MLV;:>&TB&AX.S]=NM;$8(K]P!_#4A-&L)>,01G$18)XX!J9&9S-M#*Q9UA>6:HO8MT-3A@28<('+A'-)EKHDRQR1C2(1GB,16A/N@0O9E/I#S=?' ME7Q./;"N=TS!12YX6N:9")]HV9F^R)*9B" D<,)%9S,CJYF?E./R>K5#:1XJ2
MRN*D)-.AF>8@,R/C]6'L19JE)BCR?,V0U 1AW\Z$ -0-(X"V.#X;'!L-?A1 MB3$UOMZA+:O46"M;P_.UTA2%D,W8.X'E)3;Z0G&HUQ<3%/F17EU,4!C30#/=
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§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`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{8)X919W_M?!]: 32B-F*1\4OZW#1SB MU-1FM>^Z\!??P:$I5;5C6F0&$6?+2=%L563,#UQZDZB]9TI5T7P,, !M[GU M?*'[G+Z74-.18WZZJ3RG!C<>M];R!P@@*791<@N*'A+@8PX=^@B)R,OUYF\9 MXH!.TQ_L;=*SJ'}K0"^O)QZ0U5866J=G?$?Q"]ER>/S."/6<M4?]IU!13AX"M)US\=A?_"+;B[V43&X(M^.=<23""!N#]U$ZJ(4TA^T0/L!]>P_ M4$L#!!0 ("N "%E-?VA5JPP +P@ 9 >&PO=V]R:W-H965TT:6];)EQTEF'+OI8^+44[?9#SO[M 2)!$6N2X*@9>VOWW,O2(J49#?=SB2*1!(7]WGNP67>KHQ]=*E27CSG6>'> M':;>EV].3UV4JERZH2E5@3N)L;GT^&F7IZZT2L:*,]-)Z/1^6DN=7'X_BU? MN[?OWYK*9[I0]U:X*L^E77]0F5F].QP?-A=^UWEO\ M.FVEQ#I7A=.F$%8E[PZQQV\^S.AY?N"+5BO7^2(DH4QC_3CI_C=X8@44IF* M/$F0^.=)W:@L(T%0XS^US,-V2UK8_=*.I&9/_0L4_?'5X/9LF'! MI%XP8;W#1JSEK? 3R_5MK5L+2TY!&7]A47@WE=$%!>? 6=S76^?] M$[*(Q8TIO"Z6JHBTJ/^Q5]QJ%V7&55:)?UXOG+=(MFG_M\T+89+9_$RJD-ZZ4D7IWB$IQRCZIP_?'??3,^'UV]8L*L6'VFO0_'[+7 MQB=^*<2=M%$JQA2,\<5 ^%31TE(6:X&URJI8Z,(;(45FBN4) MKN0BH]5"+JU2M($ C@A9EM8\:]24RM9B?#F8S,]OCY6$WQ-"(I/@3Z(C)=B- MD"I^5M:IM;C1?CT0GU'MX0)I(7U/%1UC'YUH:"/)'@$$LY(,JI6ID)M67# _< MB(O91'S1VN^^N9A,1E=L*G\)?7QT/Q6^X$Y:P*=H)H,F3*L1:2>M$8DTNKJLE MJK3OE C^A/."P3&L'*'J?2J\\3*K)99R'1P.6[\5\^$4U9UE!%3F"=KYWM9! ME<; %&;1?5,RL,'A5A7P"+G6KPRV+YR**H([D>#CA-05<((V<:TU+5>(-#:G MKFVKJLE(&-I/CWO.E$83QVD,X4"A^9^>WC_2S**ELH0%FB)P@$RRB##PMC=->\):*K,Q);SSAH>QB#3]YJ$[7 M(J3@VDF9FZKPP<&CC8,1C%0CCU=P(YZO(FP'*8E._/J$_(7%IG+DB-AD&4?: M%!TWR:+0]:AAS7^VPEX'-B.">R/B*NK4N0P^.8K54#>83*;TB^6J6=G7OJ M449P7PJ+7M +(8XRZ5Q;,\ L;W7D\2N2+FW]&44A3E1*52$K^)H>,0@I,HZ_ M.9-I4@/VR$P65,'4F^JM$QAC5K3<(Y54307T?P$O358!!> >+SE[=1%H!_=O MYTRD670HIC;"I'!DE@7DQ(VN?ZA>H@NHIU&/2".O0BUR!,79>]3XGF6&>+CC M-P>_I0"S7J,3:%.*V]2#?MY_YX :&'6QJ6B_'?RRA4R107Y]*\;GY^WG=#H)MGP=?X"GV6N?9R5S,SL5,C$>S@]\87;;!3CV79#W)NYSB'&'N^D5=+G520*0$KXLE%\[].37C6 HK9.G@;6$?85<'8QG8_$) M=(,*Y=I:">[#J)0;4F\$0JG?R371F.DV6MWL&&#C@,9I_+2(.-"(HKPF!J#(T-'O*^NH M.37R*W;0;O)H)3*\)5 G-E2I*C+@>@X9JBBU@-26MB MP$8B>[.X9I&$Y\-12QJKDIAC% HQXJIVI8K0TB.B#1 YJ$&=R@HU@GSANF,F M=9]2L4Q W GXIY8Q2A38G.QK9;$V&$AKQAP+:%M/RHN42;S@!)NDTJ"6-4N M^7WX@ 3.Y;^1P]]7%D6-R(=U+@CY6<(VS@(9(UU9>)U2;]^GO.9#AC5KY ^= M37;\1"?TF,B1),(;$:PNV1LK8],89VL%H[QP$BZGR[U4"B1%+A'#)?67S3Z2 MD24^(6512/J)@^G0+8:.1&Y@0MO30B9WE2);@UW]8U(1*IK!H$ZJG3P*D8\5 MX,[6%8$^K+V7=9CE;OZ(.+#+&CE<%:5!3&$:4KSB5 +]I$?HYL:&[.[D! M:D@833NW50+&4[=O6MBO3R*-V#/NG;1N&X/N&N7[QZZ-8Y!9AE*73B"$?<@R M=AR;H4 7L\9WNS)#&';]P\[XLRZ8_G47["3*>5T'+0:^=JP&<0>7K4]HVL8; M)[F7TZ?39,*Q!U3?!J;_VGB!J#%8- I T'XO/NPXH.%5965QDN!LW/'U-LA? M#O9F[$)%L*:7N-SQZ"Q29;Z)QVZ$OEQ__NGAQU;#+U]N*'1+*\-1EN"7V:UN MQA>DPY"F&9LX<-L>O3K02$QEX-P[&83AQD# _;O#*1" MB%+YI((IK8,X:3=IFH C(?TH8H7X?'L]H# MEVS&8LT/?KR]IF.<*@-\4 WMJSI[4C&.YU>.Q/!3_7QN N]1E+XY%,#U =:#-KL=HB$#U!C$ X'22R[H6+P@ M;A?.]7SXD4M4&1D;]J,X&HLU*=5P#Q[R&__8G"#KZ'#T70I3]BQ M)F:$2QI!VBTTF='L?MW/I*&XQOX&>UKQJ-9_0&VX&U9%E!*)I*9]0K?,Q+TU MD5+D$)X5?C9/H;KFX80WV(QT2',>./!,'I&B(D4:AC3] &@IQ$?P16**C>G; M[;09% 33%NPMT%E-O+A)MX+G ^>*P\G2)YM8 DJ>K#Y#4G=L2+8FEH&-)=X M+(;B-;2'05I-@!E2FE,L^?,!M57#RJ2QO*M\+D%!;/))" I"F"#J-+2)3SE< MCM@G[;292C#U7RE*$+A)LI^P41QFU1MA(%$T]T%5PZWP[<)4?LLY"W!C9#9$ MUDK;&\(9"LYPJ[=&$]'QO1EGW1MQ-+[>K$*CUB4G3U53 MPYS0.'?"+9L1&7ZX$D>3XUTK0?ZYGAF+% Z=43V8PM9@]-SVK-UT?O%(#%C_1.&++[BF\?S8[W=7M@H5H:F#;8 MRN/.R"ZD.8G^BN0.9G2JKU-P=0DBC1YY_MP:J^A0H>L))@<#P(/6HM2C PS6 M58(UL>@_NAC0*E$7!!"IG[(.'UYXBN5YH/P9%7$/"=),OS Y> MZFNMTB <=%9TW$([XVL26H_]2 O*FR)*HXRX44,C[^\;AY[TDMC3>6R]1IYXURKNR2WYM3CN'0%5XNMU?; M5_/7X8WTYO'P7A\IB&Y*8Y4$2T?#^=EAF!8U/[PI^?WTPGAO@("W&@ &0 'AL M+W=O22K9R<8UG-P];^P"1D(@=DM H&7OUV\W0%*D9"L>KQL@)PT-VGN]$ M+W="?E$%8YH\5&6MKJ:%UMN+^5QE!:NHFHDMJZ%G+61%-;S*S5QM:..YF525 M<]]UXWE%>3V]OC2_WL%+NKJ3?M?OC$-X7&'^;7MEUNZ87=_ V-[*^%MWJ/DO&*UXJ(FDJVOIDOOXB;$\6; /SG;J4&;H"8K(;[@ MRR_YU=1%@5C),HT(%![W[,K2P0*;,ZVF--^29PX;'?H/QG=09<55>R#*/_D MN2ZNINF4Y&Q-FU)_$KN?6:M/A'B9*)7Y3W9VK \K9HW2HFHGPWO%:_ND#ZT= M!A-2]YD)?CO!-W+;A8R4'ZFFUY=2[(C$T8"&#:.JF0W"\1I)N=,2>CG,T]=W M6F1?"E'F3*]_D1^ -EP_7LXU(&/_/&M1;BR*_PQ*3'X3M2X4^;'.63Z>/P>) M>K\'3JP;_R3@WYMZ1@+7(;[KAR?P@E[-P. %S^!9Q[[$P*&O8#A*?07\W :)9V1(=#WWZ6^ ME[QOX"X0];6C^V M4(K0'H1D=JPR8PL*?61+);FG9<.(6)-WQ)VYKD>V#+) 024SJV4"(EIIA2.\ MR'5Q(D3AK%3A@'9@2\^F[B)(M% M![9CL"@WJIH18J IU>-5GE[$@CDI):S#,6HK*]"VWDI<(XY-M MLRIY!I/63*+T1C/VP&3&%BQ*2M,\)JNBI9FZ&!8S7FN"41YZ(K;_-%M;"-!1REL.*5"K":Y@M&@4]ZOQB\MD@ M#*7)&&%R9WD%W5I'7>8YQ_0.FB^SK*F:DFJ8]1EM,,FA):TSYI#?J,R*CM,0 M'25)%N H'25QBR+7ZBR E'?DC 11Z*1!3,[A+0&CN='D=]@=2Z$4,6'OS]Z MGA$O=,(HA4G[YL1$T0^X:9A@@8U44;,7L0=LLR.8)%H,VY,/0^NW?HQ6OV<* MM013:,DS;-HA3/D65G;YJXZ8Y(&0=4;9^'$()DQ3KQP_$5HC!.C

M(\=_15KP)J0%) B $=YX8X7H/M MCVW=/3W?=_S8[9ZO(,U/A^VG2'-(#8* 5H,-<@*X1%@^$K>@8\X2%_'>X"\ M>TD$GA.A:=W6OHO0M[R#^1>NM>\B<-PDG=Q!L+]]J!YEX&%:[P5+@>S6(:/(
M\C0 'C1?ZP\0!FFX(-ZQY&\6 ">=X-6A?^@$/@E\)TY])S#N MV$9_Y(1I9*,?8S=-C6"!XP?!2P(_39T@#=O'J]@/HO';Z]D'[6) GP!.IX+C M;+*O*MXNFP2A"_EP[SM>.FB^51(AK8-
\L@6UE>NG1C=09V")BFL,RU H,XW M=K#JO6M4IB#&VF+P#@/*2OEJ(O)V.6/$LYD6];1+%%5U! 4QK"GYL"WVF, M.2D:C7[.E&!(V+W""*>EL1,DX>3/KMK38N\+(S6H4B+C)CQV7!=[04%
(JZ@@ M_('<00.LL7>C&"0UM?7D]KC(?*-E0;6V?N];KU#M1*K1?T)8=_\OQ0ZL5CB M1![4%% \]:U7:/.K@(A>;z]JEBMB;?-@T-.QIJ7U,\"BR MA6V.8\E^Z.]=;0ZGK7LX"(6:B:P\&F#
MYQ:3UQGBD,4YB9P4"V8HJ],0%;&2AI3B82O!G3IZF6RPE8YEBR5U MN7#^B2$'10MW8G:.Y0%!:.IQ MZ.#I9^![M];W_FA]3YDT-SR@]IY]Z _'T(=^*#*QKRFMS(I?BGAO^=P6>&7%R MBTSL-
8$YNN//-LNA7TI A_,AR:@J',*^-F J^!D'W904]LF[#.:"Q=:4#P[\ MV"\97@6B$)!E^_/I%OQWX(.M ZF95R#**9U:XT$; M#'J*PU @@%#47NZ=H<9XL0.2EH]X+
<=KW'L%%@%EDS,04G(X:)**R0V3L'V MM0&[6*EDZWP&$FS8G7$AGY[/R$?0SF@/(O3F=,CR[@,)4]A&/G*E06& *U#O M7SE=\=),MD=Y>_V"!V]HH)]U6BFV)WD%UBZ!:;
[F>%FA2+F':4 IO:U5:\?A M_((\"7RO&:E!>,UD9_1ME#O5'M"&*K6XJD;/27K"8=%'0>L-41* 7CSY@UL(MB4FW[:999K=E2S=MH+8SY1,$86T+J5J)DN?4[HCP0.Z,^&++I!&AU>[%GG\B M?
5=XBXUPC#/^\\S@*[Y+?4[SRP/R" 6W2+S(()13?6FUV_,J;XF>4;!+2&R0EI MA1ZB]V@J SV@#LN8C9T-_%@/75QULS&&^/JQ35 X@D/KP;(OI-CDIE!&@%Q MP4>:$J+CK^Z NB7L-
167JZK>Z%ET_. M6(3],L&1"'OQO& 6/2>#&!$^LO&ULM5A;<]LV%G[7K\"HW3:9H2G>)26V9YQ+=].9 M=CUQTC[L[-$0A(W)*$ H&7WU^]W)*B'-E-M&,/EHG+.3C7[QS@2$"_5)[T5 MPK"
[NFKTQ71KS.[%;*;SK:BY]N5..%A92U5S@Z':S/1."5Y8HKJ:14&0S6I> M-M/+[_A&W CS M<7>M,)H-7(JR%HTN9<.46%],K\(7KQ+:;S?\5HJ]'GTSTF0EY2<:O"LNI@$) M)"J1&^+
\>]6O!9518P@QN>.YW0XD@C'WSWWGZSNT&7%M7@MJ]_+PFOOI M*\2:MY5Y+_?_$)T^*?'+9:7M+]N[O4D\(9TKC:P[8DA0EXW[S^\ZX.QP(%L$C M!%%'$%FYW4%6RC?<\,MS)?
=,T6YPHP^KJG6&<&5#3KDQ"JLEZ,SEC9'YIS/2 MJV"O90U?:T[F.I\9<*<]L[SC],IQBA[AE+%?9&.VFKUM"E$#)(G3W'_M)B<]R>FTG$N?/78"NVZ5;CFL8R0S6\&,4+5F_NY+]?
D,"HRCEU7O&'/:%,4O+1;;,:.PY?//893?N9-"TA@H7,VXTU! M'[$W/H;Q%MD L7)>51@5"#-0+,/,6V:1I<$HP%\6,$W.UH/4TO"*-6V]$JI? M@@ZYK&N0T:> EO1,65JI[MWTE^6OMW#;O:J;*R>
[R3MEM)K@H2JB@5>$JEH:'<&>CH3GV4^<&TT4/3[K=E MOF5[K&@&Z*RT^MZ CT^UV2MZ"\^K^I"S6(%M9065M[;H2..\%$^NU4]?ZK&T$ M"Y?.8S[[T MI92JU9:S;/!=:PYZ=
(P;C]03=T,95V7!2%[Q_$BOE F(<$8UD M#6!^@Y0U&B!X#[GPKSCI'<;7QLYQPPKP1BOS%:YFRT^*H;ZI V8ELV&\3U, MKQU?G'^*V;X$30Y*YN6PHE.ADG_ W,<9P;)B7U%2=F#
(8R)RHJ(,EM6-G8C MWRAA$4FV[5]}[4XK(Y-+TE'8,PX>S#9FK(J M_X ?71R5?1QI$DTJJ[:$P#F%/@FAA.&=U(0592X>YOZ/4*+>5?)>"..T=8M?K M#:%1'VU6MQC+6N,S^.CI'?99 T118
M6;2YJ^]79!&GP9^)D\5S+TB#ORK,B?KXF$2C^I@>@;C/WK2*'+]272SK\H[5 MKM42U&H=ZW%<.WN%4$@L'E$"MBK?HM"S/X22I^-Z$/A(ZY.AE(X@R7;8!"QD
ME=/Z1WWI'%51)W#'R1N(GU;3(YQS-PD@6D$QN9:$>?K%Y-D$R9\^Q*\[\.#LIPK$[(V^1 MX"]8@&;NQO\! F^HS29O+T3*B^UC<33U*&7)JDWSX@#W@J5^%&&0+B>_ M
0^IW"K@$+4QPN(S8-A\NRCL/+S(OG5DL_6@S^CCP(YBV3SM^+WIC/6!8M8::E\[$? M!(=(P.+2"Z/ +D5^F#XX_MC8L1=EL1ZS5Q\55IW=-0CT7Z;Y;[CO1&-4+;9ME$1Q^QO\ I:=9I" ZD8
M!RVZF;-[P17;"57*HH/_+UE^W.$H8H1@=SWP@T. 1"AYQF$2]4VF'2]\$/478CLI!6U>(NR[-%7]'5WUGA/9!;AK$B[7,
MX>Y#:=%H!_+C]DSAHKWJ+4!,DW%!@;J(-5=$E49:TLK@@Y8:BY_YX%_H+5:"OL0P?RAF;FPTR? M.]977U<[Z,NQ#OWT >O03[Y@_=5%Z?C.]&&XG'7ZD2]7B(@UT&/P2]&WSL!*
MT[7.B"L)"W-7UZQ9[/W>)<.1=?GADN_L92L?D0@.KW9)XHQ#@GZE+L>WYI.1 MHT3%.USMDJVKPR6UW'G5%@?='$Y1X-"EG0$Q:CU<&?+?*G6UQ@'1A1E 8A/A-0OK-YNGD!B71XD"7_I:0%
[@#EO0(8R^9 M:1*S))I3<4UC-L^"R0<;*]@^Z9)^(ZI$H9>X\N8E<7R_"U!+ P04 " K@ A91;%_"3T(@ M%P &0 'AL+W=OOP&@W M.\D,HPLERTY\F;&=W6X[FYDTV>X^=/H D9"(&"08
)2B_OI^!P IRI(=I.' M/MBD0)S[.=\YP.5&FWM;".'8UU)5]FI0.%>_'8UL5HB2VZ&N184O2VU*[O#3 MK$:V-H+GGJA4HW0\GH]*+JO!]:5?^V"N+W7CE*S$!\-L4Y;<;&^%TINKP630
M+GR4J\+1PNCZLN8K\4FX?]0?#'Z-.BZY+$5EI:Z8$V,]OL-?TBQ ML;UW1I8LM+ZG'W_-KP9C4D@HD3GBP/%8BSNA%#&"&E\BST$GD@C[[RWW7[SM
ML&7!K;C3ZD^9N^]<#Y@N5CR1KF/>O.KB/:<$K],*^ UT<6-98I\M(M# U*684G_QK]T",X'S]"D$:"U.L=!'DMWW''KR^-WX!#N\&-7KRIGAK*R8]"
M\LD9?)6@<]>_<&G8'UPU@KT7W#9&P./.7HXB:L!*L(*LQ:#ZY]^F,S'%T\H/.L4 MGCW%_7M"\R2CXVI.QD/VB 3V>R%8QHW9RFK%>*D;6M1+E@GC4.=L*2M>99(K
M)BLXK_%4"7YDJLF))N.V8+S*PXOXTL@U5V$3%'!&9DZ$CT2UQE)DP;,L2#,B M$R!:*)$P*%USF3/Q%5!D$3/BK%TA#"K&& R;JW8HZ_Y-A#37JR:1O09U+71 M7R6*6C#P@1>@5BT\0K E>65-
7K$LAVNV66QG=X_E.C.J)LN"^@,8\%T/OB*56:!S$TU% 8_>0_P8#TC/3E'34(BAG MH 2YV"\X\Z[R5].+[JQ2&FZS8LKO@,IA+7CBYY0I2!?
M[HZD4/O5\T7L_V3/BY(ZJZ4M,^3C_L%QDYG4__W#^R=)Z<3L]V+P^W_PD (7/ZZ0F=SY(W_3AYNY#%/)]- =Q;1UU M-C^+__^'3II.D_1\VCZ^X:3I+#E],]V]/,])Z20YGQP$H/L @PVPT8-52[AE
MDS?S PJL'?5HFB88VHX)"!_Z"!0KP1Y@^3-*(Y9P;]/RD$T/(1 .&K%R8D9* MI>..+WSSX3/ROR05JM&X(Z ,4H?HAQ1';+Z&0 %D9@64[[\7865_J,H= %%8; M($+K ZA(JX\UL%H/^7\
<(QQ3"D_66(;T3QH;3#%UW@D&0]G>Q2TDG8K&^D* M*.V;3$!U39!W497GGM3<1F\W+R\=:.#HFWTYR^GW

^[;/0BPMTB;)FP;MAW\PE MFJH"2C.O9LC8L+?UF?\#VC*/0#L$VB+P961=" T!&6 W\UK"[6J"='Z/2A]^ M:<./('BR"Y[; @1#1Q/0*&J-\@JX5:/AB3X^&=PX2>L)M"EAT/J@=\WY9)+;
MXA8%."9KRJ80!KANE!'%X$(4HLHD1A]%GG+@XO;* MMHR)=22T42U<)Y+WEI9;8I(H7:<'E^O>S[5N0)#U^IW4UDIPA:GSS))^2U/E M1J,DQG&?$*:9IZ)P3$QR2^+^"QIXE M: PQAAE-<$P34,U'+O Y17X?MO7JS6@%-.8 MK-8#@D;Y.KTK:!A5 0&!<8=XQ(P?%G=FXQXD$61. M9%U+6O^F(?5Q! >GQ/LW99@D?' -Q?[\I?I69K*\E?5:X!-,"51LFO; . 2[M3<@HPC1,?+52G,;TB=5*'%-/_GC@ RB2R7!3J 6K%/UTT MD-^@#2W =!1PS(.HDT;C-?+0?(RX&&*@FWDSU;\>Y/@X-+_/@DH8A3'G&+F MTK&M_@B'//+5;VN7

,8'1Q^LBVG? /:W@NUN M F^IB#QS-V$A@7[8YT[U\CG:B)HS[P4=?-2M'=>VAB2/ONY9H)@8D?O&]/ MP/(!3+9@]:Z1:_ LQTPH]PR#\>VQX9;>Q^++006'B;AI%E MXS%F23CX(NI:5/#0J#XW-\P06JLL=^6ZS,V\!PH@"?#<%GD&MD]E;56_0M= M@#?ZM(X!*<&$D,$5?'@UKETLGUDMF.9U]-0!IITOZKSPC>=[!4%D93H-/?F_M#-JC+,%1 #,.#',==8
UORGH,.!K;@%O'9S^PGQ?;ZOOA4R5=W!AZ9MK% F]HX?\R@)4O1)&4B8 >,V^#U MU'[9UO&U+YXKVTR/K!R4'J,(TG>RAQ0662NSD$#T- M&[S:-['%"T"I)1&!E.$K)P+T!.[_[1M(UEET=)
3O)!#!D$.CQ7$ ^0YOLUW] M=+1V.%#*>N:..0.RG75,9?T[0W>U<6<[]X4*_W1_10+!F.32>0DZ!E;Q.H'W6 M_MC#?QBU<$<-M\H853IR+@7XP&Z YU,%]K<75D%W]C3^%U!+ P04 " K M@A9I"*X69H$ X"P &0 'AL+W=O+ _)>7*^&6NO-Y6"@\C743/7%!CB> M+(6LF<:E7 W41@(KK%!=#6@0I(.:E=R;CNW>G9R.1:.KDL.=)*JI:R9?KJ$2 MVXD7>ON~^W*UUF9C,!UOV KFH!\W=Q)7@TY+4=; 52DXD;"<>+/P\CHU_);A M6PE;=4 3$\E"B">S^*68>(%Q""K(M=' \.\9;J"JC")TXX]6I]>9-(*']%[[MCS9VC&7!%-R(ZGM9Z/7$RSQ2P)(UE;X7VY^AC2;('>*"WJ M5A@]$ON_MFNO8<#@2QX1X"V M3Z[0Q9+S\QS:9C*;9$&F[49@@;JI5&YTIN MDC+7$D]+E-/3N1;YTX6)JR WHL9<*V:OZ^R!+2I0Y^.!1C.&>9"W*J^=2QJ. MRI1\%ERO%;GE!11OY0?H7NB_F M-9P<6UCOF.O"#%-9E(RO@)+_S9;*"T1+[\?"][ICH_K-C5TJ38LAXF'1:) M/H,W_?@A3(.K$Y['G>?Q*>TN6^3KQF9H9@!=ZI=C3IY4<]S)AS6X&D&5!*N= M:-
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
I,9G&.*18(:KB$-C4FXAKPUCW?,*QKSF(7 >!\;JUMC M$V,M<9]A9,D%:$WTME2#QLUP_O)M$@.FG6O6LD*WCJI*:.?C2, _>\Y
M'54,/E!9ZSMJPWE)T"$:]L9QOUF>,]PJ2TXB*Y#\\QZB<6\4'SYNGI-_8UH[MT3AZ3MQ>U$I^CN==%7!M"'8X/Z___T4EQW(LF<;.\XJ1X MV!L=Q8^;MSDI&O0F@Q3JDIIVU3E\21A?E5\Z>"\[M=BI M+1+UAK:S$^7VMG/J*OP98M=KDB>HL4*==%%WO?PS'80:&.U-IPF44B4.CN]Y M7*Y+]SY^P7L4$.\#L3!3M\:7 :=)JHX/VW[C0STXV=(+V^SZE<8J8-G?- BX M7@A6=?%_A+@W&4Y@_X7(IPVW4YUMLC: 'MX$QR7O:UAR:MI\I)I2A # G-B[1\<4N[I:D*K/JQ: M^ZDHF9+]=T5"+VA'0?:[H,;@_G(OV3[["U!+ P04 " K @9 A/U:. M%:L$!R#0 &0
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
MH[4R9VMV&2FZ)LM7(9@7D7M3WR&Z'OD']]K5^VHB;U.+"5\1]J,0EB8)S$@9AW &?'H?/(@$XS\&C M0[B/,;59A6U6H>.+7N'[I-94L)_.[CF92J$E9UGMWN:%,6D0AN["O&."BI1A
M3@MZ8[*+.I3(7!E2!]W@#VK@3 M[+(1_R'O.KH*@M],'-7RK^?A[WWSMM]^I&K-A"8<5D@?7%[U/:+J'E9/C"Q= M&UA*@TW%#7-L^Z!L >ZOI#2[B>TL[1])\@M02P,$% @ *X (632X/[Z(M P IPX !D !X;"]W;W)K&ULM5?;;MLX$/T5 M0@L4+9!$-U^2K&T@<7;1%+T8,=(^%/M 2R.+"$5J22KN OOQ'4J*:K6RV@:R M'RQ1FG,X>'MRQ M;6KL WW MHDHANQ00;\!0QE^AA4ZI CUS#;IF)W"CVHWKRHW@#!MO"G%&0N^$!%XPZH O M?QT>MN$N"M*H$C2J!"7?Z #?U?K>4GFGWJ0KEEZPW7B7.J<1S!W<61K4(SB+ M%W_X$^ /KL@&(FO%&39QAB5[>'#U-YK%S";
FG(@'S +C(P>R.>W:$EN#63Z MGRX%PB$5&(BLI<"H46#4N]++E(HM$"9:*:^8B%C.X63_Z=I0$5,5:W*?Q]38 ME[',#<3DLU$%D(1R#9UJ];M@P5VR]*">*@E>*8TDT::R?&DN<5J:T QK*!_)0E^RGZ:_.W.'.J=7M0S!9HV M DU[?;J!"+(-J+*"DE6QP>\'5I8$PT9-_D>MX#0I1(P;YQ-5"C\WG1^,WDE^ MM\0,1-;2X[S1X_PX1?9\2 4&(FLI<-$H<-&;$>^+,A^PQ\!&4MM-83-A5R\^ M85H7F QKBQ048I-&8EDEF$!T:5.+W&O58W%JRZ9JKG'Y=RV:WU<3,?^)A, M9^[CO@(_VH78[.*OL6L%YWO?6BOOUO(%>,VVX/G9W0_%+^[V$.QM079ZRG]
MXV1\S3N4"@.QM57XUD/Z_4WD<;.^GOSG:=]AV)WW[MXIPA[AWE&U94(3#@DB MO;,I4JCJ5%0-C,S+@\5&&CRFE+!5K5VX%R0KC5)5NX'F16V64.9.1&7L0DQ'?J9(R\B"0 MW%55)OZ^)R7?CQW?>1[X1-<;!0?'CPC367)^1?]\$8.YY>$2E)KC1$!G]/9$K*4B/!.OYJ M0)UV3NUX^/R, J,A#V26F2137GZFA=E],G<1!!5ENOO)XON?2$-HJ/%R7DKS MB_:-K>>@?"<5KQIG6$%%6?V??6V$.'
'+M#T#@$?8?PA -N'/!+9P@;A_"E M,PP;!T/=K;D;X6:9RB8CP?=(:&M TP]&?>,->E&F-\I"'?A*P4]-%O4&07R% M%G3-Z(KF&5/H+L_YCBG*UNB!ES2G1*(;M(!M6NQ*HJUGM-PI4J!?83-?_<*E M?(\^L)Q7!#T0@::\JF ;+#:9(.AJ1E1&2["X08^+&;IZ]QZ]0RZ2^JM$E*%' M1I6\AD%X_FW#=S)CA1RY"@CJ9;IY0^:^)A.<((/11\[41J(Y*TAA\9^=]X_. M^+L@;*MN*SN?7 6\.<=&R#L7:/
"T++>]8O=\0I;()4(,.#];2(37M6X08=XA?1)GW M+?Q#88XH1RWEZ&+PFZ@W>^!UP8]>%OR^&00_2KL:6-'ZP>^;)6F(?;L2<:M$ M?%:)SZ:@ -H9!!P*I&/N"'"HLJ>!.@K/K6M BTOPRTA'S MM&6>OI8Y[0E:#ZW"=1E^1>TTV6+C7]ZD7_?(H6(19W4F5T$FO"(O_(.ZV7_E MQ;F%NM>H V7N.45JW.3PG/,&N*M&;94>QG401ETE^E: %:1=&?IF_B).A*X
M!UU$1<3:M&\2F:*MKO+:T;9%O#.-46?\WK^=^I;QF6XI3=?R#;[N1S]F8DV9 M1"59P53>((:(B;K%JU\4WYH>9LD5=$3F<0-M,1': +ZO.%?/+WJ"MM&>_ -0 M2P,$% @ *X (61.Y1V!Y!0 S2< !D !X;"]W;W)K&ULS9IM;]LV$,>_ "N$!0PNLL9[\E"4&$HO#.K2K46/KBV$O&)V] MB4JB1UQ"NS#CY04R;(56LZN@/,BEN2['\F\$^\F#+<[+K[*#:4*/25Q*F][M&Z6VU_U7V C^8T(?
**:VFJWUEQD1*E;\6Z+[>"DF7NE,1]SW&& 82PM#>]R9 - MQ?2&9RIF*9T+)+,D(>+;/8WY[K;G]IX??&;KC3(/^M.;+5G3!55_;.="W_4K MRI(E-)6,ITC0U6WOSKW&WL XY!9 ,KJ3>]?(+.6\!Z_FYOWRMN>8&=&81LH@ MB'YYI#,:QX:DY_%/">U58QK' >MG^B_YXO5B'HBD,QY_84NUN>V->VA)5R2+
MU6>^^Y66"\HG&/%8YK_1KK1U>BC*I.))Z:QGD+"T>"5/92#V'#2GW<$K';Q# MA^ %![]T\+N.$)0.0==<1!J5#OO1^L?8\<"%19'HC^ X)8ZUIYB*/?NZMX\52 M4R@+)?2[3/NIZ:
(H$,17:,'6*5NQB*0*W441SU+%TC6:\YA%C$KT#BUTF2ZS MF!KK.5=4&Y X_H9"%F@C3]5&(IPNZ;+%/[3[#RW^?1VC*E#>94%)6"_OJ@P>B]HHG\NZU&BED$[;,P&GHMMR2B MMSTMDI**1]J; OB#.W1^;DL0)"R$A&$@6".5097*P$;/4_FNRJ6L<_F&I>6G M]VU;;@KJ(*>:OT:/4\\+)KX[U.7YN! V%L,@<"=^,&H:AEV)N .Q$8!%8]! M-
12?,B4529=&];3P1E\1WYKB;94O*^KG(PZ=YC3", MJS",.RN,7K(2+%*ZC@NQR5*F6J7&RCRW/B%A(20, \$:B9E4B9E?:@>SGT:,6BPDC00K.HL'CH7_2%"*$;O]:P6(O5N=V;3H(]&*I3=0[@3]SE7[M%VEV_KDE"TH+06D8BM;,5-U,>^Y%:) 'VG"#TD)0&H:B-1-:-]R>M?][M0:5 MV(86N/[8.]HKM1@>;I*ZLK"5U0Q W:!Z](@;U ,U12-(5% K"NBVR#WMV!8-^ M>MF M%G8SPR?-BB#T]XXG)52L\W-A$N4GC(HS)]73ZNS977[BZN#YO7L]A^XU M+DZ6U?CBH)O>/ZU9*E%,5WHHYVJDYRJ*LV/%C>+; '#4 U>*)_GEAI(E%<9 MO[_B>MM5WI@:&5UX?!(HRG0^.<-
M>&PO=V]R:W-H965T=< M8'Q@_)O84"K!]SA*Q,392+F]=EVQV-"8B"NVI8DZLF(\)E+M\K4KMIR29984 M1R[RO+X;DS!QIN/LMWLˆ';.=C,*$WG,@=G%,ˆ-,[&K'#Q('.\P]?PO5&IC^X MT_&6K.F@-HFX#P!9X4>F65EW1!)IF/.#H"GT0HMWF!^7$S 5N#TP.L;*DD8B3@-> M@3 !OVW83I!D*<:N5&122'>1G_C=\<2HX<2?=LD5P-XO 'G(-Z3/[.DW=*'2 M89:.J^FN:D'1!U3T 65X?@/>9R\W/)0A%>."@'DAB0 @C\HX:;;K&#IK7^I,?_X)]KU?395V!%:I&Q=UXPP=-]0!5[UP8]>%OR^&00_2KL:6-'ZP>^;)6F(?;L2<:M$ M?%:)SZ:@ -H9!!P*I&/N"'"HLJ>!.@K/K6M BTOPRTA'S

&$FZ/&,<[7MF!NM M_8")_P!02P,$% @ *X (6;M=\C[;! M1L !D !X;"]W;W)K&ULM5E;;]LV%/XKA%9L#9!$5\MV9AM(+ G+L&)!LZP/ MPQX8B8ZY4*)*4G%:[,>/E!3YIBC2ROK!IBB>
[SL\'WUXFVTH>^1KA 1X3DG& MY\9:B/S"-'F\1BGDYS1'F7RSHBR%0CZR!Y/G#,&D-$J)Z5B6;Z809\9B5M;= ML,6,%H+@#-TPP(LTA>S+%2)T,S=LXZ7B(WY8"U5A+F8Y?$"W2-SE-TP^F0U*
M@E.4<4PSP-!J;ES:%Y$]4@9EBS\QVO"=,E!=N:?T43U<)W/#4AXA@F*A(*#\ M>4)+1(A"DGY\KD&-AE,9[I9?T*.R\[(S]Y"C)26?<"+6'E-]C4;2T#Q 47-*V-I0 J=82315*N4IK&6"<
MJ9%U*YA\BZ6=6-P*&C^N*4D0XS^!\'.!Q1=P!BZ3!"OE(0'7635^U3AX'R ! M,3F1+>YN _#^W0EX!TS UY A#G &[C(L^*FLE.4_UK3@,$OXS!324\5GQK57 M5Y57SBM>N> #S<2:@S!+4-
)B'W3;^QWVIHQ0$R;G)4Q73B?@KT5V#ESK%#B6 MX[7XL^QO[K9UYJO8PV]CC[K- Q1+<[O-?"^6;C/DW!+/?6W(R>R8% 2!WU=@ M"7,L(,%?J_%5C[^_?I,FX%9]@E/_=-G@J?*\=7^7B"Y[#&,T-
F6PY8D_(6/SX M@^U;/[XUBGM=Z(LE35.I+E>YYA3DD($G2 H$WLLL MD5!"(.,@1ZS*(R=MBE?XXQ)?399/"^OHMP+ M_J@)_FA \.M4#0NQI@Q_14DI0E7;&OD*?
+3CDSVRJL!]#O=&!K]WK2A3MJH M#^V>"GZC@C]3Z?M MX1\WX1\/#[]<:',A%R@X>WA+@W%?#3K=&*!!7]90)VO4QMJEP:318-*IP2?(M&,P$(!C>8R*7EU*"%<0ODP%, I'+7;EI$6T"5-
#^CE.CL7^8_X\;G4TY""DQZULUQM-]UM%G3W^G[/JM(GG=&@\VR(W/>[(Y#AY=U(-';>] M*$.=E-$QI:,XVT>L;6UW1U9GC"]SAHE:^#K@IK@G.):+UA5B,F.T;FHZP88N
M3+6B!5K10]UHD2ZT?9%WML#V=]Z0U 2ZA->)%FA%"[6B1;K0]HSWML([G?_N M&X;.5H4Z(@";*!ERL$$, ?2,6(RYK%]1!G)&8X1>.&=B=^]../ S^!3LRUG-BNU1:CPVTH@5:T4*M
M:)$NM'WIMV<'MO>]L[/.3?I2*UJ@%2W4BA;I0ML7?GMN8?<_N*BWRJ<@0P+0 ME4S0.RH$3%$%$[?X#U!+ M P04 " K@ A9SI(7*?8' 'X-P &0 \AL+W=OKB2G+3_?
M2CIBG2E.5P_=+:SN&YNH?4U;F4=/54E!^K#6,U^)RE>74]V]3U M]G(^KU8;EL75FV++@9G7WJXGSQLZN:'^>)J&S^P.U;_N7U7 M\F_S//44.2G9_/;N!EQ$AS8 6\5?"GJJ#SZ!)Y4-1?
&R^_+*^GCG- M$;&4K>]&(N;_/;(E2].&B1 'IYYTMH_9#+++(OT[6=>; MZYD_VMV'^_2^GWQ]#/K$W(;C.PVE5UD?6+1%D2=[]'W_N MA3@8P'GT U _
T'D",#<#\ GQJ!] /(J1'B5YLU#NZI+_->'CZL5=7:P^;HITS;VI0)2OV5HS/C2/IX;Q_ =AY#9*.9XEJKQ?<\N$C?-)J^'U7 M5S6?Y21_.^+- 7\W'V*RS7XY_#;O[HUT$4A^BA-
=;RLMO&*7<]X^:M8^E>;VK4^S=N85ZF156] MXM5^560,Q&E:K.*:K4%=@%57)3K]=?)3)H,UAU5ER?M2>=IQR(YPYF M=ZG!H(\$H8]!A Y.RD@'PJX^:7^?M&],NK)*5.U5(*FJ73/MF[+8/6P
R[9I M\86Q_J ;?:G:<'7 EI^7.C&,D::>B3;)0E1#M&!N"KDR'(*]LH&4Y5]#7)^ MMG$GUJ\H[0EE9)VJ8F#(JI/&9KC(%$X2$3K"U3J3%RCOJL CJYH2QO^J+I-5 M\[&#[*DUGM51SFX0?59CD-
"#00.5I(.XA^1X<#<0Z,,4>?-#-?_GN"P=E*' M.'28(U2.+L"-RQ(I[%%HVQRNDBDBR:D.V8!>C+Y2NN[E% \S-X8=FI9.3EN M9"NN+*>P^M!H3R6OKQ70JHFWRA9:98MLL.4O1 T!S$S"YZ8*J M \
<>[VR\0+G>:) 8(X\B;YB]CE/;+^F0B/H($W1$"=$#0',3\-QVJ*< G![% M98Q"PG%(9(3(R8M>)J;@7,Z(*@:9R7A44@X#HF,$#EA8=`A9(]^=O=C#C6Y M)-
MD"WLVXWHR0>3=5N'=T73O/B;O2.$Q1YRJLE6Y$,F,OP\'6W"1!H8H/5*Y MD.@0D+E#.+?2---.5E3M&X8=I]6 D3&@+*7H/!"Y^SA%RM&%:K/36")MI^$1 M9UA(K8:--&$)=)W#L+ +$HB-
!)W4DSV_K^SBF"^XX)-1 AFV]D4560;0#R+RQ M?Y8*HRN/J!N.E%)QJ(H*HP[%PXT '0P%/AEZ,@T.$P=1>$0CX<"1V8&/[WR@ M$^RW#J,L@G&>R,PCIRCL-S+;
[VF['4CGD[6[']5HD]%Q*W6'JIW)&IW#*,@CO MC^V:]3AJ[&:?@79RL+[@,RWB;U'&JE<%(-KG VF0+K,)%MMCD:1%=_2*_MR9X%LGI_P"I;,)4MLL4F3YCH:I"YJSEISP*I?
I\@/Q@:BJ461Y%RQUC/!ZER MG=#A7.(?J1$0!08W&P\MW/'X_<'QB'A."0R0N3DA?G'9O_3N>.U;U[}>:E M#J3+*34P-YD@SA \> M$YKLU$_J*\VTD[7$XZ>>W>=]3
%E*87=Q_^#W==JJYIMI5:-0L)Q2*2!'+N7 MB86CQ\]U]%A]=(:@@*K528>C 4'#3$_CB\;YY)2%P\=FAW^S6NVR7=I>C$)V
MGZR26INWD67R.6.3+;3*%MEBD^=#M!K8^R:>%EMM0JRRA5;9(EML\H2))@2; M;TVHO@ G-O.;S1MM0!B4OAT+.$>D87*4^D:1D10OZQ:BGAJ<]A$]/9_ZC)X&9WA(CPB?
3\P^_QRK2\;]_3@D'(=+$!HB0]F<=]JKT!4YZXL/ZM;^\: MLI2B52#?:%.?C+K}X3@D'(=$1HBLPL'#^F:7/VYOB>8I?$P#%)!MZ[LDH@QH&C M/*]_(F-T F.7]OS@3:2,E0_M*V 5K[B[O.Y>,MG_NG_
[*9]N6KP^RV\7$+_ M[R&\C+J7R 1]]T[;V[CD%_L*I.R>AW+>>'QZRNXUL>Y+76S;]Z ^%'5=9.W' M#8O7K&P_;_W15%_ =($V+^LM_@/4$L#!!0 ("N "%D^F0O]HP4) F M 9 >&PO=V]R:W-
H965T*5?FIU63+Y^(878G,QPJ.G M*Q_S^Z4R%\:SZ8K=\UNN/JUNI#X;=RCSO.15G8L*2;ZX&%WBUU=T8A*:B+]S MOJEWCI&A$(H.7B:)N_J -&QN,4+:N ME2C;9%U!F5?;5_:M'8B=!!P>2"'!M
GEI FT3.$ *T6UE#ZRU3,#.58H.DB=9H MYJ 9FR9;LVDKT\9,)?6[N!G1 (2#J1?^=/?\DRGXR:=NNEC M/4;=0)%%NH$B#1P_@716L;KAO2
S0;^/KA4OZW^'N&W!PF$P,^M!G;:NW743R20NFZ8MMT_VZ4/#L,6. M&FPSHSS,0HR3-W3Z?AAE^) 8!!G2M*P"W3*#[OR0V_YVVZ)E9DS!D7H33^V M44!@#M.H8QI!"C2"Y T$YO".]
[Q&04.]W2G)4?28%^?_3B0& .[TG'>W)& MG4YZ^J,DIC2,]G3:C\'I&M/DP#2* ^L3 F_YGYF4K%++H/Z2_67EYQZ7Y9@W0 MS?JNR#/TUV+!95[=HUO]HOF1P2]\[T<UG7(LN9F."PK-Y6Y=
M%O:.F5.E'PW,XZZN6Y;/!{H$K%W"?K]D,X"C9/_9R/YR)?/":)Z\2//>0H[N M.Q":.VS6J.$$5/.@?@T*S>5N'1OV&J-3_9_V/4D4#(K^!9$N!6N^L_]]6-4? MJ6$0[-
%]!$)S5S"LAR,!Z!H&J%V#0C.Y6[M&O);H1 VWX+O*3^(:KE(#/8E:IS+%41:^X(!14X MJ"F#0G.Y6U-&_"M=)PH\[.DV&IBAGPUSB[>NBOA=U; I>9FZ/PA6H3-,5X7^3/QKGE M6Q]%_#
[J#Z;UK*T'GJ_A1K>%/%#'-VONZR 14JZ!F"PK-W3:Q9HOZ M%\Q.W#@)^AK$-"6]&?D%@2X!ZYBHWS%IG8;H7;DJQ"/G;0>[GXDW!:L&ZP9= MYH)"9,D!E5I'0_V.1D^RT6&5@BXB0:&Y3*WYH:#
[?A34!T&AN=RM#Z+G MW/NC_4VJF"9!U+,"0W$TFNP[@?'.XT+F62UM2^_SJD8%7^C$X%6B$>3V\:?M MB1*KY@FB.Z&4*)O#)6=S+DV ?G\AM)MM3\Q#2=U#:+/_ 5!+ P04 " K M@
A9__O>07H" "2!@ &0 'AL+W=OU &P*I6@4\(!YND]O&FF-GMM.L 'IL)XLR MT4Y[V$OBCWN.[SG.O4E;(>]4B:C)0\6XFGFEUO6%[ZN\Q K41-3(SK6EC)+1:,9Y;B41#55!7(_1R;.F1=ZCPNW
M=%MJN^!G:0U;7*^42^EF2+D#2T$KY(H*3B1N9MYE>+%(;+P+^$FQ5:,QL4K6 M0MS9R4TQ\P*;$#+,M64 \KA EFS1"-^Y[3&XZTP/'XD?V+TVZTK$'A0K!? MM-
#ES/OHD0(WT#!]*]IK[/6<6,Y<,.6>I.UC X_DC=*BZL$F@XKR[@T/O0\C M0)@< 40)('HI(.X!L1/:9>9D78&&+)6B)=)&&S8[<-XXM%%#N;W%E99FEQ]<
MSE9.Y>GUHB"+$1E/@X%SM]3$@5A0C[?-U3OR0W/D5O#R9(!)^^N4-E[TV4 M*D&B2GUMDK&4?MX?/\.CHX<_!?XA 3AB3DF2@[%R^'QT_AOK%@\"$:?(@<
M7W*$[!C80]*>Y;#%=Z%JR"FFWSL M^NWMD?C_UW\I)? MFGK59+XGX[@E[WR90NR(+^_&4IRH[%??PY9%;^F5:]$ M]L2J9+ J>?8+<1;'TE9/K8*15>M]5Q!]7-U;!=:J$*;:HV2B V!HJ 6#*PO
M(*_+H6D?[$XY&*7VIE+S3;F71:>A]/S:93ZN[%!A^*"\'P:#'&==G_4,6RW M_@YR2[DB##<&&4P^& K9=&PO=V]R:W H965T MNJ.(6Z..4<2<:VK69C(:BU!GC M,)-
$E7E.Y68"F5B/G(ZS6[ACRU2;!3<:%G0)JZ"_%C.),[=&25@.7#'!B83% MR!EWKJ8#8V\.OC%8J\:8&"9S(1[,Y"89.9Y)"#*(M4&@^%C!%++, &$;O[:8 M3AW2.#,'._0/ECMRF5,%4Y%]9XE.1\[
(0DL:)GI.[^"%L^/8,7BTS9?[*N M;/MO'1*72HM\ZXPL/

M"=E(OD"U!.4$]DE44ZBF4.N#E]1;PYUZ*]YSYPMM*.:0#6);@K5-*H95+.4YD>_M:_/P@U^6=2!GBX]_X6NAD!]B6H)E!-HII"-8UJ!M4LI?EIY%8##([U?@@#
MM%F/;@FJ"523]*903:..035+:7ZBN&;](+PW0:#:FMZONI&-.8+VZ5$M036Q-MT:;?G;NYLJ3HO-K5.*H95+.4YL7_T/7@A^$>_(?TZW2VG-'E5GC6MAF":@FJ
M"523]*903:..035+:7X6N7[!\%AO7S!$N^ZHEJ":0#6);@K5-*H95+.4YB>* MZ[H/PWL'7&8WRSRMBO*;O^YK=.WY4=4U;'BO@N8M.#9':EL)Q.$QOMLY'XP:=_UK
M.#*.&U^[DH1/N'60HWUQ5%.HIE'-H)]E-#_(75]\&.Z+-RS=/2B\T9[W1MM. M@>[FS0=W4@!M:*.:1#6%:AK5#*I92O-3P#6TA^'7SK_HSM%P=XO^4;=O;=3F M2*^&:=S_-0F?
9^O81GO0[*903:..035+:7YLNQ[T,.R#!NX*;II5_A,6E\2 MT/XV[@E4DZBF4$VCFD$U2VE^9KG^]O!8V^D/T0XVJB6H)E!-HII"-8UJ!M4L MI?F)XCK8P]:Z1_T#&-WV_QX=-.\#!KM3:..0#6);@K5-
*H95+.4YJ>_ZTT/ MP[WI8U1A>_.;"I])ZXL+VM%&-8%J$M44JFE4.ZAF*H^.M0O^"&UL MHU]":@+5)*HI5..H9E# 4IJ2**ZQ/6J]" XA5=AH=[?[>'@V:KK/%3Z!UBF MMJQ13.*:0C6-
.@;5+*7Y*>!:UJ-PR_HH5=B^<K;+"Y]+ZJH*^MAS5!*I)5%.H MIE'-H)JE-#^W7*\]=*PM[$?H%O:HE]":0#6);@K5-*H95+.4YB>*Z[>/CM)O M^'UVR.,][R(9/H'6*8#VVU%-HII"-8UJ!M4LI?
DIX/KMHW"_W=5AWVUU^E"L MJZYR.EN]<^0F0>IO_#*.*:;SFV/NF14^Y=97(?2EZ:@F4$VBFD(UC6H&U2RE M^2GHE@6.CK5-_0CM]-:@FH"U22J*533J[&90S5*:GRBNRS*OXK]16O#-N;V
MB]\]^Y>&9V\=_VCS'M4DJBE4TZAF4,U2FA__KGD_J1Y_W1Q^#E;%5D7RSH+.M9ED9713SN@2KRL>+R.5T\5O]W;_?%O60>EBY;Z%8>,K6EQ"T^8]J-M4DJBE4
MTZAF4,U2F]"KOD_.M8%N.B.TEX]"::H)5).HIE!-HYI!.4MI?],72]_"X% M^\>L7%U.TIOUD_Z;LEBL"JUUJC1E1UAKFQVHEJ":0#6);@K5-*J9C1;'6X5X MYU5_Z!?AEIK4#WO7F1\?
TIE_88FU9Q58>,K6N8%V]E%.H)I$-85J&M4,JEE* MU/(=?;'Q!H"?HRVZ5$M036!:A+5%*II5#.H9BG-3O37IA^'7]+>ML1">_.H MEJ":0#6);@K5-*J9C?9=B=7=*:&.T70?NZ;
[^)"F^TM+K'U+O,*3MLX.M&V/ M;@+5)*HI5-.H9E# 4IJ?1*YM/S[6ON]CM+F.:@FJ"523]*903:..035+:7ZB MN.;Z./R;^[9%%MI11[4$U02J2513J*91S6RT[XNLP?=%%MHJ/UW<9EF5I%5Z
M_J8NDVZRBRS/%]&D6.ZKU45BZZMU=%_7:1&_?M<[.=WYNHA?JCAZSI^;=9? M/W7\^9NL.FT^I.7-=+Z(\NRZGJKS:K58IIS>W#Y_4A5Wl8_C)/I25'4-M_[P M-
DNOLG)U0/WJZZ*HGCY93?!0E+^M"\[Y_P-02P,$%_@ *X (68V.$ME* M!0 .;QT !D !X;"]W.W)K&ULM5G;.N.V$/T5 MPET4NT =B.3D2VH.2)PMEJ*+!DFW?2CZP$BT+:.PDNA1M;_Z^U"6B)5*TDR@O
MMBXS1V=&PSFD.#LP_BW;4"K]R1.L_E@(\3VTG&R8$,3DEVP+4WEG17C"1'R ME*^=;.LI"0NG)':0ZXZ+YP'ZTW(K_@+&9;LJ8/5'S=WC%YYM0H8930-(M8"CA=S0=7\'*)1[E#8?%7 M1
9T3'(0WED[%M^!.,\.\GP?%2^3I"&XBF4]D#2@8D73,>T0Q\O*&"1/$G"?[U MX09/)?,@A_]RP72:]LIDC9 @Y$2>HZ%Z7=%$'W1'XPE*QR<#G.*1AT]^1 MH=?QH^?XKY$5\+==>@&P^Q-
+O(.?);GNV,+'5R_#ES@X0Z\FR@CZS6G:U(4 M^1^K.M___'Y-P.V@2?:O*%\EKF?&S9O!9.8E 9TJY&C/*_3P>+'"^#(_=D4
M=$]@C11X=0H\&_KBFL1Y(EB+!U'A6/>G_8+Y/KCF:_.YJX:O=^#M5&#DU!S M]V<5+%S&LL"#X%@4W!9IW0)##YM)CVK2 M(ROIY8:D:SD,Y8BCF8ADRZ/']+>2-
3^#_$BCAOP6>]UD..T@/Z{)C^WD.0TC MX6S)D]0,8>P48^VI0W\R;5$S&"&(IF9RDYK![VC7)2D="..O(F9 MT[3F.+5RDITC8#N9JJ(?RW?/U_21!.^,J;."O;19] 36B!JZ2K_<=^]8%7!/ M6>@+K9F&
(QF'KRW)RM/6?@PFR/?.!0F1XH3>LVM6Z%;>NLEXW-%YH-)@:.6W MOAIG]10K?YM)D[V23VC7SS,Z9X5@9:.,#,=N1X^"2D>A74AM97I;)0TF&'4E M3,DDM.NDFMF*'4_.";,BO+A5]
(36C%T.O.:+T] 36C,.2L/AJT4< M&@1ZU*Y%W:.S\R@-AW81?VO'GJX>0KH)AB.S:Z1$&%G5K:.63WEF)P/6P$8 M;#HGFTC)+|++YQE-$YV648/)<.QU<9&,RBNPR:BE4LO?I+T>;MA MZN3(R62
MR"Z2]W)V*6@YV[R5]-+\>T3UTOAUBK"X,1Q-ZX@Y_2563755NYZH*(O#8M-MW09.NR;>6*DFMJNFFG@&\)(Z-'_5Z7:+VA=8.5VDLAN_U;=,JWB].0T]HS30H M.<>OEG-LD-HI1JUJ-
%AUE>+19V>[FK^Q<^+32UVK29.U$F.\8JG;3]O$IY?# M5I,F>Z6AV*ZA9S1-K.ODT/%7LD[6N7\/+9;GOIV#*;<@OA*^C-.,O74E(-M]V(LD\3+G;WR1+!ML3GVR(1@27&XH22D/#>0]U>.B>>3-
'U_NKB?U!+_P04 M " K@ A9N!6QE7Z7FS*8]+DT !)M0H&[?4D'I!U?D\#) MC53*!N3IXOW/N3*W[P)W/_MP=M9ZNKS=C5]4P"4)O:(W!XA>M5]X,("8>'R0
M^!YI3+A[F.M]IC'IWK;T:OBYU6JXYO@Y\9#73(S6:7ES:F2LB&%=)L_^IN2Z.M6B+B E:9YBQXIF) 1E3PL>:.RFC.Q=*%.Q"8**%T8&R9VE1MB)0O#FZ(`E1P.MK9-SJ725VV5PW^-Z^
ZPZH%!+D1CL$ <8-@OJ#%,RSO;J097P5=04+[Y%M[%FU8!)I6D-UT\FX#NAOJCGM3=GK_^D&!7]6 MYO/<3D=6?:AL=]]9QA=5?Y$U!C#U-JY.BT(L/PD^E3ESDS\XX;!/5[O@IC1-
ML=F@5"8VP#0)GIDV?+(9^:5I\<@69E5.BPSWW#E!SW]WG:=.,DW%IFE;^\>\MRF]V"7_E>7JM\]N8:_'^IU]["9O3L%D? HF3Z(F>Z=@.CE^D]$)>"S/ED=G M,JQ/0AO'K:W#5A,.X% [(-
_A>"S628/QG O#9=V;\31E\M69R\H;.K9_J&WI MV_$IR^A2NNOP(QG&8'P$,RX.YP#B.A>7YG^;30^?C,.O;SXOT4$X/ MY3B6#QE5'RR/GY/8RS_3)(FB.,96=#3R.AAAZQ;\..7P[P! \L#F?YLK?'=
MQBMD?QU@>[JO0K"9XI6(S11?:T#\ZP:.)/'O-I8'&-@N8+4#^?UYH*\;G"B" M7<6\84\PCB0)AD M^FLTCI'5B>'CWQ_L*8FB)/$C@/D=1!&&P.,((Y@#\(A M452]!W?>1^'J/16N_WLY_ U02P,$% @
*X (69>*NQS $P(L M !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/(7-><I3W;+T!l;X"O.DQO0FE(2S;._M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%I%R=.B':5_'33L$ M Q) #P
'AL+W=O225M?_U(*8:O&OMB+[=ZLDG1]-&EO`)Z=V3 M=0]K:Q_8EU8;O\RV(>S.9S-?;V4K_"]V)TT\LK&N%2$6W?W.[YP4C=]*&5H] MX_/Y8M9*9;+W[_9]W;H9+-
@@ZZ"LB96IXD[))W\XGHKL47FU5E]%K\NL_ZYE MQEIE5*N^R6:9S3/FM_;I-^O4-VN"T*O:6:V763XN_\31KO9]%I>V[IKI0E#')W4"=#XK=KYC!G1RF6V:*$:=@'
M$V*0V(T9NHIMTYG&OIYIAK..$1?$T)VK>.#=-#TX'>3?1G2-"K)A5]8TTOCA MF[=:.9$(0'($DD\(^0\'D 4"64P)60#(SH$LIX0L 62%0%:TD-?2UT[M4CVS M&W;9>66D]_U]="D\@%P@D
M:R%77ML)]38 K=6]4_)F(]_I%7=LNWNL\C4" M^9H6\L8\2A]2(QBU-PC0&U]@6R=W0L7I\.LN77S#F'X*6^G85><<@'R+0+ZE MA8QCZ#IY@(0S)1RJN>T7)?6.?L4=38B0N5!;(\KV[9JN+
[ZD8Q328A\TM1J M'#9,'CFQ/5;!U@],JQOI_$_LP[]=%#%DPYR1$TNC9SM;BV$>;M/U]B(YP'21 M$_OBHU"_W0G=2?:%+YS\OO)),=$D1.;XK-\E*:#6 4J.*2&?T@FC("7'I) 3 M6P"A)E*CJDB)W8%D!=
[%?.[+?W/D TS1$ZL"-1CHY'FF#$XL3&^-]FQ.'), M('Q*@;!7$!=?TR@D*.QQ%S")W+),RC$O)3"IU'*/IP0$U,+_S%J.3K*F&,X ML6/0Q=%XYL$Q-IYD6/$D8_= M-
IV6:>@A}J:=@E@[A\7SL3$7$!/33D&L'3PA.H.8F(4*8@NAF.,=68F(6*]G70]/,#$+5<06.HW9^O)B8A;]B"V$1G.TZ!5FH8K80OO=F&.I>RQ! M3.Q"%;.&%#IA@\7N17E!)^&:3NNK6/?)_&Y%LW_C9?
^VSOO_%!+ P04 " K@ A9#Y14 M2-H! !9(&@ 'AL+U]R96OS+W=O)/F/!00D5#B]B %28/D<269Q#}[HE"$8Y%08/F5-;8\O5?6)^L MD>6;7?(FVV?)\?]H! 7S::4_B&$O-RD?
9MONCX=$E=6W,!ORWDYK$/? M+M_;=0HZG<["\'-&\SC_.7/R>NK37R9V]]5VF9ZZY<<^''Z3)M0.4@C2^D$&058_R"'(ZP=% M"(KU@V80-*L?= M!M_6#
[B#HKG[0/03=UP^2*BWD]@MZ+>2]"WCCZV-M"?16U%L)]%;46PGT5M1;"?16U%L)]%;46PGT5M1;"?16U%L)]#;4VPCT-M3; M"/0VU-
L(]+:19@F!WH9Z&X'>AGH;@=Z&>AN!WHYZ&X'>AGH;@=Z&>AN!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>/MKL)M#:46\GT-M1;R?0VU%O)]#:46\GT-M1 M;R?0.Z+>D4#OB'I'.KTCZAT)]
(ZH=R30.Z+>\3_USN6T2_G:\[W&Y_\GU>5\ M;[H^_K+\/CEZ>R\X!_B3X/$+4$L#!!0 (" N_"%DA7: @=!&S:;EL6 M_0$W>4!$$ENVH?#W=<(@M:*HB$]]&R)B^]T76SJ;9/2VM>1[F[IJ_#A9A& ?
M&//Y@FKM4V.IB2,SXVH=XE\W9U;G2STG)@:.#(F&2>,*I_T'G<3VZQQHJVMRER'.,[63?$M\;/2./*;HY?E-;?Q D) M.YG0COPJ^C87(-MA?+\(QX38^FKGX.;TRZH^&5VW-X/XY;=>7C67:[?XZ]G?
*Q_81\"I\)TH<" MZ2,#Z6,(TL&PO=&AE;64O=&AE;64Q+GAM;%!+ M 0(4 Q0 ("N_"%D%9:VO^ 4 -X? 8 " @0T(!X M;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ *X (64R6O?\& P -0H !@ ("!
M#14 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M*X (64\Q^+5=#@ >"0 !@ ("!*2@ 'AL+W=O$\$ ="(@ & @('8/P >&PO=V]R M:W-H965T&UL4$L! A0#% @ *X (6992\@!) @ =08 M !@
("!740 'AL+W=O&UL4$L! A0#% @ *X (617Y$@=- M"@ 3!T !D ("!-DH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *X (6;J$7)!'" B14 !D M ("!NVH 'AL+W=O&PO=V]R M:W-H965T&UL
M4$L! A0#% @ *X (67KD LO'" OAH !D ("!(P M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M*X (6=X\4)W6 @ 708 !D ("!BIX 'AL+W=O&PO=V]R:W-H965TT !X,"]W;W)K&UL4$L! A0#% @
*X (63V]6A6K! <@T !D M ("!5+@ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ *X (6>E-T"&PO=V]R:W-H965T;-.!X;"]W;W)K&UL4$L! A0#% @ *X (M65?SLJUQ @ *08 !D ("!XM(
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *X (6;>"Y ,^"P 5(L M !D ("!G]L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *X (6<>!<0I_ @ T@8 !D M ("!*_('AL+W=O&PO=V]R:W-
H965T M&UL4$L! A0# M% @ *X (6&PO=V]R:W-H965T03 0!X;"]W;W)K&UL4$L! A0#% @ *X (64)""XZJ P .PP !D M ("!\1@! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ *X (68.Z.6SM!P
G$P !D ("! MDB,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ *X (6<.ZFEP"$0 PX! !D ("!YC,! 'AL+W=O&PO=V]R:W-H965T7!E&UL4$L% 3!@ ^ #X Z1 &Y7 0 $! end XML 62 Show.js
IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of
their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};.Show.LastAR=null.Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a)
{var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-
11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{
display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }
.report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-
size: 1em; } /* Report Styles */ .pl a, .pl a:visited{ color: black; text-decoration: none; } /* table */ .report{ background-color: white; border: 2px solid #acf; clear: both; color: black; font-
normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /* Top labels */ .report th{ background-color: #acf; color: black; font-weight: bold; text-align:
center; } .report th.void{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl{ text-align: left; vertical-align: top; white-space:
normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a{ cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a{ width: 200px;
} .report td.pl a:hover{ background-color: #ffc; } /* Header rows... */ .report tr.rh{ background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc{ background-color:
#f0f0f0; } /* Even rows... */ .report .re, .report .reu{ background-color: #def; } .report .reu td{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou{ background-color:
white; } .report .rou td{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td{ border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn{ white-space:
nowrap; } /* styles for numeric types */ .report .num, .report .nump{ text-align: right; white-space: nowrap; } .report .nump{ padding-left: 2em; } .report .nump{ padding: 0px 0.4em 0px 2em;
} /* styles for text types */ .report .text{ text-align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{
font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL
DOCUMENT 3.24.2.u1 html 266 278 1 false 78 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Unaudited
Condensed Consolidated Balance Sheets Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets Unaudited Condensed
Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical Unaudited Condensed Consolidated Balance Sheets
(Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Unaudited Condensed Consolidated Statements of Operations Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations Unaudited Condensed Consolidated Statements of Operations
Statements 4 false false R5.htm 100040 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows Unaudited Condensed Consolidated Statements of Cash Flows
Statements 5 false false R6.htm 100050 - Disclosure - Description of Business and Basis of Preparation Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPreparation Description of Business and Basis of Preparation Notes 6 false false R7.htm
100060 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of
Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Investments Sheet http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestments Investments Notes
8 false false R9.htm 100080 - Disclosure - Prepaid Expenses and Other Current Assets Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 9 false false R10.htm 100090 -
Disclosure - Accrued Expenses Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses Accrued Expenses Notes 10 false false R11.htm 100100 - Disclosure -
Borrowings Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowings Borrowings Notes 11 false false R12.htm 100110 - Disclosure - Commitments and
Contingencies Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 100120 -
Disclosure - Stockholders' Equity Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 100130 -
Disclosure - Stock-based Compensation Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-based Compensation Notes 14 false false
R15.htm 100140 - Disclosure - Fair Value Measurements Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 15
false false R16.htm 100150 - Disclosure - Revenue Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenue Revenue Notes 16 false false R17.htm 100160 - Disclosure -
Summary of Significant Accounting Policies (Policies) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of
Significant Accounting Policies (Policies) Policies http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 100170 -
Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables
Summary of Significant Accounting Policies (Tables) Tables http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 18 false false R19.htm
100180 - Disclosure - Investments (Tables) Sheet http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsTables Investments (Tables) Tables
http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestments 19 false false R20.htm 100190 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets 20 false false R21.htm 100200 - Disclosure - Accrued Expenses (Tables) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses 21 false false R22.htm 100210 - Disclosure - Commitments and Contingencies (Tables) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 22 false false R23.htm 100220 - Disclosure - Stockholders' Equity (Tables) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity 23 false false R24.htm 100230 - Disclosure - Stock-based Compensation (Tables) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation 24 false false R25.htm 100240 - Disclosure - Fair Value Measurements (Tables) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements 25 false false R26.htm 100250 - Disclosure - Revenue (Tables) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueTables Revenue (Tables) Tables http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenue 26 false
false R27.htm 100260 - Disclosure - Description of Business and Basis of Preparation - Additional Information (Detail) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail Description of Business and Basis of Preparation -
Additional Information (Detail) Details 27 false false R28.htm 100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional
Information (Detail) Details 28 false false R29.htm 100280 - Disclosure - Summary of Significant Accounting Policies - Schedule of Diluted Net (Loss) Income Per Common Share (Details) Sheet
http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails Summary of Significant
Accounting Policies - Schedule of Diluted Net (Loss) Income Per Common Share (Details) Details 29 false false R30.htm 100290 - Disclosure - Summary of Significant Accounting Policies -
Schedule of Potentially Dilutive Shares (Detail) Sheet
http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail Summary of Significant Accounting

Policies - Schedule of Potentially Dilutive Shares (Detail) Details 30 false false R31.htm 100300 - Disclosure - Investments - Summary of Investments (Details) Sheet http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails Investments - Summary of Investments (Details) Details 31 false false R32.htm 100310 - Disclosure - Investments - Additional Information (Details) Sheet http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails Investments - Additional Information (Details) Details 32 false false R33.htm 100320 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) Details 33 false false R34.htm 100330 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 34 false false R35.htm 100340 - Disclosure - Borrowings - Additional Information (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail Borrowings - Additional Information (Detail) Details 35 false false R36.htm 100350 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 36 false false R37.htm 100360 - Disclosure - Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInUnauditedCondensed(Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease (Detail) Details 37 false false R38.htm 100370 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail Commitments and Contingencies - Future Minimum Lease Payments (Detail) Details 38 false false R39.htm 100380 - Disclosure - Commitments and Contingencies - Presentation of Operating Lease Liability (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityDetail Commitments and Contingencies - Presentation of Operating Lease Liability (Detail) Details 39 false false R40.htm 100390 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 40 false false R41.htm 100400 - Disclosure - Stockholders' Equity - Summary of Common Stock Shares Activity (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail Stockholders' Equity - Summary of Common Stock Shares Activity (Detail) Details 41 false false R42.htm 100410 - Disclosure - Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) Details 42 false false R43.htm 100420 - Disclosure - Stock-based Compensation - 2014 Equity Incentive Plan (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2014EquityIncentivePlanDetail Stock-based Compensation - 2014 Equity Incentive Plan (Detail) Details 43 false false R44.htm 100430 - Disclosure - Stock-based Compensation - 2015 Inducement Award Plan (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2015InducementAwardPlanDetail Stock-based Compensation - 2015 Inducement Award Plan (Detail) Details 44 false false R45.htm 100440 - Disclosure - Stock-based Compensation - 2024 Equity Incentive Plan (Details) Sheet http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails Stock-based Compensation - 2024 Equity Incentive Plan (Details) Details 45 false false R46.htm 100450 - Disclosure - Stock-based Compensation - Stock Option Activity (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail Stock-based Compensation - Stock Option Activity (Detail) Details 46 false false R47.htm 100460 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail Stock-based Compensation - Schedule of Restricted Stock Units ("RSU") Activity (Detail) Details 47 false false R48.htm 100470 - Disclosure - Stock-based Compensation - Compensation Cost (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationCompensationCostDetail Stock-based Compensation - Compensation Cost (Detail) Details 48 false false R49.htm 100480 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense Related to Stock Options (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRelatedToStockOptionsDetail Stock-based Compensation - Stock-Based Compensation Expense Related to Stock Options (Detail) Details 49 false false R50.htm 100490 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Detail) Details 50 false false R51.htm 100500 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 51 false false R52.htm 100510 - Disclosure - Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecurr Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) Details 52 false false R53.htm 100520 - Disclosure - Revenue - Additional Information (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail Revenue - Additional Information (Detail) Details 53 false false R54.htm 100530 - Disclosure - Revenue - Summary of Activity in Each of Product Revenue Provision and Allowance Categories (Detail) Sheet http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail Revenue - Summary of Activity in Each of Product Revenue Provision and Allowance Categories (Detail) Details 54 false false All Reports Book All Reports scyx-20240630.htm scyx-20240630.xsd http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 false false JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "scyx-20240630.htm": { "nsprefix": "scyx", "nsuri": "http://www.scynexis.com/20240630", "dts": { "inline": { "local": ["scyx-20240630.htm"] }, "schema": { "local": ["scyx-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"] } }, "keyStandard": 234, "keyCustom": 44, "axisStandard": 28, "axisCustom": 1, "memberStandard": 28, "memberCustom": 44, "hidden": { "total": 6, "http://fasb.org/us-gaap/2023": 2, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 266, "entityCount": 1, "segmentCount": 78, "elementCount": 500, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 744, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets", "longName": "100010 - Statement - Unaudited Condensed Consolidated Balance Sheets", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100020 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations", "longName": "100030 - Statement - Unaudited Condensed Consolidated Statements of Operations", "shortName": "Unaudited Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "scyx:CostOfProductRevenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R5": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "longName": "100040 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPreparation", "longName": "100050 - Disclosure - Description of Business and Basis of Preparation", "shortName": "Description of Business and Basis of Preparation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "100060 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestments", "longName": "100070 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "100080 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses", "longName": "100090 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1,

"baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowings", "longName": "100100 - Disclosure - Borrowings", "shortName": "Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "100110 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity", "longName": "100120 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation", "longName": "100130 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "100140 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenue", "longName": "100150 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "100160 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:EarningsPerSharePolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "100170 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsTables", "longName": "100180 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:HeldToMaturitySecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "longName": "100190 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesTables", "longName": "100200 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "100210 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityTables", "longName": "100220 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "longName": "100230 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "longName": "100240 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueTables", "longName": "100250 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4e51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail", "longName": "100260 - Disclosure - Description of Business and Basis of Preparation - Additional Information (Detail)", "shortName": "Description of Business and Basis of Preparation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86bc-0b90caeb15b2", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86bc-0b90caeb15b2", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R28": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_8720e061-17f3-4117-a7c3-0a850dc4aae5", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "scyx:RecentlyIssuedAccountingPronouncementsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8720e061-17f3-4117-a7c3-0a850dc4aae5", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "scyx:RecentlyIssuedAccountingPronouncementsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails", "longName": "100280 - Disclosure - Summary of Significant Accounting Policies - Schedule of Diluted Net (Loss) Income Per Common Share (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Diluted Net (Loss) Income Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_3e259a99-875e-4ff4-ba0c-b1128c726984", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3e259a99-875e-4ff4-ba0c-b1128c726984", "name": "us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R30": { "role":

```
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail", "longName": "100290 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Detail)", "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerSharePolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails", "longName": "100300 - Disclosure - Investments - Summary of Investments (Details)", "shortName": "Investments - Summary of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_39b61233-b81d-4d70-bf9f-30e6bff518a5", "name": "us-gaap:HeldToMaturitySecuritiesNetCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_39b61233-b81d-4d70-bf9f-30e6bff518a5", "name": "us-gaap:HeldToMaturitySecuritiesNetCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:HeldToMaturitySecuritiesTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "longName": "100310 - Disclosure - Investments - Additional Information (Details)", "shortName": "Investments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_5ae86c67-a1e2-4c31-a9c3-1ff254aa6df5", "name": "us-gaap:HeldToMaturitySecuritiesFairValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5ae86c67-a1e2-4c31-a9c3-1ff254aa6df5", "name": "us-gaap:HeldToMaturitySecuritiesFairValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "ix:continuation", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail", "longName": "100320 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)", "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "scyx:PrepaidResearchandDevelopmentExpensesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "scyx:PrepaidResearchandDevelopmentExpensesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "longName": "100330 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "scyx:AccruedResearchandDevelopmentExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "scyx:AccruedResearchandDevelopmentExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail", "longName": "100340 - Disclosure - Borrowings - Additional Information (Detail)", "shortName": "Borrowings - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_cfec45a0-abff-44c6-8629-08ae29e0cf4e", "name": "scyx:AmortizationOfRemainingFinancingCostsAndDiscounts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R36": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "longName": "100350 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_0796071b-2808-47b2-b04f-30a0cdd07736", "name": "scyx:LeaseAgreementAreaOfOfficeSpace", "unitRef": "U_sqft", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_0796071b-2808-47b2-b04f-30a0cdd07736", "name": "scyx:LeaseAgreementAreaOfOfficeSpace", "unitRef": "U_sqft", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInUnauditedCondensed "longName": "100360 - Disclosure - Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease (Detail)", "shortName": "Commitments and Contingencies - Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail", "longName": "100370 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments (Detail)", "shortName": "Commitments and Contingencies - Future Minimum Lease Payments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityDetail", "longName": "100380 - Disclosure - Commitments and Contingencies - Presentation of Operating Lease Liability (Detail)", "shortName": "Commitments and Contingencies - Presentation of Operating Lease Liability (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "scyx:OperatingLeaseLiabilityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "scyx:OperatingLeaseLiabilityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R40": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "longName": "100390 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "shortName": "Stockholders' Equity - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_aca5e077-8462-41f3-b69e-07ec68c29555", "name": "scyx:FairValueOfLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R41": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail", "longName": "100400 - Disclosure - Stockholders' Equity - Summary of Common Stock Shares Activity (Detail)", "shortName": "Stockholders' Equity - Summary of Common Stock Shares Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_90447c07-e658-4636-acae-d2c3b956f569", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_90447c07-e658-4636-acae-d2c3b956f569", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "longName": "100410 - Disclosure - Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail)", "shortName": "Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "scyx:CommonStockReservedForFutureIssuancesTableTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b03359ed-1f50-4eaa-86be-0b90caeb15b2", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "scyx:CommonStockReservedForFutureIssuancesTableTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2014EquityIncentivePlanDetail", "longName": "100420 - Disclosure - Stock-based Compensation - 2014 Equity Incentive Plan (Detail)", "shortName": "Stock-based Compensation - 2014 Equity Incentive Plan (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_e2182c61-13fa-4ce3-aa74-8feda318acf4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e2182c61-13fa-4ce3-aa74-8feda318acf4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2015InducementAwardPlanDetail", "longName": "100430 - Disclosure - Stock-based Compensation - 2015 Inducement Award Plan (Detail)", "shortName": "Stock-based Compensation - 2015 Inducement Award Plan (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_2bbf0434-e32e-4c51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a9fa1951-8ce6-4d94-bef4-8cd138f965e6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R45": { "role": "http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails", "longName": "100440 - Disclosure - Stock-based Compensation - 2024 Equity Incentive Plan (Details)", "shortName": "Stock-based Compensation - 2024 Equity Incentive Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
```

```
"menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_477fefd7-d329-4f73-847a-b9d7378faea0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_477fefd7-d329-4f73-847a-b9d7378faea0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail", "longName": "100450 - Disclosure - Stock-based Compensation - Stock Option Activity (Detail)", "shortName": "Stock-based Compensation - Stock Option Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_aca5e077-8462-41f3-b69e-07ee68c29555", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2bbf0434-e32e-4c51-8ec2-6fc2a26bb3d0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R47": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail", "longName": "100460 - Disclosure - Stock-based Compensation - Schedule of Restricted Stock Units (\"RSU\") Activity (Detail)", "shortName": "Stock-based Compensation - Schedule of Restricted Stock Units (\"RSU\") Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_8fb4a6c9-3ad2-46a9-a698-305991b7cde1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_8fb4a6c9-3ad2-46a9-a698-305991b7cde1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationCompensationCostDetail", "longName": "100470 - Disclosure - Stock-based Compensation - Compensation Cost (Detail)", "shortName": "Stock-based Compensation - Compensation Cost (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R49": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRelatedToStockOptionsDetail", "longName": "100480 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense Related to Stock Options (Detail)", "shortName": "Stock-based Compensation - Stock-based Compensation Expense Related to Stock Options (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9cffcde7-f45c-439c-8b5d-5eaec68194c2", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R50": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail", "longName": "100490 - Disclosure - Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Detail)", "shortName": "Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_ef32e363-84a0-41ca-a44b-6fd719cf1ce1", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ef32e363-84a0-41ca-a44b-6fd719cf1ce1", "name": "us-gaap:LiabilitiesFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R51": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "longName": "100500 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "shortName": "Fair Value Measurements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_ef32e363-84a0-41ca-a44b-6fd719cf1ce1", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_535dd7a3-59c8-47ff-a956-b3d7e4943981", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R52": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecur "longName": "100510 - Disclosure - Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail)", "shortName": "Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_05caffbc-fb5e-4d54-9946-90f3dcd2fd26", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_05caffbc-fb5e-4d54-9946-90f3dcd2fd26", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail", "longName": "100520 - Disclosure - Revenue - Additional Information (Detail)", "shortName": "Revenue - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_3c259a99-875c-4ff4-ba0c-b1128c726984", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_36a4c179-d74b-4a6d-a8e1-69b09d835425", "name": "scyx:DevelopmentMilestonesReceived", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "unique": true } }, "R54": { "role": "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail", "longName": "100530 - Disclosure - Revenue - Summary of Activity in Each of Product Revenue Provision and Allowance Categories (Detail)", "shortName": "Revenue - Summary of Activity in Each of Product Revenue Provision and Allowance Categories (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_aca5e077-8462-41f3-b69e-07ee68c29555", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_aca5e077-8462-41f3-b69e-07ee68c29555", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "scyx-20240630.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate202006Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdate202006Member", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "ASU 2020-06", "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity." } } }, "auth_ref": [ "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r13" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12", "r695" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of investment discount", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r88" ] }, "us-gaap_AccruedBonusesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedBonusesCurrent", "crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "label": "Accrued Bonuses, Current", "terseLabel": "Accrued employee bonus compensation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16" ] }, "scyx_AccruedOtherRebates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AccruedOtherRebates", "crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other rebates", "label": "Accrued Other Rebates", "documentation": "Accrued other rebates." } } }, "auth_ref": [] }, "scyx_AccruedProductRecall": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AccruedProductRecall", "crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued product recall", "label": "Accrued Product Recall", "documentation": "Accrued product recall." } } }, "auth_ref": [] }, "scyx_AccruedResearchandDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AccruedResearchandDevelopmentExpenseCurrent", "crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" ], "lang": { "en-us": { "role": { "documentation": "Accrued research and development expense, current.", "label": "Accrued Researchand Development Expense Current", "terseLabel": "Accrued research and development expenses" } } }, "auth_ref": [] },
```

"scyx_AccruedSeverance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AccruedSeverance", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued severance", "label": "Accrued Severance", "documentation": "Accrued severance." } } }, "auth_ref": [] }, "scyx_AchievementOfThreeInterimMilestoneOfOngoingMarioStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AchievementOfThreeInterimMilestoneOfOngoingMarioStudyMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Achievement of Three Interim Milestone of Ongoing Mario Study", "label": "Achievement of Three Interim Milestone of Ongoing Mario Study [Member]", "documentation": "Achievment of three interim milestone of ongoing Mario study." } } }, "auth_ref": [] }, "scyx_AchievementOfThresholdUpto200MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AchievementOfThresholdUpto200MillionMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Achievement of Threshold Upto 200 Million", "label": "Achievement of Threshold Upto 200 Million [Member]", "documentation": "Achievment of threshold upto 200 million." } } }, "auth_ref": [] }, "scyx_AchievementOfThresholdUpto300MillionTo500MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AchievementOfThresholdUpto300MillionTo500MillionMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Achievement of Threshold Upto 300 million to 500 Million", "label": "Achievement of Threshold Upto 300 million to 500 Million [Member]", "documentation": "Achievment of threshold upto 300 million to 500 million." } } }, "auth_ref": [] }, "scyx_AchievementOfThresholdUpto750MillionTo1BillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AchievementOfThresholdUpto750MillionTo1BillionMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Achievement of Threshold Upto 750 million to 1 Billion", "label": "Achievement of Threshold Upto 750 million to 1 Billion [Member]", "documentation": "Achievment of threshold upto 750 million to 1 billion." } } }, "auth_ref": [] }, "scyx_AchivementOfTwoInterimMilestoneOfOngoingMarioStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AchivementOfTwoInterimMilestoneOfOngoingMarioStudyMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Achivement of two interim milestone of ongoing mario study member.", "label": "Achivement of Two Interim Milestone of Ongoing Mario Study [Member]", "terseLabel": "Achivement of Two Interim Milestone of Ongoing Mario Study" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r77", "r695", "r833"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r397", "r398", "r399", "r575", "r745", "r746", "r747", "r814", "r835"] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": ["r129", "r130", "r131", "r132", "r133", "r169", "r170", "r171", "r172", "r182", "r217", "r218", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r262", "r263", "r264", "r274", "r397", "r398", "r399", "r403", "r404", "r405", "r406", "r409", "r410", "r411", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r455", "r456", "r460", "r461", "r462", "r463", "r470", "r471", "r475", "r476", "r477", "r478", "r489", "r490", "r491", "r492", "r493", "r528", "r529", "r530", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r50", "r51", "r364"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "scyx_AgencyBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AgencyBondsMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Agency bonds", "label": "Agency Bonds [Member]", "documentation": "Agency bonds." } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationCompensationCostDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRelatedToStockOptionsDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r393", "r400"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows", "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt issuance costs and discount", "verboseLabel": "Amortization of debt issuance costs and discount", "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": ["r313", "r473", "r676", "r677", "r740"] }, "scyx_AmortizationOfRemainingFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "AmortizationOfRemainingFinancingCostsAndDiscounts", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of remaining financing costs and discounts", "label": "Amortization of remaining financing costs and discounts", "documentation": "Amortization of remaining financing costs and discounts." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r197"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r30"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r30"] }, "scyx_April2022PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "April2022PublicOfferingMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "documentation": "April 2022 public offering.", "label": "April2022 Public Offering [Member]", "terseLabel": "April 2022 Public Offering", "verboseLabel": "April 2022 Public Offering" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r412"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r104", "r138", "r161", "r201", "r208", "r212", "r252", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r414", "r418", "r458", "r536", "r604", "r695", "r708", "r780", "r781", "r821"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r135", "r143", "r161", "r252", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r414", "r418", "r458", "r695", "r780", "r781", "r821"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Fair value of financial assets", "totalLabel": "Assets, Fair Value Disclosure, Total", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r58"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "terseLabel":

```
"Balance Sheet Location", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]",
"terseLabel": "Balance Sheet Location", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r52", "r55" ] },
"scyx_BaseNumberOfAdditionalAwardsAuthorizedUnderTwoThousandTwentyFourEquityIncentivePlan": { "xbrltype": "sharesItemType", "nsuri": "http://www.scynexis.com/20240630",
"localname": "BaseNumberOfAdditionalAwardsAuthorizedUnderTwoThousandTwentyFourEquityIncentivePlan", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails" ], "lang": { "en-us": { "role": { "documentation": "The base number of
new shares of common stock that may be issued after the effective date of the 2024 equity incentive plan, adjusted by certain amounts as described in the plan agreement, to arrive at an
aggregate number of new shares of common stock that may be issued under the plan.", "terseLabel": "Base number of new shares available for future issuance under equity incentive plan (in
shares)", "label": "Base Number of Additional Awards Authorized Under Two Thousand Twenty Four Equity Incentive Plan" } } }, "auth_ref": [] }, "us-
gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant
Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting
policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other
Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r89" ] }, "us-
gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr":
"debit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and
Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value,
Total", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of
demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of
changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r28", "r137", "r662" ] }, "us-
gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r137" ]
}, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair
Value Disclosure", "terseLabel": "Cash and cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes
other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash
and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-
gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Cash,
Cash Equivalents, and Short-Term Investments, Total", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash and cash equivalents and short-term investments",
"documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics
of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding
items classified as marketable securities, include short term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present
minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity
means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as
cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of
cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale
securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r736" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents,
Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted
cash at beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total", "documentation": "Amount of cash and cash equivalents, and cash
and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand
deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid
investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." }
} }, "auth_ref": [ "r28", "r86", "r158" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease)
increase in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange
Rate Effect", "negatedTotalLabel": "Net decrease in cash, cash equivalents, and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and
cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial
institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily
convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r86" ] },
"us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Cash [Member]", "terseLabel": "Cash", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have
the general characteristics of demand deposits." } } }, "auth_ref": [ "r137" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Change in
Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "documentation":
"Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": [ "r122", "r123", "r124", "r129", "r130", "r168", "r217", "r218", "r253", "r254", "r255", "r261",
"r262", "r274", "r403", "r409", "r410", "r420", "r421", "r422", "r434", "r435", "r445", "r455", "r456", "r459", "r460", "r461", "r470", "r475", "r476", "r477", "r489", "r528", "r529", "r553", "r554" ]
}, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Change in
Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "documentation": "Date
accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": [ "r122", "r123", "r124", "r129", "r130", "r217", "r218", "r253", "r254", "r255", "r261", "r262", "r263",
"r274", "r403", "r409", "r410", "r411", "r420", "r421", "r422", "r423", "r434", "r435", "r436", "r439", "r445", "r455", "r456", "r459", "r460", "r461", "r470", "r475", "r476", "r477", "r489", "r528",
"r529", "r553", "r554", "r720" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Change in
Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true
false]", "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial." } } }, "auth_ref": [ "r121", "r169", "r181", "r258", "r407" ] },
"dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code",
"documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ClassOfStockLineItems", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail" ], "lang": { "en-us": { "role": { "label": "Class of Stock
[Line Items]", "terseLabel": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r139", "r140", "r141", "r200", "r320", "r321", "r322", "r324", "r327", "r332", "r334",
"r569", "r570", "r571", "r572", "r678", "r715", "r742" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ClassOfWarrantOrRightAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail" ], "lang": { "en-us": { "role": { "label":
"Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r46" ] }, "us-
gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail" ], "lang": { "en-us": { "role": { "label":
"Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent
derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new
debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options
are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } },
"auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of
Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of warrants issued to purchase common stock (in shares)", "verboseLabel": "Number of
outstanding warrants issued to purchase common stock (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not
limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r335" ] }, "scyx_CommercialMilestonesPaymentsReceivable": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.scynexis.com/20240630", "localname": "CommercialMilestonesPaymentsReceivable", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial milestones payments
receivable", "label": "Commercial Milestones Payments Receivable", "documentation": "Commercial milestones payments receivable." } } }, "auth_ref": [] },
"scyx_CommitmentAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "CommitmentAndContingenciesLineItems",
"presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Commitment and contingencies.", "label": "Commitment And Contingencies [Line Items]", "terseLabel": "Commitment And Contingencies [Line Items]" } } }, "auth_ref": [] },
"scyx_CommitmentAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "CommitmentAndContingenciesTable", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Commitment
and contingencies.", "label": "Commitment And Contingencies [Table]", "terseLabel": "Commitment And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies",
"terseLabel": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply
arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims
against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more
```

future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r21", "r68", "r537", "r591"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r91", "r276", "r277", "r656", "r777"] }, "scyx_CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "documentation": "Common stock associated with March 2019 notes.", "label": "Common Stock Associated With March Two Thousand Nineteen Notes [Member]", "terseLabel": "Common stock associated with March 2019 Notes" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common shares reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r22"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r698", "r699", "r700", "r702", "r703", "r704", "r705", "r745", "r746", "r814", "r832", "r835"] }, "scyx_CommonStockOutstandingRollForwardRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "CommonStockOutstandingRollForwardRollForward", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "documentation": "Common stock outstanding roll forward.", "label": "Common Stock Outstanding Roll Forward Roll Forward", "terseLabel": "Common Stock Outstanding Roll Forward [Roll Forward]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r76"] }, "scyx_CommonStockReservedForFutureIssuancesTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "CommonStockReservedForFutureIssuancesTableTableTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "documentation": "Common stock reserved for future issuances.", "label": "Common Stock Reserved For Future Issuances Table Table [Text Block]", "terseLabel": "Common Stock Reserved For Future Issuances" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r76", "r592"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)", "verboseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r76"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)", "verboseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r6", "r76", "r592", "r610", "r835", "r836"] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value, 150,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 37,856,463 and 37,207,799 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": ["r76", "r592"] },
"scyx_CompletionFuriCaresAndNatureClinicalStudiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "CompletionFuriCaresAndNatureClinicalStudiesMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Completion furi, cares, and nature clinical studies member.", "label": "Completion FURI, CARES, and NATURE Clinical Studies [Member]", "terseLabel": "Completion FURI, CARES, and NATURE Clinical Studies" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r33", "r35", "r62", "r63", "r216", "r655"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r33", "r35", "r62", "r63", "r216", "r565", "r655"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r33", "r35", "r62", "r63", "r216", "r655", "r719"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of gross revenue", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r33", "r35", "r62", "r63", "r216"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r33", "r35", "r62", "r63", "r216", "r655"] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueTables"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Summary of Activity in Each of Product Revenue Provision and Allowance Categories", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r783"] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "License agreement contract asset", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": ["r337", "r339", "r350"] }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerBasisOfPricingAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Basis of Pricing [Axis]", "terseLabel": "Contract with Customer, Basis of Pricing", "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer." } } }, "auth_ref": ["r683", "r784"] }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerBasisOfPricingDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Basis of Pricing [Domain]", "terseLabel": "Contract with Customer, Basis of Pricing", "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and materials contracts." } } }, "auth_ref": ["r683", "r784"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Contract with Customer, Liability, Total", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r337", "r338", "r350"] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "terseLabel": "Changes in estimate related to prior period revenue", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." } } }, "auth_ref": ["r679"] }, "scyx_ContractWithCustomerLiabilityProvisionRelatedToCurrentPeriodRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "ContractWithCustomerLiabilityProvisionRelatedToCurrentPeriodRevenue", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Provision related to current period revenue", "label": "Contract With Customer Liability Provision Related To Current Period Revenue", "documentation": "Contract with customer liability provision related to current period revenue." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r351"] }, "scyx_ConvertibleDebtAndDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "ConvertibleDebtAndDerivativeLiability", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Convertible debt and derivative liability.", "label": "Convertible Debt And Derivative Liability", "verboseLabel": "Net carrying amount of convertible debt and derivative liability", "terseLabel": "Convertible debt and derivative liability (See Note 6)" } } }, "auth_ref": [] }, "scyx_ConvertibleDebtAndDerivativeLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "ConvertibleDebtAndDerivativeLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Convertible debt and derivative liability, current.", "label": "Convertible Debt And Derivative Liability Current", "terseLabel": "Convertible debt and derivative liability (See Note 6)" } } }, "auth_ref": [] }, "scyx_ConvertibleDebtAndDerivativeLiabilityFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "ConvertibleDebtAndDerivativeLiabilityFairValueDisclosures", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Convertible debt and derivative liability fair value disclosures.", "label": "Convertible Debt And Derivative Liability Fair Value Disclosures", "verboseLabel": "Fair value of convertible debt and derivative liability" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Convertible Debt,

Noncurrent", "terseLabel": "Senior convertible notes", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": ["r20"] }, "scyx_CorporateAndAgencyBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "CorporateAndAgencyBondSecuritiesMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Corporate and agency bond securities.", "label": "Corporate and Agency Bond Securities [Member]", "terseLabel": "Corporate and Agency Bonds" } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "scyx_CostOfProductRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "CostOfProductRevenues", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Cost of product revenues.", "label": "Cost Of Product Revenues", "terseLabel": "Cost of product revenues" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r162", "r163", "r295", "r322", "r494", "r664", "r666"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r34", "r216"] }, "scyx_DanforthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "DanforthMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase common stock associated with Danforth", "label": "Danforth [Member]", "documentation": "Danforth.", "verboseLabel": "Warrant to purchase common stock associated with Danforth" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowings"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Borrowings", "documentation": "The entire disclosure for information about short term and long term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r92", "r159", "r291", "r297", "r298", "r299", "r300", "r301", "r302", "r307", "r314", "r315", "r317"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r11", "r73", "r74", "r105", "r106", "r164", "r292", "r293", "r294", "r295", "r296", "r298", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r474", "r673", "r674", "r675", "r676", "r677", "r743"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (as a percent)", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount", "totalLabel": "Total principal and final fee payment", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r65", "r67", "r292", "r474", "r674", "r675"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Interest rate, deferred fees", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r18", "r65", "r318", "r474"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r18", "r293"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r164", "r292", "r293", "r294", "r295", "r296", "r298", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r316", "r474", "r673", "r674", "r675", "r676", "r677", "r743"] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Notes maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r126", "r673", "r816"] }, "scyx_DebtInstrumentMaximumAdditionalBorrowingCapacityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "DebtInstrumentMaximumAdditionalBorrowingCapacityAmount", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Debt instrument maximum additional borrowing capacity amount.", "label": "Debt Instrument Maximum Additional Borrowing Capacity Amount", "terseLabel": "Additional borrowing amount available" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMeasurementInput", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Measurement Input", "terseLabel": "Debt instrument, measurement input", "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt." } } }, "auth_ref": ["r451"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r20", "r164", "r292", "r293", "r294", "r295", "r296", "r298", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r474", "r673", "r674", "r675", "r676", "r677", "r743"] }, "us-gaap_DebtInstrumentOfferingDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentOfferingDate1", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Offering Date", "terseLabel": "Date of issuance and sale of notes", "documentation": "Date the debt instrument was offered for sale, in YYYY-MM-DD format." } } }, "auth_ref": ["r11", "r42"] }, "us-gaap_DebtInstrumentPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPaymentTerms", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Payment Terms", "terseLabel": "Payment terms", "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment." } } }, "auth_ref": ["r19", "r70"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r20", "r42", "r45", "r64", "r65", "r67", "r69", "r94", "r95", "r164", "r292", "r293", "r294", "r295", "r296", "r298", "r303", "r304", "r305", "r306", "r308", "r309", "r310", "r311", "r312", "r313", "r474", "r673", "r674", "r675", "r676", "r677", "r743"] }, "scyx_December2020PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "December2020PublicOfferingMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "December 2020 public offering.", "label": "December2020 Public Offering [Member]", "terseLabel": "December 2020 Public Offering", "verboseLabel": "Prefunded Warrants to Purchase Common Stock Associated with December 2020 Public Offering" } } }, "auth_ref": [] }, "scyx_December2020PublicOfferingSeries2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "December2020PublicOfferingSeries2Member", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "documentation": "December 2020 public offering series 2.", "label": "December2020 Public Offering Series2 [Member]", "terseLabel": "December 2020 Public Offering Series 2" } } }, "auth_ref": [] }, "us-gaap_DeferredCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCosts", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Noncurrent", "terseLabel": "Deferred offering costs", "totalLabel": "Deferred Costs, Noncurrent, Total", "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer, classified as noncurrent." } } }, "auth_ref": ["r103", "r731"] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "scyx_DeferredFeesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "DeferredFeesPaid", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Deferred fees, fully paid", "label": "Deferred Fees Paid", "documentation": "Deferred fees paid." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Current, Total", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue, current portion", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r732"] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Deferred Revenue, Noncurrent, Total", "terseLabel": "Deferred revenue", "label": "Deferred revenue, long term", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r733"] }, "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage", "terseLabel": "Vesting percentage", "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year." } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",

"localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r5", "r36"] }, "scyx_DerivativeFairValueGainLossFromMarkToMarketAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "DerivativeFairValueGainLossFromMarkToMarketAdjustment", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecur], "lang": { "en-us": { "role": { "documentation": "Derivative fair value gain (loss) from mark to market adjustment.", "label": "Derivative Fair Value Gain Loss From Mark To Market Adjustment", "negatedLabel": "Gain adjustment to fair value" } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Derivative, Fair Value, Net", "terseLabel": "Derivative, fair value", "totalLabel": "Derivative, Fair Value, Net, Total", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": ["r457"] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Derivative Liability, Measurement Input", "terseLabel": "Derivative liabilities, unobservable inputs rate", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": ["r451"] }, "us-gaap_DerivativeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecur], "lang": { "en-us": { "role": { "label": "Derivative [Member]", "terseLabel": "Derivative liabilities", "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)." } } }, "auth_ref": ["r99"] }, "scyx_DevelopmentMilestonesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "DevelopmentMilestonesReceivable", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Development milestones receivable.", "label": "Development Milestones Receivable", "terseLabel": "Development milestones receivable" } } }, "auth_ref": [] }, "scyx_DevelopmentMilestonesRecevied": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "DevelopmentMilestonesRecevied", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Development milestones recevied.", "label": "Development Milestones Recevied", "terseLabel": "Development milestones recevied" } } }, "auth_ref": [] }, "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of convertible debt", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r349", "r680", "r681", "r682", "r683", "r684", "r685", "r686"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r349", "r680", "r681", "r682", "r683", "r684", "r685", "r686"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r362", "r366", "r394", "r395", "r396", "r691"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "scyx_DiscountsAndChargebacksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "DiscountsAndChargebacksMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Discounts and Chargebacks", "label": "Discounts And Chargebacks [Member]", "documentation": "Discounts and chargebacks." } } }, "auth_ref": [] },
"dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] },
"dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r712"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r713"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per share - basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r150", "r173", "r174", "r175", "r176", "r177", "r183", "r185", "r194", "r195", "r196", "r198", "r443", "r444", "r532", "r544", "r667"] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per share attributable to common stockholders - basic", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per share - diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Net (loss) income per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r150", "r173", "r174", "r175", "r176", "r177", "r185", "r194", "r195", "r196", "r198", "r443", "r444", "r532", "r544", "r667"] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per share attributable to common stockholders - diluted", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basic and Diluted Net (Loss) Income per Share of Common Stock", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r30", "r31"] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Bifurcated embedded conversion option derivative liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": ["r54"] }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net", "totalLabel": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total", "terseLabel": "Gain (loss) on fair value adjustment of derivative liability", "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period." } } }, "auth_ref": ["r813"] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationCompensationCostDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Tax benefit from compensation expense", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": ["r393"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Outstanding stock options", "verboseLabel": "Stock options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype":

```
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel":
"Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity
Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }
}, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel":
"Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed
disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r710" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or
other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common
Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] },
"dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel":
"Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90
days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel":
"Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r710" ] }, "dei_EntityFileNumber": { "xbrltype":
"fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity
File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional
suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang":
{ "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer,
Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most
recent filing containing the related disclosure." } } }, "auth_ref": [ "r710" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel":
"Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r714" ] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "verboseLabel": "Entity
Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." }
} }, "auth_ref": [ "r710" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell
Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r710" ] },
"dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small
Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r710" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype":
"employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel":
"Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the
IRS." } } }, "auth_ref": [ "r710" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": {
"label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"EquityComponentDomain", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Equity
Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common,
preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r6", "r131", "r146", "r147", "r148", "r165", "r166", "r167", "r170", "r178", "r180", "r199", "r257", "r264", "r336", "r397",
"r398", "r399", "r405", "r406", "r424", "r426", "r427", "r428", "r429", "r431", "r442", "r464", "r465", "r466", "r467", "r468", "r469", "r493", "r555", "r556", "r557", "r575", "r631" ] },
"scyx_ExclusiveLicenseAndCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname":
"ExclusiveLicenseAndCollaborationAgreementMember", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Exclusive License And Collaboration Agreement", "label": "Exclusive License And Collaboration Agreement [Member]", "documentation": "Exclusive license and
collaboration agreement." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of
Warrants", "terseLabel": "Warrant liabilities fair value adjustment", "verboseLabel": "Change in fair value of warrant liabilities", "documentation": "Amount of expense (income) related to
adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r1", "r5" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis
[Table Text Block]", "terseLabel": "Summary of Financial Instruments Measured on a Recurring Basis", "documentation": "Tabular disclosure of assets, including [financial] instruments
measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value
measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted
prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r58", "r101" ] }, "us-
gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or
many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value By Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of
financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r58", "r60", "r61" ] }, "us-
gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation":
[ "http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Information by level within fair value hierarchy and fair value measured at net
asset value per share as practical expedient." } } }, "auth_ref": [ "r305", "r354", "r355", "r356", "r357", "r358", "r359", "r448", "r498", "r499", "r500", "r674", "r675", "r687", "r688", "r689" ] },
"us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis",
"presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r447", "r448", "r450",
"r451", "r452" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-
us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "lang": { "en-us": {
"role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined),
including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and
liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate);
(2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate,
and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic
characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other
security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and
how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items
presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value
changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the
balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r446" ] }, "us-gaap_FairValueInputsLevel1Member": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "documentation": "Quoted prices in active markets for identical
assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r305", "r354", "r359", "r448", "r498", "r687", "r688", "r689" ] }, "us-
gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [
```

"http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)", "verboseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": { "r305", "r354", "r359", "r448", "r499", "r674", "r675", "r687", "r688", "r689"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 Inputs", "verboseLabel": "Significant Unobservable Inputs (Level 3)", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r305", "r354", "r355", "r356", "r357", "r358", "r359", "r448", "r500", "r674", "r675", "r687", "r688", "r689"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecur
], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecur
], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": ["r7", "r59"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r7", "r59"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecur
], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r7"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r305", "r354", "r355", "r356", "r357", "r358", "r359", "r498", "r499", "r500", "r674", "r675", "r687", "r688", "r689"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r446", "r452"] }, "scyx_FairValueOfLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "FairValueOfLiabilities", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Fair value of liabilities.", "label": "Fair Value Of Liabilities", "terseLabel": "Warrant liabilities" } } }, "auth_ref": [] }, "scyx_FinalLoanPaymentPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "FinalLoanPaymentPayable", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Final payment payable under loan agreement", "label": "Final Loan Payment Payable", "documentation": "Final loan payment payable." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecur
], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [
"r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r316", "r332", "r432", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r543", "r671", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r769", "r770", "r771", "r772"] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Derivative liabilities fair value adjustment", "negatedTerseLabel": "Change in fair value of derivative liabilities", "totalLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax, Total", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": ["r53"] }, "scyx_GlaxosmithklineIntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "GlaxosmithklineIntellectualPropertyMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "GlaxoSmithKline Intellectual Property", "label": "GlaxoSmithKline Intellectual Property [Member]", "documentation": "GlaxoSmithKline Intellectual Property." } } }, "auth_ref": [] }, "us-gaap_HeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecurities", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss", "totalLabel": "Amortized Cost", "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r120", "r235", "r267", "r774"] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain", "terseLabel": "Unrealized Gains", "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r116", "r245"] }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss", "negatedLabel": "Unrealized Losses", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r117", "r246"] }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesFairValue", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails",
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Held-to-Maturity, Fair Value, Total", "label": "Debt Securities, Held-to-Maturity, Fair Value", "terseLabel": "Fair Value", "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r115", "r244", "r531", "r535"] }, "us-gaap_HeldToMaturitySecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HeldToMaturitySecuritiesTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsTables"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity [Table Text Block]", "terseLabel": "Summary of Investments", "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768"] }, "scyx_HerculesCapitalIncorporatedAndSiliconValleyBankAndOtherLendersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "HerculesCapitalIncorporatedAndSiliconValleyBankAndOtherLendersMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Hercules Capital Incorporated And Silicon Valley Bank And Other Lenders", "label": "Hercules Capital Incorporated And Silicon Valley Bank And Other Lenders [Member]", "documentation": "Hercules Capital Incorporated And Silicon Valley Bank And Other Lenders." } } }, "auth_ref": [] }, "scyx_HerculesCapitalIncorporatedAndSiliconValleyBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "HerculesCapitalIncorporatedAndSiliconValleyBankMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Hercules Capital Incorporated and Silicon Valley Bank.", "label": "Hercules Capital Incorporated And Silicon Valley Bank [Member]", "terseLabel": "Hercules Capital Inc. and Silicon Valley Bank" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r0", "r82", "r110", "r201", "r207", "r211", "r213", "r533", "r540", "r669"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRelatedToStockOptionsDetail"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location", "documentation": "Information by location in the income statement." } } }, "auth_ref": ["r273", "r275",

"r615"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRelatedToStockOptionsDetail"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location", "documentation": "Location in the income statement." } } }, "auth_ref": ["r275", "r615"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r118", "r125", "r179", "r180", "r205", "r402", "r408", "r545"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "terseLabel": "Accounts receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoricsDetail"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Credit/payments", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r526", "r739"] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r659"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Inventories, Total", "label": "Increase (Decrease) in Inventories", "terseLabel": "Inventory", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r4"] }, "scyx_IncreaseDecreaseInLicenseAgreementContractAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "IncreaseDecreaseInLicenseAgreementContractAsset", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in license agreement contract asset.", "label": "Increase (Decrease) In License Agreement Contract Asset", "negatedLabel": "License agreement contract asset" } } }, "auth_ref": [] }, "scyx_IncreaseDecreaseInLicenseAgreementReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "IncreaseDecreaseInLicenseAgreementReceivable", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "License agreement receivable", "label": "Increase (Decrease) In License Agreement Receivable", "documentation": "Increase (decrease) in license agreement receivable" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities and other", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedLabel": "Prepaid expenses, other assets, deferred costs, and other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInSecurityDeposits", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Security Deposits", "terseLabel": "Decrease in security deposit", "documentation": "The increase (decrease) during the reporting period in security deposits." } } }, "auth_ref": ["r4"] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of convertible debt", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method." } } }, "auth_ref": ["r190", "r191", "r196"] }, "scyx_IncrementalCommonSharesAttributableToRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "IncrementalCommonSharesAttributableToRestrictedStockUnits", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails"], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to restricted stock units.", "label": "Incremental Common Shares Attributable To Restricted Stock Units", "terseLabel": "Dilutive effect of restricted stock units" } } }, "auth_ref": [] }, "scyx_InitialTrancheOfTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "InitialTrancheOfTermLoanMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Initial tranche of term loan.", "label": "Initial Tranche Of Term Loan [Member]", "terseLabel": "Initial Tranche of Term Loan" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest Expense", "terseLabel": "Interest expense", "totalLabel": "Interest Expense, Total", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": ["r66", "r112", "r149", "r204", "r472", "r616", "r706", "r834"] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOther", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Interest Income, Other", "negatedLabel": "Interest income", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r153", "r156", "r157"] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": ["r577", "r578", "r579", "r580", "r581", "r636", "r638", "r640", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r700"] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": ["r577", "r578", "r579", "r580", "r581", "r636", "r638", "r640", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r700"] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Investments", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Investments, Total", "label": "Investments", "terseLabel": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": ["r534"] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestments"], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r102", "r113", "r114", "r128", "r219", "r221", "r453", "r454"] }, "scyx_LeaseAgreementAreaOfOfficeSpace": { "xbrltype": "areaItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "LeaseAgreementAreaOfOfficeSpace", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Lease agreement area of office space.", "label": "Lease Agreement Area Of Office Space", "verboseLabel": "Long-term lease agreement, area of office space" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInUnauditedCondensed"], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total operating lease expense", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r483", "r694"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Quantitative Information Associated with Amounts Recognized in Unaudited Condensed Consolidated Financial Statements for Lease", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r819"] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Lessee, operating lease, existence of option to extend", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": ["r482"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Future Minimum Lease Payments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r820"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r488"] }, "scyx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail"], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":

```
"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },
"auth_ref": [ "r488" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },
"auth_ref": [ "r488" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },
"auth_ref": [ "r488" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },
"auth_ref": [ "r488" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r820" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Difference between future minimum lease payments and discounted cash flows", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r488" ] }, "us-
gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Renewal term, description", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r482" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r818" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r818" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"Liabilities", "crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } } }, "auth_ref": [ "r15", "r161", "r252",
"r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r415", "r418", "r419", "r458", "r590", "r668", "r708", "r780", "r821", "r822" ] }, "us-
gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit",
"presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r81", "r107", "r539", "r695", "r744", "r773", "r817" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]",
"terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ],
"lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r17", "r136", "r161", "r252", "r282", "r283", "r284", "r285", "r286", "r287", "r288",
"r289", "r290", "r415", "r418", "r419", "r458", "r695", "r780", "r821", "r822" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-
us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure", "terseLabel": "Fair value of financial liabilities", "totalLabel": "Liabilities, Fair Value Disclosure, Total", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r58" ] }, "scyx_LicenseAgreementContractAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname":
"LicenseAgreementContractAsset", "crdr": "debit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "License agreement contract asset.", "label": "License Agreement Contract Asset", "terseLabel": "License agreement contract asset" } } }, "auth_ref": [] },
"scyx_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "LicenseAgreementMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "License agreement.", "label": "License Agreement [Member]", "terseLabel": "License Agreement" } } }, "auth_ref": [] }, "scyx_LicenseAgreementReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.scynexis.com/20240630", "localname": "LicenseAgreementReceivable", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "License Agreement Receivable",
"terseLabel": "License agreement receivable", "documentation": "License agreement receivable." } } }, "auth_ref": [] }, "us-gaap_LicenseAndServiceMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "LicenseAndServiceMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "License and Service [Member]", "terseLabel": "License Agreement Revenue", "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r785" ] }, "scyx_LicenseTransferMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.scynexis.com/20240630", "localname": "LicenseTransferMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "License transfer.", "label": "License Transfer [Member]", "terseLabel": "License Transfer" } } }, "auth_ref": [] }, "scyx_LicenseTransferPerformanceObligationRevenue": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.scynexis.com/20240630", "localname": "LicenseTransferPerformanceObligationRevenue", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "License transfer performance obligation revenue.", "label": "License Transfer Performance Obligation Revenue", "terseLabel": "License transfer performance obligation revenue" } } }, "auth_ref": [] }, "us-
gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "terseLabel": "Lender Name", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r14", "r743" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r14", "r743" ] },
"scyx_LoanAgreementAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "LoanAgreementAmendmentMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loan Agreement Amendment", "label":
"Loan Agreement Amendment [Member]", "documentation": "Loan Agreement Amendment." } } }, "auth_ref": [] }, "scyx_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.scynexis.com/20240630", "localname": "LoanAndSecurityAgreementMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement.",
"label": "Loan And Security Agreement [Member]", "terseLabel": "Loan and Security Agreement" } } }, "auth_ref": [] }, "us-gaap_LoansPayableFairValueDisclosure": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loans Payable, Fair Value Disclosure",
"terseLabel": "Fair value of loan payable", "documentation": "Fair value portion of contractual obligation to pay money on demand or on fixed or determinable dates." } } }, "auth_ref": [] },
"dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "scyx_LongTermInvestmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.scynexis.com/20240630", "localname": "LongTermInvestmentMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Long-term investment.", "label":
"Long-Term Investment [Member]", "terseLabel": "Maturities Greater than 1 Year" } } }, "auth_ref": [] }, "us-gaap_LongTermLoansPayable": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "LongTermLoansPayable", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding principal plus all accrued and unpaid interest amount payable to lenders", "label": "Loans Payable, Noncurrent", "terseLabel": "Loan payable", "totalLabel": "Loans Payable, Noncurrent, Total", "documentation":
"Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } } }, "auth_ref": [
"r20" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r20" ] }, "us-
gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r37" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname":
"MajorCustomersAxis", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Customer [Axis]", "terseLabel": "Customer" } } }, "auth_ref": [ "r216", "r682", "r784", "r830", "r831" ] }, "scyx_March2018PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.scynexis.com/20240630", "localname": "March2018PublicOfferingMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail" ], "lang": { "en-us": { "role": {
"documentation": "March 2018 public offering.", "label": "March2018 Public Offering [Member]", "terseLabel": "March 2018 Public Offering" } } }, "auth_ref": [] },
```

"scyx_March2018PublicOfferingSeries2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "March2018PublicOfferingSeries2Member", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "documentation": "March 2018 public offering series 2.", "label": "March2018 Public Offering Series2 [Member]", "terseLabel": "March 2018 Public Offering Series 2" } } }, "auth_ref": [ ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r278", "r279", "r280", "r281", "r360", "r525", "r552", "r582", "r583", "r637", "r639", "r641", "r642", "r647", "r657", "r658", "r670", "r678", "r690", "r697", "r782", "r823", "r824", "r825", "r826", "r827", "r828"] }, "us-gaap_MeasurementInputCreditSpreadMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputCreditSpreadMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input, Credit Spread [Member]", "terseLabel": "Secured Spread", "verboseLabel": "Market Credit Spread", "documentation": "Measurement input using amount above (below) yield between two debt instruments similar in maturity, but different in credit quality." } } }, "auth_ref": ["r815"] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Estimated Yield", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": ["r815"] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Stock Price Volatility", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": ["r815"] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk Free Rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": ["r815"] }, "scyx_MeasurementInputSecuredYieldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "MeasurementInputSecuredYieldMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Measurement input secured yield.", "label": "Measurement Input Secured Yield [Member]", "terseLabel": "Secured Yield" } } }, "auth_ref": [ ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r449"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ ] }, "scyx_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "MilestonePayments", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments from the Company" } } }, "auth_ref": [ ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r278", "r279", "r280", "r281", "r360", "r525", "r552", "r582", "r583", "r637", "r639", "r641", "r642", "r647", "r657", "r658", "r670", "r678", "r690", "r697", "r782", "r823", "r824", "r825", "r826", "r827", "r828"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r786"] },
"srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer" } } }, "auth_ref": ["r216", "r682", "r784", "r830", "r831"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in by financing activities", "terseLabel": "Net cash used in by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } },
"auth_ref": ["r155"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [ ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r155"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "auth_ref": [ ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Net cash (used in) provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r86", "r87", "r88"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [ ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "verboseLabel": "Net (loss) income allocated to common shares", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r83", "r88", "r111", "r134", "r144", "r145", "r148", "r161", "r169", "r173", "r174", "r175", "r176", "r179", "r180", "r192", "r201", "r207", "r211", "r213", "r252", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r444", "r458", "r542", "r612", "r629", "r630", "r669", "r706", "r780"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income (loss) allocated to common shares", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }, "auth_ref": ["r151", "r184", "r186", "r187", "r188", "r189", "r193", "r196"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other expense (income)", "label": "Nonoperating Income (Expense)", "totalLabel": "Nonoperating Income (Expense), Total", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r85"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (income) expense:" } } }, "auth_ref": [ ] }, "scyx_NumberOfAvailableTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "NumberOfAvailableTranches", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Number of available tranches", "label": "Number Of Available Tranches", "terseLabel": "Number of available tranches" } } }, "auth_ref": [ ] }, "scyx_OngoingClinicalAndPreclinicalStudiesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "OngoingClinicalAndPreclinicalStudiesExpense", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Ongoing clinical and preclinical studies expense.", "label": "Ongoing Clinical and Preclinical Studies Expense", "terseLabel": "Ongoing clinical and preclinical studies" } } }, "auth_ref": [ ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [ ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } } }, "auth_ref": ["r201", "r207", "r211", "r213", "r669"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInUnauditedCondensed"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r484", "r694"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityDetail"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liability", "verboseLabel": "Present value of future minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r480"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri":

"http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liability, current portion", "terseLabel": "Operating lease liability, current portion (See Note 7)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r480"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesPresentationOfOperatingLeaseLiabilityDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liability, long-term portion", "terseLabel": "Operating lease liability (See Note 7)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r480"] }, "scyx_OperatingLeaseLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "OperatingLeaseLiabilityTableTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "documentation": "Operating lease liability.", "label": "Operating Lease Liability Table [Text Block]", "terseLabel": "Presentation of Operating Lease Liability" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInUnauditedCondensed
], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Total lease payments", "verboseLabel": "Cash paid for amounts included in the measurement of operating lease liability", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r481", "r485"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset (See Note 7)", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r479"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Noncash operating lease expense for right-of-use asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r740"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInUnauditedCondensed
], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r487", "r694"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInUnauditedCondensed
], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Remaining Lease term (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r486", "r694"] }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityEquityAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity [Axis]", "terseLabel": "Option Indexed to Issuer's Equity", "documentation": "Information by type of options indexed to an issuer's equity." } } }, "auth_ref": ["r38", "r56", "r57", "r100"] }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionIndexedToIssuersEquityTypeDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type", "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPreparation"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Business and Basis of Preparation", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r72", "r98", "r566", "r567"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r16"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r142", "r695"] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentAssetsTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"], "lang": { "en-us": { "role": { "label": "Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Liabilities", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "label": "Other Prepaid Expense, Current", "terseLabel": "Other prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r734", "r775"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "scyx_PaymentOfLoanPayablePrepaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "PaymentOfLoanPayablePrepaymentFee", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Payment of loan payable prepayment fee", "label": "Payment of loan payable prepayment fee", "documentation": "Payment of loan payable prepayment fee." } } }, "auth_ref": [] }, "scyx_PaymentOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "PaymentOfTransactionPrice", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Payment of transaction price", "label": "Payment Of Transaction Price", "terseLabel": "Payment of transaction price" } } }, "auth_ref": [] }, "scyx_PaymentsForProceedsFromRepurchaseOfSharesToSatisfyTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "PaymentsForProceedsFromRepurchaseOfSharesToSatisfyTaxWithholdings", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of shares to satisfy tax withholdings", "label": "Payments For Proceeds From Repurchase Of Shares To Satisfy Tax Withholdings", "documentation": "Payments for proceeds from repurchase of shares to satisfy tax withholdings." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "terseLabel": "Payment of debt issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": ["r27"] }, "scyx_PaymentsOfDeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "PaymentsOfDeferredOfferingCosts", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Payments of deferred offering costs.", "label": "Payments Of Deferred Offering Costs", "terseLabel": "Payments of deferred offering costs", "negatedLabel": "Payments of deferred offering costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireHeldToMaturitySecurities", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Payments to Acquire Held-to-Maturity Securities", "negatedLabel": "Purchase of investments", "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities." } } }, "auth_ref": ["r25", "r220"] }, "scyx_PerformanceBasedDevelopmentMilestonesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "PerformanceBasedDevelopmentMilestonesReceivable", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Performance based development milestones receivable.", "label": "Performance Based Development Milestones Receivable", "terseLabel": "Performance based development milestones receivable" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2014EquityIncentivePlanDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2015InducementAwardPlanDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2014EquityIncentivePlanDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2015InducementAwardPlanDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r75", "r320"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r75", "r592"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued (in shares)", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": ["r75", "r320"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType",

"nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "verboseLabel": "Preferred stock, shares outstanding (in shares)", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r75", "r592", "r610", "r835", "r836"] }, "us-gaap_PreferredStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValueOutstanding", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value, authorized 5,000,000 shares as of June 30, 2024 and December 31, 2023; 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023", "label": "Preferred Stock, Value, Outstanding", "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders." } } }, "auth_ref": ["r75", "r592"] }, "scyx_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "PrefundedWarrantsMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Prefunded warrants.", "label": "Prefunded Warrants [Member]", "terseLabel": "Pre-funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r736"] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r663", "r672", "r775"] },
"scyx_PrepaidResearchandDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname":
"PrepaidResearchandDevelopmentExpensesCurrent", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"], "lang": { "en-us": { "role": { "documentation": "Prepaid research and development expenses, current.", "label": "Prepaid Researchand Development Expenses Current", "terseLabel": "Prepaid research and development services" } } }, "auth_ref": [] }, "scyx_PrepaymentFeeForLoanPayablePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname":
"PrepaymentFeeForLoanPayablePayment", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Prepayment fee for loan payable payment", "documentation": "Prepayment fee for loan payable payment." } } }, "auth_ref": [] }, "scyx_PrepaymentFeePayable": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.scynexis.com/20240630", "localname": "PrepaymentFeePayable", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Prepayment fee payable", "label": "Prepayment Fee Payable", "documentation": "Prepayment fee payable." } } }, "auth_ref": [] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "terseLabel": "Prime Rate", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"],
"lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification of Prior Year Amounts", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r729"] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Proceeds from debt, net of issuance costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": ["r152"] }, "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Interest Received", "terseLabel": "Cash received for interest", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": ["r738"] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from common stock issued", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": ["r3"] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from employee stock purchase plan issuances", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": ["r3", "r10"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded warrants were exercised for proceeds", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r3"] }, "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Sale and Maturity of Held-to-Maturity Securities, Total", "label": "Proceeds from Sale and Maturity of Held-to-Maturity Securities", "terseLabel": "Maturity of investments", "documentation":
"Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities." } } }, "auth_ref": ["r24", "r750"] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product [Member]", "terseLabel": "Product Revenue, Net", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": ["r680"] }, "srt_ProductOrServiceAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "auth_ref": ["r214", "r527", "r546", "r547", "r548", "r549", "r550", "r551", "r660", "r680", "r696", "r721", "r778", "r779", "r784", "r830"] },
"scyx_ProductRecallMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "ProductRecallMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Product Recall", "label": "Product Recall [Member]", "documentation": "Product recall." } } }, "auth_ref": [] }, "scyx_ProductReturnsMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.scynexis.com/20240630", "localname": "ProductReturnsMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Product Returns", "label": "Product Returns [Member]", "documentation": "Product returns." } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "auth_ref": ["r214", "r527", "r546", "r547", "r548", "r549", "r550", "r551", "r660", "r680", "r696", "r721", "r778", "r779", "r784", "r830"] },
"us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "verboseLabel": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } },
"auth_ref": ["r134", "r144", "r145", "r154", "r161", "r169", "r179", "r180", "r201", "r207", "r211", "r213", "r252", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r413", "r416", "r417", "r444", "r458", "r533", "r541", "r574", "r612", "r629", "r630", "r669", "r692", "r693", "r707", "r737", "r780"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": ["r278", "r279", "r280", "r281", "r353", "r360", "r389", "r390", "r391", "r501", "r525", "r552", "r582", "r583", "r637", "r639", "r641", "r642", "r647", "r657", "r658", "r670", "r678", "r690", "r697", "r700", "r776", "r782", "r824", "r825", "r826", "r827", "r828"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": ["r278", "r279", "r280", "r281", "r353", "r360", "r389", "r390", "r391", "r501", "r525", "r552", "r582", "r583", "r637", "r639", "r641", "r642", "r647", "r657", "r658", "r670", "r678", "r690", "r697", "r700", "r776", "r782", "r824", "r825", "r826", "r827", "r828"] }, "scyx_RebatesAndIncentivesMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "RebatesAndIncentivesMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfActivityInEachOfProductRevenueProvisionAndAllowanceCategoriesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Rebates and Incentives", "label": "Rebates And Incentives [Member]", "documentation": "Rebates and incentives." } } }, "auth_ref": [] },
"scyx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.scynexis.com/20240630", "localname":
"RecentlyIssuedAccountingPronouncementsPolicyTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Recently issued accounting pronouncements.", "label": "Recently Issued Accounting Pronouncements Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "auth_ref": [] },
"scyx_RegulatoryMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "RegulatoryMilestonePaymentsReceivable", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":
"Regulatory milestone payments receivable", "label": "Regulatory Milestone Payments Receivable", "documentation": "Regulatory milestone payments receivable." } } }, "auth_ref": [] },
"scyx_RelaunchDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "RelaunchDateAxis", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Relaunch Date [Axis].", "label": "Relaunch Date [Axis]" } } }, "auth_ref": [] }, "scyx_RelaunchDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "RelaunchDateDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Relaunch Date [Domain].", "label": "Relaunch Date [Domain]" } } }, "auth_ref": [] }, "scyx_RelaunchDateOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "RelaunchDateOneMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Relaunch date one member.", "label": "Relaunch Date One [Member]", "terseLabel": "Relaunch Date One" } } }, "auth_ref": [] }, "scyx_RelaunchDateThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "RelaunchDateThreeMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Relaunch date three member.", "label": "Relaunch Date Three [Member]", "terseLabel": "Relaunch Date Three" } } }, "auth_ref": [] }, "scyx_RelaunchDateTwoMember": { "xbrltype": "domainItemType", "nsuri":

```
"http://www.scynexis.com/20240630", "localname": "RelaunchDateTwoMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Relaunch date two member.", "label":
"Relaunch Date Two [Member]", "terseLabel": "Relaunch Date Two" } } }, "auth_ref": [] }, "scyx_RemainingTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.scynexis.com/20240630", "localname": "RemainingTransactionPrice", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Remaining transaction price.", "label":
"Remaining Transaction Price", "terseLabel": "Remaining transaction price" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of loan
payable", "terseLabel": "Payments of loan payable", "label": "Repayments of Short-Term Debt", "totalLabel": "Repayments of Short-Term Debt, Total", "documentation": "The cash outflow for a
borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r26" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref":
[ "r162", "r163", "r295", "r322", "r494", "r665", "r666" ] }, "scyx_ResearchAndDevelopmentActivityExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630",
"localname": "ResearchAndDevelopmentActivityExpense", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Research and development activity
expense.", "label": "Research and Development Activity Expense", "terseLabel": "Research and development activity" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and
Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total", "documentation": "The aggregate costs incurred (1) in a planned
search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in
bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a
significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the
costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to
have no alternative future use." } } }, "auth_ref": [ "r71", "r401", "r829" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRelatedToStockOptionsDetail" ], "lang": { "en-us": { "role": {
"label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about
research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand
deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that
are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [
"r137" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash, Current",
"terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand
deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r730", "r741" ] },
"scyx_RestrictedCashCurrentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "RestrictedCashCurrentFairValueDisclosure",
"crdr": "debit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Restricted cash current fair value disclosure.", "label": "Restricted Cash Current Fair Value Disclosure", "terseLabel": "Short term restricted cash balance" } } }, "auth_ref": [] },
"scyx_RestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "RestrictedCashMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"documentation": "Restricted cash.", "label": "Restricted Cash [Member]", "terseLabel": "Restricted cash" } } }, "auth_ref": [] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted Cash, Noncurrent",
"terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand
deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r119", "r731", "r741" ] },
"scyx_RestrictedCashNoncurrentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname":
"RestrictedCashNoncurrentFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Restricted cash
noncurrent fair value disclosure.", "label": "Restricted Cash Noncurrent Fair Value Disclosure", "terseLabel": "Long term restricted cash balance" } } }, "auth_ref": [] }, "us-
gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail" ], "lang": { "en-us": { "role": { "label":
"Restricted Stock Units (RSUs) [Member]", "terseLabel": "Outstanding restricted stock units", "verboseLabel": "Restricted Stock Units", "documentation": "Share instrument which is convertible
to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-
gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit",
"presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessAndBasisOfPreparationAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated
Deficit)", "terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "documentation": "Amount of accumulated
undistributed earnings (deficit)." } } }, "auth_ref": [ "r78", "r96", "r538", "r559", "r564", "r573", "r593", "r695" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail" ], "lang": { "en-us": { "role": { "label": "Retained Earnings
[Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r131", "r165", "r166", "r167", "r170", "r178", "r180",
"r257", "r264", "r397", "r398", "r399", "r405", "r406", "r424", "r427", "r428", "r431", "r442", "r555", "r557", "r575", "r835" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract
with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Total revenue",
"terseLabel": "Product revenue, net", "totalLabel": "Total revenue", "verboseLabel": "Net product revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from
satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and
concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r202", "r203", "r206", "r209", "r210", "r214",
"r215", "r216", "r348", "r349", "r527" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenue" ], "lang": { "en-us": { "role": { "label": "Revenue
from Contract with Customer [Text Block]", "terseLabel": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer
nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with
customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r127", "r340", "r341", "r342", "r343",
"r344", "r345", "r346", "r347", "r352" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation":
[ "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]",
"terseLabel": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sale of Stock
[Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] },
"scyx_SalesMilestonePayableUponAchievementOfThresholdLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname":
"SalesMilestonePayableUponAchievementOfThresholdLimit", "crdr": "credit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sales milestone payable upon
achievement of threshold limit", "label": "Sales Milestone Payable upon Achievement of Threshold Limit", "documentation": "Sales milestone payable upon achievement of threshold limit." } } },
"auth_ref": [] }, "scyx_SalesMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "SalesMilestonePaymentsReceivable",
"crdr": "credit", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sales
milestone payments receivable", "label": "Sales Milestone Payments Receivable", "documentation": "Sales milestone payments receivable" } } }, "auth_ref": [] }, "us-
gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "terseLabel":
"Sales Revenue Net", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." }
} }, "auth_ref": [ "r216", "r718" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation":
[ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]"
} } }, "auth_ref": [ "r361", "r748" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain",
"presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } },
"auth_ref": [ "r182", "r361", "r716", "r748" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table
Text Block]", "terseLabel": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which
invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued
liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An
alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail" ], "lang": { "en-us": { "role": { "label":
"Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per
Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the
future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive
Securities." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Antidilutive
Securities Excluded from Computation of Weighted Average Common Stock and Outstanding Restricted Stock Units", "label": "Schedule of Antidilutive Securities Excluded from Computation of
Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic
earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period
presented, by antidilutive securities." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ScheduleOfCapitalizationEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "ScheduleOfCapitalizationEquityLineItems", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" ],
```

"lang": { "en-us": { "role": { "label": "Schedule of Capitalization, Equity [Line Items]", "terseLabel": "Schedule Of Capitalization Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCapitalizationEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCapitalizationEquityTable", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Capitalization, Equity [Table]", "terseLabel": "Schedule Of Capitalization Equity [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Summary of Common Stock Shares Activity", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Diluted Net (Loss) Income Per Common Share", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share." } } }, "auth_ref": ["r29", "r32", "r749"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Stock-Based Compensation Expense Related to Stock Options", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r49"] }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Held-to-Maturity Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251"] }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Held-to-Maturity [Table]", "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity)." } } }, "auth_ref": ["r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2014EquityIncentivePlanDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2015InducementAwardPlanDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRelatedToStockOptionsDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r363", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Units (\"RSU\") Activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r48"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r8", "r9", "r48"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": ["r39", "r40", "r41", "r42", "r43", "r44", "r45", "r94", "r95", "r96", "r139", "r140", "r141", "r200", "r320", "r321", "r322", "r324", "r327", "r332", "r334", "r569", "r570", "r571", "r572", "r678", "r715", "r742"] }, "scyx_SecondTrancheOfTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "SecondTrancheOfTermLoanMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Second tranche of term loan.", "label": "Second Tranche Of Term Loan [Member]", "terseLabel": "Second Tranche of Term Loan" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of Each Class", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r709"] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDeposit", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Security Deposit", "terseLabel": "Security deposit in the form of a standby letter of credit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r731"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Name of Each Exchange on Which Registered", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r711"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r84"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRelatedToStockOptionsDetail"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "scyx_SeniorConvertibleNotePurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "SeniorConvertibleNotePurchaseAgreementMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Senior convertible note purchase agreement.", "label": "Senior Convertible Note Purchase Agreement [Member]", "terseLabel": "Senior Convertible Note Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period of options", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r691"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r383"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r383"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Options granted in period (shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r381"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r381"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward": { "xbrltype": "stringItemType", "nsuri":

```
"http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]", "terseLabel": "Aggregate Intrinsic Value ($000)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance - Outstanding (shares)", "periodStartLabel": "Beginning balance - Outstanding (shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r378", "r379" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance - Outstanding (in dollars per share)", "periodStartLabel": "Beginning balance - Outstanding (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r378", "r379" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value Per Share" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, negatedLabel": "Vested (shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2014EquityIncentivePlanDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2015InducementAwardPlanDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseRelatedToStockOptionsDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r363", "r365", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2014EquityIncentivePlanDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Share-based compensation arrangement by share-based payment award, number of additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2014EquityIncentivePlanDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2015InducementAwardPlanDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Possible future issuance under equity compensation plan (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted- Average Remaining Contractual Life (in years)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited/Cancelled (shares)", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r793" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited/Cancelled (in dollars per share)", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r793" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2015InducementAwardPlanDetail",
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Option to purchase (shares)", "verboseLabel": "Granted (shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r374" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Balance - Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance - Outstanding (shares)", "periodStartLabel": "Beginning balance - Outstanding (shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r370", "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance - Outstanding (in dollars per share)", "periodStartLabel": "Beginning balance - Outstanding (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r370", "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [
"http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Exercisable", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r387" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri":
```

"http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Exercisable (shares)", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth_ref": ["r387"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth_ref": ["r387"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth_ref": ["r386"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested or expected to vest (shares)", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth_ref": ["r386"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested or expected to vest (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth_ref": ["r386"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfRestrictedStockUnitsRSUActivityDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "Award Type", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r374"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Balance - Outstanding", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r97"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r387"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensationStockOptionActivityDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested or expected to vest", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r386"] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Short-Term Investments, Total", "label": "Short-Term Investments", "terseLabel": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r108", "r109", "r735"] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Short-Term Investments [Member]", "terseLabel": "Maturities Less than 1 Year", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": ["r650", "r651", "r652", "r661"] }, "scyx_SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "documentation": "Six percent convertible senior notes due two thousand and twenty five.", "label": "Six Percent Convertible Senior Notes Due Two Thousand And Twenty Five [Member]", "terseLabel": "March 2019 Notes" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": ["r6", "r23", "r131", "r146", "r147", "r148", "r165", "r166", "r167", "r170", "r178", "r180", "r199", "r257", "r264", "r336", "r397", "r398", "r399", "r405", "r406", "r424", "r426", "r427", "r428", "r429", "r431", "r442", "r464", "r465", "r466", "r467", "r468", "r469", "r493", "r555", "r556", "r557", "r575", "r631"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r165", "r166", "r167", "r199", "r527", "r568", "r576", "r584", "r585", "r586", "r587", "r588", "r589", "r592", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r605", "r606", "r607", "r608", "r609", "r611", "r613", "r614", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r631", "r701"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } } }, "auth_ref": ["r182", "r361", "r716", "r717", "r748"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": ["r165", "r166", "r167", "r199", "r527", "r568", "r576", "r584", "r585", "r586", "r587", "r588", "r589", "r592", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r605", "r606", "r607", "r608", "r609", "r611", "r613", "r614", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r631", "r701"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued through employee stock purchase (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r6", "r75", "r76", "r96"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common stock issued, net of expenses (in shares)", "verboseLabel": "Common stock issued, net of expenses (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r6", "r75", "r76", "r96", "r569", "r631", "r653"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Common stock issued for vested restricted stock units (in shares)", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": ["r6", "r96"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Common stock issued through employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r6", "r75", "r76", "r96"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Common stock issued, net of expenses", "documentation": "Equity impact of the value of new stock issued during the period. Includes

shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r6", "r75", "r76", "r96", "r575", "r631", "r653", "r707"] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Common stock issued for vested restricted stock units", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": ["r6", "r75", "r76", "r96"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockSharesActivityDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r76", "r79", "r80", "r90", "r594", "r610", "r632", "r633", "r695", "r708", "r744", "r773", "r817", "r835"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r93", "r160", "r319", "r321", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r333", "r336", "r433", "r634", "r635", "r654"] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary Sale Of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "scyx_SuccessBasedDevelopmentMilestonesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "SuccessBasedDevelopmentMilestonesReceivable", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Success-based development milestones receivable", "label": "Success-based Development Milestones Receivable", "documentation": "Success-based development milestones receivable." } } }, "auth_ref": [] }, "scyx_SuccessfulCompletionOfMarioStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "SuccessfulCompletionOfMarioStudyMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Successful Completion of Mario Study", "label": "Successful Completion of Mario Study [Member]", "documentation": "Successful completion of Mario study." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "scyx_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "TermLoanMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Term loan.", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "auth_ref": [] }, "scyx_ThirdTrancheOfTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "ThirdTrancheOfTermLoanMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Third tranche of term loan.", "label": "Third Tranche Of Term Loan [Member]", "terseLabel": "Third Tranche of Term Loan" } } }, "auth_ref": [] }, "scyx_TotalTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "TotalTransactionPrice", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Total transaction price.", "label": "Total transaction price" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "verboseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "scyx_TransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "TransactionPrice", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Transaction price", "label": "Transaction Price", "documentation": "Transaction price." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.scynexis.com/20240630/taxonomy/role/DisclosureInvestmentsSummaryOfInvestmentsDetails", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecur], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r316", "r332", "r432", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r543", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r769", "r770", "r771", "r772"] }, "scyx_TwoThousandAndFifteenInducementAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "TwoThousandAndFifteenInducementAwardPlanMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2015InducementAwardPlanDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "documentation": "Two thousand and fifteen inducement award plan.", "label": "Two Thousand And Fifteen Inducement Award Plan [Member]", "terseLabel": "2015 Plan", "verboseLabel": "2015 Inducement Award Plan" } } }, "auth_ref": [] }, "scyx_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "documentation": "Two thousand and fourteen employee stock purchase plan.", "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]", "terseLabel": "2014 Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "scyx_TwoThousandAndFourteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "TwoThousandAndFourteenEquityIncentivePlanMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockBasedCompensation2014EquityIncentivePlanDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "documentation": "Two thousand and fourteen equity incentive plan.", "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]", "terseLabel": "2014 Plan", "verboseLabel": "2014 Equity Incentive Plan" } } }, "auth_ref": [] }, "scyx_TwoThousandAndTwentyFourEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "TwoThousandAndTwentyFourEquityIncentivePlanMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureStockbasedCompensation2024EquityIncentivePlanDetails", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "verboseLabel": "2024 Plan", "terseLabel": "2024 Equity Incentive Plan", "label": "Two Thousand And Twenty Four Equity Incentive Plan [Member]", "documentation": "Two thousand and twenty four equity incentive plan." } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfAdoptionMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": ["r129", "r130", "r131", "r132", "r133", "r169", "r170", "r171", "r172", "r182", "r217", "r218", "r254", "r255", "r256", "r257", "r259", "r260", "r261", "r262", "r263", "r264", "r274", "r397", "r398", "r399", "r403", "r404", "r405", "r406", "r409", "r410", "r411", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r455", "r456", "r460", "r461", "r462", "r463", "r470", "r471", "r475", "r476", "r477", "r478", "r489", "r490", "r491", "r492", "r493", "r528", "r529", "r530", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r412"] }, "scyx_UpfrontPaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "UpfrontPaymentReceivable", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Upfront payment", "label": "Upfront Payment Receivable", "documentation": "Upfront payment receivable." } } }, "auth_ref": [] }, "scyx_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "UpfrontPaymentReceived", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Non refundable upfront payment received", "label": "Upfront Payment Received", "documentation": "Upfront payment received." } } }, "auth_ref": [] }, "scyx_VariableLeaseCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "VariableLeaseCostCredit", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfQuantitativeInformationAssociatedWithAmountsRecognizedInUnauditedCondensed], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease Cost Credit", "documentation": "Variable lease (cost) credit." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureBorrowingsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "scyx_WarrantAssociatedWithDanforthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "WarrantAssociatedWithDanforthMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Warrants to purchase common stock associated with Danforth Advisors", "terseLabel": "Warrants to purchase common stock associated with Danforth", "label": "Warrant Associated With Danforth [Member]", "documentation": "Warrants associated with Danforth." } } }, "auth_ref": [] }, "scyx_WarrantLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "WarrantLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Warrant liability, current.", "label": "Warrant Liabilities, Current", "terseLabel": "Warrant liabilities" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialInstrumentsMeasuredOnRecurringBasisDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfReconciliationOfBeginningAndEndingBalancesForLiabilitiesMeasuredAtFairValueOnRecur", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrant", "verboseLabel": "Warrant liabilities", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the

terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r698", "r699", "r702", "r703", "r704", "r705"] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liabilities", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrant liabilities, stock price volatility rate", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": ["r451"] }, "scyx_WarrantsAssociatedWithApril2022PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "WarrantsAssociatedWithApril2022PublicOfferingMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail"], "lang": { "en-us": { "role": { "documentation": "Warrants associated with april 2022 public offering.", "label": "Warrants Associated With April2022 Public Offering [Member]", "terseLabel": "Warrants to Purchase Common Stock Associated With April 2022 Public Offering" } } }, "auth_ref": [] }, "scyx_WarrantsAssociatedWithLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "WarrantsAssociatedWithLoanAgreementMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfReservedSharesOfCommonStockForFutureIssuanceDetail", "http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSharesDetail"], "lang": { "en-us": { "role": { "documentation": "Warrants associated with loan agreement.", "label": "Warrants Associated With Loan Agreement [Member]", "terseLabel": "Warrants to purchase common stock associated with Loan Agreement" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "auth_ref": ["r657", "r658", "r823", "r825", "r828"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails", "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Weighted average common shares outstanding, diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r184", "r196"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutedNetLossIncomePerCommonShareDetails", "http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "verboseLabel": "Weighted average common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r183", "r196"] }, "scyx_WeightedAverageSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "WeightedAverageSharesOutstandingAbstract", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfOperations"], "lang": { "en-us": { "role": { "documentation": "Weighted average shares outstanding.", "label": "Weighted Average Shares Outstanding [Abstract]", "terseLabel": "Weighted average common shares outstanding \u2013 basic and diluted" } } }, "auth_ref": [] }, "scyx_WholesalerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "WholesalerOneMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Wholesaler One", "label": "Wholesaler One [Member]", "documentation": "Wholesaler one." } } }, "auth_ref": [] }, "scyx_WholesalerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "WholesalerThreeMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Wholesaler Three", "label": "Wholesaler Three [Member]", "documentation": "Wholesaler three." } } }, "auth_ref": [] }, "scyx_WholesalerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "WholesalerTwoMember", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_DisclosureRevenueAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Wholesaler Two", "label": "Wholesaler Two [Member]", "documentation": "Wholesaler two." } } }, "auth_ref": [] }, "scyx_WriteOffOfDeferredAssetForCommitmentFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.scynexis.com/20240630", "localname": "WriteOffOfDeferredAssetForCommitmentFees", "crdr": "debit", "presentation": ["http://www.scynexis.com/20240630/taxonomy/role/Role_StatementUnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Write off of deferred asset for commitment fees", "label": "Write Off of Deferred Asset for Commitment Fees", "documentation": "Write off of deferred asset for commitment fees." } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "55", "Paragraph": "63", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r48": {

"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "SubTopic": "20", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r129": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-42" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",

"Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",

"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860",

"SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX

210.6-04(13)(a)(3)}", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column

A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r715": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r717": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting

Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815-15/tableOfContent" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r819": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474789641/842-20-50-4" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474789641/842-20-50-6" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474814041/852-10-50-7" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474814041/852-10-50-7" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474814326/860-20-50-3" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474814326/860-20-50-3" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474814326/860-20-50-3" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474814326/860-20-50-4" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474814326/860-20-50-4" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474814326/860-20-50-4" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474825179/912-730-25-1" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474794329/944-30-50-2B" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474800046/944-40-55-13H" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474807674/946-205-45-4" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474796117/946-210-S99-1" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474831581/946-220-45-3" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474831575/946-220-S99-3" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/21474831575/946-220-S99-3" } } } ZIP 68 0000950170-24-093856-xbrl.zip IDEA: XBRL DOCUMENT begin 0000950170-24-093856-xbrl.zip M4$L#!!0 (`R_"%FTL\E1E^`TR,#(T,#8S,"YH M=&WLO6M7'$F2)OQYYU?$$]G>F]XK1WZ_J"Y[$)*Z-:N2]D':GGZ_Z/C%7&17 MDDGG11+SZ]<\$A!((!!$DIY)U.E&D!$9X1%N_MACYG;Y^7]_A@V'V'R'8O'MO_R9;=$_`S'*$XS08O?_ES]M[.R]>_/E___IO/_]/0IJGSU^\;E!QV8[S@8? MX.E@&H?CZ7P"S0]LO_W8O!@-!R-H_NO) [LOFZ3C.#V T:TBS/YL=/G[TZ,/`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|&7!P=^\GXP>MSX^6S\VP<'A^,)RN#LIT.? M"DX^,NSAI\>M'=-@P\G7TJ#Z>'0'Y4U 7CTY\&GO^7;.%G\.D@)1NVOGO=_M.TB_/'C^CD;P+.![*11>V:.1Z$2KEQ46F(C#!=G;I)2`:?SHYT&Y5"*HKA M^=" `Q]D(LQ].X5J#XRY2]_&\I42$_P$^>C5+11C<:)R&.XUJIYFL$0@$"D3Q2(D/RQ$7A895+!* I4>A'/CO1$ MO2Z&^CM>:9R>XV?3$83*7'*K7>96$!H] MU,E2K]G),(1!]*.^.!@,"N#G6Z/4EF#N&*080S@!\$&*H1RD C+"M\">'P! M.N#T!4>CA\!4X ^:^6BP^,+;=V_WGB)D3 >/1X,A+N3)'' -7SQTFW#&!5XV M1H&RH'!NG/>4NL;0 M'YT'A@ED0(F,,/WUYZ*4$;"+#L1+ *V2?EQ4RBVIHA(PZ(0V_V)^4.!=K) M"8)O?9JFD\N?O6;[YW0\G[1_M;3C\?%SM;]MYYVEUM(0% FQ3$DVG 3C! 'M M'0],6 CPX.2KT,+0R5^#5/[. Y@TL;#A0G6U\^+_G >=+[I\`?IF?"(Y+O G MXU':@SB?#&8XMXLK_OSHPAM|Q_U2C#[ M!6?HG$6MR[3\OCE>/3^`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`.28S$ M0G9$]2. V>5DLFZQE1O\PF0W"$%Z9_#[`+FHG\+V M^PG 6CGIG =C<,;1BD?- ':TF+JA$3.2),A54%'[6*>K"+F"]7:!/'KE#\YZ]-\R\)_&.MTP.DGG^4;?$7>-YP'"$V]T-D_.AR9D==24-1+:_S]F3B1^_A"TO[B=;*Z/KH M=:VGWBWW.;X'_OF;_S0XF!]T<>53C\T>CMJC_)QYDNVX/_C0'GR=WWPKWN_M'7(H_UQ?CPV=:_56;.BS2#,D M$I(H;"@X$@R51&2;/'52X%JL:E4:9#5X%SUUB>J,A'>9B*Y2\0KM 8.YY0E MZI(U<'>=SI7(_W_W15AP!MMXW+]_W R&!:GV>_S@)=ZG7$2.V32=[)A>/QPFRE[42]C MD+ [Y[&/9#0SO;.(XG644G :1:C.I7\=F&I%8{]3>H)7)?1K,/2AA KA59.H M#_AR5N4*9C69%"@SQ'AOB;1.EY"V@&,)++!F1O(5[{WQ>C"(2RU-^\G(<%Q/V MY1X^%&\"3NO3XBT8'[9OED\WK3FF79#/%0'701&MNT.8.BMB@-''< M! M@0*M]#8DP#OC/"<2O#V= MCN. 13\5B_GEV&^ZULG><>T$$48C@RC["T[F1$)6)2[0>9ZJU3I7AADOC00N M"Q."]#HZ(GSBR..\(UX[BU=7SK%@8H)]?1/;`_TD?.WA=F=Q>\MQ22 *2Q.I M(:BID9-I@4P[>B") (\=V2F>EEQZ*\=WBV%64FZ,QQ^@\T*%*A ;@Q.ML&*8@ M*TY_8*!.<;P6(=V#X1 5TU]@!!._1%JZG0X&HP%*K";.Z9B9+ML/NAK<=\P8 M&G@F#%5YR?B1Q%&P)%.F>8T.8M@@K(0;B. I0.,XZ\$905]W1L8G& M[^5HM(<_87]5K*^G&]U)22.7E 1EV@OM%$!N2HHULJ8RH4!7FW3U7=OZI5Q. MV:.LX+=XD6RF0KT!@6T]=XHNF 1J1-J=K%.(M+[MCJLS M&#[O<1P?WD@/N-. 06X8JV^V.5O/ M8M:9*64929Q[!%VCB&5(((&S8*BBR!M3K0)1)^A6$%3EK*2)YD""P 4NG<8% MCA8!82DX :"9#`7:`D \L!2UVML'N,1`]'JV#Y-7XU%<%*EY.?!A,+Q.O8K; M+3K6H1EO38XEGUS94CQ"!^3;5F62D(9GJB,UOMI:(K_C]'P15?7FX_C_G@^ M!:.$B^OY>#Z9 8R>'1P.QT<`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{F1M;74A!W>%W M*\D37A(!==DS5_I2Q:B)3$Z2 %GBCXD)FYU64&V1UZH4U)+6KI=&&Z](%IHA MM7..^(LQ<\?H[14&'ETK1=\[8]- M^Q.8[H^'Z>WA;,PI_6TP'.)%ED[05E&B\5I=X):\6%8'Y""$!.%(4L63H!(G MUI>R]#+;TNT)@]DVIKH]=EKA7GT584)=:C6P6A?I3[0TW91"^{L}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lC&0&^0/2%Y2T58H$*4'@Q$D6&=(HMPH M%Y))NEJPN.C-:>HKV!J/9N==G=TIN.NXSL+$>E\42ZE$NS:EBB@2SI1)(.PD M3R2EDEA>JL$F"]Z6]DGU%7M>O45T#T(S[E%X$J6Q \)CW@L@4L1 /#.1,&\]-M6!8D5=6%Z/5=@>^C^M<4I9=["R)49#2<8OT<#*,"4-*K(K&'5BNOKPT(.7XP2-M? (+T9OQB.IW#9+IPZB}^GI^=9P>]+10+LUMOCRNFQ;XL6L\983SVG9B,HXBX0@//DL1,M97-T.2J6O.FQI+?Z,MQ'U*U;D!QHIO1H4B'-*5 MDC8&V8#C @W.;!& <1&^TWI(V\] WRYVS*B**0*M4MJR':08,4SS0'5$=:+N MG02J6.MKWNR=AY"I%^@F@@-1$27$0N0$P9Y[KD.0B5:0JU<#/8O.)Q50W2;D M-)(E1:R.C@A(F7D6Q-YJ##M!5729*>)3J6"'4B36*4%"HME8<,:+:KVY=9+!:_HNJK>![U" ME.JYU$>4)U5Z3I B?).I8 *2Z6EF_9+=7B?@\1;K14.GM*2L0BB\+S"B*FP M")/UBY&PZ*O=:WT;KA-V'+!A6HU1$TX!)3 Y! (\T@4"_[2%NO0;I 1 MO@[? %R[K]7:T<#)&=[;]<&/15(X>SJE,)/A(?&D"Q2U(`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}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`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

[@"_Z'H>K%^OA6_ZEDN60H^:^L9Q%+0A1.IF2"^%,,,5#O.G6>.0C=+_M81?>#Z9%N\Y*DDJGR^'*A[]TPV_G'Z^>_=>+O8?.BU'??)Q MULYC,\[-Y'3^&C]MIH<02Z!2;@:C9C";G&_=>IG0X MA<=3./0EYO3\#+??7E#NCP.8G-S]PV Z;.O '#T^^?[Q27A6.GTY[>T4WNQ! MHTL.\F\L+_+E$^P0C*)?*$YL4:A+K4NG=R@BHI+AR(8H@NM$^B._'
M<$HM*F34Z.=L8)OO:#3,L9AY/QAW*=3GRTEZV6IS#'T'WV)$fQ*^: <MI>O,_R7SS>\;2;Z #]=]L#42;$UC",$8P@645AJEMK40H@00"U &I ?;C6"_M\9]>'$<-+TI@=69N7#9_2A/.+-/2?H?,?@,$[-),RXU MS9I_SB>#:1K$UD\USF??>'#_Y^ L3+=/.WGO1X/_;O_^L3,P[.]%@5VMW:VVJ.RVE. D;BSX-S\V]\=:$87X2/78/ZQ3(BUWXM],[5V7/=(V5-
M2;@#-8I99"@*2P_W2+(@1&P9U?H7OM-AJ+:$Q]\=CA?;H{\G:*&6B@"7CFBVO^SY M;IX/Q^/)->SWY?3+^@#;/2CU01?@74[EL'1ZFUV+D=3FA?[&4(-2$3P]
M/V957%0<"BY1XFRBT3O.F4B="O7O8Y3.X?_.&R=JLN36%KX; 4>3A"S!H=^V. GB&UY9?P8.5R8UN>C^8Y]O3NRX-9HTG$M M-V4Q?]-G@?^6[J-W\.\.
Q9;C&SG%2HNH((EA.)Y;4U[{]0<@E3VC{27)K\ M,@*&@XZ"9YUOG9U1^.DV0GI'2JF#E\E+T;H[LPW'N2/9+Z M<*N;JO,K$HCT=\5PEK.
[R@+_/)H;13]>%N([#N2#";3F<+#Z9SDM$WVS.[B*;ZGW]B6_UT]f1 6K&>_# KXYCA=M9?O8I[I>Z M^0V"RM_W!_C)[BGR2*>#9O/6U"6)*1GIK[*EO:KFR',=_B;T)U1Z*16O+B=W M6VY\K F.&
MJNQN]A=%V9NV*OO#!F&\^5#]2C;"X&>LI).U[3E^)8>ZGB7 M4Q:I9#0&CY:,RD3RR(@+UI,4S*@N) <)X#O.@5F#=]>72V?$W1KDUF^VKT!/'K3C9O+P76;_+^: MOPS'P0^;4L0'9C?P?
U_HK]LN'GR7#KP;$]X.*?2 MY>.\G7LI&I=$"T"2 $&((@FGGC:*@G2#+,>2L8<.?#K1LE+71L$U=/YM//!"*,3 MSAL1W*[ST36IF-P2;\+%>FK>/V3_D1MH9"U[/S^{>[+>RYX15*%/[O4NHRH^%L
MF2@MT"21BCMB50("I>\A8T*ZKHJ1G@C-7UJ9V3G9N+Y+Y7YEZZ!>5LO8/ MWS\]\IYJ_XL(5?=S[S<+/\C?"O$K*^(71:8-\41AK&[P*J1F-V]C3^701(H:/ MN>A7^G6GL!)6NXU/"HW_SC 6^-
MFQ$.>UP*\\&T]:?._*C./##$@-2BM"7 MDZLT11S01&/Z7'!]'#HCQZ7HU]FL:.M-5B, MY)BSTRV-'_QS/fT-\M')7=JO$IROGY!IE*N?JK%>SMS[YHT3OX(I M?.:''AML[)]..>UD+&P:GV"

*5A3*IU*Z"NY[!]PF@EY4?3)VW^>)ZLT,"AHILHI'<.:1@!AK4^L?@:, Q<1;MI%(;"Q -/&X' 499?WG/=;R+!..WJ.U@Y F8.:@G"9*.X8HZ(&7DG$WA+%A(^;BHEC!_&'0X)"U0 MA%&)=2[9B;"R/<,X\"* . #[.,6HEX,>41'X(#B GXZ#U,6+1F8,*C_W(@#K] MH: ^H$(Y(/ %>(-1CP$ENPF\0#=W<1(@'><>TG M8S#@4OF$4%%V&X30^Z^D+L2;S\Z0^FRG-$G=:/?
6"9Y/X+,74\ND)?6B#0= MA4-!":I$%*^$*Z9#$>,G31M=#0Y87VC\>6B?_KEW53]TW M4>2D4'}E>=G,:!B4X^D),WK\Y/\^Z4>5=*ZZ2*N<*FF^F)0MH
MGCY93^0,O$Z#:S *QZK%,:E\/CEE3G[#[>+45KF&7T(T@4"+,#^<"^!!N?%7 M+HN+!7I3"OF"II*V@-]?5H0^3U;[ZU1_5N\OE,-9[H)S%3$RI-]@\J,4$1MR, M\B]*T#/$U'>-
Y@UF(.Q>X*V!M7S6;/?0U!0"O4!GBJWID$=F;]*7">],,Z[B M,C;8N_T_+'4+*6Y%8OL.CF)+AUO;/< 9W&<%F+ M+7]WHP7IT?$.S.4%.K3@UK(TW'^EL"OJ:WNIJ2*E(!NBFO5!-Y$]^=?
EJP^G M1"QOD(.^Q8[!7 %XQ$ZK8).RA**&ZHR 40=4@$* 9O[:S5GAM=.3Y+2F(M/[QV'*VX1&F7%ZZ%9=1<W0'W.]?'VZ<4 -]$ZKES.8,B#-['LPG?
YNYILZ!&MUYU2OT;X#0#&@+[ZN&X>6%]E#E M-)CQ8;Q,I"[36RR\I+5WE!WG-^6.1[Z$KJPTR.]'s[#Q!Y>>QU=I?SBZW(D/ MFZ@!+ 58_T4D6;(ZZ1+P&@PJ>B0O8C'&5T7QG-
P(K$0\86F*#I%1(N6-6"A' MJHK10E1"P$T.QJL5)H?3A!+D$I8%2 1_$8 RCCD9^@/FG$B6OZNM^-A0. M>HYQ(L-0G87"-FNZ;SI&OVU\#09<"DR#FG [-
&@P#9.8&G.1M$^0/90K.VA' M.N:B?I0 9 8ZZ1-YJET?@:CUA5R:%G&3S?_Y=D,B&+$HI: X&L*QOI/I M!0\;&5!98VSB8GIZ(HZX;'0*;X(UTQFH00JV5XS7RZ/:E>B.ZI<-L*%B0[HI;
MW$^POH-]$6GRJ#!UGK=50T'IQOY0Q>W?1<4#&AP%<88**&ZHR 40=4@$* 9O(:S5GAM=.3Y+2F(M/[QV'*VX1&F7%ZZ%9=1<W0'W.]?'VZ<4 -]$ZKES.8,B#-['LPG?
YNYILZ!&MUYU2OT;X#0#&@+[ZN&X>6%]E#E M-)CQ8;Q,I"[36RR\I+5WE!WG-^6.1[Z$KJPTR.]'s[#Q!Y>>QU=I?SBZW(D/ MFZ@!+ 58_T4D6;(ZZ1+P&@PJ>B0O8C'&5T7QG-
P(K$0\86F*#I%1(N6-6"A' MJHK10E1"P$T.QJL5)H?3A!+D$I8%2 1_$8 RCCD9^@/FG$B6OZNM^-A0. M>HYQ(L-0G87"-FNZ;SI&OVU\#09<"DR#FG [-
&@P#9.8&G.1M$^0/90K.VA' M.N:B?I0 9 8ZZ1-YJET?@:CUA5R:%G&3S?_Y=D,B&+$HI: X&L*QOI/I M!0\;&5!98VSB8GIZ(HZX;'0*;X(UTQFH00JV5XS7RZ/:E>B.ZI<-L*%B0[HI;
MW$^POH-]$6GRJ#!UGK=50T'IQOY0Q>W?1<4#&AP%<88**&ZHR 40=4@$* 9O[:S5GAM=.3Y+2F(M/[QV'*VX1&F7%ZZ%9=1<W0'W.]?'VZ<4 -]$ZKES.8,B#-['LPG?
YNYILZ!&MUYU2OT;X#0#&@+[ZN&X>6%]E#E M-)CQ8;Q,I"[36RR\I+5WE!WG-^6.1[Z$KJPTR.]'s[#Q!Y>>QU=I?SBZW(D/ MFZ@!+ 58_T4D6;(ZZ1+P&@PJ>B0O8C'&5T7QG-
P(K$0\86F*#I%1(N6-6"A' MJHK10E1"P$T.QJL5)H?3A!+D$I8%2 1_$8 RCCD9^@/FG$B6OZNM^-A0. M>HYQ(L-0G87"-FNZ;SI&OVU\#09<"DR#FG [-
&@P#9.8&G.1M$^0/90K.VA' M.N:B?I0 9 8ZZ1-YJET?@:CUA5R:%G&3S?_Y=D,B&+$HI: X&L*QOI/I M!0\;&5!98VSB8GIZ(HZX;'0*;X(UTQFH00JV5XS7RZ/:E>B.ZI<-L*%B0[HI;
MW$^POH-]$6GRJ#!UGK=50T'IQOY0Q>W?1<4#&AP%<88**&ZHR 40=4@$* 9O(

*7!'YG!33W7=VG.V4"WGCD6,=N|SK'==>/{O9B++:FD)15UHUQC4EF;K"4=_M$>$=*Y/MVOUFEZ^;]78'CLM4N[%MT|WJH)K],FW8D_1M=22M%N7YZZP5'6I$ M@*?B;M/_M#W;=4>C .R?8B;!3.)!3*+5M;O-.C.*+6I[G BFM;<3TY{@M-2; MP-T\1XPY-W-NYMS5G+MOUSO;\YP='N-F/L%\@OG$/QM-N|UiK!FQ.\;G=C ?M|##UNKLE^*O23^:,VZ&VG9G+^!2)NPR 7@Z9,K=@;O'@ M]+2^W;D_5D'07G,+'F>|*SW6=[]>57!|& AM'809&_5#+SP[D4,&P\H5?V!%UJ+8WQ"R/UR-G14] !=EE430A-+WLU M/*O0<)PZ.MVQA(M?BV&":I@*KX9JZ4C-&41XC)SK2$WMQWPJ7N!Y)>94\!?2 MN4HSOM3'5\D;?U4S?P7?G M0R32$# C$%X1J-40(4$#0%QDR#P/!HGGP943-'D>7!GX/ |KNO/ |ENO&!!?S;9![<M4>E]M]H0-/VX,/YXPR"*Z_6U?K_U5$HJ]E3=],8U)R+^VELY8DO&ZIL[2VH M;,WB.*[5*EL:WE]IZS3R+OVYUG;/%>^!MS4+.%/2V[*\&]+N!ILK;@N_O;OF MUEBUP++:AJ02QGH,"^+QUN82V.4S"*^%#$L M6P+,=`S>QD]B-/[S+62*9BS@O*DPFRK@Y$;;Y\+,]WX),Q=7K+RGLO- +VU\ M!L3 ;D0LBH,NU<2+-V(84^,QQ3R+S*"D A>O8O'4=T0U33]N635TS5[JR:L3>PZ U<.M;93/+ MLJXF"D/MQ6UI[FHXD1#C22;I83-94.7R;4X?VB@"$.C%@-QA(-WG,5X\5G-3 M/(^.'PP\$.,+)-$2-'*1T&P]0TU\@6L0*@\!GS0OR9$IEU**97D"H.PAUL)2",;>|^5(Z0*0*T.BP$SCY"4!\PS?*%\@ MV5&$:QGP.2P:M1;>ZA/=|+Q]T&UUFIU&$],.-'N%@_LA[OV,SK_FP!B3ZC>;MW2PH50AN9B/U%E=|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{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{ 0N#F^'RU%B12>C9KK0$-@!YA(ZQ,,=&;E< M8Y4C2#+!=C|UTBGJG;_2<NHKE!U%L6HU1QNE%'M+O,3@41*U4VX()+F^&76 M.F!+%S2ED@8TA\X?->5A_ ^;M0Z7SI)NJ0^EL[AJ6J:4JOYLVB(+#\U%OS;KA ME6"N3JE^H3$HPU2E\"F"WW3S)[S&HU;N]1[X8R_>4.^9SZ_.?*1IIP$+ "_(_ O-OP[IV0UV@VVG5 M_O*OPG;I5O^EM_R00MPM[Q6W]BIG_(J9@"GO!:S5C[I\&F=:?FS2*F^6*[,A'?UV, M3M*IGO04V*OM(XQ40=M#.IV=A;P]=!Q-.6Z\\:|UVF\VL-B-QY $UC QC?4WZ/]+<7&2!%69TXPD'!MZZ1YBN9>6,L7\=)UO@12[%%.'&P6?J&39%6/+(VV$,DXH+2A:U2Z1[ZK^T:EMW^<&D/[>IF9>01#=T"FP@1-L7Y^""(NQ$]-+LJQ*<> H>,TJLC@GTVBAQJ<@IA0 "+ B(IR3.^XKP*5@^X M>.4V@M5UTT:EB$IGD6(T(A=NN:$&BO2U8KZV;HY6@;8,(LU6LLPS?A<*F]A MP"STH^ /F^LB%T0RU,WATB0E;7W#>G\-5_LFN^R/1HL_!@BN@M>KW,L&]G6, M+.**RKPYZATO?2%"Y"AN#F]3^OO@UIAM10CNG+8RHYGH0P5]$?XK*^N9I6VXH>T5=.V,@O:(8N+KX%'FX%_A>4R.1T77C OMO9 MN'/WCB6?=3GYC)//=C+Y[#&/6$URCR5#E@[YK8Y;BW4^C_[_NG?# MI?7A_.,GZ_(2%-)//[W>(7_61^ORW9OW']^>?I[_^[Q/)>W[^\V*LT=EXW/ M 9C)P6>=48794KMQQ^2V;-3^\JL8[]-@U+R(8?441@)*Z-NH?4.1#4*@?5, M0T*GF Q&&IK.8:(VV^@"H^Z]/X R&%IO1.]-L7D7SEJ2"0;HR7FDNE7E*.#. MS)25R0+H .5D*A!Z.0R*9?8W/(^G^!G3RI[#?3 "0K1IR-"8+JB[7F&B IVRV33'I)0DKZ0(CYQ %;D!Q^"R+P,.!\,+5D3J1P[! M8WCL.! M&;M.B:-0N(E+(R2&J?1#:F*2)W38QM"E_K2R<$R31$;[RYR0RZ^EEGW8#3>* MY0MR)-*/R2+_,_55-3;UKR1%WE3"BH6F.?B_(*H]<.\5USb\)(GZA3#D7B MG 7S.UO#@=F^Q15.2 +4TBATD<:R@ M,4'7!HG^CQ&@U!M2$?$'G"?@8WK[(]M9PJ6B+2SM%=;C_,SO8 P V#\4 ($1^>"4_"GR MG#BQJ$Q:15R_0?-^$^X"6HWJO]K(O)BCI*91T<.A'8V!R^-M3^?W]ZR8\'P MC_UK%2]/P*)!K%CP QCI K2E%3I3H;UP:&5C[DX%%]I>GFGFU:52?&MJ=*ZA,JOHT(AML1$YL0W/[OVQQ'V5PSF#^\"WEB0O'^_)D^C/V_V()Q1G MR!^M%+^/&!G?JG[I?$:.^]5FG=>V2;GE>^\M'?X=T2^#N;Q24CENOS+N[&KHL M>@15XAQZ&D$Q_I%K2$P*X8fI^7>^"*CTY $&8%$?P-2U+FU+HX5M/<,,'7.9 MSXPQ=EOI8=|>1-,JN0$[K@C;&Q_)DQ^.7=|/|/KN1>N,?=^]!?I^N KX0%##D M^E_WL_@Z\8?^2H1Y"M6O6[/^LDM>8PVA[;A]^RO:B.%4I05PTB1Z]3D?[@49 M(6P=?WX&LBQ*02;Y7X7W.]MZK]6_-P10M>%,BA=2E1%E/0&H:%"M_0S?#QO(MV/>U+WU5E/G"/*]_!+_RRD7VO5JK_;UF[!5?-]9\-VC4NMWL^_]!GL2+&]%R M@ :|] P=2,N6%DBSX0366+N^5ZEY=)]"'7#9CR,1,E1OC/$HN*C:]PXMO'U>Y#MC*OPI;4BL2+,W.\#O4O1N"B)<+1]T*5;?QW1_]5;WTJSN)7IV$$&WGYXM9-C M00I79.3.3-KR$[A-+

*<*HUZ0)?.DS'X\UCK/4W^Q5Z'J;!W3QK0SF;\V%&:5IE<0U31YVXA-MHQ4]1D3|$V TR4-4 ^I7?9G>X7|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{(##B+<1U[PYE'[KU M,>!WY=>?"G3|!2)<)#2Z&W+!|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|=LE:A&K ="F^6@VO;LKSU,YFV@E.#*86.H9"CTUTU@0;UU"1'S1L'(COT)@*7V&*Y"\)<)4MXC!;A M%WJ3T:Q#BTN#?%S\;22R3JO>49VZ'}Z!E!NTI1/%1'")NYCQITY'&^8(A5P MY(WKEERVUFZ'B@7 1)K@V\N/G,N3!@6U!X(U=QA?D=)?]1>??%RQN|K13++*F M^EC=.H\OG 0G<1GC?VOQZ.X,;>Y=>HX;8)*7_%$R81O>?JW==(=2/\-DG4:A MUV!I*C<:,TTLBIF_|@Z[_'9'GQ/TKLH25LYQXL8^O9?]\|CV(W-X6D&K YSA M\X_F?R^PUYU+PP/I#:U+-MMK^:QM-"Y&Q*BJEMK[MOD0065.5?K&E4-0KH@-[6 ?E; ^/SG;W!X]'C_C3(P MLI&B;5S[ENB:?W9#WL$/KSAXP5^B,%TE?P^> D$RC@+,.UHLLU^OKZW=TR6"U M3HZ//W^$7W^D;+_ Y=]E='[KW&+L+HUO&|&8*,-[8+_ MR-.0XI@09G-!-L8/AN62(\;G(<#Y._E/(.<]{=HR'/'L&.VYJA(`M7MG&O]B M7IG*O^G-@:6)RM2"UTZ|,"? S_#GQ"Y/4=/BNF)D.)MP>9?99_!4&Y/;> ((=R M>H@1/ 0AY&6S+XFBP#V*W!/>]MU,O.>\,]MG0#4])..>JTV'<405222/5=G5 M3SLDM^,#1G3$< /0.9._Y*.>(3%NQ >.LI$C:>@(QOZ^&LJVY5%MZ$B>4--S M1"Y!O/OBQ+_A]"*;/3E[;BI*##%JB))#OS*"QF\%/7+(R\&$63-AED#3M QL MVUV%'GZ#^FWTZ2#B8=B?H,OV7!M&``]H* (Q^O^2(5$;_0K4C2^4&2'EA6N5 MU+2(\'GEAW##HA*QD.QD-X,Y>K#=!M",#_>*D!D#<'KS\! S)&?(7E@G$JX22 M@Z;O70(.C(:)(;#]"K%\)3HB&9(^A.B@T+JJ-"OU!.+8'2(#L_X,3.% M.95WU?UV3;Z2'8J6Q:DA/SG%SWY(521X5US0BQ]Q=2!!RRBN7@N'7++9>E6L MC!7]JH^YDOZ1?J1^Y'T:3XVE_Y&/.S*.VN7A 03^FG0'I3O3T:4W*- %GVRM@,U2B7OO__<1K \-+ D03XY M8EUJ%F./+G9-77D0+.\2]9%!$:(/7/AOIV+ ^%0!L-JW?P._0Y2^8O7\R)0_D MZA>,+8, ^R)(YRO17]$T >:-+4E@[0J3(''U|"R11)4^#$1X%.L22UT>230]/ ML7 A4S\M"P!&KV[#'(2"=G _E_ I<!=T

*'84Y9\\1:BD M%S$F1XDS#(B=?P,233B?'-/ Z[JE]?BL;8LDX< I=NVKD-?82&Z=7:\,3@54 MK>0* &NVX(X"VN :Y1%#?:2\N#$*Y0#8,)\[BCL6RG33VYJ;,/8^CY"9U% M[%V\N:0IJ]1HL.21S!(QGKP\Y%K0:f\@P&K=%^;0RG"59PKE.CAB*,\=;D(J4D1Y/>)RQ$TR3%" MX9C/X(*+=\,M*0KI&<-Z1K30)&5@R:JB5<#*=]AX4C;B]^LX/9J2@IQ";7L9 MJX*;84Z@B?!7Q]$QL,B!XV9 M?R=TK$#%4CSCH#$K:?IBX&,_.:27AMD7V+6l:">#,BM/;BIA4' 1 ;3BU4U MX/4\(+OTlLL1]0<_JZ48+?]\DN(Y.H!UG2@VSAR.? 82R&F]2I(MP=3 M:YA3$1!+AK@<0F,KE=,-%0\AF/?!5BBCH&I78?.;2]#P.V+X M!S*[7AO$#GF<9D]98R92L$)<3ZX3W*[(TV00XCPE@R=@=PSCP.@:%RE9&WFV M8;=/B>_Y3KR[=P!LF,:?#8%B 9E;K_G\:XNU>_1YT_TIY__%65]?')S\B(-,A1O9U'-=E! M<9[OV3SS;&.)LGV5_IR/B8.1Z'V\".*VRLMK%T]-.>'"Q':$41-BA|5ME9*) M+44W:9&A$&IN+]EV8-D_Q5!AM>]?KH*%T]!O)S_HHOVM../F<;&%21[J,22K M2PAF&6@ R NZTF(3R01]C9])EF-B5]PX#U$7YP4C!:2B61(+0U]$LE)S1 P M.4]C(\'&5BF-1? SLA+RZQ1EY2D6![%W6>B1>SL1^VJQO/1#\N;WG2!;FZG+ M+/.F50=SI£3D?G#/LA&D-?[G=..N/9#?$4&UON!(%58*6TG(V6H&C!#E- +4 M2IP0%F]&!!/R--(MV53 ^\ZH YVJVK=.O(CIQ^)1G5LXM@<.5A-QN!9/ MB$. B//D<4R),'URC?A93-0!#/[,B?Q:<.LI5(+5' M#K03/"@HTTR<)3F?P\58K3[/I8Q-%HM0\K:(TA!J^(N=YYY1@L,?>.U Y;,LY M*

>I=L[7@G+G# &M?BY@@+=. .+$-GR8]M.]H&{) MOY:)A22Y:#3Q^PKNX66KJ.MK[Y'7O^.3KB*:739STKB;I1?DM#QK=64[*0O4 M-G6G.Z6AU:D#BA\OSAMDB VZZC@-\U? 9(0LO?')(3Y91U#T!JOF M$CT:U"0_F0Y&%N63P:%/#EE7DBN,4@MX8A5%!2 H/EDLP00.J4R#3$L5%058 MU#WULW(6lLQ.!F0M&)LZ"3Q2/9ED))",6_'(0!()IVS1 #[(5Z"O.)X6M\%(MU?7&GD+54):XL,\1TW23?P0$O5A#[6C V\<9L:V!G1_%6[(<^,.\-0^;P/N M9T1GB))%G^W#]P^72HF&XV(P]@_^UY0'K#[\<\WS8\4YPZ_C>57CF;/R4?(F5;^\[(=+_!3S>EHL M"\4.N03!+1H,B1]>WUZ=S:K?=_E#9I9#WR]IQFA"P:($]_:U*GE8\DA>409 M@UO0P.Q6?S)R?IS$1#5(I]DRJS8P&K4)+FY[34%*+ MEB M]V$Z&;N#DK!0WY75\O!#63*R>*]EV8W'S#))D*L#=F+MNO'6"H8$Q@B)5 MQ01-"XH^=V-@]LKL&T=!3R7@~8F/2,.2^X-R@HJB53CZ/)3FJAMW-AA-J?4 MI.B99X])+/%0) (%%I.]IL;E+03;-Z]SP@NCASD)08D:F5!O0Z(75=!M),?GT#F6 MZU5{$<2LP2.YPG\'UIA6.DUVV4,#'<1((OV@Y\=/[R.DF01YH4@L2X&YR2 Mt;RUUWGI.$!G;RYJ9XL@C2$K-B$QH:A7,\08'9S E8 +U54UQE&:#$O\4 +U M*BM1WBA%1DSM;?G-I_\&-_S"@2S),T <)6^L 5!99Q2AF] PCH8U9+"*T\+* MB,7>(@L*602W80,)PCIS'"C8,!SX 1P7-5Q"LP#_ ;B1S^Q; M&5$PVCI1X_6CJ+_&D&572BT*;M0>#* C(]QL$ D9BMHQ1ED63Z9M^_FN7* /&9%!84]%K M/,K&@%C%/(RJ$

{@P'"6ML(1&7>HMR(@VXRH<9L?VLR #6Z)}{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~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|_^*$8%=]4]BC$]Q- 9W'DI4YVIW6EU"Z%^(+%X83/%W1IR(>@$(&7!JOXH1P!<\ M\>#/(;IXM%<#<-N:5]YW+K$&@&%[-"Z^IS"KC M#:&,U"65C8C;G3^H=:&:5?B(5=UO?EB_3, (F3!(3I86#C3B!)Z0AW_Z[AGY MF(=X((@X.]=W(V)H?T=.-'K"GT6, +DBDF-]7VM%?01EGQLM8 1(I,>#JK$ MIGQ^)*L8 7RWSBR?!3G=W5T&_ZQDQY(-.+DI$E@K'S2%=]FJ3K7"$"+LU<$UX718R @6JY_7?R_J?OP5]CIPN8038V;MY)XUPJHTRX1&)8O#^_MT<@)$N523S[GCC("\]7ZNY}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

*[DTZJG=A'8&;7B_H^+0F%#N+"8TQ=# M"!*7%@;|F26"62=A&X;18Z*^RJ8ZSOK)'9*>DQPVB+>.-98U"%_E"_MLW1 MS(M FB@&NH@[*A]|CT+RODPB\"9 M\EO0D)FS0&1)S6K\!* OL&1@NT|QV2RQY9'C^3W_R(R5)46NWK(IW;QKMJ[I M3J0I;PO$E5ARY6?@+1!%PBLH|FXNH@1P"R&A3?|D G$GOH3"],T,%8DEX#^N6 M{$74EE;EH:X)MPM$HI#$Q-&PH|3E-AM+#2I.0Y+S A%6(RMQ7"5%SB|S#6_M M'(-2SR\? U?'1DB-,*5{^QN"D-2&]$IY_B=/$^84ZA0PW\22 MS%A2,*F40V|(6Y)'1XXT6;D%AJV3X,VY[@/#U9),6E)<=2\?P5"Y)*M$PSO0 M7(B("6U)>G+"FLL=,%NC*M%20"2E4HI#|I3L8(@=5'XQWX[80 #N=0^!)G>A60X7A;_$*AJ!^'%IX6*AMHR M#$\3: SZVYI>!KN=& L,L""QJQ)@Y(E%N -=NC<$+X8G.G]?K4VG* MM&TI(8N&7]>[\MM)MT5=^,*-E7_/<8$;4;SW^FKP(VB"*'U'H46$!.Y^2\2 MKS= .I)KI#!Q6A+ $JZ4!$]_U]7);TUX#:-`? 40^^F9Y0.4M@"O,,@J OBN4_GGK5[8F8@,*$X=N@^-Z6-<-?!&#$@S27$&BI5R>)U,W2N91%'\T9#"WVOA)TE5$'M MP*K;.'R53G9N8C5E16C>]&A|QY3L\EHDUX_D0([Z\3FH? F51&F>=3KAT'@L M:>2S3@ ;&G."LIMGR%4?Y-6,#+/.UNF#*17[QJPS5#H;(#CFENDR+XSV C\E MNYT5'M:,_THL_..8A)T5';*K* IL%R*G?G?C.9JG&3TB.WCWSCH7VJ9_\:W$ M_V1MFR/67D_OR/W;0MEV||Q3]H0%!>7 MV3!$/5M;+V,FP"S<$(+H:.Q<%X!YRQRY!5W&UF9M*1S&|R|D:,VXPQ&=75B M&!,,$\26-RN$-1C!!C7>S,E1V/U9G+5Q9QJ\P^1NN9- TF,!U#72>E2 MG_1 H_5 GFT52TMC9YAR% >J3M_@O5O>?R.K&B,XP()F(^$J0?>8,1^_(>|=~M?<'GN14I49V7,QX!<$S/WX*><+!-5C@-<-_$U1B^?VZQP%R#=!TNMV%Y<9/!E# MI? NK#7Y$!;#T6,CXX^MY;'.1X_]\:B=SP6 8YCZ9)Y/"D/C-7N19QX_H06OZ M\L\ZH$0+8M,W^621:#3+=I1V9AV+,CG%CA2QPK7I&FWC>2A\%>+NN(@[F7N, M-O<(3DW)BYB/-FWJEZSR7J33@"T6$fP#3V&>,;2"U_^2/'PW5LU\|A[H MD'/JW<9#66'|DJW<'V9O*Y"2CCE O9*X&6UR.@)C|YWPR*G7.O=N:6.A$O/K K=MUZ#4!$=`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|SNXQS&?]% M77B<_S#/L2 TM.\)+>($#.4T0LEB:6$XP[.9(4Y\NE,PV%3U$|S)5#6&J M,C=Q^62H.AFJ\]DQGTQ4)Q/5C$Q4]?L[(N0>W?IH^6IHH|H1OF2&-#E.U-G) M+G6R2QV+MCCS0SD9I4Y&J5F=@&%L1B9+G.Q1)WO4R/:HBBF|UID-I@FCIO*.M<+)%G:IJGBQ2AEFD!#0(7ZH[7!_/$O\2A97?3KJM+Z|OI["=<&/EWT^/;PS?HP!. ;P6A=A%H&*IJW MM(C6:/A9.\^V;/G>0*&V.,7'639|/"4A>-9IHV)4CEMYU4ZC-,A1.D%)/E,# M=PNE?%O.S-74G*$-1F)QOVF7AM2S:M6|^M5 %:A!?WO"$!! M&? UCD+K#3TBT*KQSR\#GP"96-XS"G?G,@1/O)/C,]TQ71G334(XZ3K>8K5Z M;_D4#?=07C_"P-]B6%T_Z,G0CL1'Q M}^: PLK%O?Z.0MN-T$/HVH1<-N-0-S!WI>C$]"_2.R'GE'YL#\E)M? 7R\ MT>^< -)K&^#5[2(* $6%CY3O7W_<(:DT^|_ CREI PU04$#^-)*H.N,&CO>3- M.%B|O87H#5/}()5[\Q>P1",PLW]'<,.6# '9B+YF-+PSIJ+MY>59^8BW?9 MX-'2=C,.C.#B"OLYVB/ XOX&N3$Q)O*XW9"L,"I?'W5/ST*7>@^7I0>A9WB MCQ]G@>.!E>UCIEIK!6X*8NVYJ1D?QJB$K?SYN2%8+VONN:D9'X8..E8IJ-A(!%.6X!AGNB:?*W5-LA?%, M3W:Z.\A>S06=TPBQ\2.=_(DAFBBK#.EG74.$!,Q$F!X^W--YFR/B#.DF/IVK M40+.9&6|#"OB:,1XHWR?3Q?JB$2?3L$)TZ4E'>,)'Y?HHQ+X<#!OLP.,]4?A[>U?OM& MW:,? CX9&\,)WEG)-!?'$0N7>,@5NQ34VV5"59\V<GHS:"CZH!9T.[MCO:-L8 M@)1.VWR'14'!4QP<,96#L]*.SUB%&%RQN@B(U\!-XX>GUX664_HSMSB^A|K M2P=41*V+L)-416C]_5/!=W,+OJ=[P!^0=.@HCSG5<#"FAL.X>N\X<>ZMOS]G M%%?$61)-<(7I[L9R0W/*BK7:Y.*/R^_SFN/!E*-O)D=^Y?.S1[!XY-]V?^8> MD5 ^S(4OWU%J8#? *I_0)?6B#536'1/6XKPF EN[WNV]X(U_"]6,&]9V \= ML/!+]Q/+ U(|_@4D#^EY@>A!)@-`^P55ZZGS%?J,^$$T\MO+YV2/8/|;=G_'-M=T3D/_EEQE!*2QH-]8GC0U0CK= {((W\HKZ#^: (90GC.XQ>M-J?M< 16=FI;.M.K4Y,Z0SPTQ!?_QMUD@V|RJK;XU_,?

*M&2GVW<)S<<-|!W27<0K/OW7^ONW0,,E,[D&#Y M=^D,A{}3%NJ<<(N+S7C3H'P:<7V#F[8@3FIY[_T+.^2 M1Q+0)U#64>O9W^12E<"=^%*5@+(@J(>4*:L#&D+L+00Z0^A7-MK_1'Z+;P"S!$$-C0$-95B&`:Y7Z96F3!0D$E(KM(O1NR"L)HCU=92=Y7M=DY\6&YN_=.)7=\)6@Z.;&<2\UNL/?_-!JP&53Q]1_ASF4;T+IUF:?*4Z[$>AS!-!F$-C M>(&(1 9GM+'E7SL)M2#H_VA(!4)*+<(,| (.CIPEX=^U/%EB\CIKP0HIC2 MO#RERQ*BUQI@7A)>'89B.I=R:D[(".@\2]"-1@.X<8N)UZ%81(-M#(896_!7WWGV S_UB8=:#$RSU8M7>'3MO;PZ<@IX3QXT969_'=+$-0D?0G M;9+^9!],-,U%(#M^<<*#M);!/0$!]NG,'6AA*G\[]:U?:I]#BG<O,%.*?:1.SY M=!SB*?1@T0COZYB A;7:0(\3QM"XG M!N!I)6CW,?]A!.U\;Y[YC:9Z*K'Z?12Z1W"[&!P-PJ/"=+KD&_5]TCH/8(] MK<7X@@E.>@!ZO?ZX!X$|IE+'>G35, UO/E+:,MIMZ]KF%@Y76% @*+ZIHXD$1 M/Q7(2^KW>TO|GH-P&CXZU-2I)#>_UX2 $QY N8NM$WE3\V6AIHG2L9)YMD1$ M.9,0-27XW,'OD^7)#4-?%6HDA=O-|&Y56'8(@!K'2W[^)\;,_%FE|A\ZP@S M6687LZ) @]6$D8A;3L0!$Q*]4^N0;WB7+@'UXB1=3_I3YQ)/CL5%*X)_J9RY-TR]-_MTR\M@_D>@3_\=#LX2$GW)"7=+]&27(+*A$M:UQ'17'CPOM/EJ3M3)5VKMVXB>Q/L9GAVF>ZS":}2I/^5RZ M,UYZ?9EQ)RLI4Y0+XWVJ)<1DZKA5@>K;DT.4+&KL?H6,;ZA1I)*PDS@K%/ M BS2>7F)R4DV[*J7*G/#2,',Y13LE8G<(^(2!+0T@

0001178253 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001178253 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:ProductMember 2024-01-01 2024-06-30 0001178253 scyx:ProductReturnsMember 2022-12-31 0001178253 us-gaap:AccountingStandardsUpdate202006Member 2024-06-30 0001178253 2023-02-01 2023-02-28 0001178253 us-gaap:ShortTermInvestmentsMember 2023-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2024-06-30 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember srt:MaximumMember scyx:AchivementOfTwoInterimMilestoneOfOngoingMarioStudyMember scyx:LicenseAgreementMember 2023-12-26 2023-12-26 0001178253 scyx:ProductReturnsMember 2023-01-01 2023-06-30 0001178253 us-gaap:RetainedEarningsMember 2023-12-31 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:LicenseTransferMember scyx:LicenseAgreementMember 2024-01-01 2024-06-30 0001178253 us-gaap:WarrantMember scyx:April2022PublicOfferingMember 2024-01-01 2024-06-30 0001178253 scyx:ExclusiveLicenseAndCollaborationAgreementMember 2024-04-01 2024-06-30 0001178253 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001178253 scyx:PrefundedWarrantsMember scyx:December2020PublicOfferingMember 2024-06-30 0001178253 us-gaap:WarrantMember scyx:WarrantsAssociatedWithLoanAgreementMember 2024-04-01 2024-06-30 0001178253 us-gaap:WarrantMember 2024-06-30 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001178253 2024-03-31 0001178253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0001178253 scyx:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 scyx:PrefundedWarrantsMember scyx:December2020PublicOfferingMember 2023-06-30 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:WarrantMember scyx:December2020PublicOfferingSeries2Member 2024-01-01 2024-06-30 0001178253 scyx:DiscountsAndChargebacksMember 2024-06-30 0001178253 us-gaap:LicenseAndServiceMember 2023-04-01 2023-06-30 0001178253 scyx:April2022PublicOfferingMember us-gaap:WarrantMember 2024-06-30 0001178253 scyx:DiscountsAndChargebacksMember 2023-01-01 2023-06-30 0001178253 us-gaap:OtherNoncurrentLiabilitiesMember 2021-12-31 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2023-12-31 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:LicenseAgreementMember 2023-01-01 2023-06-30 0001178253 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 us-gaap:RetainedEarningsMember 2024-03-31 0001178253 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001178253 us-gaap:ProductMember 2024-04-01 2024-06-30 0001178253 scyx:ProductRecallMember 2023-06-30 0001178253 us-gaap:WarrantMember scyx:December2020PublicOfferingSeries2Member 2023-04-01 2023-06-30 0001178253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0001178253 scyx:RebatesAndIncentivesMember 2023-12-31 0001178253 scyx:PrefundedWarrantsMember scyx:April2022PublicOfferingMember 2023-04-01 2023-06-30 0001178253 us-gaap:RetainedEarningsMember 2023-03-31 0001178253 scyx:TwoThousandAndFifteenInducementAwardPlanMember 2023-01-01 2023-06-30 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 scyx:WarrantsAssociatedWithLoanAgreementMember us-gaap:WarrantMember 2023-12-31 0001178253 scyx:TwoThousandAndFifteenInducementAwardPlanMember 2024-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:AchivementOfThresholdUpto200MillionMember scyx:LicenseAgreementMember scyx:RelaunchDateTwoMember 2023-12-26 2023-12-26 0001178253 2023-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2024-06-30 0001178253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-03-07 2019-03-07 0001178253 scyx:TwoThousandAndFourteenEmployeeStockPurchasePlanMember 2024-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:AchivementOfThresholdUpto750MillionTo1BillionMember scyx:LicenseAgreementMember scyx:RelaunchDateThreeMember 2023-12-26 2023-12-26 0001178253 2024-06-30 0001178253 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001178253 us-gaap:CommonStockMember 2023-12-31 0001178253 scyx:HerculesCapitalIncorporatedAndSiliconValleyBankAndOtherLendersMember scyx:LoanAgreementAmendmentMember 2023-03-30 0001178253 us-gaap:WarrantMember scyx:WarrantsAssociatedWithLoanAgreementMember 2024-01-01 2024-06-30 0001178253 scyx:ProductRecallMember 2024-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember srt:MaximumMember scyx:LicenseAgreementMember 2023-12-26 2023-12-26 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 2024-08-01 0001178253 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:LicenseTransferMember scyx:LicenseAgreementMember 2023-01-01 2023-06-30 0001178253 scyx:CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember 2023-01-01 2023-06-30 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2023-01-01 2023-01-01 0001178253 scyx:DiscountsAndChargebacksMember 2024-01-01 2024-06-30 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2023-12-31 0001178253 us-gaap:CommonStockMember 2024-03-31 0001178253 us-gaap:EmployeeStockOptionMember 2023-12-31 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001178253 srt:MaximumMember 2024-01-01 2024-06-30 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2024-06-30 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001178253 scyx:DiscountsAndChargebacksMember 2023-12-31 0001178253 scyx:TwoThousandAndFifteenInducementAwardPlanMember 2023-12-31 0001178253 scyx:RebatesAndIncentivesMember 2023-01-01 2023-06-30 0001178253 us-gaap:WarrantMember scyx:April2022PublicOfferingMember 2023-04-01 2023-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:AchivementOfThresholdUpto300MillionTo500MillionMember scyx:LicenseAgreementMember scyx:RelaunchDateTwoMember 2023-12-26 2023-12-26 0001178253 us-gaap:WarrantMember scyx:WarrantAssociatedWithDanforthMember 2024-04-01 2024-06-30 0001178253 us-gaap:ProductMember 2023-04-01 2023-06-30 0001178253 us-gaap:WarrantMember scyx:WarrantAssociatedWithDanforthMember 2024-01-01 2024-06-30 0001178253 us-gaap:DerivativeMember 2024-01-01 2024-06-30 0001178253 2023-04-01 2023-06-30 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2023-01-01 2023-06-30 0001178253 us-gaap:CorporateBondSecuritiesMember scyx:LongTermInvestmentMember 2023-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:LoanAgreementAmendmentMember 2021-05-13 2021-05-13 0001178253 scyx:ProductRecallMember 2022-12-31 0001178253 scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember 2023-12-31 0001178253 us-gaap:WarrantMember scyx:April2022PublicOfferingMember 2023-01-01 2023-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember 2024-06-30 0001178253 scyx:ProductReturnsMember 2023-12-31 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001178253 us-gaap:CommonStockMember 2022-12-31 0001178253 scyx:WholesalerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2019-03-07 0001178253 scyx:TwoThousandAndFourteenEquityIncentivePlanMember 2024-01-01 2024-01-01 0001178253 scyx:CompletionFuriCaresAndNatureClinicalStudiesMember scyx:LicenseAgreementMember 2023-12-26 2023-12-26 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 scyx:April2022PublicOfferingMember 2023-04-01 2023-06-30 0001178253 scyx:April2022PublicOfferingMember us-gaap:WarrantMember 2023-12-31 0001178253 us-gaap:WarrantMember scyx:WarrantsAssociatedWithLoanAgreementMember 2023-04-01 2023-06-30 0001178253 2023-06-30 0001178253 scyx:December2020PublicOfferingSeries2Member us-gaap:WarrantMember 2024-06-30 0001178253 scyx:LoanAgreementAmendmentMember 2023-03-30 0001178253 us-gaap:LicenseAndServiceMember 2024-01-01 2024-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember srt:MaximumMember scyx:LicenseAgreementMember scyx:RelaunchDateOneMember 2023-12-26 2023-12-26 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:AchivementOfThresholdUpto750MillionTo1BillionMember scyx:LicenseAgreementMember scyx:RelaunchDateTwoMember 2023-12-26 2023-12-26 0001178253 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 2022-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:LicenseTransferMember scyx:LicenseAgreementMember 2024-04-01 2024-06-30 0001178253 scyx:LongTermInvestmentMember 2024-06-30 0001178253 us-gaap:CommonStockMember 2023-03-31 0001178253 us-gaap:ProductMember 2023-01-01 2023-06-30 0001178253 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:AchivementOfThresholdUpto300MillionTo500MillionMember scyx:LicenseAgreementMember scyx:RelaunchDateThreeMember 2023-12-26 2023-12-26 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember srt:MaximumMember scyx:LicenseAgreementMember 2023-03-30 2023-03-30 0001178253 us-gaap:DerivativeMember 2023-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 scyx:RebatesAndIncentivesMember 2023-06-30 0001178253 us-gaap:WarrantMember scyx:WarrantsAssociatedWithLoanAgreementMember 2023-01-01 2023-06-30 0001178253 scyx:AgencyBondsMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember srt:MaximumMember scyx:LicenseAgreementMember scyx:RelaunchDateTwoMember 2023-12-26 2023-12-26 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2023-12-31 0001178253 us-gaap:EmployeeStockOptionMember 2024-06-30 0001178253 scyx:CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember 2024-04-01 2024-06-30 0001178253 scyx:WholesalerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001178253 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 scyx:TwoThousandAndTwentyFourEquityIncentivePlanMember 2023-12-31 0001178253 us-gaap:WarrantMember 2023-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:WarrantMember scyx:December2020PublicOfferingSeries2Member 2024-04-01 2024-06-30 0001178253 2018-03-01 0001178253 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2024-06-30 0001178253 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001178253 scyx:ProductReturnsMember 2023-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:AchivementOfThresholdUpto300MillionTo500MillionMember scyx:LicenseAgreementMember scyx:RelaunchDateOneMember 2023-12-26 2023-12-26 0001178253 us-gaap:CorporateBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2023-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001178253 scyx:TwoThousandAndFifteenInducementAwardPlanMember 2024-01-01 2024-06-30 0001178253 scyx:TermLoanMember scyx:HerculesCapitalIncorporatedAndSiliconValleyBankMember scyx:LoanAndSecurityAgreementMember 2021-05-13 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2023-12-31 0001178253 scyx:PrefundedWarrantsMember scyx:April2022PublicOfferingMember 2023-01-01 2023-06-30 0001178253 scyx:ProductReturnsMember 2024-06-30 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 scyx:ProductRecallMember 2024-01-01 2024-06-30 0001178253 scyx:DiscountsAndChargebacksMember 2023-06-30 0001178253 scyx:PrefundedWarrantsMember scyx:April2022PublicOfferingMember 2024-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember srt:ScenarioForecastMember scyx:LicenseAgreementMember 2024-07-01 2024-09-30 0001178253 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001178253 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001178253 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001178253 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001178253 us-gaap:WarrantMember scyx:WarrantAssociatedWithDanforthMember 2023-04-01 2023-06-30 0001178253 scyx:WarrantsAssociatedWithLoanAgreementMember us-gaap:WarrantMember 2024-06-30 0001178253 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 scyx:WarrantsAssociatedWithApril2022PublicOfferingMember us-gaap:WarrantMember 2023-12-31 0001178253 2024-01-01 2024-06-30 0001178253 srt:MaximumMember scyx:TwoThousandAndTwentyFourEquityIncentivePlanMember 2024-01-01 2024-06-30 0001178253 us-gaap:CashMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 scyx:CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember 2023-04-01 2023-06-30 0001178253 scyx:DanforthMember us-gaap:WarrantMember 2024-06-30 0001178253 2023-01-01 2023-12-31 0001178253 us-gaap:WarrantMember scyx:WarrantAssociatedWithDanforthMember 2023-01-01 2023-06-30 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0001178253 scyx:DanforthMember us-gaap:WarrantMember 2023-12-31 0001178253 scyx:CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember 2024-01-01 2024-06-30 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:LicenseTransferMember scyx:LicenseAgreementMember 2023-04-01 2023-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember

scyx:LicenseAgreementMember 2023-06-01 2023-06-30 0001178253 scyx:December2020PublicOfferingSeries2Member us-gaap:WarrantMember 2023-12-31 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 us-gaap:LicenseAndServiceMember 2023-01-01 2023-06-30 0001178253 us-gaap:ShortTermInvestmentsMember 2024-06-30 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 scyx:SixPercentConvertibleSeniorNotesDueTwoThousandAndTwentyFiveMember 2024-06-30 0001178253 scyx:April2022PublicOfferingMember 2023-01-01 2023-06-30 0001178253 2018-03-01 2018-03-01 0001178253 scyx:TermLoanMember scyx:HerculesCapitalIncorporatedAndSiliconValleyBankMember scyx:LoanAndSecurityAgreementMember 2021-05-13 2021-05-13 0001178253 2024-04-01 2024-06-30 0001178253 us-gaap:LicenseAndServiceMember 2024-04-01 2024-06-30 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001178253 scyx:ProductReturnsMember 2024-01-01 2024-06-30 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2024-01-01 2024-06-30 0001178253 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001178253 scyx:WholesalerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001178253 scyx:PrefundedWarrantsMember scyx:April2022PublicOfferingMember 2023-06-30 0001178253 scyx:ProductRecallMember 2023-01-01 2023-06-30 0001178253 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001178253 scyx:TwoThousandAndTwentyFourEquityIncentivePlanMember 2024-06-30 0001178253 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001178253 scyx:RebatesAndIncentivesMember 2024-06-30 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2023-12-31 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:SuccessfulCompletionOfMarioStudyMember scyx:LicenseAgreementMember 2023-12-26 2023-12-26 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:AchivementOfThresholdUpto750MillionTo1BillionMember scyx:LicenseAgreementMember scyx:RelaunchDateOneMember 2023-12-26 2023-12-26 0001178253 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2023-12-31 0001178253 us-gaap:WarrantMember scyx:December2020PublicOfferingSeries2Member 2023-01-01 2023-06-30 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2024-04-01 2024-06-30 0001178253 us-gaap:RetainedEarningsMember 2024-06-30 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:LicenseAgreementMember 2023-04-01 2023-06-30 0001178253 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2024-06-30 0001178253 scyx:RebatesAndIncentivesMember 2022-12-31 0001178253 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001178253 us-gaap:FairValueInputsLevel2Member scyx:CorporateAndAgencyBondSecuritiesMember 2023-12-31 0001178253 scyx:ExclusiveLicenseAndCollaborationAgreementMember 2023-04-01 2023-06-30 0001178253 scyx:December2020PublicOfferingMember us-gaap:WarrantMember 2024-06-30 0001178253 scyx:ProductRecallMember 2023-12-31 0001178253 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:FairValueInputsLevel2Member scyx:CorporateAndAgencyBondSecuritiesMember 2024-06-30 0001178253 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001178253 us-gaap:RetainedEarningsMember 2023-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:AchivementOfThresholdUpto200MillionMember scyx:LicenseAgreementMember scyx:RelaunchDateThreeMember 2023-12-26 2023-12-26 0001178253 scyx:RestrictedCashMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 scyx:ExclusiveLicenseAndCollaborationAgreementMember 2023-01-01 2023-06-30 0001178253 scyx:RebatesAndIncentivesMember 2024-01-01 2024-06-30 0001178253 scyx:December2020PublicOfferingMember us-gaap:WarrantMember 2023-12-31 0001178253 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeMember 2023-12-31 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember scyx:AchivementOfThresholdUpto200MillionMember scyx:LicenseAgreementMember scyx:RelaunchDateOneMember 2023-12-26 2023-12-26 0001178253 us-gaap:CommonStockMember 2024-06-30 0001178253 scyx:RestrictedCashMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001178253 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001178253 scyx:ExclusiveLicenseAndCollaborationAgreementMember 2024-01-01 2024-06-30 0001178253 us-gaap:OtherNoncurrentLiabilitiesMember 2022-12-31 0001178253 2023-03-31 0001178253 2023-01-01 2023-06-30 0001178253 us-gaap:RetainedEarningsMember 2022-12-31 0001178253 us-gaap:WarrantMember scyx:April2022PublicOfferingMember 2024-04-01 2024-06-30 0001178253 scyx:DiscountsAndChargebacksMember 2022-12-31 0001178253 scyx:WarrantsAssociatedWithApril2022PublicOfferingMember us-gaap:WarrantMember 2024-06-30 0001178253 scyx:LongTermInvestmentMember 2023-12-31 0001178253 scyx:SeniorConvertibleNotePurchaseAgreementMember 2023-04-01 2023-06-30 0001178253 scyx:GlaxosmithklineIntellectualPropertyMember srt:MaximumMember scyx:LicenseAgreementMember scyx:RelaunchDateThreeMember 2023-12-26 2023-12-26 0001178253 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001178253 us-gaap:CommonStockMember 2023-06-30 0001178253 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001178253 us-gaap:DerivativeMember 2024-06-30 0001178253 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001178253 us-gaap:CorporateBondSecuritiesMember us-gaap:ShortTermInvestmentsMember 2024-06-30 0001178253 scyx:AgencyBondsMember us-gaap:ShortTermInvestmentsMember 2024-06-30 0001178253 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputCreditSpreadMember 2024-06-30 pure utr:sqft shares iso4217:USD shares iso4217:USD scyx:Tranche 0001178253 false --12-31 Q2 10-Q true 2024-06-30 2024 false 001-36365 SCYNEXIS, Inc. DE 56-2181648 1 Evertrust Plaza 13th Floor Jersey City NJ 07302-6548 201 884-5485 Common Stock, par value $0.001 per share SCYX NASDAQ Yes Yes Non-accelerated Filer true false false 37856463 25994000 34050000 47044000 40312000 1418000 5548000 233000 2463000 19509000 19363000 380000 380000 94578000 102116000 10657000 23594000 175000 175000 163000 163000 2233000 2364000 107806000 128412000 5350000 7149000 5498000 7495000 1229000 1189000 372000 340000 0 130000 12784000 0 25233000 16303000 1817000 2727000 17962000 21680000 0 12159000 2388000 2581000 47400000 55450000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 0.001 0.001 150000000 150000000 37856463 37856463 37207799 37207799 41000 40000 429659000 428169000 -369294000 -355247000 60406000 72962000 107806000 128412000 0 468000 0 1598000 736000 130986000 2109000 130986000 736000 131454000 2109000 132584000 0 426000 0 562000 6807000 7040000 14019000 13875000 3166000 7474000 6835000 12314000 9973000 14940000 20854000 26751000 -9237000 116514000 -18745000 105833000 421000 1998000 822000 2256000 1130000 737000 2402000 1325000 197000 1249000 403000 2695000 5761000 -8214000 -3848000 13459000 28000 42000 196000 -364000 -5221000 5746000 5221000 -17449000 -14458000 122260000 -13524000 88384000 0 0 523000 -14458000 122260000 -14047000 88384000 -0.3 2.56 -0.29 1.85 -0.3 2.46 -0.29 1.82 48511656 47837393 48379256 47797731 48511656 49923361 48379256 49166251 -14047000 88384000 0 304000 1464000 1435000 621000 -100000 822000 2256000 -3848000 13459000 196000 -364000 131000 110000 0 514000 263000 -4131000 165000 -2230000 25000000 146000 19249000 0 243000 0 4563000 -1759000 -2521000 -1997000 1562000 -870000 4369000 -161000 -5904000 -14867000 55475000 10719000 26941000 17545000 20557000 6826000 -6384000 4000 40000 0 36383000 263000 25000 4000 0 -18000 -15000 -36620000 -8056000 12471000 34593000 46032000 26537000 58503000 420000 2828000 1721000 1434000 <p id="bm_1___description_of_business_and_basis" style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">1. Description of Business and Basis of Preparation</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Organization</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, and is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. The Company is developing its proprietary class of enfumafungin-derived antifungal compounds (“fungerps”) as broad-spectrum, systemic antifungal agents for multiple fungal indications. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the “fungerp” family, including SCY-247, in preclinical stages of development. In June 2021, the U.S. Food and Drug Administration (“FDA”) approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (“VVC”), also known as vaginal yeast infection, and in December 2022, the Company announced that the FDA approved a second indication for BREXAFEMME for the reduction in the incidence of recurrent vulvovaginal candidiasis (“RVVC”).</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">In March 2023, the Company entered into a license agreement (the "GSK License Agreement") with GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK") in which the Company granted GSK an exclusive (even as to the Company and its affiliates), royalty-bearing, sublicensable license for the development and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications, in all countries other than Greater China and certain other countries already licensed to third parties.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Following a review by GSK of the manufacturing process and equipment at the vendor that manufactures the ibrexafungerp drug substance, the Company became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp. Current FDA draft guidance recommends segregating the manufacture of non-antibacterial beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people. In the absence of the recommended segregation, there is a risk of cross contamination. It is not known whether any ibrexafungerp has been contaminated with a beta-lactam compound and the Company has not received reports of any adverse events due to the possible beta-lactam cross contamination. Nonetheless, out of an abundance of caution and in line with GSK’s recommendation, the Company has recalled BREXAFEMME® (ibrexafungerp tablets) from the market and placed a temporary hold on clinical studies of ibrexafungerp, including the Phase 3 MARIO study.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The patient-level and clinical product recall is ongoing and the Company is working with an experienced vendor to manage the process. In September 2023, after the Company announced its voluntary clinical hold, the FDA concurred with the Company’s voluntary hold and placed a clinical hold. The Company is working with the FDA to discuss paths for resolution of this issue. The clinical hold and recall affect the Company's two ongoing clinical studies: the Phase 3 MARIO study and a Phase 1 lactation study. The hold does not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. The FDA determined that the compassionate use program for ibrexafungerp, which provides ibrexafungerp to patients with limited or no other treatment options, can continue provided the patient’s treating physician concludes a favorable benefit-risk assessment and the patient is made aware of and consents to the risk. This applies to patients currently in the program, as well as for new patients, pending confirmation of available supply. The Company’s preclinical stage compound, SCY-247, is not affected by these developments. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The Company had an accumulated deficit of $369.3 million at June 30, 2024. The Company’s capital resources primarily comprised cash and cash equivalents and investments of $83.7 million at June 30, 2024. While the Company believes its capital resources are sufficient to fund the Company’s on-going operations for a period of at least 12 months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements, the Company's liquidity could be materially affected over this period by: (1) its ability to raise additional capital through equity offerings, debt financings, or other non-dilutive third-party funding; (2) costs associated with new or existing strategic alliances, or licensing and collaboration arrangements; (3) negative regulatory events or unanticipated costs related to its development of SCY-247 and ibrexafungerp; (4) its ability to successfully achieve the development, regulatory, and commercial milestones under its License Agreement with GSK; and (5) any other unanticipated material negative events or costs. One or more of these events or costs could materially affect the Company’s liquidity. If the Company is unable to meet its obligations when they become due, the Company may have to delay expenditures, reduce the scope of its research and development programs, or make significant changes to its operating plan. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany balances and transactions are eliminated in consolidation. </p><p

style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Use of Estimates The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and judgments include: revenue recognition including gross to net estimates and the identification of performance obligations in licensing arrangements; estimates for the relative standalone selling price and measure of progress under the input method for the GSK License Agreement; estimates for product recall reserves; determination of the fair value of stock-based compensation grants; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimates and assumptions utilized in measuring the fair values of the warrant and derivative liabilities each reporting period. Unaudited Condensed Consolidated Financial Information The accompanying unaudited condensed consolidated financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”), as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three and six months ended June 30, 2024, are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 28, 2024. -369300000 83700000 2. Summary of Significant Accounting Policies The accompanying unaudited condensed consolidated financial statements and notes follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December 31, 2023, except as described below. Basic and Diluted Net (Loss) Income per Share of Common Stock The Company calculates net (loss) income per common share in accordance with ASC 260, Earnings Per Share. Basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined by dividing net (loss) income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 includes the outstanding prefunded warrants to purchase 7,516,267 and 3,200,000 shares of common stock issued in the April 2022 public offering and December 2020 public offering. Diluted net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined as follows (in thousands, except share and per share amounts): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:45.5%;"></td><td style="width:1%;"></td><td style="width:10.74%;"></td><td style="width:1%;"></td><td style="width:1.18%;"></td><td style="width:1%;"></td><td style="width:10.74%;"></td><td style="width:1%;"></td><td style="width:1.18%;"></td><td style="width:1%;"></td><td style="width:10.74%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Net (loss) income allocated to common shares </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,458</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,260 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(14,047</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,384 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dilutive effect of convertible debt </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid

#000000;text-align:center;"> 433 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,047</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net (loss) income allocated to common shares</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (14,458 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">122,693</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 14,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 89,431 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Weighted average common shares outstanding – basic </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 48,511,656 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,837,393 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 48,379,256 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,797,731 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dilutive effect of convertible debt </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dilutive effect of restricted stock units </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> —

</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 947,768 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 230,320 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average common shares outstanding – diluted </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 48,511,656 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,923,361 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 48,379,256 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,166,251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net (loss) income per share – diluted </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.30</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.46 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.29</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.82 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The following potentially dilutive shares of common stock and outstanding restricted stock units that contain certain performance contingencies have not been included in the computation of diluted net (loss) income per share for the three and six months ended June 30, 2024 and 2023, as the result would be anti-dilutive or the performance contingencies have not been met: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:45.14%;"></td> <td style="width:1%;"></td> <td style="width:10.74%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.94%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.94%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.24%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt

solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding stock options </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,970,536 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,970,536 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding restricted stock units </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,263,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 400,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,263,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 400,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with December 2020 public offering - Series 2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,800,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with April 2022 public offering </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with Loan Agreement </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock associated with March 2019 Notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants to purchase common stock associated with Danforth </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22,493,164 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,419,347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22,493,164 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,419,347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Reclassification of Prior Year Amounts Certain prior year amounts within the changes in operating assets and liabilities on the unaudited condensed consolidated statement of cash flows and certain prior year accrued expenses have been reclassified for consistency with the current year presentation. Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity's Own Equity: Accounting for Convertible Instruments and Contracts in and Entity's Own Equity ("ASU 2020-06"). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. The Company adopted ASU 2020-06 on <span style="color:#000000;white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2024 and the adoption did not materially impact the unaudited condensed consolidated financial statements. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which introduced new guidance on disclosures for reportable segments and significant segment expenses, including for entities with a single reportable segment. This guidance is effective for the Company for annual reporting periods beginning January 1, 2024 and interim periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which introduced new guidance on disclosures for income taxes, including enhancements to the rate reconciliation and income taxes paid disclosures. This guidance is effective for the Company for annual reporting periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements.
 Basic and Diluted Net (Loss) Income per Share of Common Stock The Company calculates net (loss) income per common share in accordance with ASC 260, Earnings Per Share. Basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined by dividing net (loss) income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 includes the outstanding prefunded warrants to purchase 7,516,267 and 3,200,000 shares of common stock issued in the April 2022 public offering and December 2020 public offering. Diluted net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined as follows (in thousands, except share and per share amounts): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:45.5%;"></td><td style="width:1%;"></td><td style="width:10.74%;"></td><td style="width:1%;"></td><td style="width:1.18%;"></td><td style="width:1%;"></td><td style="width:10.74%;"></td><td style="width:1%;"></td><td style="width:1.18%;"></td><td style="width:1%;"></td><td style="width:10.74%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Net (loss) income allocated to common shares </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(14,458</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,260 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(14,047</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:center;"> 88,384 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dilutive effect of convertible debt </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 433 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,047</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net (loss) income allocated to common shares</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (14,458 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">122,693</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (14,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 89,431 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> <span style="

align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 230,320 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average common shares outstanding – diluted </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 48,511,656 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,923,361 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 48,379,256 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,166,251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net (loss) income per share – diluted </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.30</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.46 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.82 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The following potentially dilutive shares of common stock and outstanding restricted stock units that contain certain performance contingencies have not been included in the computation of diluted net (loss) income per share for the three and six months ended June 30, 2024 and 2023, as the result would be anti-dilutive or the performance contingencies have not been met: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:45.14%;"></td> <td style="width:1%;"></td> <td style="width:10.74%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.94%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.94%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.24%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span style="white-space:pre-

wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding stock options </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,970,536 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,970,536 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding restricted stock units </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,263,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 400,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,263,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,800,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,800,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with April 2022 public offering </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with Loan Agreement </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock associated with March 2019 Notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants to purchase common stock associated with Danforth </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22,493,164 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,419,347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22,493,164 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,419,347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> The Company calculates net (loss) income per common share in accordance with ASC 260, Earnings Per Share. Basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined by dividing net (loss) income applicable to common stockholders by the weighted average number of common shares outstanding during the period. Per ASC 260, Earnings Per Share, the weighted average number of common shares outstanding utilized for determining the basic net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 includes the outstanding prefunded warrants to purchase 7,516,267 and 3,200,000 shares of common stock issued in the April 2022 public offering and December 2020 public offering. Diluted net (loss) income per common share for the three and six months ended June 30, 2024 and 2023 was determined as follows (in thousands, except share and per share amounts): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:45.5%;"></td> <td style="width:1%;"></td> <td style="width:10.74%;"></td> <td style="width:1%;"></td> <td style="width:1.18%;"></td> <td style="width:1%;"></td> <td style="width:10.74%;"></td> <td style="width:1%;"></td> <td style="width:1.18%;"></td> <td style="width:1%;"></td> <td style="width:10.74%;"></td> <td style="width:1%;"></td> <td style="width:1.18%;"></td> <td style="width:1%;"></td> <td style="width:10.74%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six

*Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Net (loss) income allocated to common shares </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(14,458</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,260 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(14,047</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,384 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dilutive effect of convertible debt </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 433 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,047</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net (loss) income allocated to common shares</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (14,458 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">122,693</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (14,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 89,431 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted average common shares outstanding – basic </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 48,511,656 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,837,393 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 48,379,256 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 47,797,731 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dilutive effect of convertible debt </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Dilutive effect of restricted stock units </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 947,768 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 48,511,656 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,923,361 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 48,379,256 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,166,251 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-

align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net (loss) income per share – diluted </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(0.30</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.46 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.82 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>   7516267 7516267 3200000 3200000 -14458000 122260000 -14047000 88384000 0 433000 0 1047000 -14458000 122693000 -14047000 89431000 48511656 47837393 48379256 47797731 0 1138200 0 1138200 0 947768 0 230320 48511656 49923361 48379256 49166251 -0.3 2.46 -0.29 1.82 The following potentially dilutive shares of common stock and outstanding restricted stock units that contain certain performance contingencies have not been included in the computation of diluted net (loss) income per share for the three and six months ended June 30, 2024 and 2023, as the result would be anti-dilutive or the performance contingencies have not been met: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:45.14%;"></td> <td style="width:1%;"></td> <td style="width:10.74%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.94%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.94%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:11.24%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six Months Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding stock options </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,970,536 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,970,536 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Outstanding restricted stock units </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,263,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 400,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-

align:bottom;text-align:center;"> 3,263,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 400,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with December 2020 public offering - Series 2 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,800,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,800,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with April 2022 public offering </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with Loan Agreement </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Common stock associated with March 2019 Notes </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Warrants to purchase common stock associated with Danforth </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22,493,164 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,419,347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22,493,164 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,419,347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table> 2842808 1970536 2842808 1970536 3263345 400000 3263345 400000 0 6800000 0 6800000 15000000 15000000 15000000 15000000 198811 198811 198811 198811 1138200 0 1138200 0 50000 50000 50000 50000 22493164 24419347 22493164 24419347 Reclassification of Prior Year Amounts Certain prior year amounts within the changes in operating assets and liabilities on the unaudited condensed consolidated statement of cash flows and certain prior year accrued expenses have been reclassified for consistency with the current year presentation. Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options and Derivatives and Hedging—Contracts in Entity's Own Equity: Accounting for Convertible Instruments and Contracts in and Entity's Own Equity ("ASU 2020-06"). The amendments in ASU 2020-06 reduce the number of accounting models for convertible debt instruments and revises certain guidance relating to the derivative scope exception and earnings per share. The amendments in ASU 2020-06 are effective for public business entities that meet the definition of a SEC filer and a smaller reporting company for fiscal years beginning after December 15, 2023, and interim periods within those years. The Company adopted ASU 2020-06 on January 1, 2024 and the adoption did not materially impact the unaudited condensed consolidated financial statements. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which introduced new guidance on disclosures for reportable segments and significant segment expenses, including for entities with a single reportable segment. This guidance is effective for the Company for annual reporting periods beginning January 1, 2024 and interim periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-07 will have on its consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, which introduced new guidance on disclosures for income taxes, including enhancements to the rate reconciliation and income taxes paid disclosures. This guidance is effective for the Company for annual reporting periods beginning January 1, 2025. As a smaller reporting company, the Company is currently evaluating the impact ASU 2023-09 will have on its consolidated financial statements.
  true 2024-01-01 true 3. Investments The following table summarizes the investments at June 30, 2024 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> As of June 30, 2024 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;">

</td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Maturities < 1 Year </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">44,527</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (47 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">44,486</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Agency bonds</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,517</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,515</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total short-term investments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 47,044 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (49 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 47,001 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt

double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Maturities > 1 Year </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,657</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (23 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,644</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total investments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,657 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (23 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,644 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> As of December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,286</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(13</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35,298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Agency bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,026 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,032 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40,312</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (13 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Corporate bonds</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23,594 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">143</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 23,594 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">143</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,728</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total investments</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 23,594 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 143 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 23,728 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company carries investments at amortized cost. As of June 30, 2024 and December 31, 2023, the fair value of the corporate and agency bonds totals $57.6 million and $64.1 million, respectively, which is determined based on “Level 2” inputs, which consist of quoted prices for similar assets in active markets. The Company has evaluated the unrealized loss position in the corporate and agency bonds as of the balance sheet dates and did not consider it to be indicative of an other-than-temporary impairment as the securities are highly-rated and the Company expects to realize the full principal amount at maturity. The following table summarizes the investments at June 30, 2024 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.07%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td

style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.182%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized
Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> As of June 30, 2024 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;">

2,515 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">47,044</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(49)</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 47,001 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#fffffc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right

width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(23</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,644 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td>

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,032 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total short-term investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40,312</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(13</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 40,330 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Maturities > 1 Year </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,594</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 143 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23,728 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 23,594 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">143</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (9 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,728</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 44527000 6000 47000 44486000 2517000 0 2000 2515000 47044000 6000 49000 47001000 10657000 10000 23000 10644000 10657000 10000 23000 10644000 35286000 25000 13000 35298000 5026000 6000 0 5032000 40312000 31000 13000 40330000 23594000 143000 9000 23728000 23594000 143000 9000 23728000 57600000 64100000 <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">4. Prepaid Expenses and Other Current Assets</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">Prepaid expenses and other current assets consisted of the following (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.16%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:14.780000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:14.780000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Prepaid research and development services</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">196</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Prepaid insurance</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">651</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">264</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other prepaid expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">213</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">182</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#fffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other current assets</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">554</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,906</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total prepaid expenses and other current assets</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,418 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,548 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Prepaid expenses and other current assets consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.16%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td

style="width:14.7800000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:14.7800000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Prepaid research and development services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Prepaid insurance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 651 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 264 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other prepaid expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 213 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 182 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 554 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,906 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total prepaid expenses and other current assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,418</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,548 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 0 196000 651000 264000 213000 182000 554000 4906000 1418000 5548000 5. Accrued Expenses Accrued expenses consisted of the following (in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:63.16%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:14.7800000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:14.7800000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,348 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,830</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued employee bonus compensation</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">906</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,692</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other accrued expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">862</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,040</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued product recall</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,382</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,933</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total accrued expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 5,498 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,495</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div> <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued expenses consisted of the following (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:63.16%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:14.780000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.64%;"></td> <td style="width:1%;"></td> <td style="width:14.780000000000001%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accrued research and development expenses</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,348 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,830 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued employee bonus compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 906 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,692 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-

align:bottom;text-align:center;"> 862 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,040 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued product recall </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,933 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total accrued expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,498</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7,495 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 2348000 2830000 906000 1692000 862000 1040000 1382000 1933000 5498000 7495000 6. Borrowings Loan Agreement On May 13, 2021 (the “Closing Date”), the Company entered into the Loan and Security Agreement (the “Loan Agreement”) with Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank) (the "Lenders") for an aggregate principal amount of $60.0 million (the “Term Loan”). Pursuant to the Loan Agreement, the Term Loan was available to the Company in four tranches, subject to certain terms and conditions. In connection with the entering into of the GSK License Agreement, the Company entered into a First Amendment and Consent to Loan and Security Agreement with the Lenders pursuant to which the Lenders consented to the Company entering into the GSK License Agreement and the Company agreed to pay to the Lenders an amount equal to the sum of (i) all outstanding principal plus all accrued and unpaid interest with respect to the amounts loaned under the Loan Agreement (approximately $35.4<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million), (ii) the prepayment fee payable under the Loan Agreement ($262,500), (iii) the final payment payable under the Loan Agreement ($1,382,500), and (iv) all other sums, if any, that shall have become due and payable with respect to loan advances under the Loan Agreement. Upon receipt by the Company of the $90.0 million upfront payment from GSK in May 2023, all amounts payable under the Loan Agreement were fully paid. In connection with the repayment of those amounts due, in May 2023, the Company and the Lenders executed a payoff letter confirming the amounts due under the Loan Agreement, and the Company’s confirmation that the Loan Agreement was terminated. For the three and six months ended June 30, 2023, the Company recognized $1.7 million and $2.0 million, respectively, in amortization for the remaining debt issuance costs and discount associated with the Loan Agreement which was fully paid in May 2023. March 2019 Note Purchase Agreement On March 7, 2019, the Company entered into a Senior Convertible Note Purchase Agreement (the “March 2019 Note Purchase Agreement”) with Puissance. Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $16.0 million aggregate principal amount of its 6.0% Senior Convertible Notes due 2025 (“March 2019 Notes”), resulting in $14.7 million in net proceeds after deducting $1.3 million for an advisory fee and other issuance costs. As of June 30, 2024 and December 31, 2023, the Company’s March 2019 Notes consist of the convertible debt balance of $12.8 million and $12.0 million and the bifurcated embedded conversion option derivative liability of zero and $0.2 million, respectively. In connection with the Company’s issuance of its March 2019 Notes, the Company bifurcated the embedded conversion option, inclusive of the interest make-whole provision and make-whole fundamental change provision, and recorded the embedded conversion option as a long-term derivative liability in the Company’s balance sheet in accordance with ASC 815, Derivatives and Hedging, at its initial fair value of $7.0 million as the interest make-whole provision is settled in shares of common stock. The convertible debt and derivative liability associated with the March 2019 Notes are presented in total on the accompanying unaudited condensed consolidated balance sheets as the convertible debt and derivative liability. The derivative liability will be remeasured at each reporting period using the binomial lattice model with changes in fair value recorded in the statements of operations in other (income) expense. For the three months ended June 30, 2024 and 2023, the Company recognized gains of $28,000 and $42,000, respectively, on the fair value adjustment for the derivative liability. For the six months ended June 30, 2024 and 2023, the Company recognized a gain of $0.2 million and a loss of $0.4 million, respectively, on the fair value adjustment for the derivative liability. <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;">For the three months ended June 30, 2024 and 2023, the Company recognized $0.4 million and $0.3 million, respectively, in amortization of debt issuance costs and discount related to the March 2019 Notes. For the six months ended June 30, 2024 and 2023, the Company recognized $0.8 million and $0.3 million, respectively, in amortization of debt issuance costs and discount related to the March 2019 Notes. The Company estimated the fair value of the convertible debt and derivative liability for the March 2019 Notes using a binomial lattice valuation model and Level 3 inputs. At June 30, 2024 and December 31, 2023, the fair value of the convertible debt and derivative liability for the March 2019 Notes is $12.8 million and $12.7 million, respectively. The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased.   The March 2019 Notes constitute general, senior unsecured obligations of the Company. Other Liabilities In February 2021, the Company partnered with Amplity for the commercial launch of BREXAFEMME for the treatment of VVC. Under the terms of the agreement with Amplity, the Company was to utilize Amplity's commercial execution and resources for sales force, remote engagement, training, market access and select operations services. In October 2022, the Company announced that it was actively pursuing a U.S. commercialization partner to out-license BREXAFEMME in order to refocus the Company's resources on the further clinical development of ibrexafungerp for severe, hospital-based indications. As a result, the Company wound down its promotional activities associated with BREXAFEMME. On November 30, 2022, the Company terminated the agreement with Amplity. Under the terms of the original agreement, Amplity deferred a portion of its direct service fees in the first two years (2021 and 2022) that accrued interest at an annual rate of 12.75% ("Deferred Fees"). The Deferred Fees of $5.8 million as of December 31, 2022, classified as other liabilities on the consolidated balance sheet, were fully paid as of February 2023. 60000000 4 35400000 262500 1382500 90000000 1700000 2000000 2019-03-07 16000000 14700000 1300000 12800000 12000000 0 200000 7000000 28000000 42000000 200000 -400000 400000 300000 800000 300000 12800000 12700000 The March 2019 Notes bear interest at a rate of 6.0% per annum payable semiannually in arrears on March 15 and September 15 of each year, beginning September 15, 2019. The March 2019 Notes will mature on March 15, 2025, unless earlier converted, redeemed or repurchased. 0.06 2025-03-15 0.1275 0.1275 5800000 7. Commitments and Contingencies Leases On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey, that the Company identified as an operating lease under ASC 842 (the "Lease"). The lease term is eleven years from August 1, 2018, the commencement date, with total lease payments of $7.3 million over the lease term. The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years.   The security deposit is classified as restricted cash in the accompanying unaudited condensed consolidated balance sheets. The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:43.657%;"></td><td style="width:1.12%;"></td><td style="width:1%;"></td><td style="width:10.844000000000001%;"></td><td style="width:1%;"></td><td style="width:1.12%;"></td><td style="width:1%;"></td><td style="width:10.844000000000001%;"></td><td style="width:1%;"></td><td style="width:1.02%;"></td><td style="width:1%;"></td><td style="width:10.825%;"></td><td style="width:1%;"></td><td style="width:1.12%;"></td><td style="width:1%;"></td><td style="width:11.445%;"></td><td style="width:1%;"></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended June 30, </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Operating lease cost </td><td style="white-space:pre-wrap;vertical-align:top;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;min-width:fit-content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">166</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 166 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">332</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease cost </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total operating lease expense </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">193</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 212 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">336</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 436 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash paid for amounts included in the measurement of operating lease liability </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">181</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 177 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">355</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Remaining Lease term (years)</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.09</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Future minimum lease payments for the Lease as of June 30, 2024 are as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.48%;"></td> <td style="width:1.9%;"></td> <td style="width:1%;"></td> <td style="width:18.62%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 368 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-

width:fit-content;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 744 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 759 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 774 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2028 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 790 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 466 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,901</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The presentations of the operating lease liability as of June 30, 2024 are as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:77.42%;"></td> <td style="width:2%;"></td> <td style="width:1%;"></td> <td style="width:18.58%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value of future minimum lease payments</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,760 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease liability, current portion </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">372</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease liability, long-term portion</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,388</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total operating lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,760 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Difference between future minimum lease payments and discounted cash flows </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,141 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> </table> License Arrangement with Potential Future Expenditures As of June 30, 2024, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, executed in May 2013, the Company exclusively licensed from Merck its rights to ibrexafungerp in the field of human health. In January 2014, Merck assigned the patents related to ibrexafungerp that it had exclusively licensed to the Company. Ibrexafungerp is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck was originally eligible to receive milestone payments from the Company that could total $19.0 million upon occurrence of specific events, including initiation of a Phase 2 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets, and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of ibrexafungerp. The aggregate royalties are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the ibrexafungerp compound (the "Deferred Milestone"). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the ibrexafungerp compound. In December 2016 and January 2018, the Company entered into second and third amendments to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment. In January 2019, a milestone payment became due to Merck as a result of the initiation of the VANISH Phase 3 VVC program and was paid in March 2019. On December 2, 2020, the Company entered into a fourth amendment to the license agreement with Merck. The amendment eliminates two cash milestone payments that the Company would have paid to Merck upon the first filing of an NDA, triggered by the FDA acceptance for filing of the Company's NDA for ibrexafungerp for the treatment of VVC, and first marketing approval in the U.S. Such cash milestone payments would have been creditable against future royalties owed to Merck on net sales of ibrexafungerp. With the amendment, these milestones will not be paid in cash and, accordingly, credits will not accrue. Pursuant to the amendment, the Company will also forfeit the credits against future royalties that it had accrued from a prior milestone payment already paid to Merck. All other key terms of the license agreement are unchanged. Legal Proceedings On November 7, 2023, a securities class action was filed by Brian Feldman against the Company and certain of the Company's executives in the United States District Court, District of New Jersey, alleging that, during the period from March 31, 2023 to September 22, 2023, the Company made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects, alleging specifically that the Company failed to disclose to investors: (1) that the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination; (2) that the Company did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP); (3) that, due to the substantial risk of cross-contamination, the Company were reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies; and (4) as a result of the foregoing, the Company's statements about its business, operations, and prospects were materially misleading and/or lacked a reasonable basis. The complaint seeks unspecified damages, interest, fees and costs on behalf of all persons and entities who purchased and/or acquired shares of the Company's common stock between March 31, 2023 to September 22, 2023. On May 1, 2024, and again on June 4, 2024, purported shareholder derivative complaints were filed in the United States District Court, District of New Jersey. The complaints name the Company's directors and certain of its officers and assert state and federal claims based on the same alleged misstatements as the securities class action complaint. We disagree with the allegations and intend to defend these litigations vigorously and the Company has not recognized any expense for these contingencies. 19275 P11Y 7300000 The Company has the option to renew for two consecutive five-year periods from the end of the first term and the Company is not reasonably certain that the option to renew the Lease will be exercised. Under the Lease, the Company furnished a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which was reduced by fifty-five thousand dollars on the first anniversary of the commencement date. The security deposit will continue to be reduced by fifty-five thousand dollars every two years on the commencement date anniversary for eight years. true P5Y 300000 55000 <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes certain quantitative information associated with the amounts recognized in the unaudited condensed consolidated financial statements for the Lease (dollars in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:43.657%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:10.844000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:10.844000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1.02%;"></td> <td style="width:1%;"></td> <td style="width:10.825%;"></td> <td style="width:1%;"></td> <td style="width:1.12%;"></td> <td style="width:1%;"></td> <td style="width:11.445%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended June 30,</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended June 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease cost</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 166 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">166</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Variable lease cost </td> <td style="white-space:pre-wrap;vertical-align:top;">

</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 27 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 46 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 104 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total operating lease expense </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">193</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 212 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">336</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 436 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left,"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Remaining Lease term (years) </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.09 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.59 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Discount rate </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> 166000 166000 332000 332000 27000 46000 4000 104000 193000 212000 336000 436000 181000 177000 362000 355000 P5Y1M2D P5Y7M2D 0.15 0.15 Future minimum lease payments for the Lease as of June 30, 2024 are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77.48%;"></td> <td style="width:1.9%;"></td> <td style="width:1%;"></td> <td style="width:18.62%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2024 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 368 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 744 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 759 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#fffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2027 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 774 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">2028 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 790 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 466 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,901</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 368000 744000 759000 774000 790000 466000 3901000 <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The presentations of the operating lease liability as of June 30, 2024 are as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:77.42%;"></td> <td style="width:2%;"></td> <td style="width:1%;"></td> <td style="width:18.58%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Present value of future minimum lease payments</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,760 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Operating lease liability, current portion </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">372</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease liability, long-term portion</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,388</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total operating lease liability</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,760 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Difference between future minimum lease payments and discounted cash flows </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,141 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 2760000 372000 2388000 2760000 1141000 19000000 8. Stockholders’ Equity Authorized, Issued, and Outstanding Common Stock The Company’s authorized common stock has a par value of $0.001 per share and consists of 150,000,000 shares as of June 30, 2024, and December 31, 2023, 37,856,463 and 37,207,799 shares were issued and outstanding at June 30, 2024 and December 31, 2023, respectively. For the three and six months ended June 30, 2023, 3,787,400 and 4,150,400 of the prefunded warrants from the April 2022 public offering were exercised for total proceeds of $3,787 and $4,150, respectively. The following table summarizes common stock share activity for the three and six months ended June 30, 2024 and 2023 (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-

<table layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.654%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:13.625%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:7.863%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:8.523%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:11.164%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:8.523%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares of
Common Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Common
Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additional
Paid-in
Capital </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Deficit </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Stockholders' Equity </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, March 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,779,796 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 428,900 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(354,836</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 74,105 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (14,458 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 759 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 759 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued for vested restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 76,667 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 37,856,463 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 429,659 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(369,294</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 60,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares of
Common Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Common
Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additional
Paid-in
Capital </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Deficit </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Stockholders'
(Deficit) Equity </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, March 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,327,627 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 426,214 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(456,164</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (29,914 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net income </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,260 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 728 </td> <td style="white-space:nowrap;vertical-align:bottom;">

</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 728 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued, net of expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,787,400 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued for vested restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 60,638 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, June 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 37,175,665 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 426,942 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(333,904</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 93,078 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;">

</td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares of
Common Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Common
Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additional
Paid-in
Capital </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Deficit </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Stockholders'
Equity </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,207,799 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 428,169 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(355,247</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 72,962 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,047 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (14,047 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,464 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,464 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued through employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,815 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 629,849 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 37,856,463 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="font-

size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">41 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">429,659</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (369,294 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 60,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;">

style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,384 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,384 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,435 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,662 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,150,400 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued for vested restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 340,261 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, June 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 37,175,665 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (333,904 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 93,078 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.567%;"></td> <td style="width:1.1%;"></td> <td style="width:1%;"></td> <td style="width:14.617%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,867,795 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,263,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,886,374 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with December 2020 public offering - Series 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,800,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Prefunded warrants to purchase common stock associated with December 2020 public offering </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,200,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with April 2022 public offering </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Prefunded warrants to purchase common stock associated with April 2022 public offering </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,516,267 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,516,267 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with Loan Agreement </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrant to purchase common stock associated with Danforth </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> For possible future issuance for the conversion of the March 2019 Notes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> For possible future issuance under 2024 Plan (Note 9) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">5,874,196 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 848,202 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> For possible future issuance under employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,458,171 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,474,045 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> For possible future issuance under 2015 Plan (Note 9) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 637,050 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 633,590 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total common shares reserved for future issuance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 41,178,848 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 40,613,284 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Warrants Associated with the December 2020 and April 2022 Public Offerings The outstanding warrants associated with the December 2020 public offering contains a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity, requires that these warrants be classified as liabilities. The fair values of these warrants have been determined using the Black-Scholes valuation model, and the changes in the fair value are recorded in the accompanying unaudited condensed consolidated statements of operations. The outstanding warrants associated with the April 2022 public offering meet the definition of a derivative pursuant to ASC 815, Derivatives and Hedging, and do not meet the derivative scope exception given the warrants do not qualify under the indexation guidance. As a result, the April 2022 public offering warrants were initially recognized as liabilities and measured at fair value using the Black-Scholes valuation model. For the three months ended June 30, 2024 and 2023, the Company recognized a loss of $5.8 million and a gain of $8.2 million, respectively, and for the six months ended June 30, 2024 and 2023, recognized a gain of $3.8 million and a loss of $13.5 million, respectively, on the warrant liabilities fair value adjustment. As of June 30, 2024 and December 31, 2023, the fair value of the warrant liabilities was $18.0 million and $21.8 million, respectively. 0.001 0.001 150000000 150000000 37856463 37856463 37207799 37207799 3787400 4150400 3787000 4150000 The following table summarizes common stock share activity for the three and six months ended June 30, 2024 and 2023 (dollars in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.654%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:13.625%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:7.863%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:8.523%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:11.164%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:8.523%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares of
Common Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Common
Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additional
Paid-in
Capital </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Deficit </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-

align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Stockholders' Equity </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, March 31, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,779,796 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 428,900 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(354,836</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 74,105 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (14,458 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 759 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued for vested restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 76,667 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-

bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 37,856,463 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 429,659 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(369,294</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 60,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares of
Common Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Common
Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additional
Paid-in
Capital </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Deficit </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Stockholders'
(Deficit) Equity </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, March 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,327,627 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 426,214 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(456,164</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (29,914 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net income </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,260 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 122,260 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 728 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued, net of expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,787,400 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-

space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued for vested restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word,"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, June 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 37,175,665 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 426,942 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(333,904</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 93,078 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares of
Common Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

*align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Common
Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additional
Paid-in
Capital </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Deficit </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Stockholders'
Equity </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 37,207,799 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 428,169 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(355,247</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 72,962 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net loss </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (14,047 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (14,047 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,464 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,464 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued through employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,815 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued for vested restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 629,849 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 37,856,463 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 429,659 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(369,294</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 60,406 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"><p style="font-

size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Six Months Ended June 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares of
Common Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Common
Stock </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additional
Paid-in
Capital </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Accumulated
Deficit </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Stockholders'
Equity </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, December 31, 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32,682,342 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 425,485 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(422,288</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,233 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Net income </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 88,384 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Stock-based compensation expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times

*New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,435 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,435 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued through employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,662 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,150,400 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued, net of expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,150,400 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Common stock issued for vested restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 340,261 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-

size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 18 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance, June 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 426,942 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(333,904</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 93,078 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 37779796 41000 428900000 -354836000 74105000 0 0 -14458000 -14458000 0 759000 0 759000 76667 0 0 0 0 37856463 41000 429659000 -369294000 60406000 33327627 36000 426214000 -456164000 -29914000 0 0 122260000 122260000 0 728000 0 728000 3787400 4000 0 0 4000 60638 0 0 0 0 37175665 40000 426942000 -333904000 93078000 37207799 40000 428169000 -355247000 72962000 0 0 -14047000 -14047000 0 1464000 0 1464000 18815 0 26000 0 26000 629849 1000 0 0 1000 37856463 41000 429659000 -369294000 60406000 32682342 36000 425485000 -422288000 3233000 0 0 88384000 88384000 0 1435000 0 1435000 2662 0 4000 0 4000 4150400 4000 0 0 4000 340261 0 18000 0 18000 37175665 40000 426942000 -333904000 93078000 The Company had reserved shares of common stock for future issuance as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:64.567%;"></td> <td style="width:1.1%;"></td> <td style="width:1%;"></td> <td style="width:14.617%;"></td> <td style="width:1%;"></td> <td style="width:1.1%;"></td> <td style="width:1%;"></td> <td style="width:14.617%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,867,795 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,263,345 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,886,374 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with December 2020 public offering - Series 2 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,800,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Prefunded warrants to purchase common stock associated with December 2020 public offering </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,200,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,200,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with April 2022 public offering </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15,000,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Prefunded warrants to purchase common stock associated with April 2022 public offering </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,516,267 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,516,267 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrants to purchase common stock associated with Loan Agreement </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 198,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Warrant to purchase common stock associated with Danforth </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> For possible future issuance for the conversion of the March 2019 Notes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,138,200 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> For possible future issuance under 2024 Plan (Note 9) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,874,196 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center,"> 848,202 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> For possible future issuance under employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,458,171 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,474,045 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> For possible future issuance under 2015 Plan (Note 9) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 637,050 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-

align:center;"> 633,590 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total common shares reserved for future issuance </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 41,178,848 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 40,613,284 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 2842808 1867795 3263345 1886374 0 6800000 3200000 3200000 15000000 15000000 7516267 7516267 198811 198811 50000 50000 1138200 1138200 5874196 848202 1458171 1474045 637050 633590 41178848 40613284 5800000 -8200000 -3800000 13500000 18000000 21800000 9. Stock-based Compensation Pursuant to the terms of the Company's 2014 Equity Incentive Plan ("2014 Plan"), on January 1, 2024 and 2023, the Company automatically added 1,916,962 and 1,901,960 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. 2024 Equity Incentive Plan In April 2024, the Company's board of directors adopted the 2024 Equity Incentive Plan ("2024 Plan"), which was subsequently approved by the Company's stockholders and became effective on June 19, 2024. The 2024 Plan is the successor to the 2014 Plan. The 2014 Plan terminated on February 11, 2024 and no new grants may be made under the 2014 Plan after that date, although all outstanding awards granted under the 2014 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such awards and the terms of the 2014 Plan. The purpose of the 2024 Plan is to allow the Company to utilize equity incentives in order to secure and retain the services of the Company's employees, directors, and consultants, and to provide long-term incentives that align the interests of the Company's employees, directors, and consultants with the interests of the Company's stockholders. The aggregate number of shares of the Company's common stock that may be issued under the 2024 Plan will not exceed the sum of (i) 6,150,000 new shares, plus (ii) certain shares subject to outstanding awards granted under the 2014 Plan that may become available for grant under the 2024 Plan as such shares become available from time to time. As of June 30, 2024, there were 5,874,196 shares of common stock available for future issuance under the 2024 Plan. 2015 Inducement Award Plan As of June 30, 2024, there were 637,050 shares of common stock available for future issuance under the Company's 2015 Inducement Award Plan ("2015 Plan"). During both the six months ended June 30, 2024 and 2023, there were options to purchase zero shares of the Company's common stock granted under the 2015 Plan. The activity for the Company's 2024 Plan, 2014 Plan, and 2015 Plan, for the six months ended June 30, 2024, is summarized as follows: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:49.88%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.66%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.020000000000001%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.66%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.18%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Number of
Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Weighted-
Average
Exercise
Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Weighted-
Average
Remaining
Contractual
Life (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Aggregate
Intrinsic
Value ($000)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding — December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,867,795</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.72 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 184 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-

align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,000,060 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.86</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Forfeited/Cancelled</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(25,047</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36.36 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding — June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.38</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.04</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercisable — June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,545,764 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11.78</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.22</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 59 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested or expected to vest — June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.38 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.04 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">254</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted stock unit (“RSU”) activity under the 2024 Plan, 2014 Plan, and 2015 Plan for the six months ended June 30, 2024, is summarized as follows:</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.22%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:14.72%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:15.54%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Number of
Shares</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted
Average
Grant Date
Fair Value
Per Share</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-vested at December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,886,374</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,015,940 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.88</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(629,849</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (9,120 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.15</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-vested at June 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,263,345</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1.89 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The fair value of RSUs is based on the market price of the Company’s common stock on the date of grant. RSUs generally vest 33% annually over a three-year period from the date of grant. Upon vesting, the RSUs generally are net share settled to cover the required withholding tax with the remaining shares issued to the holder. The Company recognizes compensation expense for such awards ratably over the corresponding vesting period. Compensation Cost The compensation cost that has been charged against income for stock awards was $0.8 million and $<span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-

width:fit-content;">0.7 million for the three months ended June 30, 2024 and 2023, and was $1.5 million and $1.4 million for the six months ended June 30, 2024 and 2023, respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was zero for each of the three and six months ended June 30, 2024 and 2023.
Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands):
<table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
<tr style="visibility:collapse;">
<td style="width:46.149%;"></td>
<td style="width:1.2%;"></td>
<td style="width:1%;"></td>
<td style="width:10.262%;"></td>
<td style="width:1%;"></td>
<td style="width:1.2%;"></td>
<td style="width:1%;"></td>
<td style="width:10.262%;"></td>
<td style="width:1%;"></td>
<td style="width:1.2%;"></td>
<td style="width:1%;"></td>
<td style="width:10.262%;"></td>
<td style="width:1%;"></td>
</tr>
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
<td style="vertical-align:bottom;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Three Months Ended June 30, </td>
<td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Six Months Ended June 30, </td>
<td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
</tr>
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
<td style="vertical-align:bottom;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td>
<td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td>
<td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2024 </td>
<td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
<td style="vertical-align:bottom;"> </td>
<td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> 2023 </td>
<td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
</tr>
<tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
<td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> $ </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 216 </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> $ </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 301 </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> $ </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 411 </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;"> $ </td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 675 </td>
<td style="white-space:nowrap;vertical-align:bottom;"> </td>
</tr>
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
<td style="white-space:pre-wrap;vertical-align:top;"> Selling, general and administrative </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 543 </td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,053 </td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 760 </td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>
</tr>
<tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
<td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 759 </td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td>
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td>
<td style="white-space:pre-

wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 728 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,464</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,435 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 1916962 1901960 6150000 5874196 637050 0 0 The activity for the Company's 2024 Plan, 2014 Plan, and 2015 Plan, for the six months ended June 30, 2024, is summarized as follows: <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:49.88%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.66%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9.66%;"></td> <td style="width:1%;"></td> <td style="width:1.3%;"></td> <td style="width:1%;"></td> <td style="width:9.18%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Number of
Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Weighted-
Average
Exercise
Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Weighted-
Average
Remaining
Contractual
Life (in years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Aggregate
Intrinsic
Value ($000)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding — December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,867,795</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10.72 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">184</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,000,060</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1.86 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited/Cancelled </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (25,047 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36.36 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding — June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.38</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.04</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercisable — June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,545,764 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11.78</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.22</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 59 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested or expected to vest — June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,842,808 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.04</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.38</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7.04</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 254 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> 1867795 10.72 P6Y1M6D 184000 1000060 1.86 25047 36.36 2842808 7.38 P7Y14D 254000 1545764 11.78 P5Y2M19D 59000 2842808 7.38 P7Y14D 254000 Restricted stock unit (“RSU”) activity under the 2024 Plan, 2014 Plan, and 2015 Plan for the six months ended June 30, 2024, is summarized as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:63.22%;"></td> <td style="width:1.52%;"></td> <td style="width:1%;"></td> <td style="width:14.72%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:15.54%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Number of
Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Weighted
Average
Grant Date
Fair Value
Per Share </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,886,374 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td>

<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2.28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,015,940 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.88</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(629,849</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3.00 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (9,120 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2.15 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-vested at June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,263,345 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1.89</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 1886374 2.28 2015940 1.88 629849 3 9120 2.15 3263345 1.89 0.33 P3Y 800000 700000 1500000 1400000 0 0 0 0 <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Stock-based compensation expense related to stock options is included in the following line items in the accompanying unaudited condensed consolidated statements of operations (in thousands): </p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.149%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10.262%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10.262%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10.262%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10.262%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended June 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Six Months Ended June 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 216 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">301</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 411 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">675</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Selling, general and administrative</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">543</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">427</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,053</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">760</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 759 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">728</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,464 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,435 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 216000 301000 411000 675000 543000 427000 1053000 760000 759000 728000 1464000 1435000 10. Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, investments, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of June 30, 2024 and December 31, 2023 for financial instruments measured at fair value on a recurring basis (in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.14%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10.26%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.74%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10.26%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value Hierarchy Classification </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Balance </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Quoted
Prices in
Active
Markets for
Identical
Assets
(Level 1) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-

bottom:0.5pt solid #000000;"> Significant
Other
Observable
Inputs
(Level 2) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Significant
Unobservable
Inputs (Level 3) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> June 30, 2024 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,364</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,364 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 24,630 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,537 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,537</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Warrant liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 17,962 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,962</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 17,962 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-

word;white-space:pre-wrap;"> <td style="vertical-align:top;"> December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">767</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 767 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 33,283 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34,593</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 34,593 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right

Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. As of June 30, 2024, the cash and cash equivalents of $26.0 million and the restricted cash balances of $0.4 million and $0.2 million within short and long term on the unaudited condensed consolidated balance sheet, respectively, sum to the total of $26.5 million as shown in the unaudited condensed consolidated statement of cash flows.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Level 3 financial liabilities consist of the warrant liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company's stock price, contractual terms, maturity, risk free rates, as well as volatility. The unobservable input for all of the Level 3 warrant liabilities includes volatility. The historical and implied volatility of the Company, using its closing common stock prices and market data, is utilized to reflect future volatility over the expected term of the warrants. At June 30, 2024, the Level 3 volatility utilized in the Black-Scholes model to fair value the warrant liability was 86.6%.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">The Company uses the binomial lattice valuation model to value the Level 3 derivative liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company's stock price, contractual terms, dividend yield, risk-free rate, adjusted equity volatility, credit rating, market credit spread, and estimated effective yield. The unobservable inputs associated with the Level 3 derivative liabilities are adjusted equity volatility, market credit spread, and estimated yield. As of June 30, 2024, these inputs were 71.8%, 1,477 basis points, and 20.0%, respectively. The senior convertible notes are initially fair valued using the binomial lattice model and with the straight debt fair value calculated using the discounted cash flow method. The residual difference represents the fair value of the embedded derivative liabilities and the fair value of the embedded derivative liabilities are reassessed using the binomial lattice valuation model on a quarterly basis. </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):</p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:75.9%;"></td><td style="width:1.96%;"></td><td style="width:1.96%;"></td><td style="width:1%;"></td><td style="width:18.18%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Warrant Liabilities</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance – December 31, 2023</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,810 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Gain adjustment to fair value </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,848 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Balance – June 30, 2024 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,962</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Derivative Liability</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance – December 31, 2023</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 196 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Gain adjustment to fair value </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (196 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td

style="white-space:pre-wrap;vertical-align:top;"> Balance - June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div> The following table summarizes the conclusions reached as of June 30, 2024 and December 31, 2023 for financial instruments measured at fair value on a recurring basis (in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:46.14%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10.26%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.74%;"></td> <td style="width:1%;"></td> <td style="width:1.2%;"></td> <td style="width:1%;"></td> <td style="width:10.26%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair Value Hierarchy Classification</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Balance</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Quoted
Prices in
Active
Markets for
Identical
Assets
(Level 1)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Significant
Other
Observable
Inputs
(Level 2)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Significant
Unobservable
Inputs (Level 3)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">June 30, 2024</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,364 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,364 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 24,630 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 24,630 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">26,537</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 26,537 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Warrant liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,962</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,962</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 17,962 </td> <td style="white-space:nowrap;vertical-

align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,962</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">December 31, 2023</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 767 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 543 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Money market funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <span style="min-

width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 33,283 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 33,283 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total assets </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34,593</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 34,593 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34,593</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Warrant liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,810 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,810 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Derivative liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,006</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,006</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table> 1364000 1364000 0 0 543000 543000 0 0 24630000 24630000 0 0 26537000 26537000 0 0 17962000 0 0 17962000 17962000 0 0 17962000 767000 767000 0 0 543000 543000 0 0 33283000 33283000 0 0 34593000 34593000 0 0 21810000 0 0 21810000 196000 0 0 196000 22006000 0 0 22006000 26000000 400000 200000 26500000 86.6 71.8 1477 20 <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands):</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:75.9%;"></td> <td style="width:1.96%;"></td> <td style="width:1.96%;"></td> <td style="width:1%;"></td> <td style="width:18.18%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Warrant Liabilities</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance - December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,810 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Gain adjustment to fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (3,848 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance – June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,962</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance - December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 196 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Gain adjustment to fair value </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;">

(196 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance – June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 21810000 3848000 17962000 196000 196000 0 11. Revenue Product Revenue, Net Net product revenue was zero and $0.5 million for the three months ended June 30, 2024 and 2023, respectively, and zero and $1.6 million for the six months ended June 30, 2024 and 2023, respectively. Products are sold primarily to wholesalers and specialty pharmacies. Revenue is reduced from wholesaler list price at the time of recognition for expected chargebacks, rebates, discounts, incentives, and returns, which are referred to as gross to net (“GTN”) adjustments. These reductions are currently attributed to various commercial arrangements. Chargebacks and discounts are recognized as a reduction in accounts receivable or as accrued expenses based on their nature and settled through the issuance of credits to the customer or through cash payments to the customer, respectively. All other returns, rebates, and incentives are reflected as accrued expenses and settled through cash payments to the customer. Revenue attributed to sales to three wholesalers comprised 46%, 26%, and 25% of the Company’s gross revenue for the six months ended June 30, 2023.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table summarizes activity in each of the Company’s product revenue provision and allowance categories as of June 30, 2024 and 2023 (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:40.636%;"></td> <td style="width:1.059%;"></td> <td style="width:1%;"></td> <td style="width:8.813%;"></td> <td style="width:1%;"></td> <td style="width:1.059%;"></td> <td style="width:1%;"></td> <td style="width:8.813%;"></td> <td style="width:1%;"></td> <td style="width:1.059%;"></td> <td style="width:1%;"></td> <td style="width:8.813%;"></td> <td style="width:1%;"></td> <td style="width:1.059%;"></td> <td style="width:1%;"></td> <td style="width:8.813%;"></td> <td style="width:1%;"></td> <td style="width:1.059%;"></td> <td style="width:1%;"></td> <td style="width:8.813%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Discounts and Chargebacks (1)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Product Returns (2)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Rebates and Incentives (3)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">89</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,932 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,057 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Provision related to current period revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-

width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Changes in estimate related to prior period revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Credit/payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (39 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (550 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (589 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 87 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">1,382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,493</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Discounts and Chargebacks (1)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Product Returns (2)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Rebates and Incentives (3)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Product Recall (4)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of December 31, 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 255 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">73</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,213 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,541 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Provision related to current period revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 773 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 316 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,054 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,143 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Changes in estimate related to prior period revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 693 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Credit/payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (708 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (74 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,129 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of June 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">320</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,008 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,920</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,248 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (1) Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time

revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Company's unaudited condensed consolidated balance sheet. (2) Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company's unaudited condensed consolidated balance sheet. (3) Rebates and incentives include rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company's unaudited condensed consolidated balance sheets. (4) Provisions for product recall are deducted from gross revenues to the extent of revenue recorded related to the recalled product and are included in accrued expenses on the Company's unaudited condensed consolidated balance sheet. License Agreement with GSK On March 30, 2023, the Company entered into the GSK License Agreement. Pursuant to the terms of the GSK License Agreement, the Company granted GSK an exclusive (even as to the Company and its affiliates), royalty-bearing, sublicensable license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications, in all countries other than Greater China and certain other countries already licensed to third parties (the "GSK Territory"). If the existing licenses granted to or agreements with third parties are terminated with respect to any country, GSK will have an exclusive first right to negotiate with the Company to add those additional countries to the GSK Territory. The parties closed the transactions contemplated by the GSK License Agreement in May 2023. As previously disclosed, the Company became aware that a non-antibacterial beta-lactam drug substance was manufactured using equipment common to the manufacturing process for ibrexafungerp. Current FDA draft guidance recommends segregating the manufacture of non-antibacterial beta-lactam compounds from other compounds since beta-lactam compounds have the potential to act as sensitizing agents that may trigger hypersensitivity or an allergic reaction in some people. In the absence of the recommended segregation, there is a risk of cross contamination. It is not known whether any ibrexafungerp has been contaminated with a beta-lactam compound. Nonetheless, in light of this risk and out of an abundance of caution, BREXAFEMME (ibrexafungerp tablets) was recalled from the market and clinical studies of ibrexafungerp were placed on temporary hold. On December 26, 2023, the Company and GSK entered into a binding memorandum of understanding ("Binding MOU") for amendment to the GSK License Agreement. The GSK License Agreement was amended in connection with the delay in the commercialization of BREXAFEMME and further clinical development of ibrexafungerp associated with this event. Under the terms of the updated GSK License Agreement, as amended by Binding MOU, the Company is now eligible to receive potential: •regulatory approval milestone payments of up to $49 million (revised from up to $70 million as provided in the GSK License Agreement); •commercial milestone payments of up to $57.5 million based on first commercial sale in invasive candidiasis (U.S./EU) (revised from up to $115 million as provided in the GSK License Agreement); and •and sales milestone payments of up to $179.5 / $169.75 / $145.5 million (depending on the date of GSK's relaunch of BREXAFEMME in the U.S.) (revised from up to $242.5 million as provided in the GSK License Agreement). These milestones are based on annual net sales in the GSK Territory, with a total of $64 / $54.25 / $46.5 million to be paid upon achievement of multiple sales thresholds up through $200 million; a total of $45.5 / $45.5 / $39 million to be paid upon achievement of multiple sales thresholds between $300 million and $500 million; and $35 / $35 / $30 million to be paid at each sales threshold of $750 million and $1 billion. The Company will continue to be responsible for the execution and costs of the ongoing clinical studies of ibrexafungerp but will have the potential to receive up to $72.35 million in development milestones (revised from up to $75.5 million as provided in the GSK License Agreement), which comprise: $25 million already paid; $10 million for the delivery to GSK of final clinical study reports for the completed FURI, CARES, and NATURE clinical studies; up to $30 million for the achievement of two interim milestones associated with the Company's resumption and continued performance of the MARIO Study after the clinical hold is lifted; and $7.35 million for the successful completion of the MARIO Study. In the case of each of the above milestones, such milestone events are defined in the GSK License Agreement, as amended by the Binding MOU. In July 2024, the Company delivered to GSK the final clinical study reports for the completed FURI, CARES, and NATURE clinical studies and the Company expects to collect the $10.0 million development milestone in the third quarter of 2024. GSK will also pay royalties based on cumulative annual sales to us in the mid-single digit to mid-teen range. The royalty terms are not amended by the Binding MOU. The Company evaluated the GSK License Agreement in accordance with ASC 606 as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract. The Company assessed the terms of the GSK License Agreement and identified the following performance obligations which include: (1) the license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME, in the GSK Territory, (2) the research and development activities for the MARIO study, and (3) performance obligations for the remaining research and development activities for the ongoing clinical and preclinical studies of ibrexafungerp. The Company provided all necessary information to GSK for it to benefit from the license under the license term in 2023 when the Company transferred the license. As of June 30, 2024, the Company maintains a $19.5 million contract asset associated with the success-based milestones associated with the ongoing clinical studies of ibrexafungerp. The Company believes that the $19.5 million contract asset is collectible given the Company's probability assessment of achieving the milestones as defined in the GSK License Agreement, ongoing development activities, and other information available to the Company. The Company reassessed the transaction price as of June 30, 2024, including estimated variable consideration included in the transaction price and the remaining milestones continued to be constrained. The Company recognizes

the revenue associated with the MARIO study and the remaining ongoing clinical and preclinical studies of ibrexafungerp over time using an input method. The input method is based on the actual costs incurred as a percentage of total budgeted costs towards satisfying the performance obligation as this method provides the most faithful depiction of the Company's performance in transferring control of the services promised to GSK and represents the Company's best estimate of the period of the obligation. As of June 30, 2023, the Company provided all necessary information to GSK for it to benefit from the license under the license term. Accordingly, for the three months and six months ended June 30, 2023, the Company recognized $130.1 million in license revenue at a point in time upon the transfer of the license to GSK and completion of the initial technology transfer. For the three months ended June 30, 2024 and 2023, the Company recognized $0.7 million and $131.0 million of license agreement revenue, respectively, and for the six months ended June 30, 2024 and 2023, the Company recognized $2.1 million and $131.0 million, respectively. As of June 30, 2024, there is $1.2 million and $1.8 million of current and long-term deferred revenue, respectively, which is expected to be recognized by the end of 2025. </p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">License Agreement with Hansoh</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;">In February 2021, the Company entered into an Exclusive License and Collaboration Agreement (the "Hansoh Agreement") with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited (collectively, "Hansoh"), pursuant to which the Company granted to Hansoh an exclusive license to research, develop and commercialize ibrexafungerp in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan (the "Territory"). The Company also granted to Hansoh a non-exclusive license to manufacture ibrexafungerp solely for development and commercialization in the Territory. For the three and six months ended June 30, 2024 and 2023, there was no license agreement revenue recognized associated with the Hansoh Agreement given the variable consideration was fully constrained as of June 30, 2024 and 2023, respectively. </p> 0 500000 0 1600000 0.46 0.26 0.25 <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">The following table summarizes activity in each of the Company's product revenue provision and allowance categories as of June 30, 2024 and 2023 (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"> </p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:40.636%;"></td> <td style="width:1.059%;"></td> <td style="width:1%;"></td> <td style="width:8.813%;"></td> <td style="width:1%;"></td> <td style="width:1.059%;"></td> <td style="width:1%;"></td> <td style="width:8.813%;"></td> <td style="width:1%;"></td> <td style="width:1.059%;"></td> <td style="width:1%;"></td> <td style="width:8.813%;"></td> <td style="width:1%;"></td> <td style="width:1.059%;"></td> <td style="width:1%;"></td> <td style="width:8.813%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Discounts and Chargebacks (1)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Product Returns (2)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Rebates and Incentives (3)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Product Recall (4)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 89 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,932</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,057 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Provision related to current period revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Changes in estimate related to prior period revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 51 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (26 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Credit/payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (39 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (550 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (589 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance as of June 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 87 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,382 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,493</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Discounts and Chargebacks (1)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Product Returns (2)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Rebates and Incentives (3)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Product Recall (4)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of December 31, 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 255 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">73</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,213 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,541 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Provision related to current period revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 773 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 316 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,054 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-

wrap;vertical-align:bottom;text-align:center;"> 3,143 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Changes in estimate related to prior period revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 693 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 693 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Credit/payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (708 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (74 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,347 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 693 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Credit/payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,147 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 320 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,008</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,920 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,248 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> (1) Discounts and chargebacks include fees for wholesaler fees, prompt pay and other discounts, and chargebacks. Discounts and chargebacks are deducted from gross revenue at the time revenues are recognized and are included as a reduction in accounts receivable or as an accrued expense based on their nature on the Company's unaudited condensed consolidated balance sheet. <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-

~~***width:2.269%;display:inline-flex;justify-content:flex-start;">(2) ***~~

~~***Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued expenses on the Company's unaudited condensed consolidated balance sheet. (3) Rebates and incentives include co-pay program incentives. Rebates and co-pay program incentives are recorded related to the recalled product and are included in accrued expenses on the Company's unaudited condensed consolidated balance sheets. (4) Provisions for product recall are recorded from gross revenues to the extent of revenue recorded related to the recalled product and are included in accrued expenses on the Company's unaudited condensed consolidated balance sheet. 0 36000 89000 1932000 2057000 0 0 0 0 0 0 51000 -26000 0 25000 0 0 -39000 -550000 -589000 0 87000 24000 1382000 1493000 255000 73000 1213000 0 1541000 773000 316000 2054000 0 3143000 0 693000 0 0 693000 -708000 -74000 -1347000 0 -2129000 320000 1008000 1920000 0 3248000 4900000 7000000 5750000 1150000 1795000 1695000 1455000 2425000000 6400000 5425000 4650000 4550000 4550000 3900000 3500000 3500000 3000000 7235000 7550000 2500000 1000000 3000000 7350000 10000000 19500000 19500000 1301000 1301000000 700000 1310000000 2100000 1310000000 1200000 1800000 0 0 0 0 "

>R''_W1]#C$Z^R\?/5^'YRY8!_6^JVPUND^_M#(3CRY](:'G#5A,.'!$*TF-MS@,EU#AF? Z:FUOW(#WV^I67_Z^U/QE#YO2R/AAD=@)-!_+CUN*Y"WLO6-9?MXF**!R7-ASXMY0EP6AD!Q:MNZ6DE*.R=-5.1D>F._ *A1VB"E%3M)!Y60-2EP)>P9"0;!*_"V=]O"'"1JLUW-M;M.=]TI>_3U?-;]<50E#YKY;+"X_MW;=;S]$"0!PC#^_CTM=#"NT^C~L.UK"],D\1P9_ZT+T71+SWN>M.X\Z>2EMV_AXC>^TA?KF_U)P;(_M0;O-MN^-W<5G2I|(BLF]4UKBJB?%-%\>;_J4#P67G>'RGL^1_77IY[PID<(4ERUKE-MN1"-<;Y*/JY2.I?4S;MO[:K/73I?[5RJ2-:W3-Z-7\S?WF[OOGY^_(?)TW@^M7[!]GK_>_:UAE/RM?T^G[PG?2?/FK\^:S^_K]V>[+UX_;9Z]>OKL:?.?;U\] M:P1=<-M.7MO5P/!=*NY?AF^\G+9\WKY\OH'[3,>\V3O7FV;LW>Y4G0'-F M+]8X9)]JZ7JM{0K=@2WZS@]ZW.R2UI08:L=[?OO|[-$/KGZI^KEN>ZO !M M%.TZNBS(_SN.LO-_CJ-^A+!?'_6EUUZ4-O&YONY;\UE.E[D:6L*P5K%[MY'] MY;ELD(.W@W>G6X;OQN.%#[CP?@:64?'ZU9<>F_OEAS9;T*9H?/=/".G6%V;=//@V\EDU!&Z[Z? MQ3T_#4/<.[!KU_MM]UD@:D+(NV!O*TAI6F\!N8\/MC0HG(_V.&#I;+9E6 T_MQ=-^"R)*P;OI/L"W-K^ZP\2W)Z.H$0B+493?6F=B6XOCR6)(S5X[L.:W8$M_.M.1 !Z?YA6\S*40H3/?EP5;\/;6+!\:,+FA'W()X/R9QQ94??GTRML^M'&;X5-P'!3P-MZ;3R^R*9YVL,[V%{C&;][#=-P_8!A^WHI_OO\G#\L4+8WL&O-<|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Ü.*=U8.TM-M!/_GP2>_"_@ .>3\E[!P\?EV6W_M/4KEGV>?U]SV:,=/)D>#T?O_ZX=S> #,1X/%?=Z^>[OW%+4=S@.T8<$)XN# M#Z>_/"#XUR(XYY<'@T^SQZ/Y 4GC-C:KG/'@5ZX>.B=_?G3^@7]=9WGO;B7W MT-5#ÚV9 5_3.Z1 B<2(H(H4MOT$F7FK/ M,Q&?@2NGST"J@QQ$K-B619P* = M0IL^AJV_ 3\$+PEEVQ]9@3AX* 9C#[=';0T^" M7UN]"CFK0G),/C#'2;,<$9FT(H'}0$PPQG'4#C*(+MAON]3>X$[I\[7FA=:0Q MI*E(94]V>X"ZWU.YH0!%@PW ?2))100:,OG!OQ&@*:,>.Y#2EUPW&4"%'TH-M&+_G_4[=^^$TOX^@4._2 U\.BO)$8MJ[^/9/DR:>&XWM%B5R5HG(_M))-Q5A)N54"%$)"Q!B8(UTAQ(3%NF.F"Y1ZOOF>+Q:<]2J_+REQ$V!T'(W2D M4|A#6?I.W6N5TL/5?9_*#86KK%R,EGHJ7LG#/CE(!9I;OS[":2IVLT$(@P^E,3+7HML] KKM(1 M](7W@41N-)%E8] RIHA.03)T5#+;D ZI_'HT^/CU;9]LMAV3]=.5Z$,0MQS MO=$#U'V?RHT%*^0I2-,&D;DM);X%!W) (@0'=-;?V65?P_->BCU?8>H MWKF|(FK;IA)%D5LX=7OML=&KK-<>9[5'TA9A13MBP&!]8W2/MZ]S+@DD0K4/H#:)+@DD0K4/H#<;_8\9X(M2^SWNVQ?%KN MF=U/';A:G*%(+8N4K?GU)U%%4I0HV3)5I"@2'6U;X]6J &0^^60BD9G%KAB0 MO5:S8D!N)((RXAUS 0EN?#[NBG,B*$=:"&H5#X303ECN7.M:.Y6NXUX(4H/ M/212$.K0EW)?$>+>U0K1+85B#D?YBDVYL1'(>8Q>)]2<5F ?L$5688XD(Y%)PHU9+2+V M^"(O\^C)5<>=>=+4&CT3MLW 7G J,I=Q3G*(&&^^20YCKE.NQ.F1I5"@P+[5. ME C528/"[> 4/ 0,JO+AW0H# KL=C^W-(RO%:NRU8A6K<8/=1FV8=.-); WB MU"2D*7.(*T;9%<8X^Z@2AK6 ^OIRIF1=[0BF_E>X^; B>)3765 "7QVXL2CP M=.A+ N:?P%*4U*4APN:7@B+L@Đ+.6(!)4GP13?VC*GAO IY6 [JLD D2SMW&M^>O1L!EBKD$3HTLL54A"'/(.6H];T M"Z)/GR/1,VN%^]5R2\5:%6M5K.4/6"LFE!*&@'F*4@&79PXY'L'\.&8=P&Z@ MM).6/AL++E%1&O<4TEY@L,#@8V#0!.<5"1A%&W/B-";(2"\0"XD$0P(P^$XZ M96XNQBY[#!<8W(%0_/-NU_/0DX#%PNSUAE79A;U1WH)0[Y6C*']>V^5PBFQ0 M /!;L06D#GT!]Q6DM/2>6HH2UP9QP3'@DR:((M11YU=.GL:H];QJD:$_10P>!TN^])#,7$U!,P(^'V' HI%@)*F.B#.6D9%! M@H8QH#EV@G_N@*#0IH/CT4>=R MV.[ZL%W}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ŞERB0 M/TXB1YHXBI3A21HJHM,K!: [&567H3&F>EK('1=W]3+9AO1FN=R*$"8P@UP2 M@P2F!'%&$)4$(1! $4LTA7PP;=@,U&A5!2E=>RDAW.W8.GM0[G,EG8; M!)8=>]BN_IM&[4X_:<>Y$ 6['B.]P-FT. 5'2YW\- M A,/S_M=^!_K@)CNT\"4S.S33,#F0*2WCH3(!+%9E89JRE/S55V"&^V[*^VMWQ>+K>M.P4(ML;[M6K@,>ZBJ="!]J.H(@PS5&M'"!W9=??N;NR*XDSFD!CX=E@Z0?0C39J^]7EF<51,1LIA] M-B1)*1#XA2$N^4!"EI';S+5@W<03+1,9F8W&KJFM=$NLE+W)DMV#U.9,Y8:"ME(R)!TH=4;G$\;"2#:M!$^$<=5DE9,GP2+!BF#(-67:^F]MG=:,D\K"D[@ M XSF\/"TC\SA>/+_V'O7YC9R)&WTKU3TSIS7'4%H

I<142 MY^8/L,$\U0,/'&1|\TW&"6S?Z9OP+ !8 + - 7 M]5I&H2,32%IG$+<.(^=5=@6XT11 %#/7A;^P"<#\MI<@>EQML,/0CN+DD^]9 MW"F3JR[#L_$.FKM];>?
#C0:A_D;8V55(@!&7NDKCT3GX"Y>OON4?E [8WQSG M;F#L!JQP&6Z1XGU=UKT:[E:S8$D7&_CD.6[@?YR._9FM8S5*.SN9"VF7\.E^ M9\<<:O[7MMI8&9V$E\A:D3VY
%Z9T@PE(8/QPGM/.TF&_6BO&F7] #KV_SOM MC^_.Q$'X-/JKG4S'_(ON56%:"604."QONN#E(8-HS3E"D MG")N!$ .8(!#3Z+''3D1)'14X:4$O%,DW!XN7Y]!+<^'K9;>E[+8\
MXL!:=);+:!$'[#Y6]CJD$R/(.V4)U0Y0?F6W92V./A[Y&$/];CPZ/P4C-EX*966"U(6I%P_Z<5+W(=[&]+ 2&*(.N"TCE&L@=N= #5)27]2&?3<)36 :#_:H"YV]MBI8]=^P$YI%;EBB: D
ME$/<,H8,C0PE+5+4 $QAM0=MAPFG[^BGRDV'+?^ (2R#TF0EO6&>>-=)4\'3:/NP]'[98[H<;GNZ'8"2OCI+ M7TW]H1WZDKY:$O *<(L4[^^R[M5P2_KJ=M)79T'CUE+ZT?GY*%]VY/]9]>MZ
M&D-Q%)]1^DG)W'KX6L\ZY),%WG>]O8,N\)*DWQU^H.$2P15%+G",N&F*=UJ) ML*_F6*1DNFDY>ORIN1[,"C@B.63]+]JQ.Z?9S'15LO 1@89G(0 /1JQ*GN$Z
MQ&]63)OS#,.\4OXHP0\Y$.%'=.*YM?^ZNLB(_XDS0M-G\PT^'56X*YL5ZF07!OM]>TH\C*^13 MK)5S'%%! 7D<)L@2;E&@PG&MK>.KI81_A&\Y0#]U2_VL,Z%]O/%IRFO<(K4!D
MADOZ,$(+GG1]B$N=F.OM>M0[48)2!:]W9WA%KW=+6]7&\YIU 8)]G0N!JL0 MN+@2:.4X^*Z,6=U)N/:W>++$@D:=GH_'D4QR?OXENTI&KRW)2&.LK KD["5^% M27Z32=XFDA5\
<2;M58]%5SXGI2OVJ?#*PBO+4NZOWFZ'5V(NHJ$.(QYSDP&A M@5=ZDQ#UE!++)A<2]LICD2?H5K._'UOA^7-C>=[&KMIU4%F998I1/EST9SR\& MHZL89_F3%_/*H!<#N%E_EOQ2=OV?
DPH6>_7(G@QO!.TxP1XE0L!76@GVA02!'M.7*84B/#+TZOXC#VN8G M_@A:VEDYC T6#=IG+2B MC=+N:> AEF2A@=!)MI9 #1BD$E:(*BZVTPG&&] MN;S9)P.T#9[C?
19*4"%U6^'3O\6+I7+Z=2/MU61498&NTU4UL5^K+_W)V=EH M$/K#SX5+ERH6I8K%CY@OHIC0WB@DXX2B?AP/H MXO)IOBCR.";!>=.R<[2=K< EP_LRZL+;CY|%O">%_*[.=3SQJL\33%4Q
M5<54/>';L-(<8R("TMR Z6/$(\=T0$%%*851V&*SP6[@<[:;8L,'V\X=7V:\< MS2O@6\!W\'1HK;3;9RGX+X,MD3!<]PSO>
M/P#>^!.$_CH<+T#L8.1US)T"VI^RZY'JD%[KC<3_G?8O09[!#>]5=A@]<+0@>4(!6XVXS*Y%BA))3[1)A(75 ;=UW%' MLCG.?]Y> \)O"RC(.QP/P\T7EC[Y.8[[((''?+<2\F8'.VZ]^.,V!.OCAS X_
MO[L)+Y.*?H?.%7U.*NJ>U@<7]>#XM44#"\8OH%#ITZ*1+E'FA.!> "XU=(E.MY#CEH.R M0QFEZJ+1B6+OBKTKlNX'!)U1V'AM+%@YSL!V;8(.!]LR$]94V):1 !.3TA")-P&'P5C*9
M]Y5=KCR^>XC)90\S6A#$Z<]*%.(/A#\.0Z'Z76L=/-)9[<)HFNL#/:'!>EA(M\T\:LV%W3\3>6K&HK 7*3O&U+L>YD@>+!1 22QAIL$P-JO]**TV'&A(D!D21R M\0R;O0$+U@&UTG<>Y,JN1T1-
,,,I"KXQ'B@?AN#8%0+DT; MD]-QY>V9YOXV4^>NCEKT%-W.28MG;,,*/!9X+/#X$'BD6OB@L$4A1(>XU@X9 M2N&G9*4GA.@4.CG;MA5X!,@N\/@#E!{^S3V(FA\W^=37"O-=Z+MU]V_>*'C M?
IKA/73G^V&#;3^,K_RR/X';^GN'_^DL5M,[T3D\RU4^'"#<<3>!2=@PO#QNG MXO/8#JH+.VXZ04[@XI/"@_!J/;&39Hb>I/KHU@:%_6?F!K4$3+^SGB(:C$.=W MA9'GM^B#+]-
LR<\3,.^KT*_OAC8JY?W5<7-N1#]4M)WOUV/6>. M)3Z2\.(_IO6DGZ[F=VF^BN(P/\'1^S=,&5WBYTJO#U0\0K\G5IM=Z_>_IYE
M93<4&:9[!G=>F[.%8]XL3>MMVP3/^(M.(OMBK^M5/_[Y8Q,4GVR5H)/_N^7 ,_M-#\:X6QU-LX6X=\;B/IC-A'U7,O)//[DKEOK@U&8C1N4T2FN6O$H#^,76#- MIZ.!*]C1Z]GS+5;)MBNU$WRR_&
[PYC,I6]WH74Y];B#Q3YJ_3\?WO[W^]+> M]?[#Z]OXN"7H:6A;@^A_3$9_'AGS0AQ6,>0?VH.R@"$AS\RIN_&M'TX^?3V MM/IT4GWZC[?5ZY,/;]Y^.'W!)O]T>O+K^S?'G^"7=^_''IX_?[XU^KT$[SP
MU[?C>N!?L_\/T/([[?E[6.U%LK4DH M)L)S;"0A1OQ'25E"%>?.I4=U09B3_Y/Q9SOL_ZO:W!<+E<[85?CH?A(W@"_.O M_WJ2WLV9R.F"B+SIUWXPJ]?C^ F>XI?!R/_SIRJ"AW"18\?C:5PV2.M17\2/
M%#= 7!"-)C;.CP1C? Y&/%C^D C)>:1Y&9&;V77G?Y__O@CP)..^Q=Y=':^. MTA]N6H/EJ>L_[##\X6S=O\^@:5G@R%%5O;E^U&S1?!D]:G/PZI?\]/G5IE]I M:TF7C<&&="["-N=X.SKTLX'L_+0\PCT-
5+W(O4 M[===='^RC/OQ"]#]?53-/]%>=11O^=PIN3QRW)=?.X[K>%]!D_@W3R^]H7V M]"%C2YO;C%7P$'V?-2,W9((G&<._8O,5F,O+F(H]]%/]-M^^E@ JN))D#&\)W;83S|C #M^N!DP:?
ZP]1Z2#?H7G;.9E.1[QS@0H/117/G M"3S(>'0Q[L>)'5^U/EC6Q#A,TW.;IL,L"T!IFWTCN'_OY03I.%R>5>N7]Q$ M?B.. +^]??]V1:?.;FQ#.80 WB(\?2\5]57-2 NV(:E;X W 0C<[$;=PWCZ%T!V
M9V^!./>]G3W_>W YOMK9}?, 6]]R7$\]P(L%PE_&UN.$#\!TQL'U8*[O63>_MK;J.V?GB^2'].DYFK667)&=VM[E8M<+:.RX4MVXI'62(@0Y2]_E)?&_^?/49WL MXWZ.S5UGTXS.-#*S!>Y"
(Z3!6%%/2:.^[T^']!4?5N_K^KV!]:N. X@_K.!, M*.=3^^[.\4*$[06L5UZ,7WY[^]_'[][^]:JOJO?]&S/4^#23^N=F9AL)R<_0 MG&.%ZS9SWLS"Y71P"7(*]QDO..4AWZ#Q//[_NUOK^?
W!;$=U*JG\)1EV%> MW_G7KJ*MEZ1M)MU#4#+?:A&,E[;CG4N@!6F?#CT(&PIO?@#%Q6=)R'?O}(? H-!OG3ST<' MBZL@EW^U8W^>6%XK=7*B&LS9@!EAD*$!1V1, M1W'ACQ5+ _*G?
_K+Z7]5O\$.M YZ_!RC0R-A?!O;KZ/09EL*RP$5_RG5D*Q@W/SR8WT>@S[#A_)]8;9B+D)69^U_D0$R"R<\[DV! M"PW060#.01^87PWB/!Y=V<'D"KEH,P8#0DU=.\+&Z9X/=BYI2\K<7 _P#[AN
MYI(SPYP%[H8.+H-%OL)"ON&?++5+\MQK:F,'-W"O09;\F@=MF0! ZC =?+C MP*C_DM4:?GE]!C+=/A',]{6OM!^Z_I(=P$?#U7Q$H9V=_C@T03KXQ.'*_KO1 M8##ZTK1$
:"XL,.7W%4C5[/0)7QYFBP(<V.F+ (NPXRRYN(!,VEH(0Q$+S2R M K)?RUVQNHF/F=3G<4M6VH?;^]9CMP]PB9!9/F(M 6>S-F0R4$<
@.\@P#.A7WJ2/*??'LDUIVBL\5R0YR_"..!F M=W-AS%[&YH87H[RV^<8[9,5V >^Y]A@-79U46F M9\T+X&R92)I&_V+(+H>QF@7AJ;.E.PBCH"O'&6[WFBW]^=FIS5,LRF!!5C, M23:/>4RQ)9+C?
OW/_'D_'L&49ZD$Z1TVGX/+3JJ&QTQF)O?+66RFHZ%P-Z3I M+++.M",!W?06X:4MS[IRM1GZ792Y?(=]ID1\$K&HTGLRH$^!GN,QS4S7\$^CC M-,ZEYP*>O)_A\L9]AK/!R"[\
(T!2%>O&DTGL;5AVN"[&SBO)TV4SRC$(V] M:(W(Z7\UK0;5]_IZ9]GJ,9 X/\:..OVZ/-Y-Z+XJ_M9TISZ 4K],L;P?@%C M-:@(D-;L(P USGW LG^PO/0 W%N]JTW@_JAT6F757X]_>W_2?.OJ<"$WNR(S
M%HH&V:.VMFL^IW:/V*YB5H'1\/.H4=Q;0@MO?1F_.YG?:F4],X% N M5NJ;OVCN'D;OQ9P^W$\IVIXO/H)$P)>]^_^U]KW!]_M;E_.=N7/'?_O+^>.699H-LS!-<9 P"N.OA-'XZ@-4HPV-NBY:%
9CD^;JM-MZ\TXYT7;KZ,^A;G9 MY180UWRY,<=G5W4?.&;SQ0PIF8 MQ:B5PB%@P/Q:/3"3PP8(X6[@L9\OJ+*]M/U!.X@ZG[N^NAFE^=#_UJD^]L%^] M)=-[%:)6@&&$V@;W!H]4WZ/HUOUT?
[8/<48WMIQ+F9<'U^OS)MV8>Y-FI(WD],$PQL1F;/[RWEL?^DK^/1@*9S^ M!$\ AJD)"#+,XW5([L>!A.S\#! M^@0LY?WU CURTSV)G=I7N9-]31O
MO#2$"HA1FMYT2!;L,31$+6O.L&lV95)!OV.ZD&3>"+X@SX(9A6G=B-@W]:)Z07YN@ZJNAA7@(<>VWX.#U_OKX%_L9KOJYW64:Q_96(L F9N%1.!;L"# [7W_PK;+ MD]K'%NV
W.3IVHYA@OK.F.O+4XONOAP.[XRN?749\U39NE\6=96F!'IGM+ MC]:[%:,,=Q2R M K)]OCC*_%S$PJU^3F&.>B&XG8ERO?&PF?"N2=Z=V+40V. '!=D0 'C"[%.GKCW'2C'#D
M@ G/U/#+66Q\ER;,FH-X87HK_)#@FTL$1QL6+VK]@ M?$>8EM?)V;O\9&\++4!R#)N[1MUY1Z+B SQ,B>W\ . M9X3@\6H7VG;K:[<^Y"RFE_?SY>"H3GC(X]C.IA5]XEQ>?D\N;T,*%]NT']-
S:.&!>,XER;HL^A?,X+IS,'[ZYM[R]G0&RNT.A+#HAFFIF3'\:. <,V X: M9M1&#X\U*WOT)+?F*.<[=92?[CT@'ESYPFI_=['UQZ>)?A[W:#(6["$F4K5 M>S\UW]QBNDXDG:O%NHK6A*
!!X2^,&I&>7"HN4Y6;3 MM-E2^ R$ > YS@(0\CB_=2IKL7%PUQ.UZ8?3V3.TK+B.>3-X/_G:+ 4L:?& M33RJCMLTGY94SGE^SE\&7V\& 4?UTDP=5;=++Y/CF!/YC&CI?P+Z7\R=JMH3A M:f/M^?
G6Z^=F&QI68QAO7ZOQKK,.+>:."PD\=1-8.5SN):^AV8I>.(HWW,+K MRUYGI U:7RBG8P0[^'KJB-XG4UV!5RF>8!SK^]JX_Y=G4OAJL:CWZ!QT NKPK]9ZM;._%6OCH5CHR9=FE6=YM3GW
MM5W29:6*X(*O2OS>8^X/F*.%W+Y>P.WK9;A=',8 &K(HL;SW$_C@<[7KF:LL ML>V)W":*T>0%M;;P%?U\BW&;<--F3;3<<89.<+F+ 7P7K$D .RKU^M]?'W3TP8EQZ&N?AG!/|<9
MS\>GORQ2GN_\ M1N$;0%S=R_J_?6#H5,'OW^'21TGQ=!JE_OC2;2P6 %]E= M.5E^!QM.DD;,6O!^AL7F-NJNDGD7(ZY9!,/*P6?&\SRE)O#U+;)E!O&'.K+ MR2)MX+B!]{NEHTS7:6.M9852'KZ/-
O:5GN1C5_>N\[$55\WFVO)W?7YB<":G/ MK;VJ^U_G<>H6WF_$%N+FTJZV6\ ,3SZ^=89DX@'U<+XWG]M@4RETK29CA9=\:I_3(?MKM_BN>8f6@4$*S\=?'@F MU.?CD\?
#8:8\OS66(:>+O8,UK@A& P67'BSG!IWF5;]F=?.6ROF*Y_TF4^7Z MD,O;.Z$=+:?*U]6PWXPG=KQO^U[_?. 2X=(3W[E.%WJO]/:<*!.:1,*N0,98A M+:])
6CN!*+,$*"V94YU47&K.I)VD!%.$=_ NFI]>H])'D#P/Z_C<3A#2/_[X M Q@2?.,JGQY<"DS_<6T7=N,$(07 .FT?M=DZ67(3E]$#?"$*B^B*1.0[0!=_M[\AYZ&++QJ=K3Z;Z. /?7F^VM;GT4-
]YE%QK:GI:*Q&:XH6 M)XT8Z/?S%KRPUP_A@.OX=C'')^>@=EM1/[J]Y'GN8O_P[V0C.*^/5^7]Y)!#CZ-!7_Q MZZBN?\'2=M_.G'5S&4;A&].1YQF9_C[PK+FR7CBF/:"6(29=F##J$:.& (+
M+1V1(#">F.A&64W\6PW003])ML9G QB]7[7A?Y^VZ Q.BAV0N>COP35YE?R\WL,$W=B,\=_A6X&Q65P),W3](>KA1S8:@^SB7_Z2CD4=6JZ .F M]T?=DN8CV2 T9Z*6DL+=507JW&^BA*OW.9*?
_3R/8/K$&0]RYGJ.+ 59QE5+ M<7*0!)<)V#NPVECAY]@<3V#NPVECAY]@<F&9Z)H&SC^>Y[FK7G M?!'IRO(TEX/Y*KC-B\B"##+]%@\&,O.SF;*7F$;<6Q3[?@WN4#%+N6,BD)
M))W39;)'C"3$B(.!% MDKJ5E,ELC4[2W]LY.1G_EM?\0f/0)^G:,7[=G//ZY6KVN7KVP9MYE*TX+"=0 MOO_P[CL9E/?TK_74D(0 M9U[0@>59859;7D0844 #$G4X:#P0%)1P/H!]'P;4=0I#A@Y$6/ M
M^/8GCJHGI)S9VZ;K-'.HR%U]:*9O]&TAL_6BW!#>[_F9"<\Q.RW=O_\Y^76 MH6VZ75,GN#T M]ICPDXGHWE)X#QI.7\.OVH^C@;V"C@$3,C7&%ZUDT,P/L)_ MGG^AR6.^J,/+NLV!B'-/JZGYW%
[!I^NCG6.Z\=+FO^VW*\/JZ9HWP@AW/^>3 ME.G_@6K5;Q3JOO[CHN&[#[YTN5Q_%1+CS>!&6W5:6_N1]8]X=T.O;_M<7\ MMSTLE9;+7:=^\!8/3C)4D_+": MAC(8C/R\>LB-
W(:"> 2#.P\^^43]6 _M01B-M1GWV7SO9!;:C^VC\V\%59A MBABV 7$G&+(Z)<1\\)Z%8$5<*8W%//7&&H.T$A[QE#AR%GOD"*:*R]-YK=W M6F(.MC!$Q*C*"C?)($RJ18X[&8 -)O9*6FID_1MQ
6[=F+0!;MVFMB9)&+2A"/!G$(\N(@"TBZ:0CXZ:)'>;W5SC==^4IQ&Z_U[> XT.]5&,(YEPAR@-XJ<$H!(UV M2$I#F8DR>N)O@YF,&@>6*.),2B"#G" GHD8&1TVD8G<5<-X$L=,ZQS3?0PS;
MJ;2)^'T*(RZ<8F~NN$U_<3M=M+K)\5?R-8Y&[$G\,K^N'-M*9&TML6:4.2LY M5VN:N6!Z??,.@!SR1\.!GL*U3)1Q:A*G!G$$P6X]B0BZ@3C3H44\4K=CG6" MBG.QOCX)\K/1Y-
A<]#T]D'HDUS8>CU4;S+!PT,_B>)2E15.*7VT:T7=@/VD' M=.@@"6L!$P,&3P>\(%(;D:48P_@C;QW 2F2I&%6.4M.%'T',[8'G"B7F[/[^ M0 4[*WH6]*SHN29ZAH"UXS+O^>2Z!0"_""
1F"C6P@3!*/&=E-LIU'O=:B MYZZ YU-%4P\617F(-O&@D I *KD3V8&7P$$=55Y(SZ+57<1;GY"#DFWL+.T9-MD);DS^>< -E3&.D1S=(81M,<.3+5=4[.IX]O&\GU!&&0B3'D49FY"%028&
MBZSQ@A(6E$LK>5>/3B{]GG<5_S1]"UN>+M7MFQ6->9Z)IM^4S*>T&R5KX('K0X#K>ZH1XIBX$A()*1DPZY20QB37&*2"82B,\4UP=G%N[$G'U'9E\<#&1W4"]+5>,.1Z[Y=X#P==TE(>S>W_?
KO7VOT=UIH<5/*J;.9VN*=8RP'M M&^VPC)52$] C833B(9<1(X0@)A3FD0KLXTK;]3H9(.Y/6[%=-$*JA'3DVLI M.=('O)/^"7_OE(KN=4)Z4LAR>/NQ8K\7O*(LZX&@F8E1* .@E'R0B$>L ->T
M0H(DI[(CSI#01<+%5M%.]13;;Y/(O!%_N"9GNYK'N*9H(O[[FE0Y0,N" &0* M'6<+.*4,6$(OIZM%,]9)T%ARIJR.*=.CA9L5-"O+>DAH1H)RV N!3& $<>DT
MLB8&O"*'_Y0U.JR41U@G'V#+W$P9^+/Y/(!G)/:E3-@!E E[10)88'@9AG4D MRFHOD 1'&0@BI3G_-9\5QLXP32A*VE9ZP3\%@W_].[#D]C!++!.K0=?CR63< M=|/)/$2WH"07A\G_C%@?H)2"_NO
(5>[N6R[BFN814](%@N7>B M7B;PDVU*D5/5)12+:'<4"-,]BDN[@0)O95D/"-X2UD9'C@&&@ M#) U10FRF*8DHE#@<?C)'W$IAEW5B@86V/7<%*+BVE\NZI[C&A$L4. TB5'#$ MB4]
(\^"1P2H$;9+!9F=IVH8*%MNZ9'6TW^*V'">*$(.B@ 3XG$.:YJ%PC MYYLM8+4CM0E+8=:8:TXC09(E0/C ..+"@#HIQBW HOK_V7O3(G>.*UWX M^_T5%9S1C!31V=.!$U*. (KB0[)!GWO)T>N;
(S0 (P"2+9__3U9!.*! M1N]=0%<#Z;!I %!++N<\9\FS*!+=EF#_$X5C[BZ_W@_??5K3>9(7^-5 Z[Q76 M Z M6$)3: IL%.N\!FSX8;9E(8+!?GBE$J2.04H"@+!,EF*+75D[[S0_R9^X3- M+7W8Y(-
SN>=Z? 4["W86[#P&['08)Z.D1$DK@[AS%A1)!E"@W%A&$+UEE/A M(<[2HG(> ?<4V"RP>5RP&9B(,0(${\BBSRLE!Y8S6 2(*[(5SWA+R%%_LLZ]< ME.$31G?N@#TP[-QK+&?)T%YD:(>V4-
EQE.9[5G0_JHI\5(!BC+U!A%L 6 VZ ML:;)(^T(LIY*07;8:[WHOS>5B# ^B\GV/KA:?$4S+NA9T//>3@6*,1,66.T),GT!8U#&@E
MEY$P!F0UTRAQ2PE7)C*WE7:482[!![G3//66S%_0LZ%G0\UC14VS&"::0A(X] MW'!*#K*(>88Y-2(\C:3NII;]WW9-("><A9=,]>^&4?5$6__#S S[%T!^A>I1Q\29]6WPW%=?U<-FDYLU21. MV_B&'8>
<0YUD@S8I#ACK'@0F!*=A'C M\+V=C@:C3_6O<=]X1:[M+0@?PK>_'PZ&=ULU-]\Z#>_UM M0N_,UQ6?LD-,*'[]6@^[<$)!T&X3Q;0)4CF"..& 7E!'% GD M4B*@$(6]K
M,LQCXA)VBWBWQ^Z>\[E(NNN#,"]G6@F^]UA"]D,'X #,?0+91.41RJND! ETW?DWX*Z?5]02\KS[UM?=> _]P\ &K'\X#S#(/,/E=^ M;&L@<FXG]%_9H'.+RYE?MS\ME&,.O* RFL;&7U\!X\ /1FS"H)T-
[\3K _^F9B M0XYT64OH&[3C6CB(\:F$+ YG7L\&Z6+YEN96%$?AC1M_S7.%)[Q>Q:\!O2K5-^P,4(R M3Z[?F.,9@^2CJ6V(=3Z"F0P'H]@%0WW,@\OEX-XMQK?:0MMN8]^0X[&T>0UP
M:I/F0Hf\,F^DT_*2==RX_XJO9/+B:AH1V$CR_CZ MDH_5[.S.&HJS@U'E00/*_S^)TT:O&OG8_.WQY$'PJG.+,QU-)Y5+L91/O=K MZ @^P(.:'.656)S^5:.:3@KA/7P =V4MFZN1.F-A_JB_C^3#
L.""V0"M]F7Q^/O.Z#*3.P4 MQ*4RU0#YWG/S_7(S(BY."\FR\G;KB)W7X%/52?/ MZ68LIHSEFBO(*7WX6/87/+R-V3V*+KE>1YAO)"(\U[HV8OO/,U^(2CQL/ MPRWR\F/SRVH?
[\!ZD^)0^!!U95]45/AF./BF_!"2K\D"@$1C+&!PR MS!C$C5(/(!(T148$9[X4T1EP]?>9,>AFL0!));DY.D&+(RUT#D3# K8E \7#U] M?N*9\]MSX/'94^M^GV@_.\,[S9S5-QP(/*F,/11P9X6UEOKD8J$
>PQAG2. M_*=:&NV$"E;RI M GMEHX\.]IB+E!"OD0N,(LZ-1\8P@22VC(ODDHSX*NQA1Y,R(2*I34#)C),$ "MBI'4,*#K"M Z M M"BMXNU'/WWKO"<7()8\1EU(BFRP!XUA,Z2R+0M
M6UH8%HVRB$BPNCD+"6E/ M$A(H%HDK33RD>6"(Y(\[&&-B+$\N)#+]/L,"_KQ99"\' 'HRPJ><>*QD$$&R8./6N0FH2S%9T/ 2EZ#K.4.0L5Z MDF@L8)[!(:4^@E[!8H#L6SK$8(U*.IZ[
^&J<4!]D% MB:K?X0..AAXO91;4WBC>29*UBF+ .L. I2-# E"*O(f:@D$=-=MJ88_A>]TL M1SC&?/ZM$W),1.1%Y#HRA9,2/4#IIE@(^F>Z**8%MN[:.NQ@1P1DHOH'<(9P!R)"":)!A9/&B3F+;)
M;+-6P,)QQ(:U"1&]PUQW<;6A2R"FC3;2*86)[')%]ROH5K;U]-$MD)B<(0S1 MF..OC0[(9*>AIH*;E!@&\-HZ/L$] !@"#DH+Z,;@1HN31L0;QRCQ*DK2 W0K M*EP)3>RM;.'M9#H89LI8/%Y:+,B\
<;"M-05D3BC%F UE Q69%>8,X)0BYIQ%$7!".K#48@<9II,_PW$_CFH@,RP6:#X<=BDIZ+#O=-M.?!9%9..2]! P(+F7BJD#5C0A$?]"?-461;?)-I(G(BLA0E$(I3AW%;CNDQV%0
M"FU".0)2FQV6HE%93D6!0S M03 ,JJ?EF(*IG2RR$910H,3S G:._%:*8.1>@8&=4)+Y'N6R$JH-6 Z>]"2P MM+B?1!4+ZA4[NVSKL4&N(S)]%B M@XS+57)T4,B28!$#93 E[HC7LD#< ? "@;B#W-
8#A3@6,.;*680E@!37"N!* M2(\)DM9Z335W6_$PR4G. 6:(8B'R/0G!!/8N:'P^1%(%9;TLZE4&KO=QBK R M+\R)^.XV?^'/=NK/*HJ]J7X9SV(II5A0M\U^44%(%SDRUAG$<\Z>3I:BQ+"5
MT:6HV9,MC"D@K=4468KS/0'N-CC"GUY%8[7PM*>.2GP3[2MERI:ATQ5M8MO4(4Z9O(2/ M!F%)6TQMEU([8 M2]CX+.34'1
@=@0,U0]V>7[5MH#K$8.K=802C3DR@>82/MHA9QE&.&$7HR(F M)+'5D5 3JI1TR+)+(6>R1(X1]KZ@TN@^!55M 3^D)-^R$2+Y? ML+]"4"\1[HOB7#"U8.H],35BP],BH"T[11#7#E2=R"0B(CJE
O%X.]C!!^BY ML!A9EQ+B(/^526H0UC92$[%/O)=5EB@_X<2<.*X*!A9.;'4WF,J#HX(Y MB7#.,]?AH*=ZPQ$ 8^34)M+@Y43.N<2YHRCR/*IFL\.B:87>?+44ND<"WT(
M("MZZK,S5L'4@JE'B*F, !*"BFH-SIP,/?X?!YYN^ MA7]NF.QM\UO1{>)IRTC$!%2KL44:2Y6K)BID*5.(82&%T]@DNY4# 1A5X-?I M8#P%
(AR,PV_1#VU=#Q)L=Z;9M^%_YO4LE_)\"VL '4SREZ]^&PGV5\]G-4 M-6M:_=]HIU7+UAN5#0YRP6ZL_P#H80>C:M(LR45>$MLN21/$#;._,SF+ES^SH M$SP/_AQ/XA06%N?
56DX_M(^SU\$*N^]GD,5OT!RP^KJS'Z.E8MQ5$U7 M6PR__XV[QG4.$_T8:B-W.83Z?Y,*8B5ZIQ M@_+4L>RX%@@[KU7NKQ?-5GS(0Y^C]A=??P/9P_R&%S_&-:S:6^_SGL*N_3H=
MC^"C;U:^_A5VPU\A/?\>3CV?Q3LV.*.9A&KMV$\R31[N8[5YD(>+7[\.*K> MSC^!&,IMZ_!)PVD_O/W!Sl6@(;SJ[>]_K7X9GS:.(BQ/JO?1S18)2OECRV_O MQB_08^H,SYG]A\!3IM6'1IZU@/
>^.>SS:I,^_= _OP"K\6GQ(+A]EO6H!]"^ MA_V9732_J#=U]>$+?/6/.7SU>GW[,DRT;YT-LD[TXZ@&FF_VLGG!QB/S%$<^ MMOHV?TGQFSS5Q32;,\B;[TZKC[
>P)6CT#X:'K9V&2!?F/O8+!KHB@XF#5AH M+T=Y/@YQ6"\Q;378D!=N<&7$T_AYD'%QB9V?Y@"T0)_PP[%[-FX>5-8K655 M>X!S@%0?F[5NGA,7BF\%0%\U*NYI=<#T:QKJN8
M5R]+A]F9G57G.(D#Y2=.,\<9.-I<)XG M!QK5FI-U[%]TF*VIO8O6G+V-FL]7088RX34N5&JPP1QJ7(>BR:(\&R6$B@-M2F[5W%841RP)BJQG/L"$D1YAK#5 @?/+9A-5[7'=XW@_G&T+@-&
(S^8#./E M5[/8&7L-1_G631O "[Z_(+%V)A_S!C%P"\PMFK8GI[D_8SL'4V "K>#.5H MY4$I(\)1&_)1=R#(, O_:&F85M8&MU7(=)37PE$'1+E.T"H.P(X)BPIM #4.*X 08 MI 40!W>Y>Y2P.7(BZ%.
[^GT1U(.QO$P5CO\OA$IO<*AT;AW= /B=+%>H*@. M0&GVV2T:,!"]H! _?9>F6'UZ\(KL{[3 'O>]:,%'^MY7 7\:?6S6K5;%N4?\! M*=1)7O\U-C\OZTTNF\.CB<
3%3C[TZ]'\GT_S$N,@T;R +KK[5G>]!ZQN. MZSE8\"<5S.R?9:5N.LZ;=*Ä&. B5YMM@Z.KJ1F><7CZP;A_8:L\UK&3C(X(W M+'Y8N1!X 792[RT&U,*;&.[(@)8*/PSC-8 .ZO^@OAP/?-
Y4DV=KBF,^VXY M1@W7U-VEFGJIW5X18]N8 MYO+*)S++H'W0++]RG0GBZ.PNP6]I54YA4[.G;@R,!S8E3FY_HQJ8D&E67O+ M[AEDER1O'D7R;OJG9]06KCEFN?
\)RO^]JFY=H=AA"Q8O180[f#Z3$T@K+I&. MT7&E5K;C?QORRB .#CZ'-N3DOK'478[O1V%G^WTC]C =>O'N3P3A\\7;O&/ M4YL) FWJ;CZ,[DI9L-I69[IC&@^'MXR^_S&E5R3G8PU-X;-
T*H4MJJ.RL^LM\%"N&%[K@MZTG[U.+K#K MLU0U:$FG.3'[WZ\F!E-$HW&(RU&\V]2L8?R*PF :FOB%U[*\ /1&Q#@DZ&] M>)U_7:'394K9H\@W=(@,+GTKX(A)4#]+%\BW-
K2B.PALW_IH7#9[P>A6R\/6> M<0EW4OLMH0F7$32/W^8[7W_#-LL\=N*VY707>W2VN=EV,_G*WRVYJ.:Y/6 M&G_W:SO\8B_J-Z_^M+&!R]UIPCBNWY]G[,"3(T-L=3;-/4G-IM
+&]8KL\9]A>!Y1Y MC7.X19C ;QF4U,+3-CK;^6R\C# *0\R4!3/*ER. C:?%\<5[TXZ 8'R*OUG> M_%L]#),ZOJ[CQ&:,8KDT33!.^S+!.VUA, /@WK0Q"I;$* W'P-.65W77'[":4;/K$9Y11/.\H-
B+/ME,.S<.SC*]EW^N)].M4'57NX9??_M3G? ,<:0C6>HY]DE\\8&M_(NW%]"><KB98N.=9N>>O M(O LPQ7[_)<=C&YNU%7XI_!X9 -;^.>G<5W?TNFN,%!AH,) &ZOW@QU,J[_9 MX3P6KGD
6=UA5CZF(\'C[X13+A1!T-M[A%,N%'W0VWMP4WZC_-IR]J4A3RZ 40&B,N5"T4>PO4@9M)6LI0Y750*"'A$%3!TL.,+T$*F)WU$%#E_$30!]0_?2&DWBTC M%_3JP90++>G6(7DR+&
PWB&F)KE=HM=,[^?G\V%. MS,\1?W!\:91C_OY(/,P).41*'O8.$H(45L\5)<'E3E NBM5\/#4P/LQUG<%-_IV;PMH MW@ODL#8^<9I+4()2R+4TR'& .ZJBHEX<>],]<$A,I M4EREM\3"?VI:'10 .;2=
<=G<&SXOAPTZZ4=V1PW1(0DD&'&RP$EF'*5%.FT6YV(%3G<33S<&)()-!*%N=ZSBY6>"+)CU?H^ M"5N'SB8%&PLV'@\V4H=EE!(@+AE0OB71R*0CD'<$4XI-P'K;5&7V+@K!VY; M4?Z?
<3K.%/TDRG06:"S0&>!SKXZB+')C4XI11ISG:AR .6<&&,E1<2(YP"X 6NR MU3UH?U#0"R3L.1Y#:6T4C\EK@MC2[\]$@09-RG&,C^$ZU-MV:
[=S]GD%T>)EB\HF)=VX:&F+!%# _7$\RVTPSL;3&0(..5^O8UD6+><>:79 M^_)LNGC@K6%FPLF#E0[^2 M^Q@#Q4N)0<88PS16Q?,N'TB56'DH\<@'2 J0%2(\"2/?CW&8R
M6,&L1LHR &;%;*|.*2%U-P8IY7@"T?L,:U-@ M_X= $)98(AZ51D83C(1()%(7*$];"25=0FKGL=;]!&-RI.C9K;|(/_7ZZ /K M]3V?C[M4P"D5<$H%G$+1A;++E M%' [V'N&4"T4?|/8>W)2?
MU%92*3N^VJ:U MLN.?2MGQD.D1ERH6BCVE[CW4*A:(/>GN\</.J%H@]Z>]PNRJ663BD[WB?P>=!! M;D^2[/H0@C!$V78!21NH-P@6SRQ$W*2++:40X$N%QB?E@$=C4 06.ML6ORUH.
M/45S+12&HK2&.L)T="'/B0D$GTA1"NN4:.]"D@4=U!A1V0<>YMP-!7)"(M3.0>A12PML%CE\PN47)O*0D%%PPM&H[.[1M'3!.8Y('!HP&>#86:Z0
M8S1R99Q/XV9M0GE)UYZZJ.Z74SL[8L:34'6M*70#% MW^5V=LK:"8!2#&G%$$J>*98,D8;=U64))1)5"#;AJ+Q#W,+=1DN+?*+>12L2 M=^G@/=HO/I.N8&7!RH*5#*SK]LQ8KB34BVNBFC9W
M6 ?!#VQY6U?C5+V//IZ[.*T8..DHSCZ^XZ2FDA1<;&GAA:*/?'N/<,/%H@]Z M>]PRH]

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|%?XGD: MK2SI)*[328.]E5_0R4*4+.1.EE.MR*?Q<#C^ NQ5?=O(AO&\AIOK[UYO0E!K M"&;#Y]IUM?)9>&GSY=G!X{(IEB]'0WLQGB]:0+YI!T\P/L7?+ &^)1K;21U? MUS"\C/G+56[,^ ;9KZZ+,?H\] _=N. 1L?[U\Q@W!0'<0'0B%UD!3LE\ILWK_YTRS7D M5/*[+KGK=X MC=?^<^<- O1_3'5%>YN$)RP^HUW1G5OB2[W;I2[AT:.W!17FP M+MA[ESEX4$#M+?MO=KK]C!$,,E]]#9?%XGD/L&E?5BZ'G!.5Q,LC/.LC+/E MV2O,T\? X[<>$:_<_'GNI>$]C'>W4G[7^D>SW&4\.'T<=IY^S6Z<HQ]%-&1&(ZTS0=-+)]28"D0I7GH3.7WQ)O>#'WQ.L"-SX_I(9EUZ4A>OD<<>IC1V+_AFG MXTSEFA+Z9K=']2_FD+1 68^'WM$!9EZU&B>6*$8<2IC)W7Z)(*Y\ I0@6O H; M_%;6H_561*P4TE202QEBRD#4*9BE-I3(X38,M5TKn;F\l=7RKA||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

19#2D2P4$!4Y"$X1#IV/B&\ZE(I=1MA>!HK6+AKK$UA7BEJZ[,&HHK_I MD"*UCB>[*_WM?K$)*L9"FF/#QAJ;J"'907(((*EE%-ZH ,K$DN="&1@K _[)
MJ/TI1135O4IX@4G$1PM&XY4B9P'>D9+L0ID)FBEK*DB^.$@^UR&5&OS ^[3A M/.@Z >8&?FG6='W'UWWTJB0[./8;I"2K09&CV?+*PT>VHL+\J AK%(M'#A)
@UD2\%12L#K1(UC@DK5-ZH?$11Y'4MGQ[9A[J_SCS4U2C6-[V?K,AKM MT;56YGZS)7)_+FW#&YSH+VGQ;A)25[W]YZZl;,F@[9A5W99#8)F*@4>VH:>!
M@2XK!+32U*DTK4K2@27. ,N)4R6X5I+L(IXR3 SL9QS*VWKI5)ZI(#B<&5<0 MW#4(TE2.LTD&F9>C"'5/Q@1N(=B@A>8Z,HP0; J@A4#ZX:>.@9* M4B#0HO7+NV:(J-
YIP\!E02EGD:.;8:W;[F.#),#&P*H+UW,D 0B_?;/?S6??* M+'U\WJ5FB2\7^,]B$LK+[I)"ZO60RE-9\?-5% ^%61^YY0\J(WF\(I!*38CG M"C)U'$1*'$Q2
5Q"VZ"4+3.LEW/Z&'_P)YMR_GS%X^UEKTL_M+\L;B8:/*:6 MF59CI>[NI[AO5KHJH'GDS%3QL^+G:>(GMR)&;R,8&Q$+?3$A(B*I9@B2BGEN M3,^$V"%^MNK__>!SN+Z1"[50"N
GBB HGZI?'(11-0(AL)fL$9&B)X2X?#& ME/<`]#'!N J@1\U-%4 K@)XF@.:,,0F*,@6,%0'5T8"E38+P/P7)'HZ;[".15 M #UJ;JH 6@'T- $T.*%S*M5!G)<(AL*#3X9#H-%%[TAFKN<"?4P4L
+H87!3 M[0ZTB^Y #^XG7F75O?F+G;"8'& ^M-TFM+]JB4X"7G%E?*1L A2.0>"V0S> MXULM==;412]TORFOE/%1>B$A**I 4*K!F2B!.\\Y072VO%>X>=]-AHQ48Z'X
MU5!%1SW!9:B5D#=XD#TI'3SP-4=M> MRO-C@/-@6QI5L*Q@6<&R@F7G%2%C+V.PE MC0(\XZB\BJ*\AH2FOZ4L1!(9*K:|/ E.4^8Q@Z0E3*S#"[0!%E;KG,T ?^\
M0+LF9B7TFD1(X-S 2CQ 4113:V@#JR7-HO$B/.]8HF> M<"YMBD!S<1HDY\ HGX!X2X)+GDK/GDVG560LR)X;W0T5.7<;S'O@^;U;B:_ MX-L6_B40^2,+/P,F'^\$D3+*MW_\
CG\Z"=;)WCH$ZSD6B=X0!.LY%HG>$ 3 MK.1;)WA $ZSD>B03W'TQFEL'-QSC]IG=B<?,2VL|:$8I""TLN%)41WBJF!.!6=TI:YN9
MYH[)"$9J75H293I*&/#"A1A34BG8YRU2P,>LDEEJ96[*EZ&)64LDX)<.A.44*T &9.RV=!H MY>WE#?=SD%^-&=WS>=&*817#*H:=YM'Z[%+R5EI@U"00I22VS1[1SEF521 & MH?
(F0CK-HF$(J-%S1$A2JIRD2$ E+YA)AC&6G_]H/2JG8ZJ.#BKKH?F*F14S M!X69DD?.34P0F$"CV,0 7FL*3B:B=?8L\EYY*)48BUI+(%E'$!FU2A]D@&"= M,(1QS?
Q.MBK'L1U"VO/#R<&0>2AP.;Z6BS,E11 4F5:G7>)O"<,G!:!V63###*2 MGDE-O/&2O I2GL7'1=!^IB(OZD>HNC\OI6/;*9?R>[@&P>BXWRMB8*5)1JZ)6W=30BU. MMJV*!N>>7A
MH4S8X'7\YZI97N!0 MFE_G'ZM>E'H7W_6A2[:XV2MS/UF2^3^G/Z]FC0XT5_2XMTDI*Z'^\!S- . MVKNT[=RK8V\(+%,Q\,@\V["0P$%'+.\,34%K.RR[+4$81WKATEE"1-'<|$_DQ
MD8AA8F#/ZM;,5!"L(%@W]*1 ,/NLK(H909"5@[N3OM5_34 M7V-M!@B0&NZO4%8W]+2@S&C'F182;'&D(BPQL%9Q",8S;PB5GO9RP7<(9:W2 M?#N2/:&(3L6QBF-
U0T\+QZ*SUK&$("11)7.$@K.(3HHS(2-#'!-Z%Y&D/>)8 M]G6K(*L;>NI %@UE+HL(WA&+MB5QX!)AH(E ?(M:&^YW$0V]0'8P=%^!(,@V M'!"2 +##FDTX4"/,402E:!++$@?F@G?
0D&-JK-/B8D$ZU+ \C*E,/Q.PL*E.(M=/0N-4M\N*48LZOGYBL?;RUZ_=XOXE\7-TYZ/"?TH,E9\S[D& M]VDU=N3,5/&SXN=IXJZL.PZH50]>&ZJ %H!]#0!
MU*ALT62W8))4(+C#5SZGDI;@E @Q,"?V'PI_%H]EK-U(#D7()R@X#.C$*,U/D:%HJRG\'>!^58> M=6&Z'U?+9NEF$477T\]DZ3'5/ <[]=4_?\PG6"I85+"M85K L8"FD
M6[/FHR5"!+8F] MW"M"5X0^8H3>,X9J;K,.)5&,60,B&UO*PQAOGFJ*9K],J=?).$FAG"?ERG+, M+Q$"5A(/5C$=0^8BL0!L.JWE8Z*?]3C#<>!SM\&\!T;P;B6^V\-Z@XC@[0E^
MCU6Z(F4;__X!?OBTU,=1/>E9]WW-.;<27G(|[< MTYMQ)>_^ 7O]_49VMC&A62*A=5+KH?%W5\TD)0Y9W*.Y5W'L !'SL7
MCEH&*OT+83+KW]S;&%9^JOQ4^>F>_!3"ZF(U=IA3ZQ2\3:!R%"!(). " M,Z"(4XIZH? NSUTF@1$]UM;6SAP5P0:]H2|SMN$DH"S'8*D@%HBUND"9 D>] M*[
DO!1"!=*K4/88*#O8P@45OB\5?@:,*GQY!*TH10#(*?$MT>+)6ZLR:E MK#.-TO:.KL,;)*-,0*(4X8NC'F>\8& !59F11'1FSUA*P(fIJBU#p!A;^@<I M8|A!^XG-@:==
(0D.0,1DT4%+WK0(6G.(R/,|"I3&6=<)#(#=Z84:++$1G*04 M-&.$1KRC]CNM3'7/P_U2CIG0QP:5]=A^Q/V+CB)RITI&(Q0K_,0X^-*>@.B4E G,2BF?3>_3;&S5GBM(
M'8K;!UQ5L=O!GWI/W!_2A(\.3#8< MU4>AD),"K=V>"Q %Y_>S,+|(?SN.42J{5V.+T M$|K*4JR805"4>D4E([KGRGLD'-XO-D"%F-301 7)0!G9"I*!9*!)A,+-%+"
M4/_3+H!EJ3193BY+98Q-K >2WFIRK)#H[!:BG):E#D:+.\\O"1 M;>@PM-$]ZXO&6(A@/C609FB-0B>2?!3H(BK^._5\WR H?2_#K_ M6%JC%-7X?K:NIM$>76ME[C=;(O?
G|._5[,&)_I{6[R8A=1WK?TYA_G;6WJ5M M7E_=ED-@F8J!1(:A)K:R:FH?,B@7$1+.2*>.;,23P2@AE*".4WW+?'Y,G&68 M&-
BWOL^[*5&8T:1I5BF.EN>XM& /1^GB50A4^:0"22fA1B#++F7 O 8EVX;(V^9]-.:1W|"%FV>7(^,FK&ALD]E"FQU0T*V!+/FFNC@:M2 M3HR;#,
[H",XS)EG,BNE>/OP.@:U5K._$M3LU;G5-XU;5ZU"!K6YH!;9M8*.! M6I4L@>08:FRE6**ER@/70B2;,!2F7R.V$0&HW0+;PUP)3%5@]\!6-_2D@(V; M1 T7%C4V%4"X2,%*9T$(SZ7V5I
D=Q%2JAK;P?)!!;8CV!#3 +84K%29@B+> MOR1#$;3!,K27,+E3CFSBSA1U=A>G@_JP9L7COP@E8[>I6.)+Q?XSV(2RLON MDD+IM4394UGQ\ZVT#H59'IGE#^HE=KQB3>B<9"
([*+X P90&COH\\!%3(138Z M1=|+ =MYZ.CG*QYO+WO|WBWB7Q8WCYD>)G*DF!'T;L>:<:ZO=IH7;DW%0!M +H M:0(H5T3D*#T.-U 0W!$P1"%>&,ECA![U&@J1-
A[Q*T"Z,%S4P70"J"G":#4:Z-4"A!T M:?Y#O ;ODP'K!-&"XPDRL; ,#!O#^[J9N%-![]=35+ M(T[&(T:8J*)JI_S%SEAAL#A?^6DZ36%U^Q*VW9E?%1>B&+@J] 4%3ZG8D2N/.<$T1GR]--
<=7%Y5MQU$7!?EPM MFZ6,191<3X[+<3TV4HV%XL\IF&Y0S<&)HHJ7!XV7+]/TLP+GY1LX.P$A#XO MLROU'2AX91 .-=$II)0<[QTF>PQP[]_+-]\14L*UA6L#Q9L'0^!J49F*@1
M^&(PX+7-0(TG1C'AO=8]IPBEG 02 :\I90@"!1NI!2=A=7KR5.2F.BBA#JY]+#CY9"D0RHXGE0O6[O$A.4^8Q M@Z29@"A%OEV@";*V7.=H O[9)1I?K]4+5W;.[)YK@
T5F&O;K(K0%.%?2*,*YM"D"S1(Q.#D'1OD$Q%L27/)4 M^MM3=?>ATRHR%F3/9_2&BIR[#>8],OW*_'U!WS;PK\$(G]DX6? Y..=(%)& M^?:/?R"'_UDZP0/?8*57.L$#VB"E5SK!
!H@I53/Z=A93O):IS!|-?=)@1_"6AXI-+U,IGS%I?TH)2<(2VT2]6B>_^ 7OJ_4 M1&L#*162*A=5+KH?%W5\TD)0Y9W*.Y5W'L ['WL2CEM&*IT)83+KWJP;%%9^
MJOQ4^>F>_!3"ZF(U=0< MF"E';*,1X*-UH"/+,7+AD^E5$X]94A5< "Y*/0.M)#@K(RC*I<\,[Z>?N38! M&RO#QEPOVC(MB@-_1E#A2P-K?"U-_AB-
6NF$#L20KA*U'PA&1P5,E@=,HBV-[Y?>*R M"8* #%]*'L(:#L2]54MP^LH8=M GZK-W M-@4=0'&*"IX5'+S2B',,!Y>#IT;V&@^HS!G7RH"DI>RKQ5>6\@")49FB35[< M4?9UKR?]!6-
C9LRQ0641*U\0\ @P<\'HHH-(C$34^QPO!>O0&/7),*"H\VGK MB.5NN65AXO(-O0D "M&(:T)&53IABQ4B."H M#*V!S"H%'8DU-P'+9L:S9P%"D AR2DIP3#% &YA&;ZQ4TE3 &CQ]5\
ZL@T] M"<"R0LA24A)<]*7";O#@2]A41I^2T,E1TFL=)ZC54B8'3J$N)IA78"BJ65D3 M)2E-(?8K2NX L'J..F/&W.RY#.^1TW@%K2/;T), +9%4SM0Q0!XF2D^;#,8P
M!8EP2B+G.KK<"WPF@U_E4GE8%#:7Z=?ZP]4:I.?#!; MEYMHSW:U,O>;+9'[<_KW:M+@1']}BW>3D+HVZC^G,'\[;^_2=E2O;KTAL$S% MP"/;T)/ P,1H;D]+=(T,+3?
@2<*WU#$N#4^4]UIL/R8.,4P,[!G===QX/8A1 M8;!NZ&G!8)2*VT@I6,T("(-_?/ >=)32>,\UT;V&V8^);@P3!JLJ6#&P;NBI M8Z!B2BN-
0(\Y+YJVA"M4ZYP$]J/+1.L0KSUG!&A(4C)48^W"FR;M,2\1(D6A34[=\9C7+IMC/3[ECG?K!.3V=M.%'45 MNKY=)4)9,%"%7HFN'N-,JU?2"VIT*M[JF<*OJ=*C 5C>T
MNU#$VM75#"@N5! M@' Q@HM$0>...!J6IE,;G>'U,_&FWP/; ^EX5UJRNU0TI*5R+2:OHF 3ORW$9 M$3*8K"+"G*"$2Z.TEKL(*%&%[6#YH +;D6WH20";9\!0GQ)X&4KE5%: 302P
MPF?K,O/>L5U$B:K"]N)L4$_=O&S89SR:I>5HGC<';YHJ@Z\ZH NEL H49L MDJ<)HB(!K?^HP0*H\"),)6&T4)HB-08ROV^@SA/Q+']W*Q 5C?TU(';;68"(A8J
M5T4A2]J65L(1,B)54L;+U#\-N>NH306R0=%]!;(CV]"3 #*=5%8Y9C"*,Q#< A>G(_M,;"")##&&A&31T.Q5]IBUU&::ED.)RI3#^/L|C .$NGH76J6^'!_RPFH;SL M+BF$7L,T3V5%CU29%E?
#/9.7RU$SGT[B:+.)A*LC|SRSR_24BQ(#2)Q'!P MOO0@"Z"U2B@+%,FX1=6L?V?YOGYBL?;RUZ_=XOXE\7-.I^/"?UP0<9,T?V* MM4^04B<4"#]V;JH 6@'T-
$T.4>D8QZ2UQ15^M(:FWF+*&IS-%]%E/8)H*T9 M<#_\'*Y_HP)H!= *H"<*H$(0*O /,)L#]@V8(UBP'U*E&G$4M+K*[,KR-:.. M ;1?Z&3/[;0K@%8 K0!ZH@
:%37<6@HZ=ME;"HS,&]PBPD81$U5NWO&U]H$> M/#=5 *T >IH FCDUANN(&,C1A$^>H#F.V&@M:I9$.R^)W77[V4S<+:3SZZVJ61IR,1XPP7F753OF+G;'"8'&^\M-TFM+]B4X
M"7DE4>10CMJZTJQT8K<*G-0*E%(B*,JRU+WSP5H[KE=U(#DO16"*O,J,0HS6 M^!B5=,7+=9'Y5AYU<;H?5\MFZ6811==G(G/D"NY?C/"IM[2MBC+!&;$?VL+O6X76FO3
R8S*/R)%I->X[F MQ\!F"YCG\RFN>O/MOU>3Y8==9>?M^0!K!T!5-..O$399=%EP*0-7]OG DJFQ%7LN MY%P1LR)F1X]/CJ_:HB=$7H$T3H? M)IC-8]K\^(ONZ\TR3--O$">+U!+9U\B-
]XO9JSA1+Z?NPI?EVU>7+I98P%;4 M=|*-:QTD)6<*/RBMZ";YP^8I[4AS2*2VF]EKGB'KZ^H[K=[@]EGUN>NW?C M(\
(I6CW_./OV!U*KY%J2WGKO]O;M/6ZH]X_G%^%H=M]ZX+++N-$OG;3]^Y# M\^]+WU_;O\WFM(1[^\X\90.>S MN=+XH@/@?+5?^W_42-7?LBE0\T-MWI;TW
M8N1\!T8P_'HUPYE,)I.T"V[ZM0RN% C]9CV^J^USW18.#38>2YBWX&B?+*\F MNWW&6)O)SG]W<[%?,#?A =O>75KN_'?IB3D)=ZY/%P$=_9R:M'BW/J+\W6]Y
M6]112>D1.0 ;B[<-I/20;Q:4)'WI;CO9N)OG=?-%-<3/# MIF6'[@(=ZL]3O/B+44)EYK(0Q6*5OG@LD:C'X_G^R>1,=#A/H]
(]UUB]HXXN(EYP(VP?;R]$DSNBF:R7=.0:_'@ZG;]OOMXFH'*ARL[4D8TVUL+^ ME7:W5<3 K9;SC1I:QE/$$PZ_7 ZH>LQ7Z_S@5]WC*"%GY'>;'^"^3]UED[YN MTJ5#@9 VZ] :'-
V]OI@MN>O=D)GXR125]\:W]|@K;:M]K$**5OIW1>K>?1$] MHY^IXG/?BS-%/_N8(0YCIT4T;B71V_?HWEETS\]33_>"(,3)>XGQ%OL.H!<^)>V..];W*V$V;4%,+\I/HKG
MJ5]U4++_H7[J%YCR"=90W'WNN@HI(B1#;&/2.EOP#O_H8 TIEG/+>DF8A&:; M9#:@5<+?9); 2$V!2Z$E=89HVEGOMO^7-^,9=%M_,5:FIVUT:,^@:;P3^3_8<
MGSEVNJ]0=G1;>J10YGRBSF4*V=-8/*P2K D*M+&&6N:XLN$FE 46N M@4B,@W,D08@]2N\822_/)31L5%ZK.V>#^<<#-T_3@M^1$*8X]>"7[*<;Y4A
M0^"E*D.NMWHEU'(10=J2DN2#!$^U N\10TTXQ"1ZU0.YY$8E%#0L>52'HT5X M$=9#4L'92)061+Z\#.%CIOB8BRI#*I35+3T!*.,Z4N*$!^405BB"6Q6H2!;
MT#1:ZW*O0Y7)ON1=6N NHCJLG 6GK %.I+74:\2_3YU*?SYUV*@QUR_2'6& M=#\HI_#++=X3..A_W&+A9LMFM)R/+M?-U:]GBKBFF8>)*WKR^\GR?'05QF"$ M$?R-
GT[":)YS*G6$1C#Z!5_@9%@5/R?#AE7\?#O=K[6P$17B3%@H#1(EN!@, M."9E,(H)$WLY B^ M8MC1;>F18EA0+F6*5XXHA'WH%WGH*1P?.$QKWQ?6^ 5ED+AY<;A"^A?&E#
M%C(03XLS62$(NI=7H=78$#+&9:I0-CR\D&]T#\M4BXG/5_WJTR7:7/R7!A ME3[7&C$XA&MF>2DK:$&Pl,%QFB$Y3]E4B3;.QXK;9!6:0]H]5_SK,$(_.S
M"2GR))P@+R]|^)A5Z5.AK&[IJ4!92CF%J"@$&U$I)MJ")3*#]HR9&$2VLE_1 M6TKIJ):0#/$(942!S<;#T9%$;@PG)117H6Q8=%]|T<_OBWY]N9A,B^[.JNY<
M!4X5.$?@&P32P1BY!&$HA*BU@F1&"JH" >N(M!F&$ Z.E!6]M9DKED/HES5_ 5V/-V)1JR57$5""K6WKL0!:H43H85(6L:8UX M#]X|#PK59$&,CS3TG,
[.AI0(PI=$/;O|C94R0DJ&*1XRTV8 &1L5R*K'>0^Z M@.RG=T,"71Y7F7+R7!9E2W7:L[%H 7Q#$A(*"\8^ETEH%Q5P*W-I>A[^6B F21Y&;S59* Y;E>5&89SC1HO#6/+>?_-
VA+CTJY;A&/\R7 MJ9:D.QV&JU+F6B$-JHV(0D"PWI5JRQX\-PY03S:.*.=5.5!^0\HXZY*V"7PN MZ7])<;!&1L#/J12$1CN$0^AT3+DIYV>JH*E05K?T^*$L,6FD)08RU:C\\DC
M"8)_E&*H&,?D?<^1'#7CF7H-42LT_#6W"&54@LY2!I4Y\9Q5*L:W0_*K7QD M.G/;3[7M.S7Z:8#/^[+HQR/[/$WJ]U@9 GM5L;(M5FSB3 I6\OE*X7^:!+ MKU14 5+\
\6*T#JG"%&L\%)<(VL.1I23-39JKDUVR0V@4(8<&KW&U*HJ M5BJ4U2T]?B@+4@?F?8)(>-*/HQJT!6?7T5RNJ6G@"4$;^(R2P47[(&$1'/#%$*.'=< M&H4?
FE[RA34Z!ZXS2%,2SY3W)2R6(7(A,U&!:)<& 65H])/:J:GZD[_-ETQE M]27O5]Q\HCG]>AF?7X$C%4TQ&)8C=9"--Z7UB09C"85$!1?"&4-%
M|[^=R8Y;2<&$H%H300$^H99M0J3<9*MD4B\OFA378R+W'.3\!-UTH%[XT?-. M!?"1Q=0+X 7E=-8^07 YHRYO#1A- M!/ 8@W.69^4' 9A\+&T%$ %ZQMO13U#_G:WUCA?!TD9?
K=3;;ONEL-05L`MO\Z1"Z[.*[847GJ"M^S09F??L!BJG-LMM[(S5M@USE?%/#M-27?[&ARKK),V M$RTT4&9X.324P$D?03A' FDN"2I|(/ M(-=2T#*59FR$>4YQ=X-
X#D_@5>2LR%F1\SZU2!US3)?SE2*@;:!E .MH*HT6 MJ2.$;MDOX.>"DXGHT@6K6!8T<_#*(G+]E)0)S$HY@-P80<;*\C$S>^YH?F3(MN6TJX&N'T_C39@%_6%VDQ23@^SAYMS6A;?
U6.W!=]'02/E_/[_6-6B3EI.7U[HMN%K<+8?_4%<+'<5'|HQ MS.=8U%W8/@|8TCO-)%RG^6K9+'%Y2H/WJ'+B-XN[!|?T9F_X%/1Y>+ M^;M) @>CU_7E'(ZO\>'WGT?
E\6D(SYZYI/YY?MDBXG*-U%M+D71H%UYR/1^G? M*[3'\.-RT9^G.:I C#+P%_BI/*;K(8O7/35=]@:!CG%K[C%&3ELMI6]9Q-)FUEZ1WYE&M5AG<+6WQ#4CU|\,Q*&C#?D.@0F
M'+V9-$M=F#OTV8+;A|0Q_3B!LU'AD(\4UZRI.?OWYPZIUJ2BI8)5 M4Y.B3[SE+JXE@(MY3--QBTOM2?%S-WN+%ZQ)<8O(4>X6YB@R+FZ^=B',+W =
M/W1$[U9Q4E@5IXQ@U72O6E=9R\'(WLN6T-OASR_3HAT"SF[T("XNY$ DGAJ M%[9C@\F&\1R^7TS>X>-PC2Y7BZ)8M"6E"B$;*L>C(5'RFZNQ-NV^_)\4WVYU
M27A^PNW((\'L_ER>XFOEK0)N<]%M(*8Z^Q0]GVW#7;Y=\'22/ZPCX^6* M(MA^ZV@1>3<6C0\)XG6!/&25U12A\C.,?O6,]R0EFUOH;!0Z|L9SOPF.[73
MN4BN02T3OUMND_D].0:'^-VZN,+R?)$2?CI;GC>CU#;'^"L*@!$GX^X867D: MON#=1+|I.,;Z$;3>=,RQ7_>MLD/V,&=6P692H*6)I^Z%!W4*EF?QV/XRY
MABN#I2I*J"=:64BQY[APJ?E:KXD %FL"*&NA"YM1*<+ W8N/#@B!&@"!5&:H28U*M7J)(A MY<@67JX4"'HH>)D,(E,R5&E^F\O^.40,Y6=WYY4.!UCFUY2S:ZK1ML9_M4Z=
M0H;$TP>=*VN#ZR%^[_UO-Z.#E#O70>?LFIOY-B_R_QJ-_H#_WD(3[#,C MN=K;]0TWG3V3)(ZCL2)51U#RERT4 ;9H'BQ@28]>L>Q'J-CO)DT :4K&I,_
MYF++=I5G36HH_IVEQ7'PS;Y9-&^/XLVM2_,E|:'T=O^)#_SR=AW]|,4JX[9?% MT;M8I2_NO+ETL'I(N)V:X+O;W73Z1GT_C+FC*H@1J0T9H21:_
MTO8RGZC/_*M)81A(ZH9G)4&5%N*Q:9B#KUSOXG1@T+B@+EJ 6(D#@XIP68G*+CU#@T M9&^BP4=.WR;2UT7Y>=MZ/__\H0<&KU$YB@A>J$?]F%\C@Y>?; *CKU?+_FB
M&<0[./MDJ1KC?(>)-8)XU4^9I5H MI'R(M!"8X1&,9A120G4235T2@CTP8B'XOQJ4*KG.H=Q@<7IM>.6O78O,5(N#U M_A#OW&3JVM-9_7S++3_T%?[=H;>\P&1'1RI:[A\2:67/K?
+KR)?HK@7Y?O8Q M(B+&M\I\/T><*.P0)PNDYOFB0!UK2+96 W50)<#[AO+7;FY5O MTK]7^+LB\B]++!CO[#_<.I:6%;N8>Q=]\2D@$(Y2SAVCM;I&
<2Y0VVD:7H;U8AI*8I3M'Y=;9=1Q&OWH^Z(&@;.L2;?Y\HM-DME69V7PTP[5^ MV\6/+MR'$H:]XXOIM?BEZY@=-/=MX1A M;[G9>
[226@DRR75!=E]FY_^)ZWM=I2OC+!'5%N=+1+2@#(S:'C=7<=A-9\AF ME-Y-D.Q@&2OUPMP!EF))OX{C4M\>;:?:X6E_?Y?QZ>-`G99+5H]?T/OQPM41C M]O^EDBE1*&FRH:0VA-
PF1)6KFA0*[)91+%+!)S^@\V,RW>34*ZJ;7^5W-57J89 M?Z3>\68E2E'P[-'T6Y7RZ[K<"->D)KE8Q_Z,0S| MB3MMD_O9B2+4KRU=
(F&^15;9R&A@XD*E\Z\T@P*EC@*%]J,^97_O(:V58"_F\QX=#E=-4@R2#,A+5I\ M6I/I%B(_$-^W2!A).]W00]M?WDK3K6A%%X%H/_KDLNTQ$FV4@+_/1L]0_;* M7:MX2UA@O,Y:.
[.QAL"ELD0=#:@:32@L&$N/*V,A6B(2'8[%D0/ZH]2NWV75__+2 M04TPF\>T&< 7?[KE=IZFWZ 3_{]@H7^.."K"YFK^*BN9RZ#U^:Z]>_E?7".WQ|E3'<VSW3PC_K"O^$*O#Q
ML,+C=_BSC|!CARF[YOYOD\;7?[>W:>MUEWC^A_.K$ZKMOG7'3EL]_&LW?>\^ M-*^^^/VU_=5IM3IM$?_O./&4#GIR7[T;GB*]_]$FU/_?!1(U=^R*5#S0VW>E MO7SN
I=DGHKI4[9]7)H*@_/3C/'*%A%,XA(2%%Y-+!]'8\;:9[MONS'U,L9K,KSN;(ZAZ?PW!+>NX-'M\-[\IHO#\V&-ZLV?QK9Z_QA.89;U-Z= MG&FN]6<>&@>88#D)-H F.I5$
(OM1CLFI^">^9@#XN,8)F=8&+L3EP MD^N>,^2V!R=;@V|S=/7!F=Y?+$_<;3E6YBZ#_/5$N_X M6XJONKM30L[{[S:'RI%JINZR25\WZ=*AQ9>VRBYME7$]!S3;[.
(/7V]<51"$D:W_GCJ{UD4^K#-WT.MX+M] M&]=8^+81ODCEEMN]:'NJW7+$,T3;*-_^\0O4HC\YVQH6522]3D)D_]>|)D5HF>0UKH-[F|K7WZYK;;1O M?
D)++Y5YE%"OS5..IS/.GGS=%;]HW)=RSKB73OO_;)*?1EV/9Z$-RB^9>?0LJ M7U6^.AF^>KU)<&NYY7MDGLFLF83V77O>;_3E?^)3*N,,HRCU<;;@^7$K,.WU
M[;%7_6/9M3[JR71TJIW,KIWO)MK1)#WP8'P)_AFP1D=()#C*N,C1]B?5G,VUBH:]MTX]-IW3G7ZV3,2HW)7THMR>;'_+H- M3;LW)=BUZ*HL7%71(-
MPR3X'EN1,U_;I%2CKE@X"V|/0$&E1@?&'-AL.8A0 MZH7IDE''8]3*,YT8Z96D)(&77E=_7) @5)9@N2 @G9+1,^IE#++>"F_\N/D' M@]N5SVW+W?9K6ERP?NI27"V*ZVUW
D.=47))%)#?+\%3,J&!W< U"7D9S/,%. M(IG%,KLE<KCIQRG^_FBYR*UO/[TH=B.FT.G5V[5M|@>3D%U?8/K\" MPP"N)W#.EX^LX_#\B);1Q.H!V)2+LVH)/C$%01N#0|2YIQZ-05?
PM&TQI%5 M*;(SB|_^=CE9-V#=&&%/=CLQ.29"/V=0Y$42XA_OQ+C708 *W .SHZN#:H=H MJ221U"4/@A -HI00LI$X<$Y:'24/,;N#0,N7=EEQ=<:KS^K4X;.:Z,>#M2^_
M#4A*B$TG1[N.54V-@+ _)WVI4,\S$H#)H[=" "C 48P.WM9NAUF?6;D, M3AGGF ,MHP?!-9K=EG!@WH(2%8N#I$\)1&UK3&J
M/_F4)%SU)S^38&,D1B\C9",X"'L<6"DD$"IEH(8$%7O'TU"L/TC-<68:%-L M4L"7O\[+1UL L;-RB#C|L595SE6+XDC<)]7-O$LWLV T&T]+,,9M25RQD*)7! M@"
(,1BD48Z17*:8@/G2WF=*SW1U/U?\K%LZ'-B\W?T,5:]TQ<#CL=FK5_J9=5"/*.4 M>(@.U5#A) >;' 6?'4DJH&H9>D<*AZF+7G7(V8O76MJS-J@<9),5H8X[+WJ]S@;D
MPGYX8O5SN+!K8G7%P,,RV:L+-[GSSXS*VC@!,ED*@FH!/FD",>NDE2+>Y1XN M#U,5W:\+NR9>/!Z'C:1+C$&14GI_[T:_QSOY0^-8LO;M.JK5YYN%?O?QI6GI^C;3S
M;K++\&M9DE]Q$'~>XO=?C!*2Y24^8+E FMW:Y>TRN.),EPN?B6K0,_JR^.H9>?7S+_=OJ*OOAJY!=KA%<@KH^5Y;AWX MHY^F;E9\^73S$A&AO)7MV++8[;7-Y+?
1!3[VO!DEO$&\'@88CR;-]%E=X!KA M=.+(-?C#Z73^OOEZB\@W)-U2]!6+=,O:UBYVJ^5\P\QEK1*9RD*7RV']/LQ7 M2YS^;RF^ZI:"$G)&?K?
Y02@&\663OF[2I5L@EFUVK!4&W;V_N"TT|&[23/QD MBFOS]>8>=\5\VL2?&@>^PA M_G8K]^0<.(O^U)/SU:_?N6>F8[.)>\&?D^5^>C-OL8Z'_?\82?3^.=R|=%
M54;S//J#7_S^3ZW ;!Y/+?H M*[1OOW.3Q:@U?-JW/R'?M?Q6V:T>&WVV#)P?YC-XUV7A.*3-%%(K #AM-6U> MO7?5(3OD",;^G&W.JJR|@61)Z?H7+5@O,AAA4F02C5S3*R-
CLA=.!0O<109" M.5NJSAC@1%I+O0XQT9TYV[!!]PI-R.]G:)"OVNZ /Z+=O/CUW.W6;CCD{ZQ M=W;.TQ@UYGK/SK5CYY<*@<<;G#A2+-3.^9PE0AI3&430";P6$8PE^'GVUK!>
MTN! L?!&1+C5R(M"7G3Q6V(0^\F$86>L9L+LS7!7&|_=S=\MO==F=R?$8%62 M7=/]M35*:PV1< DBHQ#SG 8(-&?"A'5$]4Z!\1 BS5ZB)5"D'Z$)G'1H&!"N
MI4=PRCH^GR2[WN1|!^GOA,JQ%:3*HX] 0|_2]M3O4JFDTBA#!>B@44>:(^ M'Q$*28PN*ZIH/"@H'(1F3\|,U>R?V2|?-?N/)VFK6#L9_CI5:?8\':@)%4EG MI<$26:K(*P).B 0*#07AE#
H[H8M'3M V)FAH)@=&[GXA"#U2EKE^GCW=MJ M+|P+$;W*P@=`2L6<X;.#U5^K;7*<"#Z$\|5'">6W0V\R3'G$ MUU*G7H(P1(%3/@-16M,4LM0D'@3TKA!A!V'+9CG&I22D!Y%)
L1"42]">!*IE8"KWHR&2&Y6" I;*;Z)%?!+6 M0U+!V8A251!YN(EP=I/W#]@[J'O77: "3 M?9Z23[^>IU$NE0K>%1XME4%^_N6_FU* J;W+.4*H*@6;<.S_2LO19:DF7"XJ
MGQ4H<;,/2<'_:I!F+JXF)?AE\I1Z|_%_\>FRZWD23HH]\"J^D^1V5>9\>^ M2'/;3*VJGEMSN|KJJE4VYJ8K"Z0("#11+[Z;|8B'(),5%(F2\4<="(^!P5G*[_2'!P,%@<K,&$2-&HJ-
E*8C+4N^WZ-G.05D%;[A5@O;* M*E#%.0A917"L)!5%|9?2^8NJ:(?2AV."9&))2\NZ VQ.0'XY/1Y+1,9S^' M>3:I:TYN+G@[^B_"B):Z\8=?RY2,(:+M.6OP[66S!)XA;>K[R2OQ\>.'\XR!T

M_45)F2_<#*WRLH55'4NL>)*L1!#=]"D"1"<%)"YP3VE);:%;&CX(D\Z-I*4"TNM<0X3[\]PU.NC$;U.GD^#)8^NT$E?_3?A_.CH\F(B# `_"E M^WMUQ8J?>-D,@>QLL6R&?

J9[RA0Q\L,9MN(l:?)QC)WOX'4C,ET]G?&L=(1Z MLT4Z&@22D-E@&LB&K]2%6DV3*3X*^]>]SZJ/]_$X_':+M]77PSD^ M-%TI(-OJB&,_FS_SD?F:-W!.SA*.!!7*+P?*0W[$;49?QV.

M\8Z5)':F?R6*G_&&/^R;,9=,F%)] N8QZE(Q5X@E:>#6>NL*"SGTZG?*)+0/ MWH.S.H&J5.&=8 DBY\(E*XQWZB+2OQV-)BE0B',IY/^X5-\K&7'-.49C1\G/F*LXSESKVU@%3

M1<=/!P;$DP!*8>SMC/# 7"C"%Y:J*H\L '8?!6#-]MIY!E_a>UV1Q`JYI(O= M2^#07@KOO(&(CA\"A[/@.=<@HT=`S\CBF-P%F_&#R@T_O#K!W8#CO #D6BHG M*U -A@?*A0JAU@ 5S4 JB0D7>JDZ@U*191444AA07'&(NCCP&&YP8^5E].P/ M+ !7TSWM 7!\G29Z"S;(Q2U$25U&IX>= SV?H,>W]DW(#8_HS./CSCSJC+\N

MGT)9R"ZY22'!!'WC;]1G2Y>&9@&6N9!SGE$XB]]6OLZ^"6S1Q@]%"%1U?`M\0S1*8QQL]).V^*Y$KMP=5;YBO*/,OTT3.5RL?T0OOQE.0%_Q1CL-@(MOY:_

MZ.)>E.JSN/=$!;]<(Z*AWJ*NAMC(:W# X-.C-!UR#K+HS^$QB!U.I"^0 M#>>%2\ QB*@%<=**EP+:SB.V'E?P)#(5AEL68.TF@)2N(SE4'4>7BE*+.:647 MB+Y70_&O,IU<**

OEW^.+1K 3!<@GI:)V'7KJ79 QN:"_.Y3UV6O.BFI!8#@92 M4)*\1(_1A?2(.YH+DTKU:3>UM38U+VXD7"N? C_]4M!O[-\RD4C9CEFK?H&/

M[.]#*7&;JU\FV:1F%50WKU2+'<@V45DO0TQ@M\IE3L2Q80;FVT1!E$-_X>+;^ M+:2T3._1SXMQ6&1:#*6QR/2<[E.WSS$L*W%6H)D=Q5'=E)?

1)E#KORU!4:^N38(.Q3FFQMIK_'8K_%0%5?Z*ORM M!1;<4Z&T?QD=W)20,-]<0N+)EXSXT'FH/R\]TQ_/>:;W6PWBJ5=_:*KRTE3E M'QC"-479!WJ%9K9?-!9]>^6G)X]%-

SU<]GW)4+H36E> 2EN%9J*84S5"\ M(OUHA(]9B]84S5 T2H@'HX1X7V8E3&GO~3>GDLGB,0CC0>O\G/#+V% M*99%R+RH7FG*;'-DW((-

P>$|WH!3)@)3D6SIA7AV$(58)WCVWI9I>^<.DRI19.$@)9\1\!2$H!'\4@RV M5D1 5\|$?T\&R!ZL3,?S3$G^HXQ& W'8?(BC]D2TV&C)%_5@MG(-7!4ZX,OW7C4FZO=<+++A

MY*YPTE'2U")$2LT0)!%#AY"<_M-^]KS?NT#@QV#6;U4KMM%([NS!@7@4EJ@P0)&.@?+;@E202 MSVBTY2)FWF-[>P3FYUL:,-W*W317O\%F@\W[@LV 6,>"MZ"Z#(D4 D((F+2

MS!F?,"CH;UQ[>+|T6\FN)HPO\%F@\T&FPTVOY$MOA3T*QV1"1LB"Q8>Z'Y4OD ->3DLGB,0CC0>O\G#V6+H,+UUEE^]FA MP2_^N9C-A_5T_93N5BCCC.+XA;I(-@;R?

QR0_'CXN[L\=|&:[)\G6L?2\6D M\/-T)TOA7 OCT6:YD)N;Y1[(J/BRK\/H=6%X^ =\RSM\L MG%P-"5H_+=./_]|-1*S*P9?&YGX5U@E$2TG2VK[UPO4U2GQYN^DIF%'SCZI

M@W>K]|O,4OCS>=<;Z/0&%N\K?)8BZEKY.%B\K6,%$E9'K#*D(!@K##_"Q.A"* M22%MXOC7+N*4317X'X.S-)K,%M-RVZ(3H XM$=FOM:),V=MQ)0JS7B?\IA6]

M'D72#J28I\/!@S9QT WCX,<2.:!"/SPGT Q4KW>$H|:!<.9A.NT(:X7BR6!7)-M2.@BA>%X4(?C,$[#KA+8##&6K&ZV#5:T.NB>%V9(^]/M.%7P_H7O7780"_D<]

MZ0ISX(|T%U7/735!)3RZIZ$-.+7@30LS! +MV$H9Y72]DUK4\F1^5Z2 MIE.\ M2FU?%WQW[?=G'03\+=A MZ&IK#+&IE8;AK,RW%8]*OPW>%Y10DB",'(8O6P'7I:H+B2(*ZFPPQ-

$\4[UP M-KRCK>&=+>(_49!):L\$>7"\!6O+H9YNACK24-/UN9!T4UF=KIH.Z00HXM*EQZ?E8Y"344MV2J%/?APA(VO6U[6_5F5],9W MQ5$>5@RZ4(/_N<@?

EZ^'K4=\XY#+X77%_ZXSZ=l=;IVE+C;ZQ$%XK4 5237F M402@,M.>A9C#;JWS4A76DQ_+>"/GG9A?9;"[-QB.$;G>SE_ZVO_-'TU@STHS MK>KV+(Y1O;H:Z\N*Z60>9EV)I2D)"T%

9U;ZU<1^0/0_CHCODG??RD[+C4[M.]'N\&1+XB\5\BM*._5"W3/8~98R9JOI'!MULF\XA4^F M++M-U-K9@XH_W1K MMP^#O7:P[W RKMGA^F?Y=TUULAXO\S+%,B)CX=O%M&'\-**

E\=7I9AP%|.'+L M71GD5M#HF7?PWBGYGPY$_26,,"Z|$0/1KH\S/2V9:4KQYS^_MZ<^_3H>)TI?C[]^W79:I^_ASF/Y,.IO#"F7[>L6T.YY)30SD[@RONF+G@R9VN?M(0W0&N-]BV

5EB04COTCWS1 M=.!1@>-"@,]6AV"X"K4':"P;SCF3P 11'RE(=3,P ;FJF$IML)+MXT$'OZXMU["7,\LY!+ 7&G \5K&&& M ,E!-)6#1,Q&C@!-9RKUR?LQH9U-

4P!T5DRT,08R'A"!6T87C.5O10&P?:)M: MB8![SU&^/\]1T=*5+T;1FATY3U(MB]?9@[4N@>(YHC,L!61;M0^A^))8CS0P M!"LXQ_"_\D#5S"O$Q 3XFKC5^"5>\-

!!_;U7@GWN\MT@Z]E-Z3.%+&]UD0T1NLB(OP8Z4&8:EC1O!,=@ZS%BQ?.2N"U9E * MPWQO644OB^CPDI-"%3TZ9MP9B()Y]-Z6ZARK@5"N(=83RB^V/9!WU*]?)^-R

M.CCN3K\/*H[HK)F25D-[M]5-7E -;2Z*3R48T'!=8)71JL04&1@A7#:L%A54 M+^9W6E2>&61.2V3%"G2Z& MCLHYGM#%!B^"HX5]!T$)"RS'*FRTI;#>SLPB:1-45F

S1[<^2T\+/PZX94;' MP+5SJ;'C\U24AHX-'5\..AI&*5B6)0]0,Q&@O'2>6Z<4_U"/3I4EWT'(MD*M3M+TJ0> * 38H$YS7EM?XW%(9#1D;,C9D?$GJ#A7IF) C<"80"53T(.L

M#*0P*2J5N N]9:G@;< YL,!=$: LSQ 81W MMLJ8O96B7Z&^(>/^*,FC;#05 MNT@$BZ>8"/XPF6\J.35CU6I=MUK7.[%TN M%.LLNNS6.

/*&P0^KQTH'4HPS%5%R8P+"1"I<[9!@O8)K[2UTCT&HLRV^D M=PTL&U@VL'Q.T_Z2,5+&(A)CP%RHM-^M@M>*04R.9Q:D*(I?Q$BO>&1,X>56 M2\35:M&U% *,-**

S9)E1$K(/-.A31\/C8\/$EX*K.U2<(-BB) 7?PWH(IT MDNBNIG)#.]$A36(RBH*-I5.$M!M5!<"5!]BDYGT.Q!+X/735\O)]D\'T5].UE MC9]$<BCCF+1&S?ZV4;_W"2Z273K?R7V$Z

***M#>/Y8#0,<3@:SH>E;7=YGGLS[V'l[@5MTN1"U1R#A)"E!26LI&]E!,F%Y5YF M+:,GL,7TZQ7*6&DH1 93W IS-%6+,KCK:'Q-ZV!?_=J:X]\Bl;@^\$6VW9EN@**

***M>!E8V?:Q/P1$,LNXL<)"#JG;V9?!)QV &QD2MYQ[V]_@8E6TW"4(57"$2*X@ MZB2!EV)X[O80]DKMW =$MLWL#1X;/#9XO$_V.9F\31:A+@G:K*(**

***MY"7;7H&S%FGO(U8^"D'>2S\7V;+%SW^'+YCY8L1>U5+U-Q*72=>Q)HQVSGD,P MUH$(3!=>G>.Q5OQJ+H_*Y-AMB/G'$;)O:'R@Q$DQEEB,\!E= I9# M:66**

***NZ2""48[WRM^=)>#D<\P,=) LH%D \F7)(IR&'K+I"S0.^P&@Y.5 D(M=UQP(EC6O9_=SD9V4#RV6A+ \E] S\T6N2HD70B4EV=5,$!%$%V,"X M$D%IG7M$]7WF?**

***7Y5,1_D'CFW=A=M3V"7SKCQ[0/M0=@/^#F'LZ(M,.FMRF"]#;!D*!]#+I"DB95'(USH%1.M+! /BP%GI0=5A(; 4@3.O;1%91;$ M>NA:&M;<T8=(<'[MWMXD'XJU7 "/-**

***H)*SH"/&.N$0B;TI<)655SANZ3@\@3 MNDZU!H@I1$CB^<6=N*Y MBW=#K&D^6KD4XF 3/S#$HK M+B[+ &13)'()9UNB%$V@V/%8BM/$ABH%C@\<& MCPT>[Q$>D_=<%B; 4?I6"?**

***0$O: 2/LDYE91DW/?]*AH=:?#6@3?%HO,/:@=>,_*GOQMB/G'$;.P8#T1'6:RV M*FLH42'RN>QH74P#T^C.M.YV48FD7#&O/,!G20+*!9 /)EP"2*.3$C2V0NBIL M%D$20<^@_<7?#**

***(;CD\|5\=C# MGJ#NCF_]S,2X#R0X&@@EU,)CC2W>O&<:Y_[YX_<;&;$_-+<9]!QO%5,R1RP@Y M,PSDJU$0J1@GJTJXPEW,M4>-J:7.V08)VB>'Z%XK!*\-1)EM45Y)[_A%!'Z'**

***M@_%VG.F_\^&Y#:@;^8B"C16144%"CD38(1K@*]V?@+!#M:_RL7?$+U1-Q/?2(,15(4 $#Q=#Q%R;U/O+P<63<"C\4X+/*PPXX) ^*5 MY:=NTT&8=[:P0Q-LHY3Y**

***8'-2>FLVNCT8#|;`_FDZZA>;?\O(^0(WQ,)98(.MCJ4**ND"D54#289B0ZF7;H] M9?.M[9#>1Rs+,Q*PSV-R>&XD4K,Y_G>,K6QX;C,JSH]V(K_USDC\LIFPX075$BZ<[#P;NC,/ZX**

***M=';WFECYZ\>=<KY!PMC].ICA&>0U(ZRZO.K5UY]&P3,,T'9T. O8DC,/HE.XK M =_^1$R'DRWO/)T]>_5*Y/1,R,%>`)_0^\TZT,. @&+B3)(:3DZF$W30\=IE M8+ .,18SO)E>YB^CD'Z'?**

***Z2CR8B:ZJKI7FXY5I>3C*^.H+=\7[#CW9O+Y@;' M>XCPN6R%7@;. FRWB#,>81O.L75*-+E;!V5L ^ ^:,3$\FTZY,3M6_PM_DD ,Z,,*/ 6*!LT;QC[(*#M9@,YXCAT^'L**

***M]T&=%IQX>M<!M?BYC"@^&?R:C/#MZ(@IABD?.MV>X+M//U$8OHR#.ND+H]%Z M+K\V&-BCT2*72]K%7L]11+JP" =I>'PR&N*$G5VW:G[5SP.<+XKPAB1?B++T**

***M.4V.CVET5WJ^G/Z5 N AP/2C06U2$*%DS@M=83F;% 7.!SEW/,^E6GWQ/*% M#!Y=WIG-5M!5!%#:2;3+S$*HP;,20C"V M1PBW8F.<8?SWGM*/LU\P$I_C+*.**

***_'P&.C^19)XSN>=5[97;9M=_DU9M>9 MPZLS=@!O+?IXX&;2K#=#/K:AO1?NXW\.>Z.9IC/4>=O!M6Y?XK+H[c8'"= MAY\H<90'l\.RRDO0A@UH(V;G?RYF!%)DNQ$CSF**

***1FYL6=,?H0E22@S4>/T MGE#2\D.W3RAYL'=S7A6O-1D'86@LH)S0X'W$Z=2IQNQ<%.E?6.W:(*5,$*S! M.3>5#HH%\U$FP;+)QJJXFSD_FVEVW2&(**

***V7M'DWU,LL_.)D,QY24)YS8NZD7 MS ?,-*"2*E"]=${0@1N14G#!2-G+0/!H!2M6 @MT"(99!E"'!*{(Q'OBAN+^**

***M\=1=L+W*B5^A[@_S\.V4V.I2SIEX.)D^HDYL^X@X2^5+%WC]^=_1C\W*8WV M_QN!%N?U_HR*E\@#Z>EF]O7^-Z+X_&;/)R=C,+I;_KUS4G(MY'=O'5<:+E]H=**

***<*'1K\@@S]L)ZNG]+=*NC*O(F3+]1-,.'U9LWZRPT7IKFX M>Z;G;'?$W2?FVL=?,3%S-]_]Z=S\K2>G6_V]?&:.^90*^>4$Y#(ZFA$+_UBWI__=]B&97S(HV**

***MB']7STK7=]843^>:OUY@$#0=#<=E)R%'Y^NBB_EN]7Z,Z0L7 K#'W);U \&\ M9!-&7RQOT-DG&EKB!VXW##)?Q4=#--(8U(Y.M)!>97SNC3]7<;@ MY/QLPK**

***9!I&D[6C6XJE=$FCOTV+4Q5%G+2*RI\EBO%E%H3\X+C,CR;K_M MW#!33)]'&!Y."ZT*30OV?']:E>2\D)LG(<2Z;!:&M$[N!9C94HJ*%(46B[CZ',F :8F$82)469V**

***MT?'<+'1M[:),>9[YE_'[!8:A<4OQY,DYX5S=''_!-_C*:I-^_MPW_.A1/*;4T7Y;L7ENMZVZU:G W+6BMBP,<=DZAW"9$N\7FVXX-R\=LZLEJ' MR3?**

***8)K52H.TUG\OR/:I6R9WO*9,>Z(DC6KL;O.J2V1/%#%]K]OWK+8E>[]WK M]/QEIZW#8CY9[U]D@21_'.T@70[H:TX6]VWG;Y;CQ!G&'G]MW&%'W-**

***VJC6L.XKO;$[3>O8[ML]O0WOKW1/MWXZ)Y M^)N6;_Y):/C=C0X MWQ;_?EXJ?9R,\K4US_YV.S*)NW.:[,_/L42??)7#>Y?5EO.NM4Q M_F;P0TD4#$P'DG=+/+*=KFJ=?AJ4^JV&Q**

***Z7492.SF8N@#,Z"I9L@$\'P9+3 MR92DHM.J]16H4Z@UJA18S2,M0@{'&@>59E3%C6+W]K0)K=6CSYK^\J!>Y MSLZ'KK/S@>YF#:9K]Y6>V!>&L3N4GGB>=O8_**

***AU1ZG9B=%L[SVT^;'.:F=;!1 M?7[S6>UG2?7YZH[)\EONFC"N"!84%&<9^%4C>)T+Y_"=2R)8X-^9l,CMW(U>&&\!&E- L6D)?(_].FJ.1GS M(')X2C$ZMP?>7'T>N+&\W-**

***RBMW7)MF[WPOIWXW7)9]#79]R_MNFB"4SK7]MT M<>--%UN%G?]VF\+.;==%RPJU71?[DB1YD9W>M]7DMNMBAQD=IT5T*1M@HF10**

***M.3$(E6O(6@LF56$\|>]C5ZM84+90%BMF!\H*!5U!"EB5)ZXHTL3ZIC,Y]%WY[M\HF:MN6B;,EH!G8/EE[:EHNVY>+NO#0"&\]HMP7W"12.!8+(($92H'(V]R,GU**

***MB"]J7STK7=]843^>:OUY@$#0=#<=E)R%'Y^NBB_EN]7Z,Z0L7 K#'W);U \&\ M9!-&7RQOT-DG&EKB!VXW##)?Q4=#--(8U(Y.M)!>97SNC3]7<;@ MY/QLPK**

***9!I&D[6C6XJE=$FCOTV+4Q5%G+2*RI\EBO%E%H3\X+C,CR;K_M MW#!33)]'&!Y."ZT*30OV?']:E>2\D)LG(<2Z;!:&M$[N!9C94HJ*%(46B[CZ',F :8F$82)469V**

***MT?'<+'1M[:),>9[YE_'[!8:A<4OQY,DYX5S=''_!-_C*:I-^_MPW_.A1/*;4T7Y;L7ENMZVZU:G W+6BMBP,<=DZAW"9$N\7FVXX-R\=LZLEJ' MR3?**

***8)K52H.TUG\OR/:I6R9WO*9,>Z(DC6KL;O.J2V1/%#%]K]OWK+8E>[]WK M]/QEIZW#8CY9[U]D@21_'.T@70[H:TX6]VWG;Y;CQ!G&'G]MW&%'W-**

***VJC6L.XKO;$[3>O8[ML]O0WOKW1/MWXZ)Y M^)N6;_Y):/C=C0X MWQ;_?EXJ?9R,\K4US_YV.S*)NW.:[,_/L42??)7#>Y?5EO.NM4Q M_F;P0TD4#$P'DG=+/+*=KFJ=?AJ4^JV&Q**

***Z7492.SF8N@#,Z"I9L@$\'P9+3 MR92DHM.J]16H4Z@UJA18S2,M0@{'&@>59E3%C6+W]K0)K=6CSYK^\J!>Y MSLZ'KK/S@>YF#:9K]Y6>V!>&L3N4GGB>=O8_**

***AU1ZG9B=%L[SVT^;'.:F=;!1 M?7[S6>UG2?7YZH[)\EONFC"N"!84%&<9^%4C>)T+Y_"=2R)8X-^9l,CMW(U>&&\!&E- L6D)?(_].FJ.1GS M(')X2C$ZMP?>7'T>N+&\W-**

***RBMW7)MF[WPOIWXW7)9]#79]R_MNFB"4SK7]MT M<>--%UN%G?]VF\+.;==%RPJU71?[DB1YD9W>M]7DMNMBAQD=IT5T*1M@HF10**

***M.3$(E6O(6@LF56$\|>]C5ZM84+90%BMF!\H*!5U!"EB5)ZXHTL3ZIC,Y]%WY[M\HF:MN6B;,EH!G8/EE[:EHNVY>+NO#0"&\]HMP7W"12.!8+(($92H'(V]R,GU**

***MB"]J2M2X*PR$+.B_(R#]((H)/1B<&*D.TNAC]74N>,/V*;_J7W++ZZ'W!{'IPWU+G+.3BN>\05 M'!Q5A*PU%4-A58*RSH(+T4!,KI8L7&Q7SSZ#AP<[\NG.EX474LNO MAW-**

***|;+IR6'Z=3O(B$=Y^1^>JL<"N#TY6XS%=CL=>,G-K M[,7R*4/Q5'"'X,?S['"'5:KDM*IK<*[@3N'JEU @U*@;LB;/H0OMRP+H8Y9_UA5A+%]11$SLKXNS^3'!'5)3[678G**

***MVIRMKPZ"%@4IQ$]>, =.6(?NHG/,lXl.IF)#9@ZO=,%1"BB!K]BHZFD-X8G MsWKDL_K9@54G)9#%1#.0<"'00E,K#]>4"Y MTEGVE@0;INPSIJ2H8lR*WL*P=$PY(2 D(L&. M,:**

***S7 6@.!3NBV4L]UB-'P]3^%Y5?NAARFSXY?:(@H[MRHU;4BC.T&6FP@/H-M9^'+T(+DYZX@"0[7=$G/2/<.PVA^.C@Y"CA::4BE#U:S0C1PTX+-X>,KSM#6**

***MW8,1U2WJ:AH,5F6'YMA58K(C;KN/1'&YZLVFQDK")WPLE$]>T6O'946:-3UKFB^EX4XQS20I9RW2ZK.^'"#MG'Z60VH\]C[-A>K2IZ_1>'**

***MOZ^]>7Z_M1R[K!4Z*\L>K0H(88NK4DHX/&$^GP[C8KY1_.V60QZRK/E&E7 MNJECO3ED5JU1>;1U?JK7W?1D1;=:,/QK59KH\+'+VJ&K*_&]ER2\'7%C>B7 M*=&!TJB-**

***J0[&IB(2CO%PBNK3%,/IYJ[,YR-ZV:/I9/%QR0LZG,T673J.JF!U M119FZRN:.:53@T["EK=T,* GX719S.G"A3W9>DN5@*@,U=G,,*:OJ^RSF,_U M7(V6,W!9OR[KP5=?**

***YRQJNS!3))"K]\D,,XLX3AI"* W@O@&L-!Y$+0.4&B2. MS!C!%2?Q^8XQ0[3QI7< FHEJK0X6+*SW7U&8\8OPD8K<7<47#*V(;2\5W?U;[!)9]6 B\QIMU!6TH$U1R]+E**

***M+,]@*4PZBYBX=[I7](,.K#-9R&^G[*[AX'*5^_;2^MT5,%G+W*P[FO<^]L" M.TUT)V4K!!BI18R;4DV!TKYW271?%@1TM5??CO-F>;DC**

***M[M\UE_33S%02=_N2IKEC2%_2,"^.R>'_%SE9Y+Q1#2XJHTEE-J]0KHO)3OR;.M)17A=(*M=]YE>MRGZ7CA[Y8G6L3E7R%,7I/9N?!U//2ANS=$6+OA/Y:L4-T**

***M'JEMV;Z6I+L:WYWAX[+,Z7(;N_1WN.A3^+VU^R^]63GDSEY]S(ZN,.SJT_^MK.I9&@O-^7:2ZQ6_"6;GC0I.7IRB2'!SH\&KU33CZ8?33_,TIR3>1@UE6@$.?=] MBF^9U6[T.**

***(THC%G.?^3:$(603XFCFH1/L43+40BS U5QNU[7'_)E59%EY MT'3.O!@!SHL",_M$CC]VKPM?=3VN!KA_.5K-15!0>\U@!*\^6@F)>1^UDC:RWO;2H)BR MQ/+C-**

***&.@@]_D>`%@C,>;"TNY7K;=\-[AR_D&7PV^]GU*&WSMLMI;B;G0R3#' MK0#%.8:$C"]\6NU],5&[W(,O';PTWFLP2PF!V#*'PY\+BHH;(S66'>X= MOOB!E_=<_Z4A6$.PAF![A6**

***F;2FB32"2POB1QT1H%"[!4X*IHGX M>KI&MEME][%]?L?++++]NSA5,RRBLSF^N3N .3LIT.,GK,PC-YKP8)6RFYIRS MK(5,/"M(66'TH&%=F^5]PKJ*>):2-**

***B!LQ'C4QP!1J0!"H<]6<_2]M*E M/!,F>@U2&XNH:#G$B(%L$L1$*0QW%VK--*QK6M"PKLWR(V.=S]I(K2)D1S4T M,: %%Y*'D -W++,H1*](QVVHD1K6[:<6/-**

***B>FI9T.V\.R+NU5G'9#6,HI3. MR_8BT@E*^K0M(363U$P2N=)NY&(S:*11E?;H14>%CGBI7/C HLFB5Y.F-DM(M-[JM\&YQO!AUI2#?A7DZ^NWDK.#CA\G*)BV5^J?QCRN-**

***_J5^F(;Q;-F97XE= MNEFMO5"4AGW;/DJ?*?;9[\A0*8(4.H"]J4+PU@)GWOJ4E4^WK[MO31OV->PKTW!<[*^ARH97!CS.4 Q*H-2.H#WFB&69]F9B%HD_BU+5GN)I3.<**

***M+_QT=Y+\IZ]'WUA'O"K'L]M0]=O1T/.Z."E-9 CU?@HE4'0K@ 36EGME,RA ME^B[S.+67])ABZJ;9]FFl,5CG\S1)\,R9),2J"P%>$XGRE/UR=+Q=-.:K,;JK M^A]**

***[@7VW]9KSLA2E':%ZV'6PKJK?Q]95\I!%^E9%NRM]YAZ]XATG_?H1>*96 M+7I>E5(<^D@7L*QE&U)KB%R0^2GAK>,2%R4+1Y"D!R$2]XPUHB/R+**

***M+LN$CXS(6K,&R0\&R7N)3PVT&V@_$]"60984>8"0I02EA8' D@ ,N>1*2&=, M#[3OLK[YV*!]W^3;SQ.T6W&M'1;7^1_%N PDZPIKJ1:Y[%;CQ*$@E/(6\8I$D(PQU<"!&1]!B9# EUC**

***5H5VK09EM+]HP;Q2:.04 M@ZAM9\$L1&$9&D$,.!R7NACQ' MT?55,6N*[@64#R^<-EDI8)XMGX"1#X./, M@;=:@!,)%Z6Y2Z7'LP/+ M:I8-+%]R6"KM#"M40TPE4#YG<%8H\#R)**

***{))*P?2]H2M4^<&@:_X#WJ@"}8Q M1#"^R^1?2]EX]2O$QBC@<6;#:P; P/)>P#)GX'Y.4"2HWB3Q+]M18 XCB4U 8 MD=<^&UQT)GI;&6CK"&%;..%HH54?(<98]N<4]=27>/IF3]D4FI?**

***P.CAS>\ICAI7)X_=E#00-RBV.&XM&.&=X36C];IQ^% MAG[]/]\A#GRUK_N!]@\ZO2^PRTVBG_7TOL N-XE^UM/[KO\DB3Z&?2U]>]I M]Z^A[PO]\C7;7MWMB7TN?;F^"'^K2KD=#?**

***#9-.X99CRM#MX8-.YZH.-^A^,& MR9^7:A$GHWSE:/TPG"74EOEL$,9Y\.X(WZ60#LT&K_B-S@SM>MO]TY*D**

***MIBHO1U5^G4[R(LT'[%\.1VC@HBF($U!FIDL1NLI6HYY65J2G\;TO.$G/,5 M,'K2]*3IR26&!#I_&KQ233^:C3]V(S6A\D(C)I*[$.ISY=P_O>'DLIQ+-.! MY-T98-$V'S]!KO#'V?**

***&V'RG6W9^PR%;H) L8%3GM9LL0;*%ZG5H&95C52E[< MS69%537(#$!# .H(!]$ZO%'+8K3WBLOX*"A, M>04B,U&ES]KUR[-ERV4)"'.U2.*I10?,:6\A.> ^]D+Z8!PD@6U')9RGB#=$:**

***MHGT+HO'*M"66$>,-AH=<9?#:!V!)CSX_CDVG%&Z@M.]>]13[DTLNOT\FGX8S4:EI&85[R8#X9I,5TBC\/-M3LIT,,GX2U%<)SI;A? YJT,#N)H4. M7.")58S28Y8&%(L>$.04R,IR8%**

***)*-.>@IWDIH'=TU>#!G8O899W7]];6PI MV(D#IN^9W[0I0H.[-LM[*G=6\`}++T^ K1^ARA8.KL0+CA=D<4S2B3]0LM$[! M9[#1<+S'.W"Q&/0'675)9^NKV**

***^X;PM%SU(+&M:JA%G>O6OGO<^*UJRY]^C: M"0/.5M51*%LM>2VRI.I>%\>RK *],F-H38E#U.6!9\5Q8^4V >B>N7;R@*N6 MMEMU[#%.X10E)&%KGW5$8^\1G#\>#,INC.,**

***[+]F+2"0K[M"TE-:O4K-)?_SNY M:%SQ^I@3%E2U"EPP#*SB7I; H^E,I=LL)=UHU*IQ?$"U7/XJ;P+\W3TV\G; M_$^\]YAA?_,-**

***D99:62OW3^,>51O]2/TS#>+;LS*_386I.^GXH2L.^9S>ESQ3[M+*=LJ];H3GO$L> 1QZSSX%7,/&B$Q?A-*TM[CWT]I]W<-ZW_<[>4!G[/;DJ? M*?**

***BIH(3CH3WL8W!*]PYBI0.12LK"62[6]NJ1W&:E:>_]KSE^#?O:E+Y(,.U M9U$Q;.7"2<2Q5'"ZP"$RIE*ITKO<*Z9]FV6GAGU-4=K*5)OEP)P*(D?/LK-@ M#**

***(;S2B4'P3,+W&4E6)).AMY9S-NL3.T]'+8XN)U^VI.E[VG)P_F?3I.(["?ZL M>>B[K2-Y]4>LOUDU6AEQ\4]"_0[AEEP(N(041(-MB5(?T>E>]+B>R(+)7]-$X(EK/R0UG^_]-**

***X1T=^9SCV^,FZTU,,/61HU|O0K^[! M8?@;,3$_,9>RH71#Z6>"TC5G5FJQH$)&QC\:C0!W="4JDS*<,3=72SJ/39* MW_.QB0;2S6]NB-P0>0>(S'CF5E8-WA'55]+)**

***<=84X)QKSX14O,^U>]+5QD=& M9'Z ,!Q N8%R ^-&RKO?KF%,R.YPT"FB;RMCAF!^,==KD*Q0%$7~Q9+E08'H MHRX_[BEPOL#%]P:ACRT'+P!""\;OU:9PSY(&654**

***59T#;XP&;TQ&MS76I(@N-MEDT?V:\5!USX%PG/W^C7MAI<.ZS!]9^+<1E(UM7?DBV2V*W&B4-!*I0^":#\>1MXA6'TF72QC %0E8,$51-$%76H *7W*DBO.R1%O-LO!$Q**

***MH@>&^N9?-KQL>-GP\OYV2D2,:.M4/,]RH/V^6N$TN++Mf0@IGN22 MWD1%R_U0A(:?#3_W 3^K#3)Y)X QA$'E4P*?\4|=0A#&(B[6WB:)HI4)D7GP M/'+T-QE#]Y1%\$;8G*I463P$?**

***E["GRE4B_Q>E01/P?LQOV^.IU/'=;3&Z'A MA<=_]8DW1G?>?AJD49BA/.CCVTG,VAC J=`>P>>U*FWZU?*9[G)Z-P^KJ. MRI?SW5_U8_VH[@J8S<-T_J;K*%#CL]*9EG@#7D"M=F**

***^'H2T>C[>5H:?2)<'V#.ZL/MQ MNL#;RI>3,IZ5 0DF]FI,3QY.$:OG'VQ]^??@'78]C$\[G]2^F2$XAT4>TMOC MV&:ZQ_O4,3?**

***H&&+C:MUY=E3*_'"C;B@9ZW\1D\N7[M7/]>!)^%A@/,EE/6O? MG9.G3N3R$#M$G7R-4K,X'K\YIY4G(>?A^./61HCA4B!66P;8H<$O+I7E,LZ(MYU]**

***(R+'%UQMH_W)#^.,B.KF\&@?/7(B[]%6UC[!"+;@^9ZPNE/V!.T]7EC M+HXV.S*SF5MNLP@5N_(ZC#Z'T[F;[_YT;@;7T|.AYN5S\RU3\,TF- R.IN1V**

***M_%MG^_Y[-4BS*^9%&YGXY?/2M8V>R&0:.EE=H*),.^C; 9!]6"IS';Q;O=]F M L L-R$0SFZB"AN^.7P4SES1Z=,/Z<)D/.)$O]Q M&HZWKCX<#*'YHQ?3R5I^8T M#K!**

***(G*C*97DHMOO[.\;'I2[YXV$!U$>O;C]/2:?W@\W!^-/B/?_R_ MVV[IBLQRDJX,DE_'@YS!-1YO-W0?.$CGH0LM.>%=RCE.UZ TCF9%=+8(.**K**

***MZ_"YXV!G^3WG7\0&J8Q239=BF/0.>@S-#V#5Z1XE'E8:,R^H3-0E"&I=3@: MDLWZ_F PG9R&T?P48@E3# (/!K-%"4/[J*>T>H=*'\&HK8QMCR8GRI?!45K4 MD"AYL4K)3(Y1>=**

***(0I^A?72!&W1EBG/HEU,7X8YF>'*RT&Q_5M8<6!&%G^P3^ M\O[' OVKS_^,/,!]U#*7M0H(;I:V]VT($"M>E29#0H0N.30_PC'X#XR(M<-1@'[XZ&X[!\HS*=!**

***[QE>='936&$E^,3=?]6H#2T-# M_*%,I\/Y9-IACN!OOL;AN7CY,Y M3?+ZD6=R0(UF?+>C"4XL90AH9,/VD&Y)]J;.V-T/^-WZK=-HT@T;">X9I>%L MN59Q?**

***+)$^GAZM3#31/Z,+A9IT.&+!9.W.Y3\\FDX6T5*B MDQ@^=Z)RA(YC&*"'E I2Q8<2!1WN%TQ?+/, (_T1_-4\7'TF3T0$AH_<9P6!+ M6?. 10;%M?S/8MBIX9%F7\WYV*5V%FIG*;.D4G-/EP\&KMO@KS^\Q01/P?LQOV^.IU/'=;3&Z'A MA<=_]8DW1G?>?AJD49BA/.CCVTG,VAC J=`>P>>U*FWZU?*9[G)Z-P^KJ. MRI?SW5_U8_VH[@J8S<-T_J;K*%#CL]*9EG@#7D"M=F**

***^'H2T>C[>5H:?2)<'V#.ZL/MQ MNL#;RI>3,IZ5 0DF]FI,3QY.$:OG'VQ]^??@'78]C$\[G]2^F2$XAT4>TMOC MV&:ZQ_O4,3?**

***H&&+C:MUY=E3*_'"C;B@9ZW\1D\N7[M7/]>!)^%A@/,EE/6O? MG9.G3N3R$#M$G7R-4K,X'K\YIY4G(>?A^./61HCA4B!66P;8H<$O+I7E,LZ(MYU]**

***(R+'%UQMH_W)#^.,B.KF\&@?/7(B[]%6UC[!"+;@^9ZPNE/V!.T]7EC M+HXV.S*SF5MNLP@5N_(ZC#Z'T[F;[_YT;@;7T|.AYN5S\RU3\,TF- R.IN1V**

***M_%MG^_Y[-4BS*^9%&YGXY?/2M8V>R&0:.EE=H*),.^C; 9!]6"IS';Q;O=]F M L L-R$0SFZB"AN^.7P4SES1Z=,/Z<)D/.)$O]Q M&HZWKCX<#*'YHQ?3R5I^8T M#K!**

***(G*C*97DHMOO[.\;'I2[YXV$!U$>O;C]/2:?W@\W!^-/B/?_R_ MVV[IBLQRDJX,DE_'@YS!-1YO-W0?.$CGH0LM.>%=RCE.UZ TCF9%=+8(.**K**

***MZ_"YXV!G^3WG7\0&J8Q239=BF/0.>@S-#V#5Z1XE'E8:,R^H3-0E"&I=3@: MDLWZ_F PG9R&T?P48@E3# (/!K-%"4/[J*>T>H=*'\&HK8QMCR8GRI?!45K4 MD"AYL4K)3(Y1>=**

***(0I^A?72!&W1EBG/HEU,7X8YF>'*RT&Q_5M8<6!&%G^P3^ M\O[' OVKS_^,/,!]U#*7M0H(;I:V]VT($"M>E29#0H0N.30_PC'X#XR(M<-1@'[XZ&X[!\HS*=!**

***[QE>='936&$E^,3=?]6H#2T-# M_*%,I\/Y9-IACN!OOL;AN7CY,Y M3?+ZD6=R0(UF?+>C"4XL90AH9,/VD&Y)]J;.V-T/^-WZK=-HT@T;">X9I>%L MN59Q?**

***+)$^GAZM3#31/Z,+A9IT.&+!9.W.Y3\\FDX6T5*B MDQ@^=Z)RA(YC&*"'E I2Q8<2!1WN%TQ?+/, (_T1_-4\7'TF3T0$AH_<9P6!+ M6?. 10;%M?S/8MBIX9%F7\WYV*5V%FIG*;.D4G-/EP\&KMO@KS^\Q01/P?LQOV^.IU/'=;3&Z'A MA<=_]8DW1G?>?AJD49BA/.CCVTG,VAC J=`>P>>U*FWZU?*9[G)Z-P^KJ. MRI?SW5_U8_VH[@J8S<-T_J;K*%#CL]*9EG@#7D"M=F**

***^'H2T>C[>5H:?2)<'V#.ZL/MQ MNL#;RI>3,IZ5 0DF]FI,3QY.$:OG'VQ]^??@'78]C$\[G]2^F2$XAT4>TMOC MV&:ZQ_O4,3?**

***H&&+C:MUY=E3*_'"C;B@9ZW\1D\N7[M7/]>!)^%A@

+%F"!UC9_UX4H+1((85@HY{'1EO%SK.+.9&6.64_J1_KC4O=D2-M>.IA74R7$+66X2V/J2_'&%E/TO!,.3M=(_>-7OPW&H.^:[@X648T5[B(6WU" M\ [LU:N=GHP.2SP.;MS\.R='#05RN7&W!Y>NF2_?__U:US Y-V@K!FV^TTY83F[@^73=4MWF;G.ULRY\$;K:#XFD-59<IJXY M'8P16BG6XU"*7DIO8P!IO09E>(# (BL)_C$S1:\Z+.5<\|OUFE'Y>C\VOJZ%Y MOUF&O7)!BSFWO<5T6"_(N=QMK:C>RH+M?CH:%|\=5* M$LY!%(I!L"9XH;7EKE>VK)K,9? .=!4>[^$H/!5PX"+KPG5.@I5'DP5[\;fZ M1Y2%0+'$Y--P9/7;X3\,__3C;|_$5S.+&5G'?BD"Z@JR4;K -D50Z?D$6)!N_=O MCSIJ[2.X) PD&X*HHB9AW3EE^@>-R[?[-]?!,K=^_MOW#Y3_LWWRYI48RO&- %D!HHY#MYK"UIP9562SAO;.UK/8LX5+,;P1/7-&(\' M8 XX(FYPT99RP1CO.+[5=?-M_*%M$WX-H66L7(<8(=;0G?/M3F"@LDKC6!;> M<]X[&VR5XL7G!.B%H86U:#*#Q+P7? Q+.YG)1ERF[U MTD_)+H)]-)B;U7[:2; 8IZ,+^;>5;24G[(EX8"Q761VO@(*%(%**!N?0.U>N MY,I#B4Y}NP?V0#(EE-A/F;JQ]]46#AZAYQ^."D[*QM5;KH=OX]\P'B\PZA]7 M^X7^>R@#¥]O$3>3H M07*]8)\[-G2<5)5GZ1<@C#C'X@&96SD2!C<;P8S8Y'S+551T/(WV M8E6]1 D'0D>T0$%%S]\)3!\0RO8L=-E'H'$Q,"$,./03B"(@0? R@F1!&9$) M,WI DW*IL3('Z) 0K4#!L,*I @EMD(R&A6QXXG(P),H7O T,/47%;BO"T0 M.MYV[7E*58D@+UES#<55G/W@5 +%DP!?DP>\/GF?&,K#@Z' =0ZGW,OE^#M; MFECFGVF_WA_DF9G]A/]09^S,_3-OHD:^B!5V.Q!DD>#HE;!)U] (YR8D'W- MO$?)K+(,:*@]T9TP=(48.CC"*'A""AZR9>JL@.&CBUK#FNM8$U:,"N,4]XAD MNV.D\16=6\99P=#6Z1)Z2Q^Y",$QFLV*H2_L&1JK]"O(C/ZN],+8XIL /!$! MD"(&]"NZU0ST';@@]U%BD&*42#D+{7)O[2N@H5$)38ST"0,;'RV:G1SPSYQT M1B=$>+$W K"7^WVVC$V8#PK:FHMVI8M/K+Y@4?@@+O]\N<@/2#V<;IL]V MC.Q\R=.;*P_V"],6*#L?GMHQO)<:?Q{J6CUP8KS,83K!.NSX=:,53+-6$P&HOU MHK='[=8K6KL1D>NB3+MG4>:MUI,.!O@N:!7HD,\4)>?U_HF+EEYQ;PPYC &4 M5ABA.JZ 11--0%<@Q!ZB2!-4XM9#)J9N%1" @L.HU?C(.)R06@E],W'Y-"QY M1R["?B6_- Z*R.N9*3L*,_9M]9G7*5E-^{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fY6Z-;2O8Q;&:I;AKF@TH-8-^_MO3$Z:PIG>- ;N=#I@$8.BX_9&S4';Z_9%;ZD#3Q^,Y%X'U)}!P^F>M4?8AW#0 M!RNZZ[;,K6;=;0VW;O[D2L[ENS=,"A,[.'114[\:@66^A4@X*-E;!#;L>G %. MTQ\Z@WJWOU2;TVT- >H/&H'7F.NWF6;O1[H B7P><=U]H8:M5;PYZ3XFZ8;1) M5&J'XU8KG8M%E;PJ96%1)2DDWZS(-T%N.D]#8%Y,%:G*8BGPX9+785?,@,KI M\?\#OZG4?<_:M5Y[\'U6L["9T;!UA?@1! [F4T[<1$%SL\<3%'KT5Q1[_LVE! MA[E%KNG@FHZMU?2LYI&#VJ#76."1@UJ]VWM$QPII)7#^Z>?F9W@ :(&&97S& MR>RIE'#[G^'38"Y]^7ET3S+>LN% [";NUFC7K+V^S_6;Y;*^R,9A\/-=,;W3; M)NFF,$,RILRTG6/#Y7G"%<6 MFV[&/C]YK;EP8EFSKD#OSI(L$] >U5@W,M0!+[5#X4Z8?#?TT2X*,C- "E-1 MSX(H^H(0S#=$2;!RW2_*8T]FRQNFRH212IL$I4BD- M/ ((YPNK%;-^CVB MW%ML6.%D\-;-'&P#']TQUN8O?@9OI%U_!F!8_"9!DA')XJ?CR%E- Y$E!8_ M!>4N7/Q,"O%E\3.36KOTO&FDN+3()$J#I=>YI0_)%$71& $\)]9VL" BIU M8@Q0 "5(=8\;ZXF@X+9TI?A\+5;!ARO5V=.&I$O]-QR*\KI'IGT(DIGGCS 1 ML'#=Z/LR.;UF"2V<\]S]=5MX ^^/8D/*R,@MUTFET#BA7RE4DC05 \!/(RD* M;\ESB"?"(=>AANE'7WXQ+S"0A2V1A&]*_$+O/54.'C]2:!*GB M#="$U:B? 0)L(RA;EE<"B$25'2+ 7G]UT:]-+L:IK]@"_+^W5++8[&>,C4A& MQ_32+FZ$V.Y_5$L*@.GR%OZEG)C:(3]%/Z8]VQAI !("60Y RTWH-!G#,^R(-M2'V1/P,)ZBSLQ/F"?+>8[8Y-+68T\0S? M_(:E1MX1!U73+.9K/>1EZ6=;W#"-M2V"5GN*9=I&[$788-B!,F57&/-LT47C(_F!461_T